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Abstract 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder 
after Alzheimer’s disease. The causes of this disorder are not fully understood, as 
95% of cases are sporadic forms of PD. However, the genes involved in familial forms 
of the disease have been intensely studied and have highlighted the importance of 
mitochondrial quality control in PD. Indeed, PARK2/PRKN and PARK6/PINK1 are 
core regulators of mitophagy. 
Mitophagy is triggered by mitochondrial impairment through the engagement of the 
mitochondrial kinase PINK1. Upon mitochondrial membrane depolarisation, PINK1 
promotes both the activation of the ubiquitin E3 ligase PRKN and its recruitment to 
mitochondria. In turn, PRKN tags mitochondrial proteins with ubiquitin. The ubiquitin-
coated mitochondrion is then recognised by autophagy receptors that bind to the 
autophagosomal membrane for safe disposal of the defective organelle. 
My project aims at gaining a deeper understanding of the PINK1-PRKN pathway of 
mitophagy and finding regulators of this pathway. As described above, mitophagy is 
regulated through ubiquitylation, which itself is controlled by opposing E3 ligases and 
deubiquitylating enzymes (DUBs). Those enzymes are of particular interest as they 
could be chemically targeted to prevent mitochondrial failure. In this thesis I have 
focussed on USP30, a mitochondrial DUB, that is thought to remove ubiquitin from 
PRKN substrates. Mitophagy reporters enabled me to measure spontaneously 
occurring, “basal” or constitutive, mitophagy events in live cell imaging experiments. I 
found that USP30 regulates both basal and depolarisation-induced mitophagy in cells 
expressing endogenous PRKN. Serendipitously, I discovered that a pool of USP30 
was localised at peroxisomes where it regulates pexophagy. In parallel, I made use 
of those same reporters to characterise alternative means to induce mitophagy.  
I also contributed to the generation and characterisation of a new in vivo mitophagy 
reporter model, the mt-Keima fly. This tool enabled me to study mitophagy events in 
a genetically tractable organism. Preliminary results show that USP30 knockout 
induces an increase in mitophagy events occurring in the fly brain. 
I further engineered USP30 knockout neuroblastoma cells using the CRISPR-Cas9 
technology and found, through western blot analysis that TOMM20 was one of the 
main substrates of USP30. It thus appeared that USP30 removes ubiquitin from 
TOMM20 to prevent the Parkin-feedforward loop. Accordingly, I found that USP30 
deletion and inhibition results in an increase of pS65-Ub generation by PINK1. 
I performed a series of proteomic and ubiquitylomic experiments using SILAC based 
mass spectrometry to further search for substrates of USP30. I found that many outer 
mitochondrial membrane (OMM) proteins are more ubiquitylated in the absence of 
USP30, including members of the translocase outer membrane (TOM) complex, the 
very abundant VDAC proteins, and other less well characterised OMM proteins, many 
of which are known Parkin substrates. Although many OMM protein were 
ubiquitylated, I did not measure a global loss of mitochondrial or peroxisomal proteins. 
Intriguingly, the ubiquitylome datasets also suggested that USP30 loss or inhibition 
may impact on ribosomal quality control.  
 
Overall, this thesis discloses new exciting roles of USP30 in the context of pexophagy, 
basal and induced-mitophagy, and further highlights the relevance of USP30 as a 
therapeutic target for PD.   
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Chapter 1:  Introduction 
1.1 Parkinson’s disease 
 Parkinson’s disease and genetic risk factors 
Parkinson’s disease (PD) is known as the second most prevalent 
neurodegenerative disorder after Alzheimer’s disease and affects 2-3% of the 
population of over 65 years-old (Lane et al., 2018; Tysnes and Storstein, 
2017).The first detailed description of PD was published in 1817 by James 
Parkinson in “An essay on the shaking Palsy” (Digitised version: (Parkinson, 
2002)). In this assay he described the progressive motor symptoms: gradual 
tremor, rigidity, gait abnormality (walking abnormalities), bradykinesia (slow 
movement), and the associated complications such as defects in speech, 
sleep impairment and constipation. He developed the following definition for 
the diagnosis of the Shaking Palsy (PD; then also known as Paralysis agitans): 
 
“Involuntary tremulous motion, with lessened muscular power, in parts 
not in action and even when supported; with a propensity to bend the 
trunk forwards, and to pass from a walking to a running pace: the 
senses and intellects being uninjured.” 
– James Parkinson. 
 
Further histological studies revealed that PD is also characterised by the 
degeneration of dopaminergic neurons of the substantia nigra and by 
abnormal intraneuronal inclusions of alpha-synuclein.  
To date, there is no cure for PD. However, an array of treatments is available 
to reduce PD symptoms and ameliorate the patients’ quality of life. The most 
commonly used treatment is levodopa (also known as L-DOPA), which is a 
dopamine precursor. Dopamine availability can also be enhanced using 
dopamine agonists, monoamine oxidase B inhibitors or catechol-o-
methyltransferase inhibitors. Other neurotransmitter systems can also be 
affected in PD such as serotonin, acetylcholine or norepinephrine and can also 
be modulated pharmacologically. More severe motor dysfunction can be 
treated by deep brain stimulation or MRI-guided focussed ultrasound 
(Armstrong and Okun, 2020). 
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The genetic causes of this disorder are not fully understood, as only 5-10% of 
cases are hereditary (review: (Poewe et al., 2017)). Since 1997, strong efforts 
have been put into identifying the genes involved in PD and their function 
(Table 1.1), (review: (Blauwendraat et al., 2020)). The mutations in the gene 
coding for alpha-synuclein, SNCA, were the first mutations identified as 
causative of PD  (Polymeropoulos et al., 1997). Currently, mutations in more 
than 20 genes have been described to cause PD (Table 1.1), (review: 
(Blauwendraat et al., 2020)). Although monogenic forms of PD only count for 
a small portion of total patients, GWAS studies have revealed that mutations 
in genes associated with hereditary and monogenic forms of PD, such as 
SNCA or LRRK2, are also genetic risk factors for sporadic forms of PD (Simón-
Sánchez et al., 2009; Michael et al., 2011; Nalls et al., 2014; Chang et al., 
2017). This reinforces the relevance and need for understanding the 
underlying mechanisms involved in hereditary forms of PD. 
 
Table 1.1: List of genes mutated in PD 
Table adapted from (Blauwendraat et al., 2020). Shown in brackets are putative PD 
genes for which confidence is low (genes requiring replication or function validation). 
Cellular and subcellular location as well as cellular pathways were collected from 
NCBI gene (https://www.ncbi.nlm.nih.gov/gene/). Early onset = Cases where the 
signs and symptoms of the disease begin before age 50.  
 





and onset Frequency 
Cellular /Subcellular 
localisation Cellular pathway 





Dominant Very rare Neuron Synaptic activity 




Rare Cytosol/ mitochondria Mitophagy 


























Rare Mitochondria Mitophagy 
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(HTRA2) 2005 Unclear  Dominant Unclear Mitochondria Apoptosis  
POLG 2006 Loss of function? Dominant Rare Mitochondria 
Mitochondrial 
DNA replication 
ATP13A2 2006 Loss of function Recessive Very rare Lysosome Unclear 




Very rare Cytosol/Mitochondria 




(GIGYF2) 2008 Unclear Dominant Unclear Cytosol/ ER/ endosome/ golgi 
Translation 
repression? 
GBA 2009 Loss of function? Dominant Common Lysosome 
Glycolipid 
metabolism 




Rare Not recorded Phospholipid metabolism 
(EIF4G1) 2011 Unclear Dominant Unclear Not recorded mRNA translation 
VPS35 2011 Loss of function Dominant Very rare Endosome 
Retromer 
complex 




Very rare Cytosol Regulates chaperones 
SYNJ1 2013 Loss of function Recessive Very rare Not recorded 
phosphoinositide 
phosphatase 
(DNAJC13) 2014 Unclear Dominant Unclear Endosome Membrane trafficking 









(LRP10) 2018 Loss of function? Dominant Unclear Not recorded Not recorded 
 
 The case of PINK1 and Parkin  
PRKN (encoding the ubiquitin E3 ligase Parkin) was another gene found early 
on to be mutated in PD (Kitada et al., 1998). Leo Pallanck’s group later 
reported that deleting parkin in Drosophila flies produced individuals with 
symptoms reminiscent of PD (Greene et al., 2003). The parkin null flies had 
motor defects, being unable to climb or fly, and histopathological 
characteristics of PD such as disrupted muscle integrity or degeneration of 
dorsomedial dopaminergic neurons. Mitochondrial structure was also impaired 
in sperm cells and in indirect flight muscle tissues. Moreover, the flies had a 
shortened lifespan and males were sterile (Greene et al., 2003). Other studies 
by Ming Guo’s and Jongkyeong Chung’s teams described pink1 null mutant 
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flies (Clark et al., 2006; Park et al., 2006). Those flies showed the same 
physical and histological impairments as parkin null flies, with exacerbated 
degeneration of the indirect flight muscles leading to an indentation of the 
thorax (Clark et al., 2006; Park et al., 2006). Further epistatic experiments 
revealed that pink1 and parkin were genetically linked as the overexpression 
of parkin in pink1 null flies rescued most of the PD-reminiscent phenotypes 
(Clark et al., 2006; Park et al., 2006). The pink1 and parkin double mutants 
were not more severely affected than the single mutants and PINK1 
overexpression was not able to rescue Parkin null mutant phenotypes. Both 
research teams concluded that pink1 and parkin proteins were involved in the 
same process with pink1 acting upstream of parkin. As pink1 is a 
mitochondrially localised protein and that both the mitochondrial structure and 
ATP production of pink1 and parkin mutants were impaired, they suggested 
that the pink1 / parkin pathway maintained mitochondrial integrity and function 
(Valente et al., 2004; Clark et al., 2006; Park et al., 2006).  
Many studies then stemmed from this discovery with the intent of better 
understanding the PINK1-Parkin pathway.  
 
1.2 Ubiquitin  
Ubiquitin is a highly stable 76 amino acid long protein that serves as a post-
translational modification (Figure 1.1), (Vijay-Kumar et al., 1987). It was 
identified twice in the 1970’s in two unrelated studies before it became clear 
that these concerned the same protein. 
 
  Discovery 
Ubiquitin was first purified from bovine thymus by Goldstein and colleagues, 
who were searching for thymic polypeptide hormones (Goldstein et al., 1975). 
They found that this particular polypeptide was not restricted to the thymus but 
was abundant in various mammalian and fish tissues, as well as in human 
immortalised cell lines, plant extracts and yeast. They also found small 
amounts of this polypeptide in bacteria, although that turned out to be most 





Figure 1.1: Sequence alignments and structure of ubiquitin 
A) Amino acid sequence of human ubiquitin. In bold are highlighted ubiquitin’s seven 
lysine residues and amino-terminal methionine. B) Ubiquitin is conserved across 
eukaryotes. The amino sequence of human ubiquitin was aligned to its homologs 
across six model organisms: Mus musculus (MOUSE), Danio rerio (DANRE), 
Drosophila melanogaster (DROME), Caenorhabditis elegans (CAEEL), 
Saccharomyces cerevisiae (YEAST) and Arabidopsis thaliana (ARATH). The 
sequence alignment was performed using Clustal Omega (EMBL-EBI). “*” indicates 
perfect alignment. “:” indicates a site belonging to group exhibiting strong similarity. 
“.” indicates a site belonging to a group exhibiting weak similarity. C) Schematic 
representation of the gene product of the four ubiquitin genes (UBA52, RPS27A, UBB 
and UBC). UBA52 and RPS27A encode for ubiquitin-ribosomal fusion proteins, with 
a single ubiquitin fused to L40 or S27a, respectively. UBB and UBC encode three and 
nine ubiquitin repeats, respectively, ended with an additional residue (cysteine and 
valine). D) Ubiquitin 3D structure. The model was generated on PBD (PBD ID: 1UBQ). 
The seven lysines and the amino-terminal methionine are highlighted in yellow. 
  
Ub Ub Ub














HUMAN         MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYN  60 
MOUSE         MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYN  60 
DANRE         MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYN  60 
DROME         MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYN  60 
CAEEL         MQIFVKTLTGKTITLEVEASDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYN  60 
YEAST         MQIFVKTLTGKTITLEVESSDTIDNVKSKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYN  60 
ARATH         MQIFVKTLTGKTITLEVESSDTIDNVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLADYN  60 
              ****************** ****:***:****************************:*** 
 
HUMAN         IQKESTLHLVLRLRGG  76 
MOUSE         IQKESTLHLVLRLRGG  76 
DANRE         IQKESTLHLVLRLRGG  76 
DROME         IQKESTLHLVLRLRGG  76 
CAEEL         IQKESTLHLVLRLRGG  76 
YEAST         IQKESTLHLVLRLRGG  76 
ARATH         IQKESTLHLVLRLRGG  76 














Furthermore, they found that its amino acid sequence was conserved between 
bovine, human and celery (Goldstein et al., 1975). Goldstein and colleagues 
thus provisionally named this polypeptide UBIP, short for ubiquitous 
immunopoietic polypeptide, and then renamed it ubiquitin. In 1977, ubiquitin 
was found to be covalently bound to histone 2A (H2A) at lysine 119, 
(Goldknopf and Busch, 1977; Hunt and Dayhoff, 1977). 
 
Ubiquitin was rediscovered (then named APF-1) in the context of non-
lysosomal proteolysis.  
Following the discovery of lysosomes, protein degradation was thought to be 
solely mediated by those digestive organelles (de Duve, 1959, 1963; de Duve 
and Wattiaux, 1966). Rabinovitz and Fisher however found that the synthesis 
of abnormal haemoglobin led to their rapid degradation in rabbit reticulocytes, 
which were suspected to have little or no lysosomes (Rabinovitz and Fisher, 
1964). Etlinger and Goldberg, then used this rabbit reticulocyte system and 
found that abnormal haemoglobin was broken down by a soluble and ATP-
stimulated degradative system, which functioned optimally at pH7.8 
contrasting with the acidic pH optimum known to be a feature of degradative 
activities in the lysosomes (Etlinger and Goldberg, 1977).  
Ciechanover, Hershko, Rose and their colleagues then described that this 
ATP-dependent proteolysis was regulated by APF-1 (ATP-dependent 
proteolysis factor 1) a ~9kDa protein (Ciechanover et al., 1978). They had 
dissected the ATP-dependent proteolysis into a two component system with: 
fraction I (APF-1), a small 9kDa protein and fraction II, which has an APF-1-
dependent and ATP-stimulated protease activity (Ciechanover et al., 1978).  
They further demonstrated that mono-APF-1 and poly-APF-1 chains form 
complexes with the protein substrates of ATP-dependent proteolysis 
(Ciechanover et al., 1980; Hershko et al., 1980). Ciechanover, Hershko, Rose 
and their colleagues further investigated the ATP-dependent proteolysis, 
nowadays known as the ubiquitin proteasome system (UPS), and went on to 
identify all of the components involved in this pathway (reviewed in: 
(Ciechanover, 2005)). They obtained the Nobel Prize of Chemistry in 2004 for 
their discovery of ubiquitin-mediated protein degradation. 
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In 1990, Wilkinson and colleagues, revealed that the proteolytic protein APF-
1 and the highly conserved protein ubiquitin were one and the same protein 
(Wilkinson et al., 1980).  
 
 Structure and function 
Ubiquitin is a modifying protein that is involved in post translational 
modifications (PTMs). This PTM protein is a member of the ubiquitin like 
protein family (UBL). UBL proteins share structural similarities and are thought 
to be evolutionary related. All UBL members have a β-grasp fold which is 
composed of a five-stranded-β-sheet wrapped around an α-helix and are 
classified into 9 families: Ubiquitin, SUMO, NEDD8, FAT10, ISG15, URM1, 
UFM1, ATG12 and ATG8  (Cappadocia and Lima, 2018), (Figure 1.1D). 
Ubiquitin is expressed as a fusion protein encoded by four different genes: 
RPS27A, UBA52, UBB and UBC (Figure 1.1C). RPS27A (also known as 
UBA80) and UBA52 code for ubiquitin monomers in frame with a ribosomal 
protein tail: the 40S protein S27a and the 60S protein L40 respectively (Baker 
and Board, 1991). UBB and UBC code for ubiquitin repeats comprised of three 
and nine ubiquitin molecules, respectively (Wiborg et al., 1985). Those repeats 
are then processed to free ubiquitin and ribosomal subunits by deubiquitylating 
enzymes such as UCHL1, UCHL3, USP9X, USP7, USP5 and OTULIN (Grou 
et al., 2015). 
 
 Ubiquitylation: The E1-E2-E3 cascade 
The entities involved in the ubiquitin conjugation system were first purified by 
Hershko, Ciechanover, Rose and colleagues (Ciechanover et al., 1982; 
Hershko et al., 1983). These enzymes are: E1 ubiquitin activating enzymes, 
E2 ubiquitin conjugating enzymes and E3 ubiquitin ligases (Figure 1.2). 
 
1.2.3.1   E1 ubiquitin activating enzymes 
In humans, there are two E1 ubiquitin activating enzymes (hereafter referred 
to as E1): UBA1 and UBA6 (Ciechanover et al., 1982; Jin et al., 2007; Chiu et 
al., 2007; Pelzer et al., 2007), (reviewed here:(Schulman and Harper, 2009)). 
E1 ubiquitin catalyse the first step of ubiquitylation. They first adenylate 
ubiquitin, then bind to ubiquitin’s C-terminal end through their catalytic 
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cysteine, forming a thioester bond, and finally charge E2 ubiquitin conjugating 
enzymes with ubiquitin (Ciechanover et al., 1981; Haas et al., 1982). E1 
enzymes can thus be loaded with two ubiquitin molecules simultaneously: one 
at the E1’s adenylation active site and another via a thioester bond at the E1’s 
catalytic cysteine (Haas et al., 1982). 
The E1 activating reaction can be summarised as follow: 
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Figure 1.2: The ubiquitylation cascade. 
Schematic representation of the E1, E2, E3 ubiquitylation cascade. The E1 activating 
enzyme first binds ubiquitin through its active adenylation site and adenylates 
ubiquitin. The E1 catalytic cysteine then forms a thioester bond with ubiquitin. The E1-
ubiquitin pair is recognised by an E2 conjugation enzyme and ubiquitin is transferred 
to the E2’s catalytic cysteine by transthioesterification. The E2 then binds to an E3 
ligase and its substrates. If the E3 belongs to the RING family, then ubiquitin is directly 
transferred to its substrate by aminolysis. If the E3 belongs to the HECT or the RBR 
families then ubiquitin is first transferred to the E3’s catalytic cysteine by 

































1.2.3.2   E2 conjugating enzymes 
There are ~40 E2s in the human proteome, of which 35 are specific to ubiquitin 
(Clague et al., 2015). 
E2 enzymes have a crucial role in the ubiquitin cascade. They not only permit 
the transfer of ubiquitin from the E1 to the E3 but also control 
monoubiquitylation, ubiquitin chain initiation and ubiquitin chain elongation, the 
processivity of chain formation as well as the topology of the chain linkages 
(Ye and Rape, 2009).  
E2s interact with E1 and E3 enzymes via their ubiquitin conjugating (UBC) 
domain. The binding of an E1 to ubiquitin, results in a conformational change 
of the E1 which exposes a negatively charged groove within its ubiquitin fold 
domain (UFD). This groove is selectively recognised by the E1 interacting helix 
(α-helix 1) located in the UBC domain of ubiquitin E2. The ubiquitin molecule 
is then transferred from E1’s catalytic cysteine to E2’s own catalytic cysteine 
by a transthioesterification reaction (Ye and Rape, 2009). Finally, E2s select 
E3 ligases via their unique E3 interacting loops (L1 and L2 loop) residing in the 
UBC domain (Zheng et al., 2000). An example of well characterised E2/E3 
pairs are Cdc34 and SCF (Skowyra et al., 1997). 
 
1.2.3.3   E3 ligases 
There are more than 600 E3 ubiquitin ligases which are distributed across 
three major E3 families:  HECT, RING and RING-in-between-RING (RBR), 
(Heride et al., 2014; Zheng and Shabek, 2017). HECT and RBR E3 ligases 
have a catalytic cysteine in their HECT and RING2 domains respectively 
(Figure 1.3A-B). They are thus able to form covalent intermediates with 
ubiquitin. Ubiquitin is transferred from the E2’s catalytic cysteine to these E3’s 
catalytic cysteine by transthioesterification and then conjugated to its substrate 
(Rotin and Kumar, 2009; Smit and Sixma, 2014). 
RING E3 ligases are the most abundant E3 ligases in the human proteome. 
These enzymes either have a zinc- containing RING domain or U-box catalytic 
domain. RING and U-box domains are structurally similar and do not possess 
a catalytic cysteine. Thus, unlike HECT and RBR, RING E3s do not form a 
covalent bond with ubiquitin (Figure 1.3C). Instead, they direct E2s to their 
substrate and activate the E2-mediated ubiquitin-substrate conjugation via 
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their RING domain (Budhidarmo et al., 2012; Metzger et al., 2014). RING E3 
ligases also include the multimeric Cullin-RING ligases (CLR) ligase 
complexes (Figure 1.3D). These complexes are arranged around a cullin 
scaffold protein, of which there are 7 encoded in the human genome (CUL1, 
2, 3, 4, 4B, 5 or 7). The cullin scaffold is bound to an E2 interacting RING 
protein (RBX1 or RBX2) at its C-terminus and to an adaptor protein (ex: Skp1) 
and substrate recognition protein (e.g.: F-box proteins) at its N-terminus  
(Zimmerman et al., 2010). 
 
 
Figure 1.3: E3 ubiquitin ligases 
There are three families of E3 ubiquitin ligases: HECT E3, RING-in-between-RING 
(RBR) E3 and RING E3 ligases. A-B) HECT E3 and RBR ligases both possess a 
catalytic cysteine which mediates substrate ubiquitylation. Ubiquitin is transferred 
from the E2 to the substrate in a 2-step process: 1) Ubiquitin is first transferred to the 
catalytic cysteine on the E3 by transthioesterification, 2) then the ubiquitin is 
conjugated to the substrate. A) HECT E3 ligases possess a HECT domain. The amino 
terminal end of the HECT domain interacts with the E2 enzyme, whilst the catalytic 
cysteine is located at the carboxy-terminal end. B) RBRs have two RING domains, 
RING1 (R1) and RING2 (R2) separated by an in-between-RING domain (B). The 
RING1 domain binds the E2s enzyme and the RING2 domain possesses the catalytic 
cysteine. C) RING E3 ligases are the most abundant ligases and lack an active 
cysteine. The ubiquitin transfer is thus a one-step process: the ubiquitin is directly 
added by the E2 to the substrate. The RING E3 ligases are characterised by the 
presence of a RING or a U-box domain. Those two domains adopt a similar structure 
with the exception that RING domains are arranged around two zinc ions. RING and 
U-box domains bind to the ubiquitin charged E2 and activate substrate ubiquitylation. 















































E3 ligase complexes composed of an E2 binding RING protein (RBX1 or RBX2), a 




 The ubiquitin code 
Ubiquitin modifications exist in multiple forms: mono-ubiquitylation or poly-
ubiquitylation, with various chain linkages and possible post-translational 
modifications. 
 
1.2.4.1 Ubiquitin linkage 
Ubiquitin is attached to substrates by an isopeptide bond formed between its 
C-terminal glycine residue and the substrate’s lysine ε-amine group 
(Goldknopf and Busch, 1977; Hunt and Dayhoff, 1977; Clague et al., 2015). 
Ubiquitin can thus be conjugated to other ubiquitin molecules on each of its 
seven lysines. Ubiquitin’s amino-terminal methionine can also be ubiquitylated 
and form linear chains. In mammalian cells, common chain linkages include 
Lys48 and Lys63-linked chains. Met1, Lys6, Lys11, Lys27, Lys29 and Lys33)-
linked chains are more atypical ubiquitin chains (Figure 1.4A), (Akutsu et al., 
2016).  
Broadly speaking, each chain-linkage type is associated with specific cellular 
pathways. Lys48 (K48)-linked chains are well known to target proteins for 
proteasomal degradation. In contrast, Lys63 (K63)-linked chains are involved 
in a broader range of pathways such as autophagy or endosomal sorting via 
the ESCRT complex (Komander and Rape, 2012; Swatek and Komander, 
2016). Interestingly, Lys6 (K6) along with K63, K48, K11-linked chains 
decorate outer mitochondrial membrane (OMM) proteins following mitophagy 
induction with mitochondria depolarising agents (Cunningham et al., 2015). 
 
1.2.4.2 Ubiquitin and ubiquitin chain types  
Most of the cellular ubiquitin pool is conjugated to substrates as single 
molecules (mono-ubiquitylation). In HEK293 cells monoubiquitylation 
represents more than 60% of total ubiquitin (Kaiser et al., 2011; Clague et al., 
2015). Up to 50% of cellular monoubiquitylation is on histones, such as the 
aforementioned monoubiquitylation of H2A at K119 (Goldknopf and Busch, 
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1977; Hunt and Dayhoff, 1977). Histone monoubiquitylation regulates 
chromatin organisation, gene expression and DNA damage repair (Cao and 
Yan, 2012; Clague et al., 2019). 
The next biggest ubiquitin reservoir is free ubiquitin (>20% of total ubiquitin in 
HEK293 cells) whilst polyubiquitin chains represent roughly 10% of total 
ubiquitin (Heride et al., 2014; Kaiser et al., 2011). These ubiquitin chains can 
be homogenic (single linkage type), heterogenic (mixed chain linkages) or 
branched when one ubiquitin is ubiquitylated a several sites (Figure 1.4B), 
(Swatek and Komander, 2016).  
 
Figure 1.4: The ubiquitin code. 
A) Ubiquitin can be linked to other ubiquitin moieties by its methionine (Met1, M1) or 
any of its seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 or Lys63). 
Methionine chains are linear and are linked by a peptide bond between the carboxyl 
terminal glycine and the amino-terminal methionine (Met1, M1). Lysine linked chains 
have various topologies and are linked by isopeptide bonds formed between the 
carboxyl terminal glycine and the specific lysine. B) Substrates can be modified by a 
single ubiquitin molecule (monoubiquitylation), by multiple ubiquitin molecules (multi-
monoubiquitylation) or by ubiquitin chains. Those ubiquitin chains can be made of one 
particular linkage (homotypic) or made of several linkages (mixed). Within ubiquitin 
chains, some ubiquitin moieties can be ubiquitylated at multiple lysine residues and 
thus form ubiquitin ramifications (branched). Finally, ubiquitin moieties amongst 
ubiquitin chains can be modified post-translationally. C) Ubiquitin post-translational 
modifications: ubiquitin can be phosphorylated at serine, threonine and tyrosine 
residues; ubiquitin’s lysine residues also get acetylated; on top of this, ubiquitin can 































































































1.2.4.3 Ubiquitin modification  
The ubiquitin code can be further complexified by the addition of post-
translational modifications (PTMs). Ubiquitin can be modified by small 
chemical PTMs such as  acetylation and phosphorylation, or modified by UBLs 
(sumoylation and neddylation) (Swatek and Komander, 2016), (Figure 1.4C).  
 
 Reading the ubiquitin code 
Ubiquitylated substrates are recognised by ubiquitin binding proteins which 
possess ubiquitin binding domains (UBDs). More than 20 UBDs have been 
identified in the human genome (Heride et al., 2014). UBDs are classified by 
their structure into five categories, (Husnjak and Dikic, 2012): 
- α-helical (UBA, UIM, DUIM, MIU, CUE, GAT, VH8, UBAN) 
- zinc finger (NZF, ZnF UBP, ZnF A20, UB2) 
- pleckstrin-homology (PH) fold (GLUE, PRU) 
- ubiquitin conjugating-like (UEV, UBC) 
- Others (SH3, UBM, PFU, Jab1/MPN) 
The ubiquitin-associated (UBA) domain was the first identified UBD. Hofmann 
and Bucher had observed, by using sequence alignments, that a ~55 aa long 
motif was common to a subset of E2, E3, DUBs, kinases and other proteins 
involved in ubiquitylation and was also conserved across species  (Hofmann 
and Bucher, 1996). They found that UBAs were present in those proteins as 
single copies or tandem repeats. 
The majority of UBDs were shown to bind the hydrophobic residues of 
ubiquitin: around Ile44 (with the surrounding Leu8, Val70 residues), and more 
rarely at Ile36 (Husnjak and Dikic, 2012).  
 
Ubiquitin binding proteins can have multiple UBDs which enhances binding 
affinity and specificity. As an example, the DUB USP5, which recognises free 
ubiquitin chains, has one N-terminal ZnF-UBP and two C-terminal UBA 
domains. It’s ZnF-UBP domain specially recognises the C-terminal GlyGly tail 
of ubiquitin as well as its hydrophobic Leu8. USP5 thus cleaves unanchored 
ubiquitin chains to replenish the free monoubiquitin pool (Reyes-Turcu et al., 
2006, 2008; Komander et al., 2009; Husnjak and Dikic, 2012). 
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The organisation of UBDs within proteins also affects their affinity for specific 
chain linkages. The BRCA1-A subunit RAP80 and the DUB ATXN3 both 
possess a tandem of Ubiquitin Interacting Motifs (UIM) but are specific for 
Lys63 and Lys48-linked chains respectively (Sims and Cohen, 2009). One 
difference lies in the length and nature of their UIM linkers. RAP80 has a rather 
long linker (7 aa) when compared to ATXN3 (2 aa), which is thus more adapted 
to the extended conformation of Lys63-linked and less efficient for binding the 
closed conformation Lys48-linked ubiquitin chains (Sims and Cohen, 2009).  
 
UBDs have been identified in hundreds of proteins in the human genome. 
Those proteins are not only found in ubiquitin conjugating (E1, E2, E3) and 
ubiquitin hydrolysing enzyme (DUBs) but also ubiquitin receptor proteins such 
as autophagy adaptors (SQSTM1, NDP52, NBR1, TAX1BP1, OPTN), 
proteasome ubiquitin receptors (Rpn10/PSMD4 and Rpn13/ADRM1), other 
members of the UPS system, endocytosis adapters and regulators (EPS15, 
EPSIN, STAM, Hrs, RABGEF1, …) and many others (Husnjak and Dikic, 
2012). 
 
 Deubiquitylation: Deubiquitylating enzymes (DUBs) 
Deubiquitylating enzymes (DUB) are ubiquitin proteases which cleave peptide 
or isopeptide bonds formed between ubiquitin molecules or between ubiquitin 
molecules and a substrate protein. 
DUBs are involved in a plethora of pathways. Some of their major functions 
include: 1) regenerating the cellular pool of free ubiquitin through the recycling 
of ubiquitin chains and processing of ubiquitin-fusion proteins produced by 
RPS27s, UBA52, UBB and UBC; 2) protecting proteins from proteasomal or 
lysosomal degradation (removal of degradative ubiquitin); 3) controlling protein 
function or protein complex assembly (removal of non-degradative ubiquitin), 
(Clague et al., 2012, 2019). 
 
1.2.6.1 DUB families  
To date, 99 deubiquitylating enzymes (DUBs) have been identified in the 
human genome (Figure 1.5). Those proteins are categorised into 7 families 
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based on the conformation of their catalytic domains: USP, UCH, OTU, MJD, 




Figure 1.5: Deubiquitylating enzyme families. 
There are 99 DUBs in the human genome classified into seven families: USP, UCH, 
OTU, MJD, MINDY, ZUP1 and JAMM (also known as MPN). USP, UCH, OTU, MJD, 
MINDY and ZUP1 are cysteine proteases whilst JAMMs are metalloproteases. In 
total, there are 11 inactive DUBs (pseudo-DUBs) distributed across USPs, OTUs, 
MINDYs, and more abundantly in JAMMs (5 out of 12 DUBs). A single member of the 













































































Six of those seven families are cysteine proteases whereas the JAMMs are 
zinc-dependent metalloproteases (Clague et al., 2013). Cysteine proteases 
possess a catalytic triad formed of a catalytic cysteine, a histidine and a 3rd 
residue, usually asparagine or aspartic acid, which catalyse deubiquitylation.  
DUBs are able to recognise and bind ubiquitin thanks to their catalytic domains 
and more specifically to their primary recognition site (S1) (Mevissen and 
Komander, 2017). 
MINDYs (MIU novel Deubiquitylase family) were discovered by Yogesh 
Kulathu’s and Kay Hofmann's groups while investigating the small UBD Motif 
Interacting with Ub (MIU) (Abdul Rehman et al., 2016). The biological function 
of MINDYs is still unknown. However, one striking observation is that all 
analysed members of the MINDY family are highly specific for K48-linked 
chains (Abdul Rehman et al., 2016; Kristariyanto et al., 2017). The ZUP1 family 
was co-discovered in 2018 by four research teams. Currently this new DUB 
family is only composed of one member: ZUP1. Similar to MINDY proteins, 
ZUP1 has a MIU motif and multiple other UBDs.  ZUP1 was reported to 
preferentially cleave long K63-linked chains, to localise to the nucleus and is 
thought to prevent DNA damage (Haahr et al., 2018; Hermanns et al., 2018; 
Hewings et al., 2018; Kwasna et al., 2018). 
 
Amongst the 99 identified DUBs, 11 are predicted to be catalytically inactive. 
These DUBs are qualified as pseudo-DUBs (Figure 1.5). Pseudo-DUBs are 
found amongst USPs, OTUs, MINDYs and are abundant among JAMMs 
(Walden et al., 2018). Albeit being inactive DUBs, pseudo-DUBs remain 
essential (Figure 1.6). They have the ability to activate competent DUBs and 
other enzymes. Well characterised DUB-pseudo-DUB heterodimers include 
COPS5-COPS6 involved in the COP9 signalosome (de-neddylating complex) 
and PSMD14-PSMD7 regulating the removal of ubiquitin from proteins 
committed to proteasomal degradation (19S proteasome) (Figure 1.6A-B) 
(Clague et al., 2019; Walden et al., 2018). Pseudo-DUBs can also act as 
scaffold proteins for the assembly of large protein complexes: PRPF8 
coordinates the assembly of the spliceosome (pre-mRNA splicing) (Figure 





Figure 1.6: Essential cellular functions regulated by pseudoDUBs. 
A) The JAMM DUB-pseudoDUB heterodimer COPS5 (active)-COPS6 (inactive) form 
the catalytic core of the COP9 signalosome that is responsible for removing NEDD8 
from Cullin-RINGLigases (CLR). B) Another JAMM DUB-pseudoDUB heterodimer, 
PSMD14 (active)- PSMD7 (inactive) found at the 19S proteasome deubiquitylate 
proteins targeted for degradation. C) The pseudoDUBs USP39 and PRPF8 control 
pre-mRNA splicing. PRPF8 coordinates the assembly of the spliceosome whilst 
USP39 is an integral part of the triple small nuclear ribonuclearprotein (tri-snRNP, 
U4/U6.U5) a building block of the spliceosome. PseudoDUBs are shown in light 
orange and active DUBs are shown in dark orange. 
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1.2.6.2 Cleavage type 
To respond to the diversity of the ubiquitin code, DUBs have developed a 
variety of cleavage modes and affinities for specific chain linkages (Figure 
1.7).  
Overall, most USPs are not specific for a particular ubiquitin chain linkage 
whereas most OTUs have a preference for one to three ubiquitin chain 
linkages (Figure 1.7A). ZUP1 and most JAMMs have a preference for K63 
chain linkages whilst MINDYs are highly specific for K48 chains; MJDs were 
reported to prefer K48- and K63-linked chains (McCullough et al., 2004; 
Abdul Rehman et al., 2016; Kristariyanto et al., 2017; Mevissen and 
Komander, 2017).  
As described earlier, the affinity of DUBs for certain chain linkages can be 
dictated by specific UBDs as well as their spatial arrangement. Deletion of UIM 
and ZnF motifs in OTUD1 and OTUD2, respectively, significantly decreases 
their chain linkages preferences (Mevissen et al., 2013). However, other 
factors contribute to chain specificity. As an example, the deletion of OTUD3’s 
UBA domain does not reduce its affinity for K6- and K11-linked ubiquitin chains 
(Mevissen et al., 2013).  
It is also worthwhile to note that only ~30% of DUBs possess UBDs (Komander 
et al., 2009). The ubiquitin binding sites within the DUBs’ catalytic domains 
thus also play a crucial role in cleavage specificity. USP30 which does not 
present any supplementary domains outside of its catalytic domain cleaves 
preferentially K6 chains (Clague et al., 2013; Gersch et al., 2017). In this case 
the chain selectivity is encoded in the catalytic domain itself. Other examples 
illustrating the involvement of ubiquitin binding sites within the DUBs catalytic 
domain in chain selectivity include OTUD2 and OTUD3. The secondary 
ubiquitin binding site (S1’) of OTUD3 contributes to its ability to act on K11 
chains. OTUD2 possesses another ubiquitin binding site (S2) which enhances 
its affinity for longer K11 chains (Mevissen et al., 2013). Overall, chain linkage 





Figure 1.7: Array of DUB-mediated 
ubiquitin-cleavage modes. 
Deubiquitylating enzymes have a wide 
array of cleavage modes to deal with the 
various chain linkages. A) DUBs can be 
specific for certain chain linkages. These 
chain preferences rely on the structural 
arrangement of their ubiquitin binding 
domains (UBDs) and on their specific 
ubiquitin binding sites (S1, S1’, S2) 
located within their catalytic domain.  
B) Some DUBs are substrate specific 
and thus directly bind their target protein 
and then cleave off the ubiquitin 
residues. C) Depending on the 
arrangement of the ubiquitin binding 
sites, ubiquitin chain cleavage can occur 
within the chain (endo) or at the distal 
end of the chain (exo). D) Most of the 
cellular ubiquitin is conjugated through 
monoubiquitylation. Thus, some DUBs 
specifically recognise mono-
ubiquitylated substrates (left). Others 
can cleave a whole chain at once, “en 
bloc” cleavage (right). E) UCHs have 
been reported to cleave small residues 
adjacent to the ubiquitin C-terminus, 
such as peptide left-overs from 
proteasomal degradation. They have a 
crossover loop which is thought to 
restrict them from binding large or folded 
ubiquitin conjugates (left). USP5 
possesses a ZnF-UBP domain which 
recognises the C-terminal GlyGly 
residues of unanchored ubiquitin chains 
(right). It can thus process unattached 
chains into free ubiquitin. Both UCHs 
and USP5 are essential for ubiquitin 
recycling. F) Branched ubiquitin chains 
have been reported to be processed by 
DUBs. However, it is not yet known if 
there exist specific modes of ubiquitin 
chain debranching such as the direct 
targeting of branching points. G) Up to 
date, three DUBs (COPS5, USPL1 and 
USP18) have been identified as UBL proteases (targeting NEDD8, SUMO and ISG15, 
respectively). Those could potentially cleave off UBLs from ubiquitin chains. Arrows 
indicate cleavage site.  
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Several DUBs show substrate specificity rather than chain linkage affinity 
(Figure 1.7B). This is exemplified by the USP family. Most USPs show no 
chain specificity but instead have additional motifs directing their localisation 
and promoting protein-protein interaction (Faesen et al., 2011; Mevissen and 
Komander, 2017). 
Ubiquitin chains can be cleaved from the extremities (exo) or within the chain 
(endo) (Figure 1.7C). MINDY-1 is an example of exo-deubiquitylating DUB. 
Due to its MIU arrangement, it can only strip off ubiquitin from the C-terminal 
end of chains in a stepwise manner (Abdul Rehman et al., 2016). Conversely, 
OTUD2 and OTUD3 have an additional S2 site which promotes endo-cleavage 
(Mevissen and Komander, 2017; Mevissen et al., 2013). 
Deubiquitylases can also be sensitive to the length of the ubiquitin chains. Due 
to the arrangement of their MIU tandem motif, MINDY-1 and MINDY-2 
preferentially cleave long poly-ubiquitin chains. MINDY-1 was shown to have 
no catalytic activity against mono-ubiquitin (Abdul Rehman et al., 2016; 
Kristariyanto et al., 2017). 
Although several DUBs have no affinity for monoubiquitylation, cellular 
ubiquitin is mostly found in form of monoubiquitylation (Figure 1.7D, left). 
Roughly 50% of monoubiquitylation occurs at histones (Kaiser et al., 2011). 
DUBs such as MYSM1, USP3, USP16, USP22 and BAP1, are involved in 
histone deubiquitylation (reviewed in (Clague et al., 2019)). 
Another mode of chain cleavage is the “en bloc” cleavage (Figure 1.7D, right). 
Such cleavage is observed in proteins committed to proteasomal cleavage. 
The DUB-pseudo-DUB heterodimer PSMD14-PSMD7 and USP14 mediated 
“en bloc” cleavage at the 19S proteasome (the “lid” of the proteasome). 
 
Other cleavage particularities have also been observed in UCH enzymes. 
Those enzymes have a unique cross over loop (also known as active site loop) 
which restricts the access to the catalytic core (Figure 1.7E, left). Thus, UCHs 
with a short cross over loop, such as UCHL1, cannot cleave bound-ubiquitin 
molecules unless they are attached to short and unfolded C-terminal 
extensions (Less than 10 aa long). UCHL1 can therefore remove short peptide 
remnants from ubiquitin such as those left-over from proteasomal degradation 
(Bishop et al., 2016). 
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Certain DUBs are also able to recognise detached ubiquitin chains, such as 
chains removed by en-bloc cleavage or endo-cleavage (Figure 1.7E, right). 
Those DUBs, like USP5, mentioned above, possess a ZnF-UBP domain that 
recognises the C-terminal GlyGly. ZnF-UBP containing DUBs include USP3, 
USP5, USP13, USP16, USP22, USP33, USP44, USP45 and USP49. 
Currently, only USP3, USP5 and USP16 were reported to recognise and 
cleave unanchored ubiquitin chains (Bonnet et al., 2008; Reyes-Turcu et al., 
2006). Both ZnF-UBP, containing DUBs, and UCH play an important role in 
the recycling of cellular ubiquitin and replenishing of the free ubiquitin pool. 
 
Further layers of ubiquitin code complexity are added by chain branching and 
PTMs. The cleavage of branched chains is not yet understood. However, it is 
hypothesised that some DUBs have the capacity of directly cleaving branching 
points (Mevissen and Komander, 2017), (Figure 1.7F). 
Small chemical PTMs (phosphorylation, acetylation) and UBLs (SUMO, 
NEDD8) can be tackled by specific proteases (Figure 1.7G). Three DUBs have 
been reported to selectively cleave UBLs: COPS5 is part of the COP9 
signalosome and removes NEDD8 moieties; USPL1 is a SUMO protease and 
USP18 targets ISG15 (Cavadini et al., 2016; Schulz et al., 2012; Malakhov et 
al., 2002). Those UBL specific DUBs thus also have the potential to remove 
SUMO or NEDD8 from ubiquitin chains.  
Two ubiquitin phosphatases, PTEN-L and PPEF2, were recently shown to 
specifically oppose the phosphorylation of ubiquitin at Ser65 by the 
mitochondrial kinase PINK1  (Wall et al., 2019; Wang et al., 2018). The 
removal of phosphoryl groups enables deubiquitylation by DUBs. Indeed, a 
large portion of DUBs appear to poorly hydrolyse Ser65-phosphorylated 
ubiquitin (Wauer et al., 2015a).   
 
1.2.6.3 Subcellular localisation of DUBs 
Most human DUBs, ~80%, are either cytosolic or nuclear. This was first 
assayed by systematically tagging a large cohort of DUBs with GFP in HeLa 
cells and mapping them by immunofluorescence microscopy (Urbé et al., 
2012). Later, global mass spectrometry screens from subcellular fractionations 
shed light on the abundance and localisation of most of HeLa cell proteins, 
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including DUBs (Itzhak et al., 2016). Roughly 20% of DUBs are associated 
with specific cellular structures (Reviewed in (Clague et al., 2019)). As an 
example, USP21 was found to be restricted to centrosomes and microtubules 
(Urbé et al., 2012).  
Several DUBs possess splicing variants which localise to distinct organelles 
(Figure 1.8). Splice variants 1, 2 and 3 of USP33 are found in ER and on 
COPII-coated vesicles (Thorne et al., 2011). USP33 variant 3 (USP33V3), 
which is missing an 8 amino acid sequence in its catalytic domain, 
predominantly resides at the Golgi apparatus (Thorne et al., 2011). Similarly, 
USP35 has multiple isoforms. Yogesh Kulathu’s group characterised two 
USP35 isoforms with isoform 1 (full length)  being cytosolic and isoform 2 (N-
terminal truncation of 269 residues) being restricted to the ER and lipid droplets 
(Leznicki et al., 2018).  
 
 
Figure 1.8: Subcellular localisation of DUBs. 
Mammalian DUBs are predominantly localised to the cytosol (not shown) or to the 
nucleus. However, a subset of DUBs (~20%) are associated with particular cellular 
structures. Some DUBs localise to microtubules (USP9X, USP21, CYLD), others to 
selective organelles. This is exemplified by USP33V3 and USP32 which are Golgi-
specific DUBs. USP30 and USP19 are the only DUBs to have a transmembrane 
domain which enables them to anchor themselves to the ER or to mitochondria and 
peroxisomes, respectively. USP30*: We discovered that endogenous USP30 is 
localised to both mitochondria and peroxisomes. The details are described in Chapter 




















































1.3 Protein degradation pathways 
In eukaryotes, proteolysis is primarily mediated by the Ubiquitin Proteasome 
System (UPS), the endo-lysosomal pathway and autophagy (Ciechanover, 
2005) (Figure 1.9).  
The UPS degrades ubiquitylated proteins via the proteasome whilst autophagy 
and the endosomal pathways of degradation require the lysosome. 
All three pathways are tightly regulated by ubiquitin and each involves specific 
ubiquitin receptors, which recognise ubiquitylated cargoes thanks to their 
ubiquitin binding domains,  and target them to one of the degradation 
pathways: UPS (Rpn1, Rpn10, Rpn13), endo-lysosomal pathway (ESCRT-0 
members, HRS and STAM; ESCRT-I, TGS101 and UBAP1; ESCRT-II, 
VPS36) and autophagy (> 30 autophagy receptors, such as SQSTM1, NBR1, 
NDP52, TAX1BP1, or OPTN), (Clague and Urbé, 2010). 
 
 Endo-lysosomal pathway 
The endo-lysosomal pathway targets cell surface membrane proteins captured 
in endocytic vesicles such as receptors, ion channels and nutrient transporters. 
Endosomes are sorting facilities, which can recycle endocytosed cargoes to 
the plasma membrane, recycling endosomes or Golgi thanks to the retromer 
complex (VPS35, VPS26 and VPS29) and other complexes (eg: retriever 
complex). Alternatively, cargoes are incorporated into intralumenal vesicles of 
multivesicular bodies for subsequent degradation thanks to the ESCRT 
complex (Endosomal Sorting Complexes Required for Transport). These 
multivesicular bodies, also sometimes referred to as late endosomes, 
ultimately fuse with the lysosome (Cullen and Steinberg, 2018; Norris and 
Grant, 2020). 
 
 Ubiquitin Proteasome System (UPS) 
The UPS system was first described by Aaron Ciechanover, Avram Hershko, 
Irwin Rose and colleagues (Ciechanover, 2005). In this system proteins are 
tagged with ubiquitin and sent for degradation in the proteasome, a multi-




Figure 1.9: The major proteolysis pathways, UPS, endo-lysosomal degradation 
and autophagy are interconnected. 
Endosomes are sorting facilities which either internalise endocytosed cargoes into 
intralumenal vesicles for degradation or recycle them from the tubular regions back to 
the plasma membrane (in some cases via perinuclear recycling endosomes, not 
shown) or to the Golgi apparatus. Internalisation into intralumenal vesicles is 
controlled by the ESCRT complex that recognises ubiquitylated cargoes. Recycling is 
controlled by the retromer or retriever complexes following the recognition of the 
sorting motif. Degradation occurs when the late endosome or multivesicular body 
fuses with the lysosome. Macro-autophagy (autophagy) requires the formation of an 
autophagosome which captures cytoplasmic content and ultimately fuses with the 
lysosome to form an autoplysosome where degradation takes place. Autophagy can 
be non-selective or selective. In selective autophagy, autophagy receptors target the 
autophagosome to specific protein or organelle cargoes either by binding to ubiquitin-
tags or to the cargo itself. The UPS degrades ubiquitylated proteins through the 
proteasome. Ubiquitin itself is recycled by DUBs associated with the proteasome and 
endosome respectively.  
ER: Endoplasmic reticulum; MVB: Multi-vesicular body.   
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1.3.2.1 The 26S proteasome 
The 26S proteasome is a 2.5MDa complex composed of a 20S core particle 
(CP) and one or two 19S regulatory particles (RP). The 20S CP is a barrel 
shaped proteolytic complex formed of two heptameric α-rings and two 
heptameric β-rings organised as follows:  α1-7/ β1-7/ β1-7/ α1-7.  The α-rings form 
a gate with their N-terminal tails to regulate the entry of proteins within the 
proteolytic chamber. The β-rings contain the three proteases (β1, β2 and β5) 
(Rousseau and Bertolotti, 2018; Yu and Matouschek, 2017). 
The 19S RP is involved in substrate recognition, unfolding and translocation 
into the CP catalytic chamber. It consists of a base complex and lid complex.  
Protein unfolding is mediated by a hexameric AAA-ATPase (Rpt1-6 in yeast/ 
PSMC1-6 in humans) ring located in the base which mechanically unfold 
proteins by ATP hydrolysis and engages the substrate to the proteolytic core 
of the CP (Bard et al., 2018; Schweitzer et al., 2016). The base also contains 
four non-ATPase RP proteins (Rpn1, Rpn2, Rpn10 and Rpn13 in yeast/ 
PSMD2, PSMD1, PSMD4 and ADRM1 in human). Rpn1, Rpn10 and Rpn13 
are ubiquitin receptors that recognise ubiquitylated proteins thanks to their 
UBD domains (Yu and Matouschek, 2017). Rpn1, Rpn2 and Rpn13 also serve 
as interacting platforms for proteasome substrate recognising proteins and 
substrate modifiers such as DUBs and ubiquitin E3 ligases. Protein recognition 
is also managed by shuttle substrate adaptors which possess a UBL domain 
to bind to the proteasome and UBA domains to bind ubiquitin such as Rad23 
(RAD23A-B) and Dsk2 (UBQLN1-2) in yeast (Bard et al., 2018; Yu and 
Matouschek, 2017). 
The lid is a horseshoe structure that organises the base/lid association and 
also regulates the deubiquitylation of proteasome substrates. It contains nine 
Rpn proteins: Rpn3, Rpn5, Rpn6, Rpn7, Rpn8, Rpn9, Rpn11, Rpn12 and 
Sem1 (PSMD3, PSMD12, PSMD11, PSMD6, PSMD7, PSMD13, PSMD14, 
PSMD8, PSMD9 in humans) (Rousseau and Bertolotti, 2018). 
PSDM14/PSMD7 form a DUB-pseudo-DUB heterodimer that sits at the entry 
of the AAA-ATPase ring and removes ubiquitin from substrates engaged for 
proteasomal degradation by “en bloc” cleavage (Clague et al., 2019). Two 
other DUBs, Ubp6 (USP14) and UCHL5 (only in humans), associate with the 
proteasome by binding Rpn1 (PSMD2) and Rpn13 (ADRM1) respectively, and 
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control the fate of proteasome targeted proteins (de Poot et al., 2017). USP14 
and UCHL5 can remove ubiquitin from substrate prior to their engagement in 
the AAA-ATPase ring and prevent their degradation. USP14 has also been 
shown to cooperate with PSMD14. Indeed, USP14 has a higher affinity for 
multi-ubiquitylated proteins (Lee et al., 2016). It can therefore work in unison 
with PSMD14 in a 2-step deubiquitylation process:  USP14 first removes 
supernumerary ubiquitin chain from proteasomal substrate and PSMD14 
secondly cleaves off the remain ubiquitin chains once the substrate is engaged 
in the proteasome. 
 
1.3.2.2 Proteasome degradation signal 
The targeting of a protein to the proteasome usually requires that : 1) it is 
ubiquitylated for it to be recruited and 2) that it contains a disordered region 
(also known as initiation region) to become engaged by the RP and 
translocated into the CP (Roberts and Pruneda, 2020). 
 
1.3.2.2.1 Ubiquitin signal 
Long (> tetraUb) K48-linked chains are the best characterised proteasome 
targeting signal. However other poly ubiquitin chains such as K11 or K63, as 
well as branched chains have been found capable of targeting substrates to 
the proteasome (Meyer and Rape, 2014; Yu and Matouschek, 2017). Although 
long polyUb chains are more efficient than mono-ubiquitin, multi-
monoubiquitylation and multi-diUb were reported to efficiently target the 
proteasome (Lu et al., 2015). 
Interestingly, a few proteins, such as ornithine decarboxylase, can be 
degraded without ubiquitylation. However, the underlying targeting 
mechanisms are not fully understood (Yu and Matouschek, 2017). 
 
1.3.2.2.2 Initiation region 
The initiation region is a >20 amino-acid long disordered region of proteasome 
substrates that enables their engagement (Yu and Matouschek, 2017). Not all 
proteasome substrates possess an initiation region, however ubiquitin 
modification is able to induce localised protein destabilisation which exposes 
these disordered regions (Carroll et al., 2020; Roberts and Pruneda, 2020). 
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1.4 Autophagy 
Autophagy, meaning “self-eating” in Greek, is a term coined by Christian de 
Duve in 1963. This term englobes pathways where intracellular content is 
targeted for lysosomal (or vacuolar in yeast and plants) degradation. 
Autophagy includes macroautophagy, microautophagy and chaperone 
mediated autophagy (CMA) (Figure 1.10) (Yim and Mizushima, 2020). 
Microautophagy and CMA occur directly at the lysosome. During 
microautophagy, the lysosomal membrane invaginates to engulf cytoplasmic 
content. The mechanisms underlying microautophagy are yet unknown. CMA 
involves the cytosolic chaperone HSC70. HSC70 recognises a five amino acid 
sequence on target proteins, KFERQ or variants, and recruits those proteins 
to LAMP2A, a lysosomal membrane protein. The cargo:HSC70:LAMP2A 
binding favours LAMP2A oligomerisation and enables the import of the cargo 
protein into the lysosomal lumen (Yim and Mizushima, 2020). 
Macroautophagy is the best characterised pathway of autophagy and will be 
hereafter referred to as autophagy. In this pathway, double-membrane 
vesicles (autophagosomes) engulf cytoplasmic components and then fuse with 
the lysosome. Autophagy recycles intracellular components in case of nutrient 
shortage. Other functions of autophagy include degrading damaged or 
impaired organelles, alleviating cellular stress (hypoxia, oxidative stress, ER 
stress, …), removing abnormal protein aggregates and eliminating pathogens. 
Autophagy can be non-selective or selective. 
 
 Mechanism of mammalian autophagy 
The steps of autophagy can be briefly summarised as follow: 1) autophagy 
induction signal, 2) nucleation of the autophagosome precursor (isolation 
membrane), 3) extension and shaping of the isolation membrane, 4) closure 
of the autophagosome, 5) fusion with a lysosome (autophagolysosome 
formation), 6) degradation of the autophagolysosome content by hydrolases. 
The ATG genes are the core genes regulating autophagy. They were first 
identified by Yoshinori Ohsumi in 1993 using the yeast Saccharomyces 
cerevisiae (Tsukada and Ohsumi, 1993; Ohsumi, 2014). The ATG genes can 
be categorised into 6 functional groups: 1) the ULK kinase complex (ULK1 or 
ULK2, FIP200, ATG13, ATG101), 2) ATG9-containing vesicles, 3) Class III 
 28 
PI3K complex I (VPS34, p150, BECN1, ATG14L and NRBF2), 4) the ATG2-
WIPI complexes (WIPI1-4) , 5) the ATG16L1 complex (ATG12-ATG5-
ATG16L1) and 6) the Atg8-family members (LC3A, LC3B, LC3C, GABARAP, 





Figure 1.10: Autophagy subtypes: Macro-, micro- and chaperone-mediated 
autophagy. 
All autophagy pathways target cytoplasmic content for degradation in the lysosome. 
These pathways include macroautophagy, microautophagy and chaperone mediated 
autophagy (CMA). In macroautophagy, the cytoplasmic content is captured by a 
double membrane vesicle called the autophagosome, which then fuses with the 
lysosome. Both microautophagy and CMA occur directly at the lysosome. In CMA, a 
cytosolic chaperone protein, HSC70, binds to the KFERQ motif of the target protein 
and brings it to LAMP2A, a lysosomal membrane protein. This enables the formation 
of a multimeric LAMP2A complex and promotes the translocation of the cargo protein 
to the lysosomal lumen. Microautophagy is the direct invagination of the lysosomal 










1.4.1.1 Autophagy induction and the ULK complex: 
As briefly mentioned earlier, autophagy is induced by a wide range of triggers. 
All of these initiating pathways are unique but often converge on TORC1. 
TORC1 constitutively inhibits autophagy by phosphorylating ULK1 and 
ATG13. TORC1 inactivation enables the assembly of multiple ULK complexes, 
also known as initiator complexes, that recruit and activate the ATG cascade 
through phosphorylation of ATG proteins (He and Klionsky, 2009; Zachari and 
Ganley, 2017; Velazquez and Jackson, 2018). 
 
1.4.1.2 Isolation membrane and ATG9-vesicles 
In mammals, autophagosome formation was reported to occur at ER 
subdomains and specifically at ER-mitochondrial contact sites (Hamasaki et 
al., 2013). The ULK complexes have been described to accumulate at ER 
subdomains rich in phosphatidylinositol (PI) synthase (Nishimura et al., 2017). 
There the ULK complexes initiate autophagosome formation. 
ATG9 containing vesicles are recruited to the site of autophagosome formation 
and are thought to be involved in the generation of the isolation membrane. In 
mammals, those vesicles cycle between the ER, the Golgi, the plasma 
membrane (through clathrin mediated-endocytosis) and recycling endosomes 
(Mercer et al., 2018; Nakatogawa, 2020). 
 
The PI3K-complexes I are then targeted to the autophagosome precursor and 
phosphorylate PI to produce phosphatidylinositol-3-phosphate (PI3P). PI3P-
binding proteins, such as the members of the WIPI family (WIPI1-4), then 
accumulate on pre-autophagic membrane (Mercer et al., 2018; Polson et al., 
2010). 
 
1.4.1.3 Membrane extension and lipidation 
The WIPI proteins bind to ATG2 and form ATG2-WIPI complexes. Those 
complexes are able to tether ER-associated membranes to the 
autophagosome precursor and promote membrane expansion (Bakula et al., 
2017; Chowdhury et al., 2018). 
In mammals, the membrane required for the expansion of the autophagosome 
can originate from the ER, Golgi, plasma membrane and recycling 
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endosomes. Lipids can originate from the ER directly through the omegasome, 
a ring shape ER-structure surrounding the isolation membrane, or through 
COPII vesicles and possibly via ER-mitochondria contact sites (Nakatogawa, 
2020). 
Another important process in autophagosomal membrane expansion is the 
lipidation of Atg8-family proteins. This 2-step process requires 1) ATG16L1 
complex formation and 2) conjugation of Atg8-family proteins to 
phosphatidylethanolamine (Hanada et al., 2007; Fujita et al., 2008; Lane and 
Nakatogawa, 2013). ATG12 is a UBL which is conjugated to ATG5 lysines by 
the E1 ATG7 and the E2 ATG10. ATG12-ATG5 can then bind ATG16L1 and 
form the ATG16L1 E3 ligase complex. The ATG16L1 complex is responsible 
for Atg8-lipidation. All Atg8-family members are UBLs and are conjugated to 
phosphatidylethanolamine’s amino group (Hanada et al., 2007; Fujita et al., 
2008; Lane and Nakatogawa, 2013). 
 
1.4.1.4 Autophagosome closure, fusion with the lysosome and 
lysosomal degradation 
Closure is thought to require membrane fission and the ESCRT machinery 
(Nakatogawa, 2020). Finally, the tethering and fusion of the autophagosome 
to/with lysosomes is mediated by SNARES (STX17, SNAP29) and is 
supported by the HOPS complex. The autophagosome content is then 
degraded by lysosomal hydrolases (Dikic and Elazar, 2018; Zhao and Zhang, 
2019). 
 
 Mechanism of selective autophagy 
In the case of nutrient starvation, autophagy is thought to be non-selective and 
engulfs part of the cytoplasm with organelles, membranes and proteins, and 
recycles them. Autophagy can also be directed towards the degradation of 
specific (or part of) organelles, protein aggregates or pathogens. In mammals, 
characterised pathways of selective autophagy include: mitophagy 
(mitochondria), pexophagy (peroxisomes), reticulophagy (ER), ribophagy 
(ribosomes), lipophagy (lipid droplets), lysophagy (lysosomes), aggregophagy 
(proteins aggregates), xenophagy (bacteria and viruses). Autophagy can also 
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target nutrients and proteins: glycophagy (glycogen), ferritinophagy (ferritin) 
(Gatica et al., 2018).   
In selective autophagy, autophagosome assembly around the autophagy 
cargo requires autophagy receptors. These autophagy receptors possess an 
LC3-interacting region (LIR) which binds the Atg8-family members LC3 and 
GABARAPs and recruits them to the autophagy cargo (Kirkin and Rogov, 
2019). This was discovered by the Johansen lab, which found that the ubiquitin 
binding protein SQSTM1/p62 could interact with LC3s and GABARAPs via a 
22 a.a. conserved motif and mediate the autophagic degradation of 
polyubiquitylated protein aggregates (Bjørkøy et al., 2005; Pankiv et al., 2007). 
Several selective autophagy receptors (SARs) can also bind to FIP200, such 
as SQSTM1 and NDP52, and thus have the ability to recruit ULK complexes 
to initiate autophagosome formation around the cargo. SARs can bind ubiquitin 
on ubiquitylated cargo or directly bind the cargoes themselves. In mammals, 
many SARs have ubiquitin binding domains (UBDs) which enables them to 
bind ubiquitylated substrates and recruit an autophagosome to ubiquitylated 
regions (Husnjak and Dikic, 2012). Other SARs function independently of 
ubiquitin binding. Such examples include membrane bound mitochondrial 
SARs: BNIP3 (OMM), BNIP3L (OMM), FUNDC1 (OMM), and BCL2L13 
(OMM), NIPSNAPs (Matrix), PHB2 (IMM), which have transmembrane 
domains as well as a LIR domain (Kirkin and Rogov, 2019).  
 
 Mitophagy pathways 
Mitophagy is the selective autophagic degradation of mitochondria. It can be 
induced by various stimuli, such as oxidative stress, mitochondrial impairment 
or damage, ion starvation (iron chelation), hypoxia or abnormal protein 
aggregation in mitochondria  (Allen et al., 2013; Ashrafi et al., 2014; Jin and 
Youle, 2013; Liu et al., 2012; Pimenta de Castro et al., 2012; Yang and Yang, 
2013; Zhang et al., 2008). 
 
Mitophagy can also be developmentally programmed. This includes the 
removal of all mitochondria from erythroblasts during erythrocyte maturation, 
the degradation of paternal mitochondria following fusion of sperm with the egg 
in mammals, as well as the elimination of glycolytic mitochondria during 
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cardiomyocyte maturation to favour a metabolic switch towards mitochondria 
adapted to a fatty acid metabolism. 
 
The best characterised pathway of mitophagy is regulated by the kinase PINK1 
and the ubiquitin E3 ligase Parkin. This pathway has been extensively studied 
due to its link to Parkinson’s disease. However, not all pathways of mitophagy 
require PINK1 and Parkin.  
Other E3 ligases were found to be involved in mitophagy instead of Parkin or 
in parallel with Parkin such as HUWE1, MUL1, MARCH5, ARIH1 (See Chapter 
V), (Koyano et al., 2019a; Rojansky et al., 2016; Strappazzon et al., 2015; Villa 
et al., 2017; Yun et al., 2014) 
There are also ubiquitin-independent pathways employing the mitophagy 
receptors mentioned above that do not possess ubiquitin binding domains. 
Hypoxia was reported to induce mitophagy through two autophagy receptor 
pathways. Firstly hypoxia promotes the expression of the mitochondrial 
autophagy receptor BNIP3L (also known as NIX) in a HIF1 (Hypoxia Inducible 
Factor)-dependent manner (Bellot et al., 2009; Zhang et al., 2008). Secondly 
hypoxia activates FUNDC1, an integral OMM protein and mitophagy receptor, 
by promoting the dephosphorylation of its LIR domain. This enables the direct 
binding of FUNDC1 to autophagosomal membranes (Chen et al., 2017; Liu et 
al., 2012). 
 
Although programmed mitophagy or acute stress, such as the complete 
depolarisation of the mitochondrial network, can lead to global mitophagy 
causing the complete removal of mitochondria from cells, localised damage 
was shown to promote bit-by-bit (also known as piecemeal) mitophagy, where 
only a portion of the network is eliminated. The mitochondrially targeted 
photosensitiser KillerRed (Mt-KR) probe can induce ROS at focal points of the 
mitochondrial network when stimulated by light. This promotes the local 
recruitment of Parkin, focal ubiquitin deposition and recruitment of LC3 and 
LAMP1 to specific puncta on mitochondria in both mammalian cells and murine 
hippocampal neurons (Yang and Yang, 2013; Ashrafi et al., 2014). Similarly, 
overexpressing a mutant form of ornithine transcarbamylase (ΔOTC) promotes 
the accumulation of misfolded ΔOTC on mitochondria and induces PINK1 
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accumulation to focal ΔOTC aggregates. This leads to the recruitment of 
Parkin to mitochondria containing ΔOTC and induces mitophagy following 
Drp1-mediated fission (Burman et al., 2017; Jin and Youle, 2013). 
 Mitochondria derived vesicles (MDVs): an alternative to mitophagy 
An alternative pathway to piecemeal mitophagy are mitochondria derived 
vesicles (MDVs). MDVs were first observed in 2008 by Heidi McBride’s group 
(Neuspiel et al., 2008). By confocal and electron microscopy, they observed 
small vesicles (~100nm) budding off from mitochondria independently of DRP1 
(Neuspiel et al., 2008). These vesicles contained the E3 ligase MUL1, 
colocalised with the retromer complex (VPS35) and fused with peroxisomes 
(Braschi et al., 2010). The transport of MUL1 to peroxisomes via the MDVs 
appeared to be dependent on the retromer complex as knocking-down VPS35 
decreased the pool of MUL1-positive peroxisomes (Braschi et al., 2010). 
Sucrose gradients, subcellular fractionations and microscopy performed in 
vitro and in vivo revealed that MDVs carry only selective mitochondrial cargo 
and exist as single membrane bound vesicles with OMM proteins such as 
VDAC or double-membrane bound vesicles (McLelland et al., 2014; 
Soubannier et al., 2012a).  
McBride’s team reported on a subset of double membrane MDVs containing 
the matrix protein pyruvate dehydrogenase (PDH) that fuse with the lysosome 
independently of ATG5, BECN1, RAB9 and LC3 (McLelland et al., 2014; 
Soubannier et al., 2012b). These MDVs were enriched in oxidised cargoes and 
their formation was stimulated following oxidative stress (ex: Complex III 
inhibitor Antimycin A treatment), (Soubannier et al., 2012a). Interestingly, the 
generation of this subset of MDVs was dependent on PINK1 and Parkin 
function and their fusion with late-endosome/lysosomes required the 
mitochondrial SNARE Stx17, SNAP29 and VAMP7 as well as the HOPS 
tethering complex (Vps39, Vps41), (McLelland et al., 2014, 2016). MDVs thus 
constitute an alternative quality control mechanism which sends oxidised 




 Rabs and mitochondria clearance 
Rabs, Rab GTPase activating proteins (GAP) and Rab Guanine nucleotide 
exchange factor (GEF) are involved in canonical and alternative pathways of 
mitophagy. 
The mitochondrial Rab7-specific GAPs TBC1D15 and TBC1D17 were shown 
to regulate autophagosome biogenesis and prevent excessive expansion of 
the autophagosomal membrane on mitochondria (Yamano et al., 2014). 
Following the ubiquitylation of OMM proteins during PINK1/Parkin mitophagy, 
RABGEF1 is recruited to damaged mitochondria through ubiquitin binding and 
recruits Rab5 and Rab7 which in turn bring ATG9 vesicles to mitochondria 
(Yamano et al., 2018). The retromer associated Rab7-specific GAP TBC1D5 
and the retromer itself were also shown to modulate the cycling of Rab7 
between the endolysosomal and mitochondrial compartments (Jimenez-Orgaz 
et al., 2018). The activity of Rab7 towards ATG9 vesicle was reported to be 
positively regulated by the phosphorylation of Rab7 at S72 by TBK1 (Heo et 
al., 2018).  
Another pathway of mitochondrial degradation involves the Parkin-dependent 
sequestration of mitochondria within Rab5-positive vesicles (Hammerling et 
al., 2017a, 2017b). The autophagic protein BECN1 mediates the activation of 
Rab5 and enables the engulfment of mitochondria in endosomes by the 
ESCRT complexes. These  vesicles are then degraded in lysosomes 
(Hammerling et al., 2017a). The autophagy adapter BNIP3 was shown to 
enhance the sequestration of mitochondria in Rab5 vesicles (Hammerling et 
al., 2017b). 
During ischemia or nutrient starvation induced mitophagy, Rab9-positive trans-
Golgi membranes were described to be recruited to damaged mitochondria 
following the phosphorylation of Rab9 at S179 by ULK1 (Saito et al., 2019). 
This pathway was shown to be BECN1 dependent and Parkin-independent. 
 
 The PINK1/Parkin pathway of mitophagy 
As described in section 1.2, PINK1 and Parkin are two PD risk genes which 
were found to be involved in a joint mitochondrial quality control pathway 
(Greene et al., 2003; Clark et al., 2006; Park et al., 2006). In 2008, Richard 
Youle’s lab revealed that triggering mitochondrial depolarisation with the 
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protonophore Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) provoked 
the redistribution of Parkin from the cytosol to depolarised mitochondria and 
promoted their autophagic degradation in mouse embryonic fibroblasts (MEF) 
and HeLa cells overexpressing Parkin (Narendra et al., 2008).  
 
1.4.6.1 Mitochondrial damage sensing by PINK1  
Genetic manipulations in Drosophila demonstrated that Pink1 acts upstream 
of Parkin (see section 1.2) (Clark et al., 2006; Park et al., 2006). This 
mitochondrial kinase serves as a sensor of damaged mitochondria and 
initiates mitophagy.  
In healthy mitochondria, the 63 kDa long PINK1 precursor is continually under 
proteolytic control (Figure 1.11). PINK1 first bind to the OMM translocase 
(TOM) complex and is imported in the IMM translocase (TIM) complex possibly 
through its N-term mitochondrial targeting signal (MTS) and in a mitochondrial 
membrane potential (Δψm)-dependent manner. Its N-terminal segment is 
cleaved by the matrix proteases MPP (mitochondrial processing protease) 
which removes the MTS, and then by PARL (presenilin-associated rhomboid-
like protein) which cleaves within the transmembrane domain (TMD) at Ala103 
into a 52 kDa protein. Finally, PINK1 is retro-translocated to the cytosol to be 
fully degraded by the proteasome (Jin et al., 2010; Deas et al., 2011; Yamano 
and Youle, 2013; Bayne and Trempe, 2019). In healthy mitochondria PINK1 
thus has a short half-life. In HeLa cells overexpressing PINK1, its half-life was 
estimated to last ~27 min (Lin and Kang, 2008). 
In dysfunctional and depolarised mitochondria, PINK1 is no longer imported in 
the TIM complex. PINK1 therefore accumulates at the TOM complex (Matsuda 
et al., 2010; Narendra et al., 2010a). This anchorage at the OMM is stabilised 
by PINK1’s OMM localisation signal and by a negatively charged triad of 
glutamic acid (112E, 113E and 117E), both flanking PINK1’s transmembrane 
domain (Okatsu et al., 2015a; Sekine et al., 2019). PINK1 stabilisation at the 
OMM upon depolarisation was also reported to be TOMM7-dependent (Sekine 
et al., 2019). PINK1 that fails to accumulate at the OMM of depolarised 
mitochondria is imported in the IMM and cleaved by the protease OMA1 




Figure 1.11: PINK1, a sensor of mitochondrial damage. 
At steady state, PINK1 is rapidly degraded by the proteasome (left). PINK1’s N-
terminal segment is imported in the mitochondrial matrix through the TOM and TIM 
complexes and cleaved by the proteases PARL and MPP. The 52kDa cleaved PINK1 
is then retrotranslocated to the cytosol and degraded by the proteasome. 
When mitochondria are impaired and depolarised, PINK1 can no longer be imported 
into the matrix and accumulates at the OMM (right). Stabilised PINK1 activates 
mitophagy by phosphorylating nearby ubiquitin at Ser65, which recruits Parkin. PINK1 
then fully activates Parkin by phosphorylating its Ubl domain at Ser65. 
 
Once stabilised at the OMM, PINK1 auto-phosphorylates at Ser228 and 
Ser402, and is thought to dimerise to be fully active (Aerts et al., 2015; Okatsu 
et al., 2012, 2013; Rasool et al., 2018). 
Once activated, PINK1 starts phosphorylating nearby ubiquitin at Ser65 to 
promote Parkin recruitment and activation (Kane et al., 2014; Kazlauskaite et 
al., 2014; Koyano et al., 2014). Parkin binds pS65-Ubquitin via its RING1 
domain and this releases the Ubl which was occluding its E2 binding site 
located at the RING1 (Figure 1.12), (Gladkova et al., 2018; Sauvé et al., 2018). 
PINK1 is then able to phosphorylate Parkin at the Ubl domain, which both 
liberates the catalytic RING2 domain and releases the REP element which was 
inhibiting the E2 binding site. Parkin is then fully active (Gladkova et al., 2018; 




Figure 1.12: Parkin activation by PINK1 
A) Parkin is an RBR E3 ligase which is autoinhibited at steady state. Its RING0 domain 
occludes the catalytic cysteine located in the RING2 domain while both the repressor 
element (REP) and the UBL domain obstruct the E2 binding site situated at the RING1 
domain. B) PINK1 phosphorylates nearby mitochondrial ubiquitin at Ser65 (pUb). 
Parkin is recruited to mitochondria due to its affinity for pUb and binds pUb through 
its RING1 domain. Parkin then undergoes conformational changes: it releases the 
UBL domain and thereby partially liberates the E2 binding site. C) PINK1 is then able 
to phosphorylate Parkin’s UBL domain at Ser65. In response to this, p-Parkin 
undergoes additional conformational changes. First, the RING2 domain and REP are 
released from the RING0 and RING1 domains, respectively. Those events expose 
the catalytic cysteine and the E2 binding domain. Secondly, the p-UBL binds RING0 
at its phosphate binding pocket. The linker region between p-UBL and RING0 binds 
RING0’s hydrophobic groove and acts as an activating element (ATC) by promoting 
the full release of RING2. Parkin is then fully active. 
Figure adapted from Sauvé et al., 2018 and Gladkova et al., 2018. 
 
 
1.4.6.2 Parkin-mediated ubiquitylation and feed-forward amplification of 
mitophagy 
Once recruited to mitochondria, Parkin ubiquitylates OMM proteins (Figure 
1.13). Absolute quantification (AQUA)-based proteomics have revealed that 
Parkin is able to generate most ubiquitin-linkages (Ordureau et al., 2014). 
Upon mitochondrial depolarisation, Parkin produces mainly canonical K48- 
and K63-linked ubiquitin chains and non-canonical K11- and K6-linked 
ubiquitin chains to a lesser extent in HeLa Flp-In Parkin (Ordureau et al., 2014). 
Although less abundant than canonical ubiquitin chains, K6-linked chains were 
reported to undergo the highest fold-increase following mitochondrial 
depolarisation in HEK293 and SH-SY5Y cells overexpressing Parkin 
(Cunningham et al., 2015).  
Known substrates of Parkin Include proteins of the TOM complex (TOMM5, 
TOMM20, TOMM40 TOMM70) which regulate mitochondrial protein import;  
































mitochondrial fusion and fission such as: MFN2, DNM1L or FIS1; proteins 
mediating mitochondrial transport such as MIRO1, and many others (Sarraf et 
al., 2013; Bingol et al., 2014; Cunningham et al., 2015; Rose et al., 2016; 
Martinez et al., 2017). Some of these ubiquitylated species are sent for 
proteasomal degradation (e.g.:MIRO1, TOMM20) in cell overexpressing 






Figure 1.13: Model detailing the mechanism of mitophagy activation. 
PINK1 initiates mitophagy by phosphorylating surrounding mitochondrial ubiquitin at 
Ser65 (pUb). This enables the recruitment of Parkin to the OMM due to its affinity for 
pUb. PINK1 can then activate Parkin by phosphorylating its Ubl domain at Ser65. 
Activated Parkin ubiquitylates OMM proteins such as members of the TOM complex 
(TOMM5, TOMM20, TOMM40, TOMM70). This serves as a platform for the 
recruitment of autophagy receptors (NDP52, OPTN, TAX1BP1, NBR1 or SQSTM1). 
Those receptor proteins bind ubiquitin via their UBDs and bind to the LC3-containing 
autophagosomal membrane through their LIR domain. The mitochondrion is then 
enveloped in the autophagosomal membrane and subsequently undergoes lysosomal 
degradation. USP30 is thought to oppose mitophagy by deubiquitylating Parkin 
substrates, although more recent models suggest a role for USP30 upstream of 




































The remaining ubiquitylated substrates enable the recruitment of the 
autophagosome thanks to autophagy receptors (NDP52/CALCOCO2, OPTN, 
TAX1BP1, NBR1 and SQSTM1/p62) (Heo et al., 2015; Lazarou et al., 2015; 
Moore and Holzbaur, 2016). As described above, these receptor proteins bind 
ubiquitin via their UBDs (UBA for SQSTM1 and NBR1, UBAN for OPTN and 
UBZ for both NDP52 and TAX1BP1) and also possess LC3-interacting regions 
(LIR) with which they attach to LC3-containing autophagosomes (Husnjak and 
Dikic, 2012). SQSTM1 has been reported by various research teams to 
accumulate on depolarised mitochondria (Geisler et al., 2010; Narendra et al., 
2010b; Okatsu et al., 2010; Wong and Holzbaur, 2014). However, the binding 
of SQSTM1 to ubiquitin was described as non-essential for mitophagy 
(Narendra et al., 2010b; Wong and Holzbaur, 2014). Youle’s group tested if 
any of the five autophagy adaptors cited above were essential for mitophagy 
by engineering pentaKO HeLa cells (Lazarou et al., 2015). They found that 
only NDP52 and OPTN overexpression could alone rescue mitophagy. The 
single KO of any of the adaptors did not affect mitophagy. The doubleKO of 
NDP52 and OPTN strongly inhibited mitophagy and more so when combined 
with TAX1BP1 KO (Lazarou et al., 2015). Intriguingly, Noriyuki Matsuda’s 
group found that OPTN and NDP52 had a lower affinity than NBR1 and 
SQSTM1 for all ATG8 proteins (Yamano et al., 2020). Instead, OPTN could 
bind efficiently to ATG9A via its leucin zipper domain and recruits ATG9A-
containing vesicles to ubiquitylated mitochondria during mitophagy (Yamano 
et al., 2020). Richard Youle’s team found that NDP52 binds to FIP200, a 
member of the ULK autophagy initiating complex, via its SKIP carboxyl 
homology (SKICH) domain and directs the ULK complex to mitochondria to 
induce mitophagy (Vargas et al., 2019). The OPTN-ATG9A and NDP52-
FIP200 axes thus enable de novo biogenesis of autophagosome to 
mitochondria (Yamano and Youle, 2020). 
The kinase TBK1 is also recruited to mitochondria during mitophagy and 
phosphorylates NDP52, OPTN and SQSTM1 (Heo et al., 2015; Moore and 
Holzbaur, 2016; Richter et al., 2016). The phosphorylation of OPTN and 
NDP52 enhances their affinity for ubiquitin and therefore increases mitophagy 
efficiency (Heo et al., 2015). Furthermore, TBK1 facilitates the interaction 
between NDP52 and FIP200 (Vargas et al., 2019), but does not affect the 
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binding of OPTN to ATG9A (Yamano et al., 2020). Thanks to the autophagy 
adaptors the ubiquitylated mitochondrion is then wrapped in the 
autophagosomal membrane which then fuses with the lysosome to proceed 
with mitochondrial degradation (Bayne and Trempe, 2019).  
 
1.4.6.3 USP30 opposes Parkin 
As mitophagy is a process regulated by ubiquitin our team and others have 
searched for DUBs opposing Parkin. Bingol and colleagues screened Flag-
tagged DUBs and found that the overexpression of USP30 antagonised 
mitophagy in SH-SY5Y and HeLa cells treated with CCCP (Bingol et al., 2014). 
At the time, USP30 was known to be a mitochondrial DUB, anchored at the 
OMM and facing the cytosol (Nakamura and Hirose, 2008). Its function was 
still poorly understood and it was associated with mitochondrial fusion and 
fission dynamics and HGF-dependent cell scattering (Buus et al., 2009; 
Nakamura and Hirose, 2008). Baris Bingol and his team discovered that 
USP30 delayed mitophagy by opposing the ubiquitylation of Parkin substrates 
(TOMM20 and MIRO1), in Parkin overexpressing cells (Bingol et al., 2014). 
They also performed ubiquitylomic experiments in HEK293 cells either 
overexpressing Parkin or expressing USP30 shRNA. These mass 
spectrometry experiments suggested that FKBP8, MUL1, PTRH2 (also called 
PTH2) and PRDX3 were common mitochondrial substrates of Parkin and 
USP30 (Bingol et al., 2014). Shortly after, our lab and others confirmed that 
TOMM20 was a bona fide substrate of USP30 and that USP30 opposed the 
autophagic degradation of mitochondrial content (Liang et al., 2015; Wang et 
al., 2015). Amos further demonstrated that CCCP-mediated ubiquitylation of 
OMM proteins lead to both their lysosomal and proteasomal degradation, in 
Parkin overexpressing cells. In those cells, mitophagy induction with CCCP 
was also accompanied by high levels of apoptosis which could be antagonised 
by PINK1 KD or proteasome inhibition. Excessive OMM protein ubiquitylation 
and their subsequent extraction for degradation possibly disrupts 
mitochondrial membranes and causes apoptosis. Interestingly, Amos revealed 
that USP30 opposed this CCCP-mediated BAX/BAK independent apoptosis 
whilst its depletion could sensitise a variety of mammalian cells to BH3 
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mimetics (Liang et al., 2015). USP30 thus potentially has anti-apoptotic 
functions independently of its role in mitophagy. 
Jacob Corn and colleagues assessed whether USP30 presented ubiquitin 
chain preferences. They found that in vitro, USP30 efficiently cleaved K6 and 
K11 ubiquitin chains. Moreover, in HEK293 overexpressing Parkin, USP30 KO 
specifically enriched K6 ubiquitin chains by 5-fold (Cunningham et al., 2015). 
Malte Gersch, in David Komander’s lab,  confirmed these observations in vitro, 
used K6-affimers to show that USP30 could remove K6-linked ubiquitin from 
TOMM20 in HeLa expressing Parkin and further expanded on USP30’s affinity 
for K6-linked chains by providing the crystal structure of USP30 in complex 
with K6-diUb (Gersch et al., 2017). 
 
1.4.6.4 Alternative DUBs involved in mitophagy 
To date, USP30 is the only DUB known to constitutively localise at 
mitochondria. However other deubiquitylating enzymes were reported to affect 
mitophagy. 
Several members of the USP family modulate the localisation of Parkin. 
USP33, which shuttles between the ER and the Golgi, was found to overlap 
with mitochondrial staining and to deubiquitylate Parkin at K435 (Niu et al., 
2019). USP33 likely controls Parkin ubiquitylation from mitochondria-
associated membranes in the ER and hinders the recruitment of Parkin to 
mitochondria. Likewise, the endosomal DUB USP8 was shown to 
deubiquitylate Parkin (Durcan et al., 2014). Unlike USP33, USP8 accelerated 
the recruitment of Parkin to mitochondria by removing K6-linked ubiquitin 
chains from Parkin (Durcan et al., 2014). USP36, a nucleolus residing DUB, 
was also reported to facilitate the relocation of Parkin from the cytosol to 
mitochondria, possibly through transcriptional regulation (Geisler et al., 2019). 
 
A small pool of USP15, which is a predominantly cytosolic DUB (Urbé et al., 
2012), was found to be enriched in mitochondrial fractions (Cornelissen et al., 
2014). USP15 was shown to decrease the deposition of ubiquitin on 
mitochondrial fractions and to oppose the degradation of damaged 
mitochondria in cells overexpressing Parkin. Interestingly, the Vandenberghe 
group found that mitophagy is enhanced in the flight muscles of WT aged flies 
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(4-week-old) compared to young flies (1-week-old). This increase in mitophagy 
with age was not observed in Parkin RNAi or Pink1 mutants. They find that 
knocking-down CG8334, which they describe as “Drosophila Usp15”, rescues 
this impairment (Cornelissen et al., 2018a). It is however important to note that 
CG8334 is more homologous to human USP32 rather than USP15 (see 
FlyBase; (Clague et al., 2013, 2019)). 
Finally, McQuibban’s team reported on a putative short isoform of USP35 (N-
terminal truncation of 468 residues) localising on polarised mitochondria with 
its unique N-terminal mitochondrial targeting sequence (Wang et al., 2015). 
Depleting USP35 (all USP35 isoforms) was shown to increase the 
ubiquitylation and degradation of OMM proteins as well as raise mitolysosome 
density during CCCP-induced mitophagy. However, the short-USP35 variant 
is missing part of the catalytic domain and the catalytic cysteine (Wang et al., 
2015). Thus, mitophagy inhibition could have been mediated by the non-
mitochondrial USP35 variants (located at the ER, lipid droplets and cytosol) or 
could be caused by a scaffolding function of short-USP35. 
 
1.5 Drosophila melanogaster 
 
 Major breakthrough discoveries made using Drosophila 
melanogaster  
Drosophila melanogaster is a model organism which has been used for over a 
century.  
Charles William Woodworth was the first scientist to breed and recommend 
the use of Drosophila for research purposes in the early 1900’s (Markow, 
2015). Using Drosophila, Thomas H. Morgan described the role played by 
chromosomes in heredity, work for which he earned a Nobel prize in 1933 
(First book published on the subject: (Morgan et al., 1915)), (Morgan, 1933). 
His success brought much attention to this model, which became the most 
employed model organism in that era. In 1946 his colleague Hermann Muller, 
received a Nobel prize "for the discovery of the production of mutations by 
means of X-ray irradiation" (Muller, 1946, 1927). Both bodies of work had an 
immense impact on modern genetics. Subsequently, Nobel prizes were 
awarded to Edward B. Lewis, Christiane Nüsslein-Volhard, Eric F. Wieschaus 
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for their discoveries on “the genetic control of early embryonic development” 
in 1995, then to Richard Axel for his “discovery of odorant receptors and the 
organization of the olfactory system”, next to Jules A. Hoffmann for his insight 
in ”the activation of innate immunity” in 2011 and then recently to Jeffrey C 
Hall, Michael Rosbash and Michael W Young for “discoveries of molecular 
mechanisms controlling the circadian rhythm” in 2017 (Hall et al., 2017; 
Hoffmann, 2011; Lemaitre et al., 1996; Lewis, 1978; Lewis et al., 1995; 
Nüsslein-Volhard and Wieschaus, 1980; Axel, 2004; Vosshall et al., 1999). 
 
 Advantages:  
The success of Drosophila as a model organism is based on the following key 
points: they have a rapid life cycle, produce many progenies, can easily be 
genetically manipulated, are affordable and are low maintenance. 
 
 Life cycle of Drosophila melanogaster 
Drosophila melanogaster have a rapid life cycle. It takes roughly 10 days from 
fertilisation to obtain a mature adult (Figure 1.14), (Ashburner and Thompson, 
1978). Key stages of Drosophila development include: the embryonic stage, 
followed by three larval stages (1st instar, 2nd instar and 3rd instar larvae), the 
pupal stage and finally the adult stage. 
Embryogenesis comprises 17 Drosophila embryonic stages and lasts for ~24h 
at 25ºC (Campos-Ortega and Hartenstein, 1997), (see also: The Interactive 
Fly website). The eggs then hatch into a 1st instar larva which molts 25h later 
into a 2nd instar larva and then molts a second time, after 24h, into a 3rd instar 
larva (Tyler, 2000). The 1st, 2nd and early 3rd stage instar larvae feed on and 
burrow into the substrate they were laid on (foraging behaviour). The 3rd instar 
larva is the largest larval stage; once mature the larva stops feeding and crawls 
out of the medium (wandering” behaviour), and prepares itself for pupation 
(Sokolowski et al., 1984).  Pupation occurs ~120h after fertilisation. During 
pupation the Drosophila undergoes morphogenesis until it ecloses, ~9-10 days 
later, into an adult fly (Bainbridge and Bownes, 1981). Adult females start 
mating ~12h following eclosion (Ashburner and Thompson, 1978). At their 
peak of fertility (4-7 day-old adults) females lay 50-70 eggs per day (Tyler, 
2000). In total, adult Drosophila can live up to 10 weeks (Tyler, 2000). 
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As Drosophila are ectotherms, their development fluctuates with temperature. 
As stated above, at 25ºC the development to an adult can take 9-10 days whilst 
at 10ºC it can take up to 57days. Conversely, high temperature accelerate their 






Figure 1.14: Life cycle of Drosophila melanogaster 
At 25ºC, embryogenesis lasts for ~24h. The egg hatches into a larva which undergoes 
two molts (first, second and third instar larva). Five days post fertilisation, the third 
instar larva forms a pupa and undergoes morphogenesis. Eclosion happens on 
average ten days after fertilisation of the egg and produces a mature adult fly. 
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 Drosophila genome 
The genome of Drosophila melanogaster is ~180 Mb long with 1/3 of 
heterochromatin. Their genome is distributed in four pairs of chromosomes 
containing ~13,600 genes (Figure 1.15). They have a pair of sex 
chromosomes (XX for females and XY for males) and three pairs of autosome 
chromosomes (Adams et al., 2000). The Y chromosome is mostly constituted 
of heterochromatin and Y-linked genes are believed to result from autosomal-
to-Y transposition. Indeed, the few protein coding genes it contains have 
paralogs in autosomal genes. These Y-linked genes were reported to be 
involved in male fertility (Carvalho et al., 2015). Approximatively 80% of the 
euchromatin is located on the autosomal chromosomes I and II (Adams et al., 
2000). Chromosome IV is much smaller than its counterparts and contains only 
1.2 Mb of euchromatin. As protein coding genes are mainly located on two 
pairs of chromosomes and are less redundant than in mammals this greatly 




Figure 1.15: Chromosomes of Drosophila melanogaster. 
Schematic representation of D. melanogaster’s sexual (X and Y) and autosomal 
chromosomes (II, III and IV). The length of euchromatin and heterochromatin are 














 Drosophila, a model to study disease 
Although the Drosophila genome is simpler than the human genome, it is 
estimated that 77% of human disease associated genes have orthologues in 
Drosophila (Reiter et al., 2001). As an example, Drosophila possess 
orthologues of the PD-causing genes PARK2/PRKN (park/CG10523 in 
Drosophila) and PINK1/Park6 (Pink1/CG4523). Mutations in those genes 
promote disease-phenotypes reminiscent of human PD in Drosophila such as 
locomotor defects or neurodegeneration (Greene et al., 2003; Clark et al., 
2006; Park et al., 2006). These early Drosophila studies were key to 
understand the role of PINK1 and Parkin. They revealed that PINK1 and Parkin 
were genetically linked and paved the way for all of the subsequent studies on 
the PINK1/Parkin pathway of mitophagy. Interestingly, drosophila also express 
the mitochondrial DUB Usp30 (CG3016 for drosophila), (Tsou et al., 2012). 
 
 UAS-GAL4 system in Drosophila: 
The UAS-GAL4 system enables the targeted expression of a gene of interest. 
It was first developed for mammalian cells by Hitoshi Kakidani and Mark 
Ptashne and by Nicolas Webster and Pierre Chambon (Kakidani and Ptashne, 
1988; Webster et al., 1988). Andrea Brand and Norbert Perrimon then adapted 
it to Drosophila melanogaster (Brand and Perrimon, 1993). GAL4 is a yeast 
regulatory protein which binds to upstream activating sequences (UAS) to 
activate the expression of genes linked to UAS. Mark Ptashne’s group showed 
that the yeast GAL4 could similarly activate transcription in Drosophila 
melanogaster (Fischer et al., 1988). Andrea Brand and Norbert Perrimon 
developed a two-piece system with “GAL4-driver” lines and “UAS-reporter” 
lines (Figure 1.16), (Brand and Perrimon, 1993). The GAL4-driver lines have 
the GAL4 encoding gene in the vicinity of tissue-specific enhancer or promoter 
whilst the UAS-reporter line has the UAS sequence followed by at gene of 
interest. When the GAL4 and UAS lines are crossed they produced F1 
progenies expressing the gene of interest in the selected tissues. Interestingly 
this method also enables temporal regulation of gene expression as GAL4-
drivers’ expression can be restricted to specific developmental stages. Further 
development of the UAS-GAL4 system allows a more refined gene expression 
with temperature sensitive GAL4 (TARGET system), ligand inducible GAL4 
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(GAL-ER or Geneswitch) or split-GAL4 (Caygill and Brand, 2016). Maintaining 
the UAS and GAL4 in separate strains allows to maintain healthy stocks in 
cases where the gene of interests produces lethal or deleterious gene 
products. This system also allows the rapid generation of a variety strains each 





Figure 1.16: The UAS/GAL4 system to target gene expression in Drosophila. 
A) Simplified representation of vectors used to generate UAS and GAL4 Drosophila 
lines by Brand and Perrimon. A1) pGaTB: the gene encoding GAL4 is preceded by a 
cloning insertion site for the subcloning of promoter sequences; A2) pGawB is an 
enhancer trap vector. It is inserted randomly into the fly genome thanks to P-element 
sequences (5’P and 3’P) driving GAL4 expression from various genomic enhancers. 
The presence of an enhancer is visualised thanks to the co-expression of the white 
eye reporter gene. A3) pUAST consists of the upstream activating sequence (UAS) 
to which GAL4 binds followed by a cloning site for the gene of interest. B) Schematic 
representation of the UAS/GAL4 system in Drosophila. To promote the tissue-specific 
expression of a gene of interest, a GAL4-“driver” fly is crossed with a UAS fly. The 
resulting F1 progeny will express GAL4 under the control of a genomic enhancer 
which will specifically drive the expression of the gene X. Figure adapted from (Brand 




 Conclusion on the use of Drosophila:  
Drosophila melanogaster is a highly interesting model for the study of USP30 
and mitophagy in vivo. It expresses orthologues of mitophagy and PD genes 
such as Pink1, park or Usp30, and genetic manipulations are straightforward. 
Pink1 and park mutants present phenotypes reminiscent of PD which means 
that it is possible to assess the effect of USP30 towards PD symptoms. 




1.6 Aims of the study and summary of chapters 
 
It is possible that mitophagy is disrupted not just in patients suffering from 
hereditary PINK1 and PARKIN loss function mutations. Mitochondrial 
dysfunctions were recorded in patients with additional hereditary mutations 
and this also extends to sporadic forms of Parkinson’s disease (Chen et al., 
2019). I thus aimed at better understanding mitophagy and finding 
pharmacological means to stimulate this pathway. Here were my three main 
objectives during this thesis: 
 
1. Unravel the mechanisms of mitophagy in a “physiological context” (basal 
mitophagy) 
2. Shed light on the array of functions and substrates of USP30 
3. Characterise a tool compound specifically inhibiting USP30  
4. Generate animal models to study mitophagy 
 
In Chapter III, I will define cellular and chemical tools available to study 
mitophagy. In chapter IV, I will describe how USP30 regulates basal mitophagy 
and pexophagy in SH-SY5Y mito-QC cells. In Chapter V, I will report on USP30 
specific inhibitors and on USP30 knock-out cells and use those tools to perform 
ubiquitylomic and proteomic analysis of USP30 substrates. Finally, in Chapter 
VI, I will characterise novel USP30 knock-out and mt-Keima expressing 
Drosophila melanogaster models. 
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Chapter 2: Materials and methods 
2.1 Cell biology 
 Materials and reagents 
The reagents employed in the cell biology experiments detailed in this thesis 
are listed in Tables 1.1, 1.2 and 1.3. 
 
Table 2.1: Cell biology reagents and resources 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Experimental Models: Cell Lines 
HCT116 ATCC #CCL-247™ 
HEK293T ECACC # 12022001 
HeLa ECACC # 93021013 
hTERT-RPE1 Gifted by Francis Barr  
(University of Oxford) 
 
hTERT-RPE1-YFP-Parkin Gifted by Jon Lane  
(University of Bristol) 
 
SH-SY5Y ECACC-Sigma Cat#94030304 
SH-SY5Y mito-QC Gifted by Ian Ganley  
(MRC-PPU, Dundee) 
 
SKN-BE2(c) Gifted by Violaine See  
(University of Liverpool) 
 
U2OS ECACC Cat# 
92022711 
U2OS mito-QC Gifted by Ian Ganley  
(MRC-PPU, Dundee) 
 
U2OS SKL-Keima Made by Aitor Martinez-
Zarate 
 
   
Medium and additives 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
Thermo Fischer Scientific #31966-021 
DMEM-F12 Thermo Fischer Scientific #31331-028 
Non-essential amino acids 
(MEM/NEAA) 
Thermo Fischer Scientific #11140-035 
Penicillin/streptomycin Thermo Fischer Scientific #15070-063 
Fetal bovine serum (FBS) Gibco #10270106 
trypsin-EDTA Invitrogen #15400 




Neurobasal™ Medium Fischer Scientific-Gibco #11570556 
N-2 Supplement Fischer Scientific-Gibco # 11520536 
Glutamax-100X Fischer Scientific-Gibco # 35050038 
   
Transfection reagents 
LipofectamineTM RNAiMAX Invitrogen #13778150 
Lipofectamine 2000 Invitrogen #11668019 
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Lipofectamine 3000 Invitrogen #L3000015 
Opti-MEM Invitrogen #409864 
GeneJuice® Transfection reagent EMD Millipore #70967 




Thermo Fischer Scientific #28908 
Triton TX-100   
Bovine serum albumin (BSA)   
Mowiol Merck Millipore #475904 
DAPI Invitrogen #D1306 
μ-Dish 35mm high Ibidi # 81156 
   
Plasmids 
pEGFP-N3-USP30 Clague-Urbé lab  
pEGFP-N3-USP30-C77S Clague-Urbé lab  
pRFP-N3-hmUSP30 Clague-Urbé lab  
pRFP-N3-hC77S-mUSP30 Clague-Urbé lab  
pCMV6-myc-ddk-hmUSP30 Clague-Urbé lab  
pCMV6-myc-ddk-hC77S-mUSP30 Clague-Urbé lab  




pCDNA3.1 TagBFP-SKL Clague-Urbé lab  
   
Kits 
CellTiter-Glo Assay Promega #G7571 
 
Table 2.2: siRNA list 









































USP30 (D1) Custom order CAAAUUACCUGCCGCACAAUU 
USP30 (D3) D-021294-03 ACAGGATGCTCACGAATTA 
 
Table 2.3: List of Antibodies used in Immunofluorescence assays 
Primary Antibodies for Immunofluorescence 
TARGET (Species) SOURCE IDENTIFIER Incubation condition 
Catalase (Rb) Abcam #ab1877 1:750, 1h 
USP30 (Rb) 
Gifted by Baris 
Bingol 
(Genetech, USA) 
 1:100, 1h 
PMP70 (Ms) Sigma  #SAB4200181 1:500, 1h 
TIMM44 (Rb) Sigma #HPA043052 
1:250* or 1:500, 
1h 
Myc (Ms) BD Biosciences #51826 1:500, 1h 
pUb S65 (Rb) Millipore #ABS1513-I 1:500, 1h 
TOMM20 (Rb) Sigma  #HPA011562 
1:250* or 1:500, 
1h 
TOMM20 (Ms) BD Biosciences #612278 1:500, 1h 
    
Secondary Antibodies 
TARGET (Species) SOURCE IDENTIFIER Incubation condition 
Donkey anti-rabbit AF488 Invitrogen #A21206 1:500, 45min 
Donkey anti-mouse AF488 Invitrogen #A21202 1:500, 45min 
Donkey anti-rabbit AF594 Invitrogen #A21207 1:500, 45min 
Donkey anti-mouse AF594 Invitrogen #A21203 1:500, 45min 
Donkey anti-rabbit AF647 Invitrogen #A32795 1:250, 45min 
Donkey anti-mouse AF647 Invitrogen #A32787 1:500, 45min 
*Higher antibody concentration (1:250) were used when conjugated with Far 
red secondary antibodies 
 
 Cell culture 
SH-SY5Y, hTERT-RPE1 YFP-Parkin and hTERT-RPE1 cells were grown in 
DMEM-F12 whilst U2OS and HeLa cells were grown in DMEM. Both media 
were supplemented with 10% heat-inactivated FBS, 1% NEAA and 1% 
Penicillin/streptomycin. The cells were cultured in a humidified incubator at 5% 
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CO2 atmosphere maintained at 37ºC and split upon confluency at 
concentrations ranging from 1:2 to 1:8 as required. 
 
 siRNA transfection 
Cells were seeded in 6-well plates: 3x105 cells per well for SH-SY5Y cells and 
2.5x105 cells per well for hTERT-RPE1 YFP-Parkin cells. 24h later the medium 
was exchanged in each well for 830µl of fresh medium without additives. The 
RNAi transfection reagent (RNAiMAX) and siRNA oligonucleotides were 
separately incubated with Opti-MEM for 5 min at RT as shown in table 1.4. 
Solutions A and B were then mixed at a 1:1 ratio, incubated further for 20min 
at RT and then added to the cells to obtain a final siRNA oligo concentration 
of 40nM. The medium was exchanged 24h later for 2ml of fresh medium with 
additives (10% FBS, 1% NEAA, 1% Penicillin/Streptomycin) and the 
transfected cells analysed after 72h of transfection, unless otherwise specified 
in the figure legends. In the specified experiments performed in the SH-SY5Y 
cells, cells were split at 24 hours following the first siRNA transfection at a 1:3 
ratio into fresh 6-well plates and a second siRNA transfection was performed 
as above (72h after the first transfection) for a total of 144 hours of depletion 
prior to analysis. 
 
Table 2.4: siRNA transfection procedure 
Solution A Solution B 
Reagent  Volume Reagent  Volume 
RNAiMAX 2µl Oligonucleotide 
(20µM) 
2µl 
Opti-MEM 83µl Opti-MEM 83µl 
 
 plasmid DNA transfection 
Cells were seeded into 6-well plates, left to recover overnight and transfected 
the following day. U2OS and hTERT-RPE1 cells were transfected using the 
GeneJuice transfection reagent at a 3:1 ratio (3µl reagent for 1µg plasmid 
DNA) whilst SH-SY5Y cells were transfected with Lipofectamine 2000 at a 24:5 
ratio (12µl reagent for 2.5µg plasmid DNA). The transfection procedures were 
performed according to the manufacturers’ instructions. Briefly, GeneJuice and 
Opti-MEM were mixed together for 5 min then the mixture was supplemented 
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with the plasmid DNA and was finally left to incubate at RT for 20 min (see 
table 1.5). When using Lipofectamine two solution were first made: 
Lipofectamine diluted in Opti-MEM (A) and plasmid DNA diluted in Opti-MEM 
(B) (see table 1.5).  The solutions were left to incubate for 5 min, they were 
then mixed at a 1:1 ratio and finally incubated at room temperature for 20 min. 
In both cases, the resulting mixtures were directly added to the cells and 
incubated for 24h. 
 
Table 2.5: Plasmid DNA transfection procedure 
RPE1, U2OS SH-SY5Y 
Reagent  Volume/ 
Mass 







Opti-MEM 100µl Opti-MEM 238µl 
Plasmid DNA 1µg B Plasmid DNA 2.5µg   Opti-MEM 247.5µl 
 
 Microscopes 
Confocal microscopes: a) 3i Marianas spinning disk confocal microscope with 
10x dry, 40x NA 1.3 oil and 63x NA 1.4 oil objectives. The microscope is 
equipped with a Hamamatsu Flash 4 sCMOS camera and a Photometrics 
Evolve EMCCD camera. The acquisition software used is the Slide Book 3i v3. 
b) Zeiss LSM800 with Airyscan confocal microscope equipped with 63x NA 1.4 
oil objective and using the Zen acquisition software. 
 
Epifluorescence microscopes: a) Leica MZ10 F modular stereo microscope 
with 8x-80x magnification (used to screen Drosophilas). 
b) Nikon Ti-Eclipse inverted microscope equipped with 10x dry N.A. 0.3, 20x 
dry N.A. 0.45, 40x dry N.A. 0.95 and 60x oil N.A. 1.4 objectives. This 
microscope was used in combination with the NIS-elements imaging software. 
 
 Immunofluorescence 
Cells were seeded into 6-well plates containing 22x22mm coverslips. For 
immunofluorescence they were first rinsed twice in PBS and then fixed using 
4% paraformaldehyde (PFA) in PBS for 15min. Once the PFA was discarded, 
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they were washed twice in PBS and the remaining free aldehyde groups were 
quenched by a 5min incubation in 50mM ammonium chloride in PBS. The 
coverslips were again washed twice in PBS and then permeabilised using 
0.2% Triton X-100 in PBS for 5min. Following two PBS washes, the coverslips 
were blocked for 30min in 3% bovine serum albumin (BSA) in PBS. The 
primary antibodies were diluted in 3% BSA/PBS as described in Table 1.3 and 
added to the cells for 1h at RT. Following two PBS washes the coverslips were 
incubated with the secondary antibodies for 45min. Finally, the coverslips were 
washes three times in PBS, then once in Millipore water and mounted onto 
glass slides using Mowiol, supplemented with DAPI (1:200) where indicated. 
 
 Live cell imaging 
Live cell imaging experiments were performed using the 3i Marianas spinning 
disk confocal microscope, the EMCDD camera and the 40x or 63x oil 
objectives (see section 1.1.5). Cells were grown in 35mm μ-Dishes (Ibidi) and 
the imaging was performed in a humidified chamber at 37ºC supplied with 5% 
CO2.  
 
 Mitophagy analysis in mito-QC expressing cells 
2.1.8.1 Quantitation using Fiji 
The images were acquired randomly and analysed using Fiji (Image J) v2.0.0. 
A region of interest (ROI) was drawn around each cell and saved using the 
“ROI manager” function. Then the GFP signal was subtracted from the 
mCherry signal using the “Image Calculator” function. The image obtained 
from the subtraction was then processed into a binary image, showing only the 
mitolysosomes (“red-only” dots), using the Threshold tool. The number and 
area of mitolysosomes per ROI was measured with the “Analyse Particles” 
function. 
 
2.1.8.2 Manual quantitation 
All images were processed using Fiji (Image J) v2.0.0. Then the number of 
cells undergoing mitophagy (= cells with more than three mitolysosomes) were 
visually assessed and counted over the total number of cells per image.  
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 SH-SY5Y cell differentiation into dopaminergic-like neurons 
2.1.9.1 Protocol#1 (RA and TPA) 
SH-SY5Y cells were grown in 6-well plates or Ibidi dishes to a confluence of 
70%. The medium was exchanged for “low FBS medium” (1% FBS, 1% NEAA, 
1%P/S) and supplemented with 10µM retinoic acid (RA). The cells were 
treated with RA up to 72h (with media/RA exchange at 48h). The cells were 
then grown in “low FBS medium” supplemented with 80nM 12-O-
tetradecanoyl-phorbol-13-acetate (TPA) for another 72h (with media/TPA 
exchange at 48h). 
 
2.1.9.2 Protocol#2 (RA and N2 differentiation media) 
This protocol was provided by Heather Mortiboys (SITraN, Sheffield). SH-
SY5Y cells were seeded at a density of 6x103 cells/cm2. They were cultured 
for 48h before switching to N2 differentiation media (49.5% DMEM-F12 
Medium, 49.5% Neurobasal Medium, 0.5% N2 supplement, 0.5% GlutaMax) 
supplemented with 10µM RA. The cells were incubated in this media for 7days 
with 50% of the media being replaced every 2-3 days. 
 
 Keima pH titration 
U2OS-SKL-Keima cells were grown in DMEM, the medium was then 
exchanged for buffers with pH ranging from pH8 to pH4 (143mM KCl, 1.17mM 
MgCl2, 1.3mM CaCl2, 5mM Glucose). The K+/H+ ionophore nigericin was 
added at 10μM to each buffer in order to equalises the extra- and intra-cellular 
pH. Finally, the cells were incubated with 50mM NH4Cl (Adapted from: 
(Despras et al., 2015)).The cells were equilibrated for 5min and imaged in 
between each buffer exchange using a 3i spinning disk confocal microscope 
(Em445/Ex610 then Em561/Ex610). Images were analysed using 
“pixelAnalysis” plugin coded by Dave Mason (CCI, University of Liverpool) for 
the FIJI. 
 
 Image processing 
Images were processed either in Adobe Photoshop CC (2019) or in 
Omero.web version 5.5. Figures were assembled on Adobe Illustrator (2019). 
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 CellTitre-Glo Luminescence assay 
Cells were seeded in the wells of a black clear bottom 96-well plate (Corning) 
at a density of 3 x105 cells per well. The following day, the medium was 
exchanged and replaced with 100µl media with 1.5 µM oligomycin or 50 mM 
2-deoxyglucose or the combination of both or untreated. After 30min, 100µl of 
assay solution (CellTitre-Glo Reagent) was added to each well. The plate was 
shaken at 250 rpm for 2 min to induce cell lysis then incubated at RT for 10 
min covered in foil. Luminescence was measured on a GloMax®-Multi 
Detection System (Promega) with the built-in Promega protocol. 
 
2.2 Biochemistry 
 Materials and reagents 
The reagents employed in the biochemistry experiments detailed in this thesis 
are listed in Tables 1.6 and 1.7. 
 
Table 2.6: Biochemistry reagents and resources 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Commercial Assays 
BCA Protein Assay (Pierce) Pierce Biotechnology #23225 
Bovine IgG Sigma-Aldrich #I9640 
2-mercaptoethanol Sigma-Aldrich #M6250 
   
Inhibitors   
Protease inhibitor cocktail Sigma-Aldrich P8340 
PhosSTOP (phosphatase inhibitor tablets) Roche-Sigma #4906837001 
   
Tools 
Cell cracker homogeniser EMBL, Heidelberg  
XCell SureLock Mini-Cell System Thermo Fischer 
Scientific 
#EI0001 
XCell SureLock Midi-Cell System Thermo Fischer 
Scientific 
#WR0100 
Genie Blotter with Platinized Titanium 
Anode, 15 x 17 cm 
IDEA Scientific 
company (MN, USA) 
#4003 
   
Buffers 
Tris- Acetate SDS running buffer Invitrogen #LA0041 
NuPAGE MOPS Invitrogen #NP0001-02 
NuPAGE MES Invitrogen #NP0002-02 
   
Precast gels and molecular weight markers 
NuPAGE Bis-Tris 4-12% gels 10 wells 1mm Invitrogen #NP0321BOX 
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NuPAGE Bis-Tris 4-12% gels 10 wells 
1.5mm 
Invitrogen #NP0303BOX 
NuPAGE Bis-Tris 4-12% gels 20 wells 1mm Invitrogen #W61402A 
NuPAGE 3-8% Tris-Acetate gels 20 wells 
1mm 
Invitrogen #EA0375BOX 
Prestained broad range molecular weight 
marker 
New England Biolabs #P7708S 
Full range molecular weight marker rainbow Invitrogen #11580684 
Unstained broad range molecular weight 
marker 
New England Biolabs #P7702S 
   
Other 
Marvel skimmed milk powder Marvel  
Amersham Protran 0.45μm nitrocellulose 
membrane 
GE healthcare #10600002 
Ponceau S Sigma-Aldrich #P7170 
Gelatin from cold water fish skin Sigma-Aldrich #G7765 
 
Table 2.7: Antibodies used for western blotting analysis 
Primary Antibodies for western blotting 
TARGET (Species) SOURCE IDENTIFIER Incubation condition 
Actin (Ms) Abcam Ab6276 
1:10 000, 30 
mins 
Actin (Rb) Sigma A2266 
1:10 000, 
30min  
Actin (Ms) ProteinTech 66009-1-Ig 
1:10 000, 
30min 
Actin (Rb) ProteinTech 20536-1-AP 
1:10 000, 
30min 
Catalase (Rb) Abcam ab1877 1:2000, O/N 
Cullin1 (Rb) Invitrogen 71-8700 1:1000, O/N  
Cullin3 (Rb) Bethyl A301-109A 1:2000, 1h 
FBXO7 (Rb)  Aviva OAAN03680 1:1000, O/N 
FIS1 (Rb) Proteintech 10956-1-AP 1:1000, O/N 
FKBP8 (Ms) RD systems MAB3580 1:1000, O/N 
GFP (Sheep) 
gift from Prof. Ian 
Prior (University of 
Liverpool)  1:5000, 1h 
HSP60 (Goat) Santa cruz sc-1052 1: 2000, O/N 
HUWE1 (Rb) Bethyl A300-486A 1:2000, O/N 
Keima (Ms) MBL M126-3 1/500, O/N 
MAGEA10 (Rb) Proteintech 15295-1-AP 1:1000, O/N  
MARCH5 (Rb) Milipore 06-1036 1:1000, O/N 
MIRO1 (Rb) Sigma  HPA010687 1:1000, 1h 
Mitofusin 1 and 2 (Ms) Abcam ab57602 1:1000, O/N 
Mitofusin 2 (Ms) Abcam ab5688 1:1000, O/N 
Mul1 (Rb) Invitrogen PA5-29550 1:1000, O/N 
OPA1 (Rb) Abcam ab42364 1:1000, O/N 
Optineurin C-term (Rb) Cayman Chemical 100000 1:1000, O/N 
p62 (Ms) 
BD Transduction 
Lab 610833 1:1000, O/N 
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Parkin (Ms) Santa Cruz sc32282 1:250, O/N 





PARP p85 fragment (Ms) Cell Signalling 9546 1:2000, O/N 
PEX19 (Rb) Invitrogen PA5-22129 1:1000, O/N 
PEX5 (Rb) Novus Biologicals NBP-87185 1:1000, O/N 
PINK1 (Rb)  Cell Signalling 6946S 1:1000, O/N 
PMP70 (Ms) Sigma  SAB4200181 1:1000, O/N 
PRDX3 (Ms) Sigma SAB1407075 1:1000, O/N 
pUb S65 (Rb) Millipore ABS1513-I 1:1000, O/N 
SYNGR3 (Rb) Abcam ab113712 1:1000, O/N 
TOMM22 (Ms) Sigma sc-58308 1:1000,1h 
TOMM20 (Rb) Sigma  HPA011562 1:1000,1h 
TOMM20 (Rb) ProteinTech 11802-1-AP 1:2000, O/N  
TOMM7 (Rb) ProteinTech  15071-1-AP Try 1:500, O/N 
⍺-Tubulin (Ms) Sigma T5168 1:10 000,  O/N 
Ubiquitin "VU-1" (Ms) LifeSensor VU101 1:2000, O/N 
USP30 (Rb) Sigma-Atlas HPA016952 1:500, O/N 
USP30 (Sheep) MRC Dundee N/A 1:1000, O/N 
USP33 (Ms) Sigma WH0023032M1 1:1000, 1h 
VDAC (Rb) Cell Signaling 4866 1:1000, O/N 
VDAC1 (Ms) Abcam ab14734 1:1000, O/N 
Vps35 (Goat) Abcam ab10099 1:1000, O/N 
    
Secondary Antibodies 
TARGET (Species) SOURCE IDENTIFIER Incubation condition 
Donkey anti-mouse IRDye 
800CW LICOR 926-32212 1:10 000, 1h RT 
Donkey anti-mouse IRDye 
680CW LICOR 926-32222 1:10 000, 1h RT 
Donkey anti-rabbit IRDye 
800CW LICOR 926-32213 1:10 000, 1h RT 
Donkey anti-rabbit IRDye 
680CW LICOR 926-32223 1:10 000, 1h RT 
Donkey anti-sheep IRDye 
800CW LICOR 926-32214 1:10 000, 1h RT 
Donkey anti-sheep IRDye 
680CW LICOR 926-32224 1:10 000, 1h RT 
 
 
 Mammalian cell lysis 
Regular lysis was performed on a metal plate on ice to maintain the cells ice-
cold. The cells were washed twice in 4ºC PBS and were further incubated with 
either RIPA buffer (10mM Tris-Cl pH 7.5, 150mM NaCl, 1% triton X-100, 0.1% 
SDS, 1% sodium deoxycholate) or NP40 buffer (25mM Tris-Cl pH 7.5, 100mM 
NaCl, 0.5% NP40, 50mM NaF) and rocked on ice for 10min. Both buffers were 
supplemented with mammalian protease inhibitors (1:250) and phosphatase 
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inhibitors tablets (Roche) where indicated. The lysates were then clarified by 
centrifuging at 14,000g for 5min at 4ºC in a table-top centrifuge to pellet out 
any cell debris. 
For hot lysis, cells were washed twice in PBS at 37ºC and then incubated with 
boiling lysis buffer (2% SDS, 1mM EDTA, 50mM NaF) on a dry-heat block at 
110ºC. The lysates were then scraped with a cell scraper (Greiner), collected 
into 2ml screw-cap tubes (Corning) and further boiled at 110ºC for 10min with 
intermittent harsh vortexing every 2 min. 
 
 Protein assay and sample preparation 
Protein concentration was determined using the Pierce BCA Analysis kit 
following manufacturer’s instructions. Briefly, a 6-point standard curve was 
generated using bovine IgG (Sigma) (1mg.ml-1) in a 96 well plate, (see Table 
1.8). The samples were loaded as triplicates and each standard curve point as 
duplicates. The BCA Reagents A and B were mixed together (50:1 ratio) and 
added to all of the wells. The plate was then incubated for 30min at 37ºC and 
then scanned at OD562 on a Thermo Labsystems Multiskan spectrum plate 
reader.  
The samples were all adjusted to a common concentration using the same 
lysis buffer used in the lysis and prepared in 5X sample buffer (15% SDS, 
321.5mM Tris-HCl pH6.8, 50% Glycerol, 16% !-Mercaptoethanol, 1.25% 
Bromophenol blue) for regular lysis or 5X hot lysis sample buffer (7% SDS, 
312.5mM Tris-HCl pH6.8, 50% Glycerol, 16% 2-Mercaptoethanol, 1.25% 
Bromophenol blue) and boiled for 5min at 95ºC. 
 
Table 2.8: Typical BCA protein assay 
 IgG (µl) H2O (µl) 
Lysis Buffer 





0 10 3 - 200 
2 8 3 - 200 
4 6 3 - 200 
6 4 3 - 200 
8 2 3 - 200 
10 0 3 - 200 
Sample 0 10 - 3 200 
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 Mitochondria enrichment 
Two 15cm dishes of cells were used per condition. The whole protocol was 
performed on ice or at 4ºC and all solutions were pre-cooled at 4ºC. Cells were 
rinsed twice with PBS and then scraped in 5ml PBS using a silicon cell scraper. 
The cells obtained from duplicate dishes were combined and centrifuged for 
2min at 1,000g. The cell pellets were resuspended in 5ml HIM buffer (200mM 
mannitol, 70mM sucrose, 1mM EGTA, 10mM HEPES pH 7.4) and centrifuged 
1,000g for 5min. The cells were resuspended in 1ml HIM buffer supplemented 
with mammalian protease inhibitors, then mechanically broken by shearing 
through at 23G needle 3-times and then homogenised by passing 3-times 
through a cell cracker (8.02mm diameter) and using 8.01mm steel ball (As 
described in (Aubry and Klein, 2006)). The homogenates were centrifuged 
10min at 600g to pellet out the nuclei and thus obtaining the Post Nuclear 
Supernatant (PNS). The PNS was further separated into a Post Mitochondrial 
Supernatant (PMS) and a Mitochondrial Fraction (MF) by centrifugation at 
7,000g for 15min. The MF pellet was resuspended in HIM buffer supplemented 
with mammalian protease inhibitors. Protein concentration of all samples was 
determined using the BCA assay (Pierce) and all fractions were adjusted to 
the same final concentration. Equal amounts of PNS, MF and PMS were 
analysed by western blotting. 
 
 Western blotting 
2.2.5.1 SDS-PAGE Electrophoresis 
Protein lysates were resolved by Sodium dodecyl sulphate (SDS)-
polyacrylamide gel electrophoresis (PAGE). The lysates were loaded into 4-
12% Bis-tris (low and medium molecular weight proteins) or 3-8% Tris-Acetate 
(high molecular weight proteins) precast NuPAGE gels using the XCell 
SureLock gel tank systems. Typically, MOPS running buffer was used to 
resolve proteins ranging 30-200kDa and MES running buffer for <30kDa 
proteins in the 4-12% Bis-Tris gels while Tris-Acetate running buffer in the 3-
8% Tris-Acetate gels for >250kDa proteins. In general, gels were ran 15min at 
80V then 60min at 150V. 
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2.2.5.2 Electrophoretic transfer and protein immunostaining 
The resolved proteins were then transferred onto 0.45µm pore-size 
nitrocellulose membranes using the Genie blotter system (IDEA Scientific, MN, 
USA). The transfer tanks were filled with transfer buffer (3.03g Tris, 14.4g 
Glycine, 200ml methanol, topped up to 1L with distilled H20) and the transfers 
were set at a constant current of 0.9A and 24V for 1h at RT, or 2h on ice when 
transferring high molecular weight proteins (>200kDa). The nitrocellulose 
membranes were then stained in Ponceau to verify equal protein loading and 
transfer, and then washed 3-times in TBS-T (made from a 20x TBS stock 
solution: 3M NaCl and 0.2M Tris-HCl pH7.6; then supplemented with 0,1% w/v 
Tween-20). The membranes were further blocked 1h at RT in 5% powder milk 
in TBS-T and then incubated with primary antibodies diluted in 5% milk in TBS-
T. For details on the incubation conditions see Table 1.7. The membranes 
were next washed three times in TBS-T and probed for 1h with secondary 
antibodies labelled with IRDye 800CW or IRDye 680CW diluted at 1:10 000 in 
5% milk in TBS-T. Finally, the membranes were washes twice in TBS-T then 
in TBS and scanned on the LICOR Odyssey CLx imaging system. Images 
where analysed using the ImageStudio and ImageStudioLight quantification 
software. 
 
 Ubiquitin gels 
To specifically probe for ubiquitin, the western blotting protocol was slightly 
modified. SDS-PAGE and transfer were performed as indicated in section 
1.2.5.1 and 1.2.5.2. However, following Ponceau staining, the membranes 
were briefly rinsed in TBS-T and then boiled for 30 min in Millipore water in 
between two glass plates. This was reported to enhance ubiquitin detection by 
possibly exposing hidden antigenic sites (Swerdlow et al., 1986).  
Following heat-inactivation, the membrane were rinsed 3-times in TBS-T then 
blocked in 0.5% Cold Water Fish skin gelatin (Sigma) in TBS-T. Antibody 
incubations and scanning were performed as in section 1.2.5.2, with the 
exception that antibodies were diluted into 0.5% Cold Water Fish skin gelatine 
instead of Milk. 
 
2.3 Molecular biology 
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 Materials and reagents 
The reagents employed in the molecular biology experiments detailed in this 
thesis are listed in Tables 1.9. 
 
Table 2.9: Molecular biology resources and reagents 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Enzymes  
PfuUltra II Fusion HS DNA 
polymerase 
Agilent #600670 
   
Medium 
S.O.C. Medium Invitrogen #15544034 
   
Cells 
TOP10 competent cells Fisher Scientific #C404003 
DH5α competent cells Invitrogen #18265-017 
   
Buffers   
TAE buffer National Diagnostics #EC-872 
Ethidium Bromide Sigma-Aldrich #E1510 
   
Kits 
Zero Blunt® TOPO® PCR 
Cloning Kit for Sequencing 
Invitrogen #K2875 
MinElute Gel extraction Kit Qiagen #28604 
QiaPrep Spin Miniprep kit Qiagen #27106 
HiSpeed Plasmid Midi kit Qiagen #12643 
HiSpeed Plasmid Max kit Qiagen #12663 
Quick Ligation kit New England Biolabs #M2200S 
Quick-DNA Miniprep Zymo Research #D3025 
   
Plasmids 
pTagBFP-H2B vector Evrogen #FP176 




PX330-Puro Gifted by Prof Ciaran Morrison  
(NUI Galway) 
 
   
Primers 
NAME SEQUENCE IDENTIFIER 
USP30-Ko-1-pcrUP-FW   GTGCCTGGCCTTGTTAATTTAG #2225 
USP30-Ko-1-pcrUP-RV CAGGCATGAGCCACTGCAC #2226 
USP30-Ko-2-pcrUP-FW   CACAGCGCAGGAACTCTGGGTC #2227 
USP30-Ko-2-pcrUP-RV TTGGCCTCCTAAAGTACTGG #2228 
USP30-Ko-2-pcrUP-FW GAACACCTGCTTCATGAACTC #2229 
USP30-Ko-2-pcrUP-RV CTGTCATCTGGACTTCTTTG #2230 
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 Polymerase Chain Reaction (PCR) 
DNA was amplified by PCR using the PfuUltra II Fusion HS DNA polymerase. 
The primers are listed in Table 1.9. The PCR mix was prepared as in Table 
1.10 and the PCR program is detailed in Table 1.11. 
 
Table 2.10: PCR Mix 
 pTagBFP-SKL PCR Control PCR 
H2O 40 µl 41 µl 
10x Pfu Buffer Ulta II 5 µl 5 µl 
dNTPs (25 mM) 0.5 µl 0.5 µl 
Primer 1.25 µl  1.25 µl  
Primer 1.25 µl 1.25 µl  
Template 50 ng (1ul) - 
HS Ultra Pfu II 1 µl 1 µl 
Total 50 µl 50 µl 
 
Table 2.11: PCR program 
Segment Step n. of cycles Temperatures Duration 




95°C 30 sec 
Annealing Tm-5°C 30 sec 
Extension 68°C 1 min/kb  
3 Final extension 1 68°C 15 min 
4  hold 1 10°C ∞ 
 
 Agarose gel electrophoresis 
PCR or restriction digest products were resolved by gel electrophoresis in 0.8 
or 1.0 % Agarose gels were made from electrophoresis grade agarose 
(Invitrogen) melted in TAE buffer (National Diagnostics) and supplemented 
with 0.5 µg.ml-1 ethidium bromide (Invitrogen). Ethidium bromide enabled the 







   
Tools   
Horizontal midi 
electrophoresis tank 
Scie-Plas # HU13 
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the DNA samples prior to loading. The DNA gels were resolved at 120 V for 
30 to 60 min in electrophoresis tanks filled with TAE buffer and then visualised 
using a UV light source. The DNA was extracted from the gels using the 
Quiagen gel extraction kit following the manufacturer’s instructions. 
 
 TOPO blunt-end cloning 
To further amplify PCR products, these were inserted into pCR4Blunt-TOPO 
sub-cloning vector (from Zero Blunt® TOPO® PCR Cloning Kit). This kit 
enables an efficient one-step cloning mediated by topoisomerase I. 
Topoisomerase I is covalently bound to both ends of linearised pCR4Blunt-
TOPO vectors and catalyses blunt-end ligations. The ligation mix is described 
in Table 1.12 and was incubated for 15min at room temperature. The resulting 
vectors were transformed into TOP10 Escherichia coli bacteria (see details in 
section 1.3.5).  
 
Table 2.12: pCR4Blunt-TOPO and PCR product ligation mix 
H2O 2 µl 
6x Salt-solution 1 µl 
PCR-product 2* µl 
pCR4 TOPO-vector 1 µl 
Total 6 µl 
*4 µl for larger constructs (>2 kb), 2 µl for 1-2 kb, 1 µl for 0.5 kb-1kb. 
 
 Bacterial transformation 
Bacterial transformations were induced by heat shock. The bacterial strain 
used were either TOP10 or DH5α cells. For each transformation, 2-6µl of 
ligated vector were added to 50µl of chemically competent bacteria and left for 
20min on ice. The mix was then incubated at 42ºC for 45s in a water bath and 
cooled back down on ice for 5 min. Finally, the bacteria were supplemented 
with 200µl of S.O.C Medium and left to recover 1h at 37ºC in a shaking 
incubator.  
The transformed bacteria were plated on LB agar plates with the appropriate 
antibiotic (Kanamycin: 10mg.ml ml-1 or Ampicillin: 100mg.ml-1) and incubated 
for 16h at 37ºC. On average, six TOP10 colonies were picked per 
transformation and expanded in LB medium with antibiotics. The plasmid DNA 
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was extracted using the Quiagen Miniprep, Midi or Max kit following the 
manufacturer’s protocol. 
 
 Glycerol stocks 
Glycerol stocks were made from 5ml overnight DH5α cultures. The cultures 
were pelleted 5min at 4,000 rpm. The pellets were then resuspended in 1.5ml 
40% Glycerol/LB medium solution and aliquoted in cryovial (0.75ml per 
cryovial). The aliquots were stored at -80ºC. 
 
 Restriction digest 
Restriction digests were set up as indicated in Table 1.13. For diagnostic 
digests 500ng of plasmid DNA were incubated for 1h in the presence of 
restriction enzymes at the appropriate temperature (37ºC for most enzymes). 
For restriction cloning, 4µg of DNA were used and the reactions were left to 
incubate for 3h at the recommended temperature (37ºC for most enzymes). 
The digests were resolved on agarose gel (see section 1.3.3). All restriction 
enzymes and buffers were supplied from New England Biolads (NEB).  
 




digest for cloning 
Restriction enzyme 
(NEB) 
0.5 µl 1µl 
10x Reaction buffer 
(NEB) 
1 µl 3µl 
Plasmid  3-8 µl  
(0.5 to 2µg) 
4-10µl 
(~4µg) 
ddH2O Up to 10µl Up to 30µl 
 
 Quick ligation 
DNA ligations were performed using the Quick ligation kit (NEB). For each 
ligation, 50 ng of vector were combined with a 3-fold molar excess of insert 
(average molecular weight of a DNA base pair ~620g.mol-1).  The reaction mix 
is detailed in Table 1.14. The reaction was incubated 5min at room 
temperature and 2 μl were then used to transform 50 μl of chemically 
competent cells as described above (2.3.5). 
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Table 2.14: Quick ligation 
 Ligation Insert control Vector control 
Vector 50ng 50ng - 
Insert 3-fold molar 
excess 
 - 3-fold molar 
excess 
ddH2O Up to 10 µl Up to 10 µl Up to 10 µl 
2x Quick buffer 10 µl 10 µl 10 µl 
Quick ligase 1 µl 1 µl 1 µl 
Total 20 20 20 
 
 
 Generation of USP30 knockout cells 
SH-SY5Y USP30 KO cells were generated using the CRISPR-Cas9 editing 
system with sgRNAs targeting exon 3 of USP30 isoform 1 (sgRNA1: 
AGTTCACCTCCCAGTACTCC, sgRNA2: GTCTGCCTGTCCTGCTTTCA). 
The sgRNAs were cloned into the pSpCas9(BB)-2A-GFP (PX458) vector and 
the PX330-Puro and sequence verified by Elena Marcassa. KOC and KOD 
were engineered by transfecting SH-SY5Y cells with PX458-sgRNA#1. The 
positive cells were selected by FACS 24h later (selection of GFP positive cells; 
central FACS facility on the University of Liverpool campus) and were single 
cell diluted. KO11 were generated by transfecting SH-SY5Y mito-QC cells with 
PX330-puro and were selected 24h later with 1-1.5 µg.ml-1 puromycin over 
72h. Individual clones were amplified, and their alleles sequenced at Dundee’s 
DNA sequencing service. 
The genomic DNA from each clone was extracted using Quick-DNA Miniprep 
kit (Zymo Research) following the manufacturer’s instructions. The edited 
region of USP30 was amplified by PCR (see section 1.3.1) using the following 
sets of primers: 2225/2226 (KO11), 2227/2228 (KO11) & 2229/2230 (KO7, 
KOC and KOD) (Table 1.9). The PCR products were then inserted into pCR4-
TOPO plasmids and transformed into TOP10 bacteria (see sections 1.3.4 and 
1.3.5).  Between 6-10 colonies per clone and sets of primer were expanded 
and their plasmid DNA extracted (section 1.3.5). A diagnostic restriction digest 
with EcoRI was performed to checked whether the plasmids contained an 
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insert (section 1.3.7). All plasmids positive for the insert were sent for Sanger 
sequencing at the Dundee’s DNA Sequencing and Services Unit. 
 
 TagBFP-SKL plasmid 
The pTagBFP sequence from the pTagBFP-H2B expression vector was 
amplified by PCR using the 2255 and 2256 primers (see section 1.3.2). These 
primers were also used to add a sequence coding for SKL adjacent to the 
amplified sequence, and flanked pTagBFP-SKL with restrictions sites (NheI 
and XhoI restriction sites for 2255 and 2256 respectively). The PCR product 
was resolved on an 1% agarose gel, then gel extracted and subcloned in 
pCR4Blunt-TOPO vector (see sections 1.3.3, 1.3.4 and 1.3.5). The vector was 
then transformed in TOP10 cells, expanded in LB supplemented with 
Kanamycin and extracted by using the Qiagen Miniprep (see section 1.3.5). 
The plasmid DNA was analysed for the presence of an insert by EcoRI 
digestion (pCR4Blunt-TOPO’s insertion site is flanked by EcoRI restriction 
sites), the NheI and XhoI double digest was also tested and SpeI was used to 
linearise the vector (single restriction site in pCR4 TOPO vector), (see section 
1.3.7).  
One positive colony was further expanded in LB with Kanamycin and extracted 
using the Qiagen Midi kit. The pTagBFP-SKL sequence was then subcloned 
into the mammalian expression vector pCDNA3.1+. The vector and the 
pTagBFP-SKL insert were digested with NheI and XhoI then ligated using the 
Quick Ligase kit (see sections 1.3.7 and 1.3.8). The ligation products were 
transformed in DH5α cells then test digested with the following restrictions 
enzymes: NheI/XhoI (insert test), Bsu361/NdeI (inside/outside), Bsu361 
(linearisation) (see sections 1.3.5 and 1.3.7). The positive plasmids were sent 
for sequencing at Dundee’s DNA sequencing service. 
 
The primers are detailed below: 
JJ-TagBFP-SKL-For (2255): 5’-GAGCTAGCGCCACC ATG AGC GAG CTG 
ATT AAG GAG AAC ATG C -3’ 
JJ-TagBFP-SKL-Rev (2256): 5’- CACTCGAGTTACAGCTTGGATGAACC 
ATT AAG CTT G-3’ 
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Primer colour legend: Restriction sites (NheI and XhoI for 2255 and 2256 
respectively), Kozak sequence, STOP, SKL, pTagBFP ORF, linker 
 
2.4 Mass spectrometry 
 Materials and reagents 
The reagents employed in the mass spectrometry experiments detailed in this 
thesis are listed in Tables 1.15. 
 
Table 2.15: Mass spectrometry reagents 
 
 SILAC labelling 
SHSY5Y, SHSY5Y-KOD and SHSY5Y-KO11 cells were grown for at least 8 
passages in SILAC DMEM/F12 supplemented with 10% dialysed FBS, 200 
mg/L L-proline and either L-lysine (Lys0) together with L-arginine (Arg0), L-
lysine-2H4 (Lys4) with L-arginine-U-13C6 (Arg6) or L-lysine-U-13C6-15N2 (Lys8) 
with L-arginine-U-13C6-15N4 (Arg10) at final concentrations of 28 mg.L-1 arginine 
and 146 mg.L-1 lysine.  
 
 Label test 
2.4.3.1 In gel digest 
REAGENT or RESOURCE SOURCE IDENTIFIER 
SILAC Amino Acids and medium 
SILAC DMEM-F12 media lacking L-
Arginine and L-Lysine 
DC Biosciences LTD - 
DMEM-F12 for SILAC Life Technologies 
Limited 
#88370 
Dialysed FBS Biosera #FB-1001/500 
L-Lysine monohydrochloride (Lys0) Sigma-Aldrich #L8662 
L-Lysine-4,4,5,5-d4 hydrochloride (Lys4) Sigma-Aldrich #616192 
L-Lysine-13C6,15N2 hydrochloride (Lys8) Sigma-Aldrich #608041 
L-Arginine (Arg0) Sigma-Aldrich #A8094 




L-Proline (Pro0) Sigma-Aldrich #P5607 
   
Other 
DNA Lobind 1.5 ml tube Eppendorf # 
EP0030108051 
Trypsin Gold Promega # V5280 
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2.4.3.1.1 Gel preparation 
SILAC-labelled SH-SY5Y, SHSY5Y-KOD and SHSY5Y-KO11 cells were 
grown in 6cm dishes until confluency then lysed in NP40 buffer with MPI as 
described previously. The lysates were resolved in NuPage 4-12% 10 well 
(1.5mm) gels. The gel was then fixed with acetic acid and methanol (10% 
acetic acid, 50% methanol in H2O) for 10mins. Identical gel slices (~ 5 x 2 mm) 
were cut out from each sample lanes using a scalpel, divided further into 1 x 1 
mm pieces and placed into 1.5 ml Lobind Eppendorf tubes. The gel pieces 
were dehydrated with 100µl of 50mM Ammonium bicarbonate (Ambic) in 
Acetonitrile (ACN) for 5 min (900 rpm, RT) and the supernatant discarded. The 
samples were further dried out using SpeedVac Concentrator Plus 
(Eppendorf) at 60°C for 5 min. 
 
2.4.3.1.2 Sample reduction and alkylation 
The dried out-samples were reduced in 50 µl/band of 10mM Dithiothreitol 
(DTT) in 100mM Ambic at 56ºC and shaken at 900rpm for 1h. The supernatant 
was discarded, and the samples left to cool for 5 min. The samples were 
alkylated using 50µl/ band of 50mM iodoacetamide in 100 mM ambic and 
incubated at 30min at RT on a shaker (900 rpm). The supernatant was 
discarded. The samples were washed twice consecutively in 300 µl of 100 mM 
ambic then in 300 µl of 20 mM Ambic / ACN for 15 min each on a shaker (900 
rpm). The supernatants were discarded. 
The gel pieces were dehydrated with 100µl of ACN for 5 min (900 rpm, RT) 
and the supernatant discarded. The samples were further dried out using 
SpeedVac Concentrator Plus (Eppendorf) at 60°C for 5 min. 
 
2.4.3.1.3 Trypsin digestion 
Trypsin Gold was added to the protein samples at a ~1:25-1:50 trypsin to 
protein ratio and diluted in the reaction buffer (40µl per band, 40mM Ambic, 
9% ACN). The gel bands were left to rehydrate in the digestion buffer for 30min 
at RT then incubated overnight at 37ºC. 
 
2.4.3.1.4 Peptide extraction 
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The digest was supplemented with 40µl of ACN and incubated for 30min at 
30ºC at 900rpm. The supernatant was collected into Eppendorf Lobind tubes 
and the gel pieces were mixed with 50µl of 1% formic acid in water for 20min. 
The supernatant of the gel pieces was added into the precedent Eppendorf 
Lobind tube. This was repeated once more. 
The gel pieces were dehydrated using 150µl ACN and incubated for 10min at 
900rpm. The supernatant was added to the same Lobind tube. The Lobind 
collection tubes containing the peptide samples were placed in the speed 
vacuum until all the liquid had evaporated. Dried peptides were stored at -20C 
until further processing. Peptide samples were re-suspended in 25μl of 1% 
formic acid prior to mass spectrometry analysis. 
 
2.4.3.2 Mass spectrometry analysis 
5μl of each sample was loaded on a high performance liquid chromatography 
column coupled to an LTQ-Orbitrap XL (Thermo Fisher) fitted with a Proxeon 
nanoelectrospray source. Samples were resolved on a 1-62% linear ACN 
gradient over 21mins. MS spectra were acquired by the Orbitrap at a resolution 
of 30,000 and MS/MS was performed on the TOP 5 ions. All spectra were 
acquired using Xcalibur software (version 2.0.7; Thermo Fisher Scientific). MS 




 Proteomics and ubiquitylomics analysis 
Proteomic and ubiquitylomic (diGly immunoprecipitation using the PTMScan 
Ubiquitin Remnant Motif [K-GG] Kit #5562; Cell Signalling Technology) sample 
preparation and analysis by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) were performed by Emma Rusilowicz-Jones in collaboration with 
both Benedikt Kessler’s (University of Oxford, UK) and Matthias Trost’s 
(Newcastle University, UK) groups as detailed in our manuscript (Rusilowicz-
Jones et al., 2020). For the proteome, samples were analysed on an Orbitrap 
Q Exactive HF. For the ubiquitylome, samples were analysed on an Orbitrap 
Fusion Lumos (one replicate of the total ubiquitylome) and Orbitrap Q Exactive 
HF (mito-ubiquitylome and three replicates of the total ubiquitylome). 
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The proteomics data files were analysed using MaxQuant (version 1.6.7.0) 
(Cox and Mann, 2008). Statistical analysis was performed using Perseus 
(version 1.6.10.0) (Tyanova et al., 2016a). Scatter plots and heatmaps were 
made using JMP (version 15.0) and Morpheus (Broad Institute, 
https://software.broadinstitute.org/morpheus), respectively. 
 
2.5 Drosophila biology 
 Materials and reagents 
The reagents employed in the drosophila biology experiments detailed in this 
thesis are listed in Tables 1.16. 
 
Table 2.16: Drosophila biology reagents 
REAGENT or 
RESOURCE SOURCE IDENTIFIER 
Experimental Models: Organisms/Strains  
Usp30 KO  Generated by WellGenetics Inc.  
UAS-Mt-Keima M2 (III) Generated by Aitor Martinez-Zarate 
in collaboration with Ugo Mayor 
 
UAS-Mt-Keima M3 (II) Generated by Aitor Martinez-Zarate 
in collaboration with Ugo Mayor 
 
UAS-Mt-Keima M4 (III) Generated by Aitor Martinez-Zarate 
in collaboration with Ugo Mayor 
 
UAS-Mt-Keima M7 (II) Generated by Aitor Martinez-Zarate  
in collaboration with Ugo Mayor 
 
UAS-mitoGFP (III) Bloomington, gift by Natalia 
Sanchez-Soriano 
 (University of Liverpool) 
BL8443 
UAS-Parkin (II) Bloomington BL37509 
UAS-Pink1 (II) VDRC  #21859 
tub-GAL4 (III) Bloomington, gift by Natalia 
Sanchez-Soriano 
(University of Liverpool) 
BL5138 
elav-GAL4 (III) Bloomington, gift by Natalia 
Sanchez-Soriano 
(University of Liverpool) 
BL8760 





Sheep Anti-GFP Ab gift from Prof. Ian Prior  
(University of Liverpool) 
 
Mouse Anti-beta Actin 
mAb 
Abcam Ab6276 




 Drosophila maintenance 
Antimycin A Sigma #75351 
Oligomycin A Sigma #A8674 
Deferiprone Sigma #379409 
Trizol Reagent Thermo Fischer Scientific #15596026 
   
Fluorescent dyes 
MitotrackerTM Deep Red Thermo Fischer Scientific M22426 
LysotrackerTM Blue DND-
22 
Thermo Fischer Scientific L7525 
LysotrackerTM Blue DND-
22 
Thermo Fischer Scientific L7525 









Addgene, gifted by Daimark Bennett 
(University of Liverpool) 
#46128 
pUAST-mt-Keima Clague-Urbé and Ugo Mayor labs  
   
Dissection and homogenization tools 
Pellet pestles Sigma Z359947-
100EA 
Dumont No.5 Forceps InterFocus #11252-30 
Dumont HP Tweezers 5 AgarScientific AGT5034 
   
Microscopy  
MatTek dish 35mm MatTek P35G-1.5-14-
C 
Halocarbon oil 700 Sigma H8898 
Coverslips No2 
22x64mm 






Scientific Laboratory Supplies 
Limited 
MIC3124 
Coverslips No1 13mm 
Dia 
Scientific Laboratory Supplies 
Limited 
MIC3306 
   
Molecular biology Kits and enzymes 




RevertAid H minus M-
MuLV Reverse 
Transcriptase 
Thermo Fischer Scientific EP0451 
iTaq Universal SYBR 
Green Supermix 
Biorad 1725120 
   
Others 
Nuclease free water Sigma-Aldrich #W4502 
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Drosophila stocks were kept at 18ºC and expanded at 25ºC for experimental 
use. All flies were fed with the standard fly food (provided by the Manchester 
Fly Facility, UK). 
 
 Climbing assay (also known as negative geotaxis assay) 
Motor function was assessed using the climbing assay (= negative geotaxis 
assays). Up to ten males or females aged 12-days-old were placed in 19cm 
graduated tubes closed at both ends (Different sexes and genotypes were kept 
separated) and left to rest for 5min, with the tube lying horizontally. Each tube 
was then set upright and taped 5 times to stimulate climbing. Meanwhile, the 
flies were filmed for 1min using a smartphone camera. Three technical 
replicates were performed per tube and were spaced at 5min intervals. The 
videos were analysed on QuickTime Player v10.5. The height climbed by each 
fly, 20s after stimulation, was recorded for each replicate. The graphs were 
produced using GraphPad Prism v6.0. 
 
 Survival curve 
50 new-born flies for each sex and genotype were grown in their regular food 
tubes (16-17 fly per tube) at 27ºC. The number of live flies per vials was 
counted every 2-3 days (Mon-Wed-Fri) for 44 days and the flies were 
exchanged to new tubes every 7days. The experiment was repeated 3 times. 
Graphs were produced using GraphPad Prism v6.0. 
 
 Drosophila lysis 
In preparation of immunoblotting, flies were snap-frozen in liquid nitrogen. 
Either whole organism or heads-only were lysed in Laemmli buffer (250mM 
Tris pH 7.5, 4% SDS, 40% Glycerol, 100mM DTT, w/v 0.05 Bromophenol Blue) 
in 1.5ml Eppendorf tubes. The tissues were homogenised using 
homogenisation pestles. The samples were then boiled 10min at 95ºC. 
 
 Drosophila neuronal embryonic culture 
Male and female Drosophila of the selected cross were incubated in a fresh 
vial for 14h to stimulate reproduction and were then discarded from the vial. 
Embryos were dechorionated for 90s in 50% bleach and the reaction was 
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ended by adding two volumes of water. They were then transferred onto agar 
plates and stage E11 embryo were visually selected using a Leica 
fluorescence microscope; each neuronal culture was derived from 10 stage 
E11 embryos. Selected embryos were collected into a 1.5ml Eppendorf tube 
and rinsed in 70% ethanol, then rinsed in neuronal media (25% FBS, 2μg.ml-
1 Insulin, 1% Penicillin/Streptomycin, in Schneider's Drosophila Media at pH 
6.8-6.9, provided by Natalia Sanchez-Soriano, University of Liverpool) and 
subsequently gently homogenised in 100µl dispersion media (1% 
penicillin/streptomycin, 50μg.ml-1 phenylthiourea, 1 mg.ml-1 collagenase and 
5 mg.ml-1 Dispase II in HBSS, provided by Natalia Sanchez-Soriano, 
University of Liverpool) using pestles. The homogenates were incubated for 
3.30min at 37ºC. The reaction was ended by the addition of 200µl neuronal 
media and the homogenates were centrifugated for 5min at 900g. The 
supernatant was discarded, and the pellet resuspended in 30µl neuronal 
media. The homogenate was deposited onto a microscopy slide coated with 
Concavalin A (provided by Natalia Sanchez-Soriano, University of Liverpool) 
and covered by a coverslip. The cultured cells were incubated in the dark at 
26ºC first upside down for 2h, then flipped back and grown for 48h. 
 
 Live imaging of whole larvae 
Stage 3 larvae were anesthetised in 10% chloroform mixed in Halocarbon oil 
for 5min. The larvae were then mounted in between two 22x64 coverslips 
coated in the 10% chloroform/Halocarbon oil mixture and separated by 22x22 
coverslips. The larvae were imaged straight after mounting for 30min 
maximum. For all anatomical analysis, images were acquired on the 3i 
spinning disk confocal with the sCMOS camera (higher resolution); the 
EMCCD camera was required for mitophagy analysis (greater sensitivity). z-
stack (100 planes, 1µM step size) were taken using the 10x objective lens and 
single plane images using the 63x objective lens. Mt-Keima: sequential 
imaging, Ex445/Em620nm then Ex561/Em620nm. Mito-GFP: Ex445/ 
Em510nm. 
 
 Lysotracker and Mitotracker assay 
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Drosophila embryonic neuronal culture grown for 48h on Concavalin A coated 
slides were incubated for 30 min with 100nM Mitotracker Deep Red or with 
5µM Lysotracker Blue. Images were captured using a spinning disk confocal 
microscope, a 63X objective lens and the sCMOS camera. Mitotracker Deep 
Red: Ex640/Em665nm and 100ms exposure time; Lysotracker Blue 
Ex405/Em422nm and 300ms exposure time.  
 
 Adult Drosophila tissue dissection and imaging. 
Adult Drosophilas were anesthetised in ice for 5min. The flies were then 
dissected in PBS using Dumont No.5 Forceps and Dumont HP Tweezers 5. 
The dissected tissues were mounted in PBS into MatTek 35mm dishes and 
tightly covered with a 13mm diameter coverslip attached to the dish using 
double sided tape. z-stack (70 planes, 1µM step size) or single plane images 
were acquired with a spinning disk confocal, a sCMOS camera and a 10x 
objective lens. Mt-Keima: sequential imaging, Ex445/Em620nm then 
Ex561/Em620nm. 
The brain dissections were performed with the assistance of Natalia Sanchez-
Soriano’s and Pilar Okenve-Ramos (University of Liverpool). 
 
 Mt-Keima analysis 
The mitophagy index and corresponding mitophagy index plots were 
generated using the pixelAnalysis function in ImageJ/FIJI from single plane 
images. This plugin was coded by Dave Mason (CCI, Liverpool, UK), (Adapted 
from (Sun et al., 2015)). The pixel intensity values in Ex561 images were 
plotted over the pixel intensity value of Ex445 images. The plots were divided 
in 4 quadrants to obtain: pixels originating from the mitochondria in acidic 
compartments “b” and pixels from the rest of the network “a”, “c” and “d”. The 
mitophagy index (M.I.) was calculated as follow: pixels b/ (pixels (a - BG) + b 
+ c + d). BG: Background signal, which was measured in the nucleus. Graphs 
were produced using GraphPad Prism v6.0. 
 
 Fly mutagenesis 
2.5.11.1 Mt-Keima fly engineering 
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The fly mt-Keima plasmid was engineered by Aitor Martinez-Zarate (Ugo 
Mayor, BioGUNE, Bilbao, Spain; Sylvie Urbé and Michael Clague, University 
of Liverpool, UK). Briefly, the mt-Keima sequence from the mammalian 
plasmid mt-mKeima (h)-pIND(SP1), kindly provided by Atsushi Miyawaki 
(RIKEN, Japan), was amplified and cloned into a Drosophila expression vector 
pUAST (Katayama et al., 2011). The mt-Keima-pUAST construct was then 
injected in wildtype (w1118) Drosophila embryo by Bestgene Inc. (California, 
USA). The resulting positive strains were screened by Aitor Martinez-Zarate 
and Juanma Ramirez (UPV-EHU, Spain) by detecting mt-Keima’s expression 
and fluorescence in the Drosophila eye after being crossed with GMR-GAL4 
flies. Four independent UAS-mt-Keima strains were selected: M3 and M7 
(insertion in the 2nd chromosome) and M2 and M4 (insertion in the 3rd 
chromosome).  
 
2.5.11.2 CRISPR/Cas9-mediated Usp30 KO in Drosophila 
CRISPR-mediated mutagenesis was done by WellGenetics Inc. using 
modified methods of Kondo and Ueda (2013). In brief, two gRNA sequences, 
CGAAGGACCCCAGAAAACGA[AGG] and GTGACCGCTGTTTGCCTCCC-
[CGG], were cloned into U6 promoter plasmid(s). Cassette Stop-w containing 
3-frame stop codons and hs-w (eye marker) and two 1kb homology arms were 
cloned into pUC57-Kan as donor template for repair. Usp30-targeting gRNAs 
and hs-Cas9 were supplied in DNA plasmids, together with donor plasmid for 
microinjection into embryos of control strain w1118. F1 flies carrying selection 
marker of hs-w were further validated by genomic PCR and sequencing. 
CRISPR generates a 1742-bp deletion allele of Usp30, deleting most of CDS 
region of Usp30 (CG3016) gene and is replaced by cassette hs-w. 
 
 mRNA extraction from whole Drosophila 
Protocol from Kevin Bogart and Justen Andrews (Bogart and Andrews, 2006). 
50 mg of frozen flies were homogenized in 1 ml Trizol with a disposable plastic 
pestle in a 1.5 ml microcentrifuge tube and then incubated at RT for 5 min. The 
homogenate was centrifugated at 12,000 rcf for 10 min at 4ºC to pellet 
insoluble debris. The supernatant was transferred to a new microcentrifuge 
tube, mixed with 200 µl of Chloroform and then incubated at RT for 3 min. The 
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sample was centrifugated for 15min at 10,000 rcf, 4ºC. The upper aqueous 
phase (~0.6 ml) was transferred to a fresh RNAse-free microcentrifuge tube, 
mixed with 0.5 ml isopropanol, incubated for 10 min at RT and centrifugated at 
12,000 rcf for 10 min at 4ºC. The supernatant was discarded, the pellet washed 
in 1ml 75% ethanol and re-spun at 7,500 rcf for 5 min at 4ºC. The supernatant 
was discarded, and the pellet left to air dry for 10min. Finally, the pellet was 
resuspended in 100µl RNase-free water. 
The concentration and quality of the extracted mRNA were assessed using a 
NanoDrop Spectrophotometer ND100 at 260nM and taking into account the 
A260/A280 and A260/A230 ratios. 
 
  Reverse transcription  
Drosophila total RNA, extracted as in section 1.5.12, was reversed transcribed 
to cDNA using the Promega’s Reverse Transcription System and RevertAid H 
minus M-MuLV Reverse Transcriptase (ThermoFisher) as follows. Total RNA 
was mixed with Oligo(dT) primers (RNA Mix, Table 1.17), and incubated for 
5min at 70ºC to prime the RNA polyA tails for reverse transcription. The 
reverse transcription mix, detailed in the Table 1.18, was then added to the 
RNA Mix, incubated for 5min at 37ºC and finally supplemented with 1µl of 
reverse transcriptase. The mix was incubated for 1h at 42ºC and the synthesis 
was then arrested by heating the cDNA samples at 70ºC for 10min. They were 
finally cooled on ice for 5 min and diluted in H2O up to 100μl. 
 
Table 2.17: Total Drosophila RNA and primer Mix 
 
Table 2.18: Reverse transcription Mix 
Reagent Volume per reaction 
5x reverse transcription buffer 4µl 
PCR nucleotide mix (Promega) 2µl 
RNasin (Promega) 0.5µl 
Nuclease free ddH2O 1.5µl   
 
Reagent Volume per reaction 
Total RNA 1µg 
Nuclease free ddH2O Up to 10µl 
Oligo(dT) primer 1µl 
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 Quantitative real-time polymerase chain reaction qRT-PCR 
The primers used for qRT-PCR are detailed in Table 1.19. The qRT-PCR 
reaction buffer was prepared as in Table 1.20 and plated into a 96well qPCR 
plates (6µl per well). Finally, 4µl of cDNA, prepared as in section 1.5.13, was 
added to each well. qRT-PCR was performed using BioRad’s CFX Connect 
Real-Time PCR Detection System and monitored with CFX ManagerTM 
Version: 3.1.1517.0823. The cDNA samples were denatured at 95ºC for 3 min, 
amplified for 40 cycles using a 2-step protocol: 10s at 95ºC followed by 30s at 
60ºC and then incubated at 72ºC for 10min.  
The cycle threshold values (Ct, also known as Cq), indicating the number of 
PCR cycle at which the samples’ reaction curve intersected the threshold line, 
were calculated by the CFX Manager Analysis software. No reverse 
transcriptase samples and no cDNA (water only) samples were included as 
controls. The mean Ct was then calculated for each condition (3 replicates per 
condition) and normalised to the house keeping gene αtub84B (ΔCt). The 
relative expression of test samples to their calibrator sample (eg: USP30 KO 
cDNA over w1118 cDNA) was indicated as 2-ΔΔCt. 
 
Table 2.19: qPCR primers 
 
Table 2.20: qRT-PCR Mix 
Reagent Volume per reaction 
SyBrGreen Biorad supermix 5.0µl 
H2O 0.7µl 
Forward primer (20µM) 0.15µl 




Forward USP30#1 AGCCGCATCTCAATAGCCAG 
Reverse USP30#1 GCACATCGGTGGTACTACAC 
Forward USP30#2 TTTCTGGGGTCCTTCGGGTT 
Reverse USP30#2 GGTCAGTCCAAAGTTGTGGAGA 
Forward αTub84B CACACCACCCTGGAGCATTC 
Reverse αTub84B CCAATCAGACGGTTCAGGTTG 
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Microscopy has been one of the favoured techniques to observe mitophagy. 
In particular, electron microscopy has greatly helped the field. In 1957, 
researchers started reporting on mitochondria found in “vesicles” (Clark, 1957; 
Ashford and Porter, 1962; Novikoff and Essner, 1962). Then in the early 2000s, 
John Lemasters and colleagues stained rat hepatocytes with mitochondrial 
and lysosomal dyes, and observed that upon nutrient starvation, depolarised 
mitochondria were colocalising with lysosomes (Lemasters et al., 1998; 
Elmore et al., 2001, 2004), [see review: (Rodriguez-Enriquez et al., 2004)]. 
Youle and colleagues followed up on that discovery and popularised the use 
of depolarising agents to induce and amplify mitophagy (Narendra et al., 2008). 
Alongside others, they discovered that Parkin and PINK1 regulate mitophagy 
(Narendra et al., 2008, 2010a; Matsuda et al., 2010; Vives-Bauza et al., 2010). 
Since then, the field has been moving swiftly and is now in search of efficient 
and reliable means to study mitophagy. 
 
In this chapter my aim is to answer the following questions:  
What means are available to amplify the mitophagy signal in human cells? 
How can we visualise spontaneous mitophagy events in vivo? Can we induce 
mitophagy independently of depolarisation? 
 
I will start by presenting the hTERT-RPE1-YFP-Parkin cells, a cell model 
introduced by Jon Lane’s group, that is used in combination with uncoupling 
agents to magnify mitophagy processes (Liang et al., 2015; MacVicar and 
Lane, 2014). Next, I will describe mitophagy probes, which permit the 
visualisation of mitophagy events by microscopy. Finally, I will introduce new 
mitophagy triggers.  
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3.2 Combining depolarisation with Parkin overexpression: A powerful 
cocktail to amplify and observe mitophagy. 
 
Mitophagy can be artificially triggered using agents that depolarise the inner 
mitochondrial membrane. Depolarisation prevents PINK1 cleavage at the inner 
mitochondrial membrane and causes its accumulation at the outer 
mitochondrial membrane (Jin et al., 2010). PINK1 then proceeds to 
phosphorylate ubiquitin and the E3 ligase Parkin, which triggers mitophagy 
[Reviewed in: (Bingol and Sheng, 2016; Harper et al., 2018; Pickles et al., 
2018)].  
The most commonly used tool to depolarise mitochondria is the protonophore 
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (Narendra et al., 2008; 
Poole et al., 2010; MacVicar and Lane, 2014; Liang et al., 2015). CCCP 
increases the proton conductance across bilayer membranes (Kasianowicz et 
al., 1984). At mitochondria, this causes a collapse of the membrane potential 
and leads to the uncoupling of oxidative phosphorylation (Heytler and Prichard, 
1962; Heytler, 1963; Liberman et al., 1969). However, CCCP is not specific for 
mitochondrial membranes and has been reported to uncouple proton gradients 
at other organelles such as lysosomes or the Golgi apparatus, and thus 
disrupts the intraluminal pH of these organelles (Llopis et al., 1998; Padman 
et al., 2013).  
I have instead been using an inhibitor cocktail, composed of Antimycin A and 
Oligomycin A (AO), which directly targets constituents of the mitochondrial 
electron transport chain and thus induces a mitochondria-specific membrane 
depolarisation. Antimycin A inhibits complex III (CIII) of the respiratory chain 
which collapses the proton gradient (Alexandre and Lehninger, 1984). This 
however forces the F1F0-ATP synthase to work in reverse and produces 
reactive oxygen species (ROS) (Ivanes et al., 2014; Ksenzenko et al., 1983; 
Starkov and Fiskum, 2001). To prevent this compensatory mechanism, I have 
used Antimycin A in combination with Oligomycin A, an inhibitor of the F1F0-
ATP synthase [for review see: (Georgakopoulos et al., 2017)]. Individually 
those inhibitors can induce mitophagy in mammalian cells but are much more 
potent when combined together (Allen et al., 2013). 
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Depolarising agents are often used in combination with Parkin overexpression. 
Overexpressing this E3 ligase increases the ubiquitylation of mitochondrial 
proteins up to an easily detectable level and accelerates mitochondria 
clearance (Narendra et al., 2008; Bingol et al., 2014; MacVicar and Lane, 
2014; Liang et al., 2015). Overexpression of tagged Parkin also allows one to 
follow Parkin’s translocation from the cytosol to the mitochondria (Narendra et 
al., 2008, 2010a; Matsuda et al., 2010; Liang et al., 2015). hTERT-RPE1-YFP-
Parkin cells have been reported to be highly sensitive to depolarisation, 
clearing close to 90% of their mitochondria following 24h incubation with CCCP 
(MacVicar and Lane, 2014; Marcassa et al., 2018). I therefore started to study 
mitophagy in this highly dynamic model. 
 
 Parkin translocates to mitochondria upon depolarisation 
 
I first characterised mitophagy in hTERT-RPE1-YFP-Parkin cells by 
immunofluorescence and assessed the effect of depolarisation on the cellular 
distribution of Parkin (Figure 3.1). I treated the cells with high doses of AO 
(5µM each) for 1, 8 and 10 hours and stained them for TOMM20, an outer 
mitochondrial membrane (OMM) protein. Within one hour, I observed a 
redistribution of Parkin from a diffuse to a punctate pattern, colocalising with 
fragmented mitochondria. Indeed, potent stressors such as depolarisation 
promotes mitochondrial fission to facilitate the autophagic degradation of 
defective mitochondrial fragments (Twig et al., 2008; Frank et al., 2012). In 
parallel, depolarisation promotes the PINK1-dependent recruitment of Parkin 
to mitochondria which initiates mitophagy (Matsuda et al., 2010; Narendra et 
al., 2010a; Vives-Bauza et al., 2010). After eight hours of treatment, the 
mitochondrial network appeared disrupted, partially degraded and retracted to 
few sites in the cytosol. At this point, all of the cytosolic Parkin had translocated 





Figure 3.1: Depolarisation induced by Antimycin A and Oligomycin A initiates 
mitochondrial degradation and Parkin recruitment to mitochondria. 
hTERT-RPE1-YFP-Parkin cells were treated with DMSO or Antimycin A and 
Oligomycin A (AO, 5μM each) for 1h, 8h and 10h. The cells where then fixed with PFA 
and stained with anti-TOMM20 antibody. The coverslips were mounted using mowiol 
mixed with DAPI. Images were taken using a 3i spinning disk confocal microscope. 





















I repeated this experiment with another mitochondrial marker, TIMM44 (Figure 
3.2). Unlike TOMM20, TIMM44 is an inner membrane protein and is therefore 
degraded in the lysosome, whereas TOMM20 is also at least partially 
degraded by the proteasome (Chan et al., 2011; Yoshii et al., 2011; Sarraf et 
al., 2013; Liang et al., 2015; Rose et al., 2016). As observed previously, Parkin 
started accumulating on mitochondria one hour after depolarisation and fully 
localised to mitochondria after 4h (Figure 3.2A-D). After 24h, OMM and IMM 
proteins were cleared and the whole mitochondrial network had been sent for 
proteasomal and autophagic degradation.  
This observation is in agreement with the literature and showed that 
depolarisation in Parkin-overexpressing cells can promote the full clearance of 
the mitochondrial network (Narendra et al., 2008; Allen et al., 2013; Marcassa 
et al., 2018). With the loss of mitochondria, newly synthesised Parkin was 
distributed to the cytosol (Figure 3.2A-B). 
 
In parallel, I assessed whether lower doses of AO would be sufficient to 
promote Parkin translocation to mitochondria (Figure 3.2D). When using the 
drugs at 1µM, 78% and 92% of cells had mitochondrial Parkin after 2h and 4h 
of treatment respectively. When I lowered those concentrations to 0.1µM, 
Parkin’s recruitment to mitochondria, which was seen in 76% of the cells, was 
delayed up to the 8h timepoint. When further reducing the concentrations of 
depolarisation agents to 0.01µM, the percentage of cells with mitochondrial 
Parkin did not exceed 22%.  
 
It was previously reported that depletion of the mitochondrial deubiquitylase 
USP30 increases Parkin-dependent ubiquitylation of mitochondrial proteins 
(Bingol et al., 2014; Cunningham et al., 2015; Liang et al., 2015). The question 
remained whether USP30 inhibits Parkin recruitment to mitochondria or if it 
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 USP30 depletion does not affect the recruitment of overexpressed 
Parkin to mitochondria 
 
I transfected hTERT-RPE1-YFP-Parkin cells with either non-targeting (NT1) or 
USP30-targeting (D1 and D3) siRNA oligos for 72h and depolarised 
mitochondria for 1h with increasing amounts of AO (0.01, 0.1 and 1µM each), 
(Figure 3.3). The knockdown process appeared to have sensitised the cells to 
the AO treatments. After 1h with 1µM AO, 67% of cells transfected with non-
targeting (NT1) siRNA oligos had Parkin puncta on their mitochondria against 
32% of untransfected cells in the previous experiment (Figure 3.3D and 3.2C). 
The additive stress caused by the transfection might have lowered the 
threshold for mitophagy induction. However, USP30 depletion itself did not 
consistently affect Parkin relocation (Figure 3.3D). With 1µM AO treatment, 
~70% of cells presented mitochondrial Parkin puncta independently on USP30 
depletion. One could argue that with 1µM, mitophagy and Parkin recruitment 
































































Figure 3.2: Antimycin A and Oligomycin A induce Parkin translocation to 
mitochondria.  
hTERT-RPE1-YFP-Parkin cells were treated with DMSO 0.01μM, 0.1μM and 1μM of 
Antimycin A and Oligomycin A for 1h, 2h, 8h and 24h. The cells where then fixed with 
PFA and stained with both anti-TOMM20 and anti-TIMM44 antibodies. The coverslips 
were mounted using mowiol mixed with DAPI. Images were taken using a 3i spinning 
disk confocal microscope. A) Images show hTERT-RPE1-YFP-Parkin cells treated 
with 1μM of Antimycin A and Oligomycin A over time. Scale bar: 10μm. B) Cropped 
and enlarged images from panel A. Scale bar: 10μM. C) Panel A quantification: The 
translocation of Parkin to mitochondria was sorted into 3 categories (Diffused, Puncta 
and Aggregates). The graph depicts the percentage of cells with either Parkin puncta 
(Punct.) or aggregates (Aggr.) on mitochondria. D) The percentage of cell with 
mitochondrial Parkin (aggregates + puncta) was plotted over time. *8h time point, 
0.01μM AO: Parkin was cytosolic in all of the cells quantified. Data from a single 
experiment 
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occured too rapidly to detect a further enhancement upon USP30 knockdown. 
At a lower concentration (0.1µM), one siRNA oligo appeared to enhance 
Parkin recruitment (D3; 53% of cells with Parkin punctae compared to 30% for 
NT1), while the second oligo had the opposite effect (D1: 16%);  although both 
siRNA oligos efficiently depleted USP30 (Figure 3.3D and Figure 3.5). 
 
A genome-wide siRNA screen performed in HeLa cells overexpressing YFP-
Parkin similarly revealed that upon CCCP treatment USP30 knockdown did 
not affect Parkin recruitment to mitochondria (Hasson et al., 2013). 
In agreement with my observation, a genome-wide siRNA screen performed 
in HeLa cells overexpressing YFP-Parkin and aiming at identifying regulators 
of CCCP-induced mitophagy also failed to isolate USP30 as a regulator of 
Parkin recruitment (Hasson et al., 2013). 
 
These results indicate that in Parkin-overexpressing cells, USP30 does not 




























































Figure 3.3: USP30 knockdown does not affect Parkin translocation to 
mitochondria.  
A and B) hTERT-RPE1-YFP-Parkin cells were transfected with either non-targeting 
(NT1) or individual oligos targeting USP30 (D1 and D3) for 72h and treated with 0.01, 
0.1 or 1μM Antimycin A and Oligomycin A (AO) for 1h. The cells where then fixed with 
PFA and stained with anti-TOMM20 antibody. The coverslips were mounted using 
mowiol mixed with DAPI. Scale bar: 10μm. C) The translocation of Parkin to 
mitochondria was monitored on a NIKON Ti-Eclipse microscope and sorted into 3 
categories: Diffused, Puncta and Aggregates. D) Graph describing Parkin’s 

































































































  USP30 depletion accelerates depolarisation induced 
ubiquitylation and degradation of the outer mitochondrial 
membrane protein TOMM20. 
 
Western blot analysis is another powerful approach to study mitophagy in the 
hTERT-RPE1-YFP-Parkin cells. Jin Rui Liang, aka “Amos”, a former PhD 
student in the Clague-Urbé lab, has shown that USP30 binds to TOMM20, one 
of Parkin’s substrates. He further discovered that USP30 depletion strongly 
enhanced CCCP-induced degradation of TOMM20 in hTERT-RPE1-YFP-
Parkin cells (Liang et al., 2015).  
First, I set out to reproduce his results and assess whether AO-induced 
ubiquitylation was regulated by USP30. To observe ubiquitylation and early 
OMM degradation events, I treated hTERT-RPE1-YFP-Parkin cells for 4h with 
CCCP (10µM) and AO (1µM each), (Figure 3.4). After 4h of mitophagy 
induction, the pool of the OMM protein MIRO1 was nearly fully degraded 
(~20% left) and the levels of other OMM proteins, TOMM20 and TOMM22, 
were decreasing.  
In agreement with Amos’ results, USP30 knockdown specifically enhanced the 
elimination of TOMM20 and TOMM22 upon CCCP treatment without affecting 
PINK1 stability, Parkin ubiquitylation or other OMM and IMM proteins (Liang et 
al., 2015). All of those results were also reproduced with AO treatment. 
 
To better observe the ubiquitylation events preceding the proteasomal 
degradation of OMM proteins, I treated hTERT-RPE1-YFP-Parkin cells for only 
1h and with varying concentrations of AO (0.01, 0.1 and 1µM), (Figure 3.5). I 
also probed for OPA1 to have an indication of the depolarisation status of the 
mitochondrial network. OPA1 is a core regulator of mitochondrial membrane 
fusion and can interfere with mitophagy (MacVicar and Lane, 2014). This 
protein has eight splice variants which can be cleaved at S1 and S2 sites. S1 
cleavage is mediated by OMA1, a mitochondrial protease, and gives rise to 
short OPA1 (S-OPA1) species which are unable to support mitochondria 




Figure 3.4: USP30 knockdown increases depolarisation-induced degradation of 
mitochondrial proteins. 
hTERT-RPE1-YFP-Parkin cells were transfected with either non-targeting (NT1) or 
individual oligos targeting USP30 (D1 and D3) for 72h and treated with DMSO, 
Antimycin A and Oligomycin A (AO, 1μM each) or CCCP (10 μM) for 4h then lysed in 
RIPA buffer. The lysates where probed for mitochondrial proteins. Higher exp.: higher 
exposure. The black arrows indicate unmodified-proteins; the red arrows point 



















































Depolarisation promotes the OMA1-dependent cleavage of long forms of 
OPA1 (L-OPA1) to enable fission of the mitochondrial network (Ishihara et al., 
2006),(MacVicar and Lane, 2014). I found that with a one-hour treatment, only 
the 1µM concentration was sufficient to promote the full cleavage of L-OPA1; 
suggesting that 0.1 and 0.01 µM AO result in an incomplete depolarisation of 
the mitochondrial network (Figure 3.5). In agreement with this, I observed that 
the MFN2 pool was only partially degraded with 0.1µM AO whilst only a small 
fraction remained intact with 1 µM AO. 
 
With 1µM AO, TOMM20 was poly- or multiply mono ubiquitylated: mono-, di- 
and tri-ubiquitylated species of TOMM20 were distinguishable by western blot 
analysis. Interestingly, knocking down USP30 clearly enhanced TOMM20 
ubiquitylation.  
Amos made a similar finding. He treated hTERT-RPE1-YFP-Parkin cells with 
10µM CCCP for 5h and blocked the proteasomal degradation of OMM proteins 
using the proteasome inhibitor epoxomicin. He was then able visualise an 
enhancement of mono- and di- TOMM20 ubiquitylation species in USP30 
knockdown cells that were absent in the control cells at that timepoint (Liang 
et al., 2015).  
My results with the more selective depolarising agents AO further confirm that 
TOMM20 is a bona-fide substrate of USP30 in hTERT-RPE1-YFP-Parkin cells. 
As is clear from the above, overexpression of YFP-Parkin is clearly a useful 
tool to amplify mitophagy and easily assess the involvement of proposed 
mitophagy players. Yet, in the cells I used here, Parkin is overexpressed at 
very high and non-physiological levels and this might have affected the data I 
was collecting: by saturating the cells with Parkin, this E3 may ubiquitylate 
nearby proteins non-specifically. 
 
Hence, I decided to turn to a cell model expressing endogenous Parkin and 






Figure 3.5: USP30 knockdown increases depolarisation induced ubiquitylation 
and degradation of mitochondrial proteins. 
hTERT-RPE1-YFP-Parkin cells were transfected with either non-targeting (NT1) or 
individual oligos targeting USP30 (D1 and D3) for 72h and treated with DMSO or 0.01, 
0.1 or 1μM Antimycin A and Oligomycin A (AO) for 1h. The cells were lysed in RIPA 
buffer and immunoblotted for mitochondrial proteins. Black arrow: unmodified 
TOMM20; Red arrow: Ubiquiylated species of TOMM20. Note that the 3rd ubiquitin 
band from the bottom appears as a double band, which may result from the 


















































3.3 SH-SY5Y cells stably expressing mCherry-GFP-FIS1101-152: A cell 
model to monitor endogenous mitophagy. 
 
 SH-SY5Y cells: A neuroblastoma cell line expressing endogenous 
Parkin and USP30 
 
I first assessed the expression levels of Parkin, USP30 and other mitochondrial 
proteins across cell lines that were readily available to me (Figure 3.6A). 
Neuroblastoma cells such as SH-SY5Y and SKN-BE2(c) expressed Parkin 
strikingly higher than other immortalised cell lines in the panel. The embryonic 
kidney derived cell line, HEK293T also expressed reasonably large amounts 
of Parkin. On the contrary, HCT116, MCF7 and U2OS cells appeared to 
express much lower levels, whilst Parkin was undetectable in HeLa and 
hTERT-RPE1 cells. It should be noted though that the HCT116 sample 
appeared to be underloaded. 
An expanding body of work suggests that Parkin is a tumour suppressor. 
Indeed, the PARK2 gene is deleted in a plethora of human cancers (Gong et 
al., 2014; Veeriah et al., 2010a, 2010b). This could explain the absence of 
Parkin form HeLa cells. Interestingly, USP30 expression appeared to correlate 
with TOMM20 across cells: the USP30/TOMM20 ratio was relatively constant 
whether the cells expressed USP30 highly or not (Figure 3.6B). Parkin 
expression did neither correlate with USP30 or TOMM20 (Figure 3.6C-D). 
As I was interested in proteins involved in familial forms of Parkinson’s disease, 
I decided to focus on cells that would be the closest to neuronal cells such as 
neuroblastoma. I chose the SH-SY5Y cells as these have been well 
documented to share neuronal features such as tyrosine hydroxylase and 
dopamine-β-hydroxylase activity and have the ability to differentiate into 




Figure 3.6: Expression levels of key mitophagy players across neuroblastoma-
derived, and non-neuroblastoma cells. 
A) SH-SY5Y, SKNBE2(c), HeLa, HEK293T, HCT116, RPE1, U2OS and MCF7 cell 
lysates were probed for mitophagy markers as shown on the figure. B-D) Graphs 
representing the relative expression of B) USP30 or C-D) Parkin over B&D) TOMM20 
or C) USP30 and normalised to SH-SY5Y cells. The images were acquired using a 
LICOR Odyssey CLx infrared imaging platform and analysed using the ImageStudio 









































































































































































































 Mitochondrial fraction enrichment: Amplifying the signal. 
 
Western blot analysis is a powerful approach to monitor global mitophagy as 
seen in YFP-Parkin overexpressing hTERT-RPE1 cells. However, SHSY5Y 
cells express a much lower amount of endogenous Parkin and thus the number 
of mitophagy events is expected to be lower. In order to pick up the mitophagy 
signal more efficiently by immunoblotting, I adopted a cell fractionation and 
mitochondrial enrichment protocol (Figure 3.7).  
 
After homogenising SH-SY5Y (mito-QC, a variant described in section 2.3) 
cells in a hypotonic buffer, I centrifuged the homogenates at 600g to spin out 
the nucleus. I then fractionated the post nuclear supernatant (PNS) at 7,000g 
to obtain a mitochondria enriched pellet (MF). It should be noted that this pellet 
also contains other heavy membranes such as ER and some peroxisomes. I 
loaded equal amounts of protein in each fraction (7µg protein) and quantified 
the MF over PNS band intensity ratio using the ImageStudio software. I found 






Figure 3.7: Mitochondrial enrichment by differential centrifugation. 
Two dishes of SH-SY5Y mito-QC cells were homogenised in HIM buffer (1 and 2). 
The nuclei were spun down at 600g to collect the Post Nuclear Supernatant (PNS). 
The PNS was spun a second time at 7,000g. The resulting pellet was labelled 
Mitochondria Fraction (MF) and the supernatant the Post Mitochondrial Supernatant 































I next used this technique to analyse mitochondrial fractions enriched from SH-
SY5Y cells treated for 1 or 4h with AO (1µM each) (Figure 3.8).  
Upon depolarisation, PINK1 gradually accumulated over time exclusively in the 
mitochondrial fraction. This was accompanied by the apparent poly- or multiple 
mono ubiquitylation of MFN1 and MFN2 as evidenced by multiple higher 
molecular weight species. In contrast, the fission protein FIS1 was strongly 
mono- and possibly di-ubiquitylated. Surprisingly, whilst TOMM20 was one of 
the most clearly ubiquitylated proteins in hTERT-RPE1-YFP-Parkin cells, I 
could not pick up any ubiquitylated species of TOMM20 in SH-SY5Y cells. The 
only bands I could observe at this molecular weight were most likely non-
specific as they were also seen in the absence of depolarisation.  
 
 
Figure 3.8: Antimycin A and Oligomycin A induce the ubiquitylation of 
mitochondrial proteins in SH-SY5Y mito-QC cells. 
SH-SY5Y MGFIS cells were treated with Antimycin A and Oligomycin A (AO; 1μM 
each) for 0, 1 and 4h and homogenised. The homogenates were then fractionated by 
centrifugation to obtain a Post Nuclear Supernatant (PNS), a Post Mitochondrial 
Supernatant (PMS) and a Mitochondrial Fraction (MF). The fractions were then 
resolved by western blotting and probed as annotated. Red asterisk: non-specific 






































 Mitophagy probes for in vivo imaging  
In recent years, a variety of reporters and dyes have been generated to 
specifically observe mitophagy (Table 3.1). I chose to use the mCherry-GFP-
FIS1101-152 reporter, also known as mito-QC, which had been characterised and 
introduced into SHSY5Y and U2OS cells by the Ganley lab (MRC-PPU, 
Dundee). This fluorescent probe consists of tandem fluorophores (mCherry 
and GFP) attached to the mitochondrial targeting sequence (MTS) of FIS1 (aa 
101 to 152), which targets it to the OMM (Figure 3.9) (Allen et al., 2013). 
This type of Cherry/RFP and GFP tandem tagged reporters have been widely 
used to study autophagy flux (when coupled to LC3 or p62/SQSTM1) and were 
first introduced by Tamotsu Yoshimori and Terje Johansen (Kimura et al., 
2007; Pankiv et al., 2007). The GFP fluorescence is quenched in acidic 
compartments such as lysosomes. Hence, healthy and cytosolic mitochondria 
appear as both “green” and “red” whilst fragments that are engulfed in 
autolysosomes appear as “red”-only puncta. 
I treated SH-SY5Y mito-QC cells, kindly gifted by the Ganley lab, for 24h with 
1 µM Antimycin A and either with 1µM (low) or 10 µM (high) Oligomycin A and 
then measured the number of mitophagy events occurring in those cells 
(Figure 3.10A-C). The “low AO” (1µM each) condition was sufficient to 
promote the ubiquitylation of OMM proteins in SH-SY5Y mito-QC cells and 
thus had the potential to trigger mitophagy (Figure 3.8). The “high AO” (1 and 
10µM respectively), was optimised by the Ganley lab to specifically observe 
mitophagy in SH-SY5Y mito-QC cells (Allen et al., 2013). I observed the cells 
using a 3i spinning disk microscope and sequentially imaged the GFP and 
mCherry fluorophores (Ex488/Em507 then Ex561/Em610) with either a 60X or 
40X oil objective lens (Figures 3.10A-C and 3.10D respectively). 
I considered that each “red-only” punctum corresponded to a mitolysosome. 
To obtain a binary image showing only the mitolysosomes, I used the “Image 
Calculator” plugin on Fiji and subtracted the image obtained with the green 
laser (Ex488/Em507) from the one taken in the red channel (Ex561/Em610). I 
then used the threshold tool to obtain a binary image and counted the number 
of dots per cell using the “Analyze Particles” function in Fiji (Figure 3.10B).   
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Figure 3.9: Schematic represent-
tation of the mCherry-GFP-
FIS1101-152 mitophagy reporter. 
This probe is comprised of a 
fluorophore tandem, mCherry and 
GFP, which is tagged to the 
mitochondrial targeting sequence of 
FIS1 (residues 101–152), an outer 
mitochondrial membrane protein. 
Upon mitophagy, mitochondria 
fragments are engulfed in 
autophagosomes which then fuse 
with lysosomes for their 
degradation. The resulting mitoly-
sosomes are acidic and thus 
quench the GFP fluorophore, 











I found that “low AO” promoted mitochondrial fragmentation but was 
insufficient to induce the formation of detectable mitolysosomes within 24h 
(Figure 3.10C). When using the “high AO” treatment, I triggered a clear and 
significant rise in mitophagy: on average the control DMSO and “low AO” 
treated cells had 0.8 mitolysosomes per cells against 5 mitolysosomes per 
cells with “high AO” (Figure 3.10C-D). I then used the “high AO” combination 
as a standard for all of the following imaging experiments. 
It is interesting to note that the “basal” (uninduced) mitophagy rate of SH-SY5Y 
mito-QC cells was strikingly low: they had on average 10-fold less 




Figure 3.10: Antimycin A and Oligomycin A promote the formation of 
mitolysosomes in SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were treated for 24h with Antimycin A and Oligomycin A 
at either low dose (AO low; 1μM each) or high dose (AO high; 1μM and 10μM 
respectively). The cells were imaged by confocal using a 63X objective lens. Scale 
bar: 10μm. B) Panel demonstrating the image analysis method: A ROI is drawn 
around each cell (in blue). Then using the Image Calculator plugin on Fiji, the green 
(GFP) channel is subtracted from the red channel (mCherry) to obtain the mCherry-
only stained mitolysosomes. The number of mitolysosmes per ROI (cell) is counted 
using the Analyze Particles function of Fiji. C) Graph representing the number of 
mitolysosomes per cell (spread of data in a single experiment). Error bars: mean ± 
SD. D) SH-SY5Y mito-QC cells were treated with high doses of Antimycin A and 
Oligomycin A (AO; 1 and 10μM respectively). The images were taken using a 40X 
confocal objective lens then analysed as in B). Average of four experiments. The 
statistical significance of the results was assessed using a t-test; ** indicates p-value 
































































Allen and colleagues had previously arbitrarily set a threshold of 3 or more 
mitolysosomes per cell to determine the number of cells undergoing mitophagy 
(Allen et al., 2013). I used this as an alternative approach to quantitate 
mitophagy. After processing all the images in the same manner, I manually 
counted SH-SY5Y mito-QC cells that had 3 or more “red”-only punctate 
(Figure 3.11). This quantitation process was faster and enabled me to quantify 
a greater number of cells. Using this technique, I found that 24h AO induced 
mitophagy in 27% of SH-SY5Y mito-QC cells (Figure 3.11B). Those results 
were in good agreement with the Ganley lab, which report an induction of 
mitophagy in 33% of SH-SY5Y mito-QC cells with 24h AO.  I also tested the 
efficiency of Deferiprone (DFP), an iron chelator, to promote mitophagy in this 
cell line (Figure 3.11A-B). Indeed, Ganley and colleagues have shown that 
DFP promotes mitolysosome formation in SH-SY5Y mito-QC cells 
independently of PINK1 stabilisation or Parkin activity, with 42% of cells having 
more than 3 mitolysosomes (Allen et al., 2013). In my hands, 1mM DFP was 
twice as potent as AO: promoting mitophagy in 61% of SH-SY5Y mito-QC cells 




Figure 3.11: Deferiprone induces mitophagy in SH-SY5Y mito-QC cells.  
A) SH-SY5Y mito-QC cells were treated with Antimycin A and Oligomycin A (AO; 1 
and 10μM respectively) or Deferiprone (DFP; 1mM) for 24h. Mitophagy was measured 
by live cell imaging using a confocal microscope. Scale bar: 10 μm. B) Manual 
quantitation: all images were leveled identically then merged. The cells undergoing 
mitophagy (= cells with more than 3 mitolysosomes) were then counted and 
expressed as a percentage of total cell number. Shown is the average of 5 
experiments. Error bars: mean ± SD. Statistical analysis was performed using the 










































3.4 Exploring novel mitophagy triggers 
 
As I was interested in expanding the current knowledge on depolarisation-
dependent and independent means of inducing mitophagy in SH-SY5Y cells, 
I performed a mini-compound screen using both imaging and western blotting. 
I chose drugs that had previously been shown to target mitochondrial proteins 
or mitophagy. I selected Gamitrinib-triphenylphosphonium (G-TPP), 2-cyano-
3,12-dioxoolean-1,9-dien-28-oic acid Methyl Ester (CDDO-Me), Ivermectin 
(IVM) and Doxorubicin (DOX). 
 
G-TPP, a derivative of Geldanamycin, is an HSP90 inhibitor that is exclusively 
targeted to mitochondria via its TPP moiety (Siegelin et al., 2011). Through the 
inhibition of the chaperone, G-TPP induces the accumulation of misfolded 
protein and activates the mitochondrial Unfolded Protein Response (UPR). In 
HeLa over-expressing Parkin, G-TPP has been reported to promote PINK1 
stabilisation and the subsequent recruitment of Parkin to trigger the mitophagy 
cascade (Fiesel et al., 2017). G-TPP has also been shown to promote PINK1 
and pS65-ubiquitin accumulation in both human primary fibroblasts and in 
iNeurons (Fiesel et al., 2017).  
 
CDDO-Me is a Lon protease inhibitor (Bernstein et al., 2012). Lon is a 
mitochondrial matrix protease essential for mitochondrial quality control. It 
mediates the proteolysis of oxidised proteins and can selectively degrade key 
proteins during stress conditions (for example during respiratory chain 
remodelling). It also serves as a mitochondrial chaperone and can directly bind 
mitochondrial DNA to regulate its maintenance (Pinti et al., 2016). The 
Cossarizza lab found that in RKO cells, CDDO-Me impairs the mitochondrial 
network structure and promotes mitochondrial depolarisation, mitochondrial 
ROS production, degradation of mitochondrial proteins (MFN2, DNM1L, 
TOMM20) and apoptosis. Interestingly, below 1µM, apoptosis is not induced 
but there still remains a trend towards reduction of MFN2 and TOMM20 levels 
(Gibellini et al., 2015). In a similar fashion to G-TPP, CDDO-Me could 




IVM is an antiparasitic drug that has been reported to have anti-cancer 
properties (Zhu et al., 2017). Mechanistically, IVM is thought to target 
mitochondrial respiration and to decrease the mitochondrial membrane 
potential. This promotes the generation of reactive oxygens species and 
mitochondrial fragmentation (Zachari et al., 2019; Zhu et al., 2017). Employing 
microscopy, Ktistakis’s group have discovered that IVM promotes the 
accumulation of ubiquitin structures and autophagosomes around 
mitochondria in HEK293T and MEF cells. They reported that this pathway 
involves members of the canonical autophagic machinery (FIP200, ATG13, 
ULK1/2, NDP52) and is accompanied by a reduction in TOMM20 and MFN2 
levels after 3h of IVM treatment (Zachari et al., 2019).  
 
Finally, DOX is a potent chemotherapeutic drug affecting a broad spectrum of 
malignancies. DOX can mediate cell death through DNA intercalation and 
Topoisomerase II arrest. Through its quinone structure, DOX has also the 
ability to produce ROS and subsequent DNA damage [review: (Yang et al., 
2014)]. One of the main downfalls of DOX is that it promotes cardiotoxicity. A 
body of work suggest that cardiotoxicity is linked to a deregulation of 
autophagy or mitophagy.  
The individual studies disagree with each other: some report that DOX induces 
the accumulation of both autophagosomes as well as accumulation of PINK1 
and Parkin at mitochondria in rat and human cardiomyocytes, respectively 
(Kobayashi et al., 2010; Yin et al., 2018). In contrast others demonstrate, that 
in mouse heart DOX inhibits the recruitment of Parkin to mitochondria and 
reduces the engulfment of mitochondria into autophagosomes in a p53-
dependent manner (Hoshino et al., 2013). 
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 Preliminary screen in hTERT-RPE1-YFP-Parkin cells 
 
I first performed a mini-imaging screen in hTERT-RPE1-YFP-Parkin cells 
(Figure 3.12). In this screen, I treated the cells for 1h and 6h with IVM (20µM), 
DOX (62.5nM and 250nM), CDDO-Me (100nM), and G-TPP (10µM). I used 
AO (1 and 10µM respectively) and DFP (1mM) as positive controls for the 
induction of the PINK1/Parkin canonical pathway and non-canonical 
mitophagy pathways. I first focussed on Parkin recruitment to mitochondria 
and classified the mitochondrial Parkin phenotype into two categories: puncta 
and aggregates (as in Figure 3.3C).  
 
The only condition that showed translocation of Parkin to mitochondria after 
only one hour of treatment was the AO treatment, with 81% of cells having 
mitochondrial Parkin puncta (Figure 3.12A-B). After 6h, all AO-induced cells 
had Parkin aggregates (Figure 3.12C). At this time point, G-TPP induced near 
complete translocation of Parkin to mitochondria: 74% of cells had Parkin 
aggregates and 12% of cells had Parkin puncta. In the case of Ivermectin, 60% 
of cells had Parkin puncta and the mitochondrial network appeared 
fragmented.  
Consistent with the fact that DFP was reported to induce mitophagy 
independently on PINK1 and Parkin, I did not observe any effect of DFP on 
the cellular localisation of Parkin in hTERT-RPE1-YFP-Parkin cells (Allen et 
al., 2013). Similarly, CDDO-Me and DOX did not promote the relocalisation of 
Parkin. 
 
G-TPP and Ivermectin emerged as interesting candidates to induce Parkin 
recruitment in cell models that overexpress Parkin. I therefore went on to 
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Figure 3.12: Mini-imaging screen for alternative mitophagy inducers in hTERT-
RPE1-YFP-Parkin cells. 
A) hTERT-RPE1-YFP-Parkin cells were treated for both 1 and 6h with Antimycin A 
and Oligomycin A (AO; 1 and 10μM respectively), Deferiprone (DFP; 1mM), 
Ivermectin (IVM; 20μM), Doxorubicin (DOX; C1: 62.5nM, C2: 250nM), CDDO Methyl 
Ester (CDDO-Me; 100nM) or Gamitrinibtriphenylphosphonium (G-TPP; 10μM). The 
cells were then fixed with PFA, permeabilised and stained with a TOMM20 antibody. 
The coverslips were finally mounted with mowiol containing DAPI. Scale bar: 10μm. 
B and C) Quantification of the percentage of cells presenting either Parkin puncta or 
Parkin aggregates on mitochondria. Data from a single experiment (50 cells 
analysed). B) 1h treatment. C) 6h treatment.  
 
 Mini-screen in SH-SY5Y mito-QC cells 
 
I treated SH-SY5Y mito-QC cells for 24h with AO (1 and 10µM each), DOX 
(250nM), CDDO-Me (1µM) and G-TPP (10µM) and imaged the cells by live 
microscopy (Figure 3.13A-B). AO induced mitophagy in 33% percent of cells 
compared to the 2% basal mitophagy levels (> 3 mitolysosomes per cell). 
Interestingly, whilst DOX and CDDO-Me did not trigger Parkin accumulation in 
hTERT-RPE1-YFP-Parkin cells, these compounds did stimulate mitophagy in 
SH-SY5Y mito-QC cells:  21% of DOX and 53% of CDDO-Me treated SH-
SY5Y mito-QC cells had more than 3 mitolysosomes. Contrary to my 
observations in hTERT-RPE1-YFP-Parkin cells, G-TPP promoted little or no 
increase in mitophagy: 6% of G-TPP against 2% of DMSO treated cells were 
undergoing mitophagy following the 24h treatment. 
 
In parallel I immunoblotted a duplicate set of cells and assessed the levels of 
mitochondrial depolarisation (OPA1 cleavage), apoptosis induction (PARP 
cleavage), PINK1 accumulation, Parkin modification and mitochondrial 












































































































































Figure 3.13: Imaging and western blotting mini-screen for alternative mitophagy 
triggers in SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were treated for 24 with Antimycin A and Oligomycin A 
(AO; 1 and 10μM each), Doxorubicin (DOX; 250nM), CDDO Methyl Ester (CDDO-Me; 
1μM) or Gamitrinib-triphenylphosphonium (G-TPP; 10μM) then imaged by live cell 
imaging. Scale bar: 10μm. B) Manual quantification of the percentage of cells 
undergoing mitophagy (= cells with more than 3 mitolysosomes). Data from a single 
experiment (100 cells analysed). C and D) SH-SY5Y MGFIS cells were treated as in 
A and harvested in NP40 lysis buffer. The lysates were immunoblotted as indicated 
in the figure. 
I probed for a marker of apoptosis firstly to verify if the drugs were toxic in SH-
SY5Y cells and secondly because it has been reported that Parkin sensitises 
cell to apoptosis following depolarisation in Parkin overexpressing cells. Parkin 
is thought to trigger apoptosis through the direct ubiquitylation and degradation 
of MCL1 or by a ubiquitylation and proteasomal degradation of OMM proteins 
leading to the rupture of the OMM (Yoshii et al., 2011; Carroll et al., 2014; 
Liang et al., 2015). In SH-SY5Y cells expressing endogenous Parkin, AO did 
not promote PARP cleavage. As expected, treating those cells with AO for 24h 
triggered depolarisation, as seen by the accumulation of S-OPA1, and 
promoted the accumulation of PINK1, phosphorylation of ubiquitin on Ser65 
and ubiquitylation of OMM proteins (MFN2, FIS1). Interestingly, Parkin itself 
was depleted after 24h of depolarisations, presumably along with the 
mitochondria it was recruited to. 
 
Similar to induction of mitophagy with OA, CCDO-Me treatment induced OPA1 
cleavage, albeit to a lesser extent, and thus mitochondrial depolarisation, 
PINK1 accumulation and FIS1 ubiquitylation. Interestingly in contrast to AO, 
CDDO-Me did not induce ubiquitylation of MFN2. The levels of pS65-Ub were 
also slightly elevated with CDDO-Me and could result from the stabilisation of 
a small amount of PINK1. In RKO cells, 1µM CDDO-Me was shown to 
promotes Caspase 9 cleavage and apoptosis (Gibellini et al., 2015). I 
confirmed in SH-SY5Y cells where I observed the cleavage of PARP. 
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I also observed a small induction of PARP cleavage with DOX but did not 
measure any changes in accumulation of PINK1 or protein ubiquitylation or 
turnover in SH-SY5Y cells. Likewise, G-TPP treatment neither triggered PINK1 
accumulation nor promoted ubiquitylation of outer mitochondrial membrane 
proteins.  
 
In hTERT-RPE1-YFP-Parkin cells, the induction of Parkin recruitment to 
mitochondria by G-TPP had appeared delayed in comparison with AO (Figure 
3.12). I thus wondered if the ubiquitylation of OMM proteins and subsequent 
autophagic engulfment of mitochondria was also delayed. I thus treated SH-
SY5Y mito-QC cells for 48h with 10µM G-TPP but did not observe any increase 
in the percentage of cells undergoing mitophagy compared to the DMSO 
condition (Figure 3.14A-B).  
Likewise, also treating the cells with higher doses (15 and 20 µM) G-TPP for 
either 24 or 48h did not result in the appearance of ubiquitylated species of 
MFN2 and FIS1 nor did I measure the generation of pS65-Ub (Figure 3.14C-
D). I used AO as a positive control and found that after 48h of treatment, an 
even greater amount of PINK1 is stabilised than after 24h, whilst MFN2 and 
FIS1 are still equally ubiquitylated and the pS65-Ub signal remains stable. 
 
In contrast to G-TPP, IVM, used at 5 and 10 µM, promoted mitophagy in 27% 
and 59% of SH-SY5Y mito-QC cells respectively (Figure 3.15A-B). IVM-
induced mitophagy was also accompanied by the ubiquitylation of FIS1 and 
the generation of phospho-ubiquitin (Figure 3.15C). The western blot analysis 
also suggested the involvement of Parkin in Ivermectin-mediated mitophagy 
as the Parkin pool was diminished by more than 50% after 24h of IVM 
treatment. Intriguingly, I did not measure any increase in full length PINK1 at 
this time point, whilst I did observe pS65-Ub accumulation. PINK1 could 
possibly be engaged at early stages of IVM-induced mitophagy and then get 
degraded. This experiment should be repeated and a positive control for 
PINK1 accumulation included, such as AO treated samples. PINK1 
knockdown experiments and IVM time courses would also help shed light on 





Figure 3.14: Gamitrinib-TPP does not trigger mitophagy in SH-SY5Y mito-QC 
cells.  
A) SH-SY5Y mito-QC cells were treated for 48h with 10μM Gamitrinib-TPP (G-TTP). 
Mitophagy was assessed by live imaging. Scale bar: 10μm. B) Manual quantification 
of cells undergoing mitophagy (= cells with more than 3 mitolysosomes). Data from a 
single experiment (100 cells analysed). C and D) SH-SY5Y mito-QC cells were 
treated for both 24h and 48h with either G-TTP (15 and 20μM) or with Antimycin A 
and Oligomycin A (AO; 1μM each). AO was used as a positive control of mitophagy. 
The samples were lysed using NP40 lysis buffer and probed as annotated. Red arrow: 












































































































































IVM did not appear to induce OPA1 cleavage suggesting that it may not trigger 
potent mitochondrial depolarisation, contrary to what has been reported in 
RCC cells: in RCC cells 5µM IVM is sufficient to significantly decrease the 
mitochondrial membrane potential and with 15µM the membrane potential was 
decreased by ~3 fold (Zhu et al., 2017). Ktistakis’ group reported that 1 and 
10µM ivermectin significantly inhibited mitochondrial oxygen consumption rate 
of HEK293 cells by 20 and 30% respectively within 25min compared to 60% 




Figure 3.15: Ivermectin induces mitophagy in SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were treated with Ivermectin (IVM, 0, 5 or 10μM) for 24h. 
Mitophagy was measure by live microscopy. Scale bar: 10μm. B) Exp#1 cells were 
treated for 24h with 0, 0.1, 1, 10μM IVM (100 cells analysed). Exp#2 cells were treated 
for 24h with 0, 5 or 10μM IVM (100 cells analysed). The images were manually 
quantified (cells undergoing mitophagy = cells with more than 3 mitolysosomes). Error 
bars: mean ± SD. C) SH-SY5Y mito-QC cells treated for 24h with ivermectin (0, 0.1, 
1, 10μM) were lysed in NP40 and immunoblotted as depicted. 
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 Magnifying and amplifying the PINK1/Parkin pathway to reveal 
core mitophagy regulators. 
 
Using the hTERT-RPE1-YFP-Parkin cells, I found that similar to CCCP, AO 
triggers mitochondrial fragmentation, mitochondrial depolarisation, 
accumulation of full-length PINK1 and Parkin recruitment to mitochondria. This 
was accompanied by the ubiquitylation of OMM proteins such as TOMM20 and 
their degradation as seen with MFN2.  
In these cells, Parkin translocation was highly dependent on the degree of 
mitochondrial depolarisation. Employing 1µM of AO was sufficient to activate 
the depolarisation-induced cleavage of OPA1 and efficiently recruit Parkin to 
mitochondria after only 1h of treatment. However, although Parkin’s 
recruitment relies on preceding ubiquitylation of the OMM that serves as a 
substrate for PINK1, knocking down the mitochondrial deubiquitylase USP30 
did not increase or accelerate Parkin translocation in hTERT-RPE1-YFP-
Parkin cells. This suggests that USP30 does not prevent mitophagy by globally 
removing ubiquitin or pS65-Ub moieties necessary for Parkin recruitment. 
However, in the YFP-Parkin-hTERT-RPE1 system, the number of USP30 
molecule per SH-SY5Y cell is most likely too low to limit the feedforward loop 
and prevent Parkin recruitment. This could be assessed by monitoring 
endogenous Parkin or by employing cells overexpressing catalytically inactive 
Parkin in which the feedforward loop would not be engaged. 
 
In contrast to my observations, overexpressing USP30 in HeLa 
overexpressing Parkin cells delayed Parkin’s recruitment to mitochondria 
(Geisler et al., 2019; Wang et al., 2015). A genome wide siRNA screen 
performed in HeLa overexpressing Parkin, specifically assessing modulators 
of Parkin recruitment, found that Parkin recruitment to mitochondria was 
enhanced by the knockdown of proteins such as BAG4 or SIAH3 (Hasson et 
al., 2013). But, congruent with my results and other screens, USP30 
knockdown did not affect Parkin translocation following CCCP treatment 
(Geisler et al., 2019; Hasson et al., 2013). The USP30-dependent regulation 
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of Parkin recruitment might be concentration dependent. In excess, USP30 
appears to have the potential to remove ubiquitin prior to PINK1 
phosphorylation and therefore limits Parkin’s recruitment. However, our data 
suggest that the endogenous expression levels of USP30 are too low to 
efficiently oppose Parkin. This is in agreement with mass spectrometry 
experiments reporting that USP30 is a low abundance protein  (Kulak et al., 
2014; Nagaraj et al., 2011; Schwanhäusser et al., 2011).  
 
Other DUBs have been proposed to regulate Parkin recruitment. USP33, 
originally characterised as an ER and Golgi localising DUB, was recently 
shown to also localise at mitochondria (Niu et al., 2019; Thorne et al., 2011). 
It was reported that overexpressed USP33-GFP overlaps with TOMM20 by 
immunofluorescence in HEK293 cells. The overexpressed protein was also 
found in mitochondrial fractions following mitochondria enrichment assays (Niu 
et al., 2019). Using Parkin truncation mutants, Niu and colleagues next showed 
that overexpressed USP33 binds to full length Parkin, to Parkin’s UBL domain 
and to its RING2 domain (Niu et al., 2019). They further demonstrated that 
knocking down USP33 accelerates the recruitment of Parkin to mitochondria 
(TOMM20 staining) in U2OS cells overexpressing GFP-Parkin treated with 
20µM CCCP. Concomitantly, they observed an increase in ubiquitylated 
species of Parkin and suggested that USP33 destabilises Parkin through 
deubiquitylation (Niu et al., 2019).  
 
Other members of the USP family, instead positively regulate Parkin 
translocation. USP8 has been reported to remove inhibitory K6-Ubiquitin 
chains from Parkin and thus oppose Parkin’s self-ubiquitylation to accelerate 
mitophagy (Durcan et al., 2014). An siRNA screen for DUBs regulating Parkin 
recruitment to mitochondria in HeLa over expressing Parkin cells, revealed that 
the nucleolus localised DUB, USP36, facilitates the recruitment of Parkin 
possibly through transcriptional regulation (Geisler et al., 2019). 
 
DUBs, such as short-USP35 isoform that is most likely catalytically inactive 
(missing the catalytic cysteine present in full length USP35) and USP15 that is 
cytosolic, were reported instead to oppose Parkin ubiquitylation of OMM 
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proteins (Cornelissen et al., 2014; Wang et al., 2015). However, USP30 is so 
far the only active DUB constitutively localising at mitochondria (Urbé et al., 
2012; Marcassa et al., 2018).  
 
Whilst my experiments did not reveal a role for USP30 in Parkin recruitment, I 
did observe that USP30 opposed Parkin ubiquitylation of OMM proteins. In 
hTERT-RPE1-YFP-Parkin cells, USP30 depletion specifically enhanced 
TOMM20 ubiquitylation as previously reported by Amos (Liang et al., 2015). 
By western blotting, I did not observe the enhancement of ubiquitylated 
species of other OMM proteins (TOMM22, MIRO1 or MFN2). Mass 
spectrometry experiments performed in HEK293 cells overexpressing Parkin 
and USP30 or depleted of USP30 revealed that other Parkin substrates of such 
as GDAP1, VDAC1, VDAC2 and VDAC3 were deubiquitylated by USP30 
(Bingol et al., 2014; Cunningham et al., 2015). Likewise, I also observed these 
additional ubiquitylation events by mass spectrometry using SH-SY5Y USP30 
knockout cells. This is further detailed in Chapter V. 
 
 The mitophagy probes: Catching spontaneous mitophagy events.  
 
To study mitophagy in vivo, multiple research groups have generated pH 
sensitive reporters (Table 3.1). Rosella and mito-QC are two reporters that 
contain a tandem fluorophore and are based on the same principle: GFP gets 
quenched in the acidic environment of the lysosome thus revealing the 
mitochondrial fragments that are engulfed in autophagolysosomes (Rosado et 
al., 2008; Allen et al., 2013).  
Mt-Keima is a dual-excitation fluorophore: at mitochondrial pH (pH8), Keima is 
favourably exited by 445nm lasers but when the pH decreases, its excitation 
shifts towards a peak of 561nm. As for the above reporters, this allows for the 
discrimination between healthy mitochondria (pH8) and mitolysosomes (pH4) 
(Katayama et al., 2011). Both mito-QC and Mt-Keima have been used to 
generate animal models of mitophagy enabling mitophagy to be observed in 
vivo:  Whitworth’s group and our lab have generated Drosophila models whilst 
Ganley and Finkel’s labs have produced mice models (Lee et al., 2018; 
McWilliams et al., 2018; Sun et al., 2015). The fly models will be further 
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detailed in Chapter VI, where I will present the generation and characterisation 
of the mt-Keima fly. One of the key differences between the mito-QC and mt-
Keima reporters lies in their targeting: mito-QC is targeted to the OMM via 
FIS1’s MTS whilst mt-Keima is targeted to the Matrix by COX VIII’s MTS. Thus, 
the use of the mito-QC probe could be limited by the proteasomal degradation 
of OMM proteins during mitophagy. However, unlike mito-QC, mt-Keima is 
incompatible with fixation and is therefore restricted to live imaging (Allen et 
al., 2013; McWilliams et al., 2016). 
 
Table 3.1: Commonly used dyes and probes to monitor mitophagy 
Probe/ dye Technique Reference 
mitoQC mCherry-GFP-FIS1101-152 
GFP is quenched in acidic pH 
Targeting sequence: FIS1101-152 (OMM) 
(Allen et al., 
2013) 
Mt-Keima pH dependent shift in excitation of Keima 
Targeting sequence: MTS of COX VIII (Matrix) 
(Katayama 
et al., 2011) 
MitoTimer Time dependent shift in emission of DsRed1-E5  
Targeting sequence: MTS of COX VIII (Matrix) 
(Hernandez 
et al., 2013) 
Rosella DsRed-GFP 
GFP quenching in acidic pH 




Mtphagy Dye Increased emission and excitation with pH 
acidification 
Fluorescent moiety: perylene-3,4-dicarboximide 
Fluorescence quencher: piperazine group  






The Mtphagy Dye is a pH-sensitive small molecule that is directed to 
mitochondria by its TPP moiety. It contains the fluorescent dye perylene-3,4-
dicarboximide that is constantly quenched at neutral pH by another moiety, the 
piperazine group. Once in acidic compartments, such as lysosomes, 
Mtphagy’s piperazine group gets protonated, thus cancelling its quenching 
effect and liberating Mtphagy’s fluorescence (Iwashita et al., 2017). Mtphagy 
gives an indication on mitophagy by highly fluorescing in mitolysosomes. To 
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assess the relative number of mitolysomes with respect to the total 
mitochondrial mass, Mtphagy can be used in combination with mitochondrial 
dyes such a MitoTracker. However, this technique is limited as most 
mitochondrial stains rely on the mitochondrial membrane potential to localise 
to the mitochondria (Padman et al., 2013).  
 
Finally, MitoTimer is a probe that uses the time depend-shift of emission of 
DsRed1-E5 also called Fluorescent Timer (Terskikh et al., 2000). It was 
originally created to follow the biogenesis, ageing and turnover of mitochondria 
(Hernandez et al., 2013). Unlike the previously discussed reporters, MitoTimer 
is not pH sensitive but sensitive to oxygen and temperature, thus the emission 
wavelength of Timer shifts linearly from green to red with time and can be used 
as a “fluorescent clock” (Terskikh et al., 2000). When tagged to mitochondria, 
Timer gives indications of mitochondrial turnover, biogenesis and enables the 
discrimination of “young” and “old” mitochondria (Hernandez et al., 2013). 
The Yan lab proposed that mitochondrial ROS can oxidise MitoTimer and 
trigger a radical shift of emission that creates red only puncta for damaged 
mitochondria (Laker et al., 2014). In Drosophila and mice models of MitoTimer, 
those red puncta have been shown to colocalise partially with mitochondria, 
LC3 and LAMP1 therefore suggesting that these are mitolysosomes (Laker et 
al., 2014, 2017; Stotland and Gottlieb, 2016). Thus, Laker and colleagues 
suggested the use the MitoTimer as a reporter of mitophagy. However, more 
studies have to be conducted to use this probe as such. Indeed, Hernandez 
and colleagues, reported that MitoTimer is denatured at pH 4.5 and loses its 
fluorescence (Hernandez et al., 2013). Hence it would not be possible to track 
mitochondrial delivery to lysosomes. It is instead recommended to measure 
the loss of red fluorescence as a readout of lysosomal degradation of 
mitochondria rather than counting the number of red puncta. 
 
All of the aforementioned assays are endpoint assays. They thus only report 
on lysosomal degradation of mitochondrial content and not on the progress of 
mitophagy itself. 
I chose to use the mito-QC reporter to follow mitophagy in the SH-SY5Y cells. 
The read-out is clear and a stable SH-SY5Y mito-QC cell line had already been 
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generated and was generously provided by the Ganley lab (Allen et al., 2013). 
Moreover, the mCherry and GFP fluorescence are compatible with the lasers 
on most microscopes. 
 
 
 Moving away from Oxidative phosphorylation uncouplers?  
 
Using the hTERT-RPE1-YFP-Parkin and SH-SY5Y mito-QC cell lines, I 
selected few potential mitophagy triggers: DOX, CDDO-Me, IVM and G-TTP. 
IVM and CDDO-Me induced mitochondrial ubiquitylation and mitophagy in SH-
SY5Y mito-QC and DOX promoted mitophagy without FIS1 and MFN2 
ubiquitylation. 
 
IVM was one of the most potent triggers of mitophagy in both screens: 20µM 
IVM promoted the recruitment of Parkin to mitochondria in 60% cells within 6h 
in hTERT-RPE1-YFP-Parkin cells and a 24h treatment with 5µM was sufficient 
to promote mitophagy in 27% of SH-SY5Y mito-QC cells. Using 10µM IVM for 
24h I also detected ubiquitylated species of FIS1 and accumulation of pS65-
Ub but also PARP cleavage.  
Ktistakis’s lab, had suggested that Ivermectin induced mitophagy was 
independent on Parkin. They compared CCCP and IVM and found that unlike 
CCCP, treating cells with 15µM IVM for 90 min did not trigger Parkin 
recruitment to mitochondria in HEK293 cells expressing mCherry-Parkin. 
Although Parkin was not present at mitochondria after 90min, they observed 
by microscopy the recruitment of the autophagic machinery to mitochondria: 
LC3, WIPI2, ATG13, NDP52, OPTN, p-TBK1 and ubiquitin formed aggregates 
around TOMM20 puncta in both HEK293 and MEF cells. After 2h of IVM 
treatment, they observed the degradation of TOMM20 by western blot 
analysis. The IVM-induced LC3 puncta were dependent on the canonical 
autophagy machinery (FIP200, ATG13 and ULK1/2). They also observed the 
mitochondrial ubiquitin puncta appearing with IVM were reduced by 50% with 
the combined knockout of the cytosolic E3 ligases TRAF2, CIAP1 and CIAP2 
(Zachari et al., 2019).  
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We could therefore hypothesise that in response to IVM treatment, TRAF2, 
CIAP1 and CIAP2 are engaged in the early stages of mitochondrial 
ubiquitylation which enables the recruitment of the autophagy machinery. 
Parkin may then be recruited at a later stage to amplify the ubiquitylation signal 
and subsequent mitophagy events. This would lead to the potent mitophagy 
induction that I have measured after 24h using the mito-QC probe in SH-SY5Y 
cells. 
 
Another potent trigger was CDDO-Me, the Lon protease inhibitor: 24h of 1µM 
CDDO-Me in SH-SY5Y mito-QC cells led to mitochondrial depolarisation 
(visualised by OPA1 cleavage), PINK1 stabilisation, a slight increase in pS65-
Ubiquitin, FIS1 ubiquitylation and promoted the autophagic degradation of 
mitochondria in 53% of SH-SY5Y mito-QC cells. 
Gibellini and colleagues have shown that Lon knockdown leads to impaired 
mitochondrial structure, degradation of selective mitochondrial proteins, 
defective mitochondrial function and further apoptotic cells death in colon 
cancer cells (Gibellini et al., 2014). Subsequently, they made use of the Lon 
inhibitor CDDO-Me in colon cancer cells and found similar results. As 
mentioned earlier on, below 1µM, apoptosis was not induced but reduction in 
MFN2 and TOMM20 levels were still observed (Gibellini et al., 2015). In SH-
SY5Y mito-QC cells treated with 1µM CDDO-Me for 24h, I did not observe any 
clear degradation of either TOMM20 or MFN2 but I instead discerned 
ubiquitylated species of FIS1. CDDO-Me potentially induces mitophagy by 
interfering with the degradation of mitochondrial misfolded proteins. EM 
imaging revealed that 24h treatment of 2.5µM CDDO in Granta cells promotes 
the accumulation of electron dense inclusion within mitochondria, which are 
most likely misfolded protein aggregates (Bernstein et al., 2012). This 
accumulation of misfolded protein in the matrix could affect PINK1 import 
through the TIMM complex and thus enable PINK1 accumulation without the 
need for depolarisation. 
The hypothesis that misfolded proteins can induce mitophagy was tested and 
proven by Richard Youle’s lab. They over-expressed a deletion mutant of 
ornithine carbamoyltransferase (ΔOTC, first introduced by Nicholas 
Hoogenraad), which generates insoluble protein aggregates in the 
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mitochondrial matrix and found that it induced mitophagy in a depolarisation-
independent manner (Burman et al., 2017; Jin and Youle, 2013; Zhao et al., 
2002). ΔOTC expression for 48h induced the mitochondrial Unfolded Protein 
Response (UPRmt) as well as accumulation of PINK1 and Parkin at 
mitochondria (Jin and Youle, 2013). ΔOTC accumulated at mitochondrial 
subdomains and promoted localised mitophagy. ΔOTC foci colocalised with 
TOMM20 and mitochondrial dyes, as well as Parkin, ubiquitin, OPTN and LC3. 
Those foci then dissociated from the rest of the network in a DRP1 dependent 
manner. Using PINK1 KO cells, Youle and colleagues reported that this 
misfolded protein-induced mitophagy was dependent on PINK1 and that it was 
accelerated by Parkin overexpression (Burman et al., 2017).  
Actinonin, a drug promoting mito-ribosome stalling and thus protein misfolding 
at mitochondria, reproduced the effects of ΔOTC expression confirming that 
overwhelming the UPRmt quality control promotes PINK1-dependent 
mitophagy (Burman et al., 2017). 
Interestingly knocking down Lon but not CLPP, another matrix protease, 
enhanced PINK1 accumulation, Parkin recruitment and mitochondria 
clearance in response to ΔOTC expression (Jin and Youle, 2013). This would 
suggest that Lon is essential in degrading misfolded proteins in the matrix and 
delays the involvement of mitophagy as a backup quality control system. This 
supports the use of Lon inhibitors, such as CDDO-Me, to trigger mitophagy. 
However, CDDO-Me does not only affect the UPRmt and mitophagy. CDDO-
Me directly targets Keap1 and IKKβ, which activates Nrf2 and supresses NF-
κB (Ahmad et al., 2006; Yates et al., 2006; Wang et al., 2014). Other targets 
of CDDO-Me include cyclins (Wang et al., 2017b). As CDDO-Me lacks 
specificity, I would not recommend it for the study of mitophagy. 
 
The HSP90 inhibitor, G-TTP (a Geldanamycin derivative), is another 
compound promoting the accumulation of misfolded proteins at mitochondria 
and subsequent UPRmt. This compound had contradictory effects in SH-SY5Y 
cells and hTERT-RPE1-YFP-Parkin cells.  
When I used G-TPP at 10µM, it induced the recruitment of Parkin to 
mitochondria in close to 90% of hTERT-RPE1-YFP-Parkin cells after 6h but 
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had no effect on mitochondrial protein ubiquitylation or mitophagy events in 
SH-SY5Y mito-QC cells after 24h and 48h. 
A study performed in HeLa cells overexpressing Parkin and mt-Keima, showed 
that 10µM G-TPP, was sufficient to induce a significant shift towards 
mitophagy fluorescence from 4h onwards. The induction was however less 
efficient than CCCP: after 12h with G-TPP the mitophagy index was ~80% 
weaker than with 10µM CCCP (Fiesel et al., 2017). Such weak mitophagy 
induction might not be detectable in SH-SY5Y mito-QC cells whereas in the 
YFP-Parkin overexpressing RPE1 cells, the Parkin amplification loop would 
allow even this weak trigger to initiate a clear mitophagy signal. 
 
They further observed that 10µM G-TPP induced the stabilisation of PINK1, 
the accumulation of pS65-ubiquitin and the recruitment of Parkin to 
mitochondria within 4h in HeLa cells overexpressing Parkin (Fiesel et al., 
2017). They also observed PINK1 stabilisation and pS65-Ubiquitin 
accumulation in human primary fibroblast and in iNeurons treated with 15µM 
G-TPP for 8h (Fiesel et al., 2017). 
This was confirmed in hTERT-RPE1-YFP-Parkin cells by my colleague Liam 
Pollock. He treated these cells with either G-TPP (10 and 20µM) or 17-AAG, a 
Geldanamycin derivative that is not targeted to mitochondria, for 4h and 24h. 
He found that both concentrations of G-TPP but not 17-AAG promoted OPA1 
cleavage, PINK1 and pS65-Ubiquitin accumulation as well as FIS1 poly 
ubiquitylation and degradation of MFN1 and MFN2 at 4h. Interestingly, he also 
observed PINK1 and pS65-Ub accumulation, to a lesser extent, in the parental 
hTERT-RPE1 cells which lack Parkin. This suggests that G-TPP mediated 
mitophagy does not require Parkin.  
 
Intriguingly, silencing another mitochondrial chaperone HSP9A, also known as 
GRP75, mt-HSP70 or mortalin, was reported to promote mitophagy in SH-
SY5Y cells (Burbulla et al., 2014). This chaperone is involved in the import and 
proper folding of mitochondrial proteins in the matrix (review: (Wiedemann and 
Pfanner, 2017)). Knocking down HSP9A promoted the accumulation of 
misfolded proteins, fragmentation of the mitochondrial network and the 
formation of LC3 and WIPI2 puncta in SH-SY5Y cells. Moreover, silencing of 
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HSP9A resulted in the colocalisation of TOMM20 with LAMP1 and a reduction 
in TOMM20 protein levels (Burbulla et al., 2014).  
Treating HCC cells with the 17-AAG HSP90 inhibitor over 24h increases the 
mRNA levels of HSPA9 and the protein levels of HSP9A possibly as a 
compensatory mechanism (Guo et al., 2014). Thus, in my experiments, SH-
SY5Y mito-QC cells might have upregulated HSPA9 in response to G-TPP, to 
compensate for the loss of HSP90 activity. This might have prevented the 
accumulation of misfolded proteins and the stabilisation of PINK1. It would thus 
be of interest to measure the influence of HSPA9 directed inhibitors, such as 
MTK-077, on mitophagy induction. 
 
The DNA intercalator and inhibitor of Topoisomerase II, DOX, was another 
drug able to induce mitophagy in SH-SY5Y mito-QC cells: a 24h treatment with 
250nM DOX induced mitophagy in 21% of cells. This mitophagy induction did 
not correlate with PINK1 accumulation, pS65-Ubiquitylation or with the 
ubiquitylation or degradation of MFN2 and FIS1. Likewise, 250nM of DOX did 
not promote the recruitment of Parkin to mitochondria in hTERT-RPE1-YFP-
Parkin. In contrast to my observations, DOX (62.5 and 250 nM) had previously 
been shown to induce PINK1 and Parkin accumulation, LC3-II formation as 
well as MFN2, VDAC, COXIV loss in AC16 human cardiomyocyte cells (Yin et 
al., 2018). Another study showed that treating HCT116 and HL-1 with 20nM-
1µM DOX for 24h downregulated CCCP mediated mitophagy: the 
accumulation of PINK1 and Parkin, as well as mitochondrial ubiquitylation was 
significantly reduced. Similarly injecting mice with DOX, decreased CCCP-
induced Parkin accumulation mice hearts (Hoshino et al., 2013).  
In vivo work in mice suggested that both acute and chronic DOX injection 
promote the accumulation of autophagosomes in mouse heart. Abdullah and 
colleagues hypothesised that this accumulation was the result of defective 
lysosomal degradation rather than due to an increase in autophagy (Abdullah 
et al., 2019). Indeed, co-treatment with chloroquine, which raises lysosomal 
pH and thus inhibits the degradation of autophagosomal content, did not 
further enhance autophagosome accumulation in mice heart.  
 125 
It would thus be essential to verify if the rise in mitolysosomes that I was 
observing after 24h of DOX in SH-SY5Y mito-QC cells results from impaired 
autophagosomal flux or from a genuine induction of mitophagy. 
 
Mitophagy can also be induced independently of drug treatment. Optogenetics 
have been repurposed to trigger phototoxic fluorescent proteins. KillerRed 
(KR) is one of those phototoxic fluorophores and has been linked to a 
mitochondrial targeting sequence to specifically trigger mitochondrial ROS 
(Bulina et al., 2006). Ashrafi and colleagues have used the mt-KR to activate 
mitophagy in rat and mice hippocampal neurons. Following the photoactivation 
of KR (Ex585/Em610nm), mitochondria become fragmented, swollen and 
finally are sent for autophagic degradation: 20min post-photoactivation, YFP-
Parkin and LC3 puncta colocalise with mitochondrial fragments and those 
disappear within 40min (Ashrafi et al., 2014). The benefit of such a technique 
is that mitophagy can be triggered in both a spatially and temporally manner. 
The disadvantage of this system is that it requires overexpression of the Killer 
Red protein prior to any experiment.   
 
In this chapter I have highlighted the efficacy of AO and Parkin overexpression 
to amplify mitophagy. I then discussed novel triggers and probes that can be 
used to study alternative pathways of mitophagy. In the next chapter, I will use 





Chapter 4: USP30-regulates mitophagy in SH-
SY5Y cells 
4.1 Introduction. 
USP30 was first studied for its putative role in the regulation of mitochondrial 
fusion and fission dynamics. Early publications have correlated USP30 
depletion and inhibition with mitochondrial elongation (Nakamura and Hirose, 
2008; Yue et al., 2014).  
It was only in 2014 that the link between USP30 and mitophagy was made. 
Bingol and colleagues performed a microscopy screen in HeLa and SH-SY5Y 
cells over-expressing Parkin to look for DUBs preventing CCCP-mediated 
degradation of mitochondria, visualised then by the loss of TOMM20 staining. 
USP30 and OTUD6A were the only two hits emerging from this study (Bingol 
et al., 2014). Complementary studies confirmed that USP30 deubiquitylates 
Parkin substrates, has a preference for K6 chains and opposes BH3 mimetic 
induced apoptosis (Cunningham et al., 2015; Liang et al., 2015; Wang et al., 
2015). 
The majority of studies analysing the role of USP30 in mitophagy, were 
conducted in cells that over-express Parkin and made use of depolarisation 
agents. The field has thus little information on firstly whether USP30 could 
oppose mitophagy in cells that do not overexpress Parkin and secondly if 
USP30 could regulate spontaneous mitophagy events occurring 
independently from mitophagy triggers, also known as basal mitophagy. 
Finally, the question remained whether USP30 functions were restricted to 
mitochondria.  
To answer those questions, I have studied USP30 in cells that endogenously 
express Parkin. Serendipitously I discovered that a pool of USP30 was 
localising to peroxisomes and I contributed to elucidating its role at 
peroxisomes. I have used of the mito-QC probe to look at basal mitophagy in 
SH-SY5Y cells and will briefly describe the work done in parallel by my 




4.2 USP30 localises at both mitochondria and peroxisomes in SH-SY5Y 
cells 
 USP30 copy number in SH-SY5Y cells 
I first characterised the expression levels and the localisation of USP30 in SH-
SY5Y cells, prior to conducting functional studies. 
I used western blotting to quantify the USP30 copy number in SH-SY5Y cells 
(Figure 4.1). Malte Gersch (then a post-doctoral fellow in David Komander's 
laboratory at the LMB in Cambridge and now an independent group leader at 
the Max Planck Institute in Dortmund, Germany) kindly provided us with a 
recombinant protein comprising the sequence encompassing amino acids 64-
502 of human USP30 (475 µg.ml-1). I used known amounts of USP30(64-502) 
to generate a protein standard curve by western blotting. On the same gel, I 
loaded 10, 20 and 30µg of SH-SY5Y RIPA lysates (Figure 4.1A). I employed 
an antibody targeting the residues 290-433 in human USP30, to detect both 
endogenous and recombinant USP30 (Figure 4.1B). I analysed the western 
blot with an infrared imager (Odyssey CLx, LICOR) and ensured that signals 
were not saturated. I then used the signals for the recombinant protein to 
generate a standard curve (Figure 4.1C). The number of USP30 molecules 
per µg was determined by converting USP30(64-502)‘s molecular mass (49.75 
kDa) into its metric mass (8.26x10-11ng) which allowed me to infer the number 
of USP30 molecules present in each standard curve point. Finally, I used a 
linear regression to obtain the number of USP30 molecules present in each 
SH-SY5Y lysate lane (Figure 4.1D). Counting the number of cells present in a 
duplicate dish allowed me to deduce the number of USP30 molecules per cell. 
I estimated that each SH-SY5Y cell contained molecules of 9.5 x 104 USP30. 
Using the same technique I teamed up with my colleague Andreas Kallinos to 
compare the number of USP30 proteins found in all four of the cell lines we 
use to study mitophagy: SH-SY5Y cells, the osteosarcoma U2OS cells, the 
retinal pigment epithelial hTERT-RPE1 cells, and the colorectal carcinoma 
HCT116 cells (Figure 4.2).   
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Figure 4.1: Quantifying the number of USP30 molecules per SH-SY5Y cells. 
A) The USP30 copy number in SH-SY5Y cells was measured by western blotting. A 
standard curve was generated using known amounts of recombinant USP30[64-502] 
protein. SH-SY5Y cells were lysed in RIPA then 10, 20 and 30μg of lysates were run 
next to the standard curve. B) USP30 was detected using an antibody targeting a 
segment of the USP domain (290-433 aa) and scanned on an Odyssey CLx imaging 
system. C-D) The intensity of the protein bands was determined using Image Studio. 
The graph represents the intensity plotted against the number of USP30[64-502] 
molecules present in each point of the standard curve point. The number of molecules 
per μg was calculated by converting USP30[64-502]’s molecular mass (49,75 kDa) 
into metric mass (8.26 x10-11 ng) using Avogadro’s constant (6.02214086 Å~ 1023 
mol-1). E) The linear function describing the standard curve (y = 0.539x – 3.2192), 
provided the number of USP30 molecules present in each lysate lane, which was 
further translated into the number of USP30 molecules per μl. The number of cells 
per μl of lysate was established using a cell counter and was used to determine, by 
USP30
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correlation, the number of USP30 molecules contained in one SH-SY5Y cell (4.76 
x104). Data from a single experiment. 
 
We loaded all lysates on the same gel and using the same standard curve 
quantified their USP30 copy number (Figure 4.2A, 2B and 2C). We 
discovered that SH-SY5Y cells express 2.9- and 1.4-fold more USP30 
molecules per cell than U2OS and HCT116 cells respectively. Interestingly, 
hTERT-RPE1 cells showed the highest level of USP30 expression, 2.2-fold 
more USP30 than SH-SY5Y cells (Figure 4.2C). In this second experiment the 
USP30 band intensity and the resulting copy number per cell was lower by 3-
4-fold in comparison to Figure 4.1, whilst the standard curve remained 
identical: 2.6 x104 versus 9.5 x104 in the first experiment for SH-SY5Y cells 
and 5.7 x104 versus 17.1 x104. (not shown) RPE1 cells. The samples used in 
this second experiment were the same ones as in Figure 4.1, it is possible that 
despite storage at -20°C in sample buffer, some protein was lost due to 
precipitation or aggregation as a result of multiple freeze thaw cycles. 
However, the relative abundance between the cells remain equivalent: RPE1 
have on average ~2-fold more USP30 proteins than SH-SY5Y cells. 
I next looked up for USP30 transcript datasets in the Broad Institute Cancer 
Cell Line Encyclopedia (CCLE) database. I used the associated Affymetrix 
microarray rather than their RNA sequencing dataset as the later had no entry 
for SH-SY5Y cells. hTERT-RPE1 cells were not captured in either datasets as 
they are immortalised but are not transformed. The USP30 mRNA abundance 
in SH-SY5Y, U2OS and HCT116 cells followed a similar trend to the protein 
copy number. SH-SY5Y cells contain between 1.6 and 1.9-fold more USP30 
mRNA than U2OS and HCT116 cells (Figure 4.2D). As SH-SY5Y cells 
express high amounts of USP30, they are ideal for the assessment of the 
localisation of endogenous USP30. 
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Figure 4.2: Evaluating the USP30 copy number in mammalian cells. 
A) The USP30 copy number in SH-SY5Y, hTERT-RPE1 (RPE1), HCT116 and U2OS 
cells was measured by western blotting. A standard curve was generated using known 
amounts of recombinant USP30[64-502] protein. Cells were lysed in RIPA then 10, 
20 and 30μg of lysates were run next to the standard curve. B) The intensity of the 
protein bands was quantified using Image Studio. The graph represents the intensity 
plotted against the number of USP30[64-502] molecules present in each point of the 
standard curve point. The number of molecules per μg was calculated by converting 
USP30[64-502]’s molecular mass (49,75 kDa) into metric mass (8.26 x10-11 ng) 
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SH-SY5Y 10 5.12 x105 264 x107 3.8 x108 3.3 x108
20 11.10 x105 439 x107 3.2 x108
30 15.10 x105 555 x107 2.7 x108
hTERT- 10 4.21 x105 238 x10 7 3.9 x108 2.9 x108
RPE1 20 7.25 x105 327 x107 2.7 x108
30 10.00 x105 407 x107 2.2 x108
HCT1116 10 8.76 x105 371 x107 8.6 x108 7.7 x108
20 19.9 x105 695 x107 8.0 x108
30 25.40 x105 856 x107 6.6 x108
U2OS 20 2.96 x105 202 x107 1.0 x108 0.9 x108


































standard curve (y = 0.539x – 3.2192), provided the number of USP30 molecules 
present in each lysate lane, which was further translated into the number of USP30 
molecules per μl. The number of cells per μl of lysate was established using a cell 
counter and was used to determine, by correlation, the number of USP30 molecules 
contained in one cell. E) Graph representing the USP30 protein copy number in SH-
SY5Y, RPE1, HCT116 and U2OS cells. Data from a single experiment. F) Graph 
indicating USP30 mRNA levels in SH-SY5Y, RPE1, HCT116 and U2OS cells. The 
data was collected from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) 
and its associated Affymetrix microarray database with Robust Multichip Average 
(RMA) normalisation. 
 
I compared the copy number of both USP30 and known mitochondrial USP30 
substrates (TOMM20, VDACs, CISD1) (Bingol et al., 2014; Cunningham et al., 
2015) using two genome wide mass spectrometry datasets from HeLa human 
cancer cells and 3T3 mouse fibroblasts (Kulak et al., 2014; Schwanhäusser et 
al., 2011). The copy number for USP30 was of 4.9 x103 and 2.3 x102 in HeLa 
and 3T3 cells respectively, whilst VDACs, CISD1 and TOMM20 all have a copy 
number ranging between 1.5 x105 and 3 x 106 in those cells (Kulak et al., 2014; 
Schwanhäusser et al., 2011). Overall USP30 is largely inferior in terms of copy 
number compared to its substrates. Therefore, USP30 most likely does not 
globally deubiquitylate mitochondria but rather acts on discrete ubiquitylation 
events. Amos Liang had discovered that USP30 binds to TOMM20 and 
TOMM22 independently on its catalytic activity and thus potentially localises 
to the TOM complex (Liang et al., 2015). The low copy number of USP30 
suggests that it only docks to a subset of TOM complexes.  
 
 USP30 knockdown optimisation in SH-SY5Y cells 
As I was going to use siRNA mediated depletion of USP30 in SH-SY5Y cells 
to assess the function and location of USP30, I started by optimising siRNA 
transfection in those cells (Figure 4.3). I used a non-targeting siRNA oligo 
(NT1) as a negative control and used two distinct oligos to target USP30 (D1 
and D3) that had previously been characterised by Amos Liang and had been 
shown to efficiently deplete USP30 in multiple cell types (Liang et al., 2015; 
Marcassa et al., 2018). I transfected the cells by lipofection using 
Lipofectamine RNAiMax. This transfection reagent was optimised for the 
delivery of siRNA in most human cell lines, including neuroblastoma cells. My 
co-workers had previously established 40nM siRNA as the standard 
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concentration used for transfection of a variety of cell lines. I thus adopted this 
concentration for my experiments and focussed my optimisation on two 
parameters: media composition and length of transfection (Figure 4.3A).  
I first assessed whether the media additives which I routinely use to culture 
SH-SY5Y cells such as fetal bovine serum (FBS) or the antibiotic mixture 
Penicillin/Streptomycin (P/S) affected the knockdown efficiency. I performed 
the siRNA transfection in medium with no additives, in medium with 10% FBS 
or in medium with 10% FBS and 1% P/S. For transfections completed in 
medium with no additives, I either supplemented the medium with 10% FBS 
6h after transfection or not. In all conditions, USP30 expression was 
approximatively decreased by 60%. The addition of P/S appeared to slightly 
worsen the knockdown efficiency. 
Overall, these results could either reveal a suboptimal transfection efficiency, 
meaning that only 60% of the cells are transfected, or that USP30 is 
incompletely silenced in all of the cells. This is an unsatisfactory result as the 
remaining wildtype cells or residual USP30 would be able to mask effects 
resulting from the knockdown.  
I decided to increase the length of the knockdown to try to improve its 
efficiency. Schwanhäusser et al., have reported that USP30 has a half-life of 
57.54h in 3T3 cells (Schwanhäusser et al., 2011). Arresting the production of 
newly synthesised USP30 for 72h might not be sufficient to see a complete 
loss of the protein. Thus, I compared the standard 72h single hit protocol with 
a protocol including two transfection hits over a 144h period. For this set I 
excluded serum and antibiotics during the transfection and supplemented the 
cells with 10% FBS after 6 hours (Figure 4.3B). Increasing the transfection 
time did not increase further the silencing efficiency. This incomplete silencing 
was not specific to USP30: A control siRNA oligo targeting USP33 transfected 
for 72h in medium with no additives similarly resulted in a 59% knockdown 
efficiency (Figure 4.3C). This USP33 siRNA is used as a standard control in 
my host lab as we have observed very efficient knockdown of USP33 in other 
cell lines. 
As the knockdown efficiency in this cell line appeared poor, I generated USP30 
knockout SH-SY5Y cells using the CRISPR/Cas9 system (see Chapter V).  
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Figure 4.3: Optimising siRNA transfection in SH-SY5Y cells 
A) SH-SY5Y cells were transfected with either non-targeting (NT1) or individual oligos 
targeting USP30 (D1 and D3) for 72h. Four conditions were tested: The cells were (1) 
transfected in medium with no additives or (2) in medium containing 10% Fetal Bovine 
Serum (FBS) with or without (3) Penicillin/Streptomycin (P/S). The addition or not of 
(4) FBS 6h after transfection in media without additives was also tested. In all four 
conditions, the medium was exchanged for medium with additives (10% Fetal Bovine 
Serum, 1% Penicillin/Streptomycin, 1% non-essential amino acids) after 24h 
transfection. B) The cells were transfected once for 72h or twice over a 144h period 
(2 x 72h transfections) in medium without additives. The medium was supplemented 
with 10% Fetal Bovine Serum 6h after the transfection then was exchanged for 
medium with additives (10% Fetal Bovine Serum, 1% Penicillin/Streptomycin, 1% 
non-essential amino acids) after 24h. C) SH-SY5Y cells were transfected with either 
NT1 or an individual oligo targeting USP33 for 72h in medium with no additives. Data 




















NT1 D1 D3 
 




























+ P/S: +- +- +





















 -    
 0.2  
 0.4  
 0.6  
 0.8  
 1.0  
 1.2  











































































 Endogenous USP30 localises to mitochondria 
In the early 2000s, no mammalian deubiquitylases were known to localise at 
mitochondria. However, the yeast Ubp16 was reported to localise at the outer 
mitochondrial membrane via an N-terminal hydrophobic domain (Kinner and 
Kölling, 2003). Hirose and Nakamura searched for a similar membrane 
topology across mammalian deubiquitylases and found that USP30 had an N-
terminal (35-54 aa) hydrophobic region (Figure 4.4A),(Nakamura and Hirose, 
2008). Although the transmembrane domain protein sequence of mammalian 
USP30 only weakly aligns with its yeast orthologue, they have a similar 
hydrophobic pattern on hydropathy plots (Figure 4.4B-C) (Nakamura and 
Hirose, 2008). This transmembrane domain anchors USP30’s N-terminal 
region in the outer mitochondrial membrane with the catalytic C-terminal 
domain facing the cytosol (Figure 4.4D). USP30 is therefore predicted to 
deubiquitylate outer mitochondrial membrane proteins and potentially other 
cytosolic or MAM associated proteins. Unlike for Ubp16, the localisation of 
human USP30 is also dependent on positively charged residues that flank its 
transmembrane domain (Nakamura and Hirose, 2008). The polybasic region 
(PBR) that follows the transmembrane domain appears to be conserved in 
mammals such as mice and humans and an alternative PBR of equal length 
and position is found in zebrafish. The USP30 fly orthologue’s (CG3016) 
transmembrane domain lies upstream of a smaller PBR of four arginine 
(Figure 4.4B). This suggests that in Metazoan, USP30 relies on both the 
transmembrane domain and a PBR to localise at mitochondria. 
As mentioned above, most prior studies looking at USP30 localisation were 
overexpressing tagged USP30 (Nakamura and Hirose, 2008; Cunningham et 
al., 2015; Wang et al., 2015). In 2014, the Bingol lab published an antibody 
able to detect endogenous USP30 by immunofluorescence and that 
endogenous USP30 co-localised with HSP60 in SH-SY5Y cells (Bingol et al., 
2014).  I verified the cellular localisation of endogenous USP30 by co-staining 
mitochondria for TOMM20 and USP30, using this same antibody, kindly 
provided by Baris Bingol (Genentech, USA) (Bingol et al., 2014). As a negative 
control for the selectivity of the antibody, I depleted USP30 using the USP30-
targeting siRNA oligo D3 (Figure 4.5). In the mock transfected set (NT1), the 
USP30 staining delineated a mitochondrial network overlapping with 
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TOMM20. USP30 depletion removed all of this TOMM20 positive 
mitochondrial signal, leaving only a diffuse and punctate background staining 
that was apparent throughout the cell. Thus, I confirmed that endogenous 




Figure 4.4: Structure and hydrophobic properties of USP30’s transmembrane 
and polybasic regions. 
A) Schematic representation of the protein sequence and domains of USP30 isoform 
1. The catalytic triad, composed of C77, H452 and S477, is highlighted in bold. 
Important features of the protein are highlighted: the USP domain, the transmembrane 
domain (TM) and the polybasic region (PBR) are annotated on this schematic. B) 
ClustalW protein sequence alignment of USP30’s transmembrane domain and 
polybasic residues in H. sapiens, M. musculus, D. rerio, D. melanogaster (CG3016) 
and S. cerevisiae (Ubp16). The transmembrane domain is highlighted in yellow, the 
polybasic region in pink and the catalytic cysteine in grey. Colour coding: red: Small 
(small+ hydrophobic (incl.aromatic -Y)), blue: Acidic, magenta: Basic – H, green: 
Hydroxyl + sulfhydryl + amine + G. Annotations: * single, fully conserved residue; : 
conservation between groups of strongly similar properties - scoring > 0.5 in the 
gonnet PAM 250 matrix; . conservation between groups of weakly similar properties 
- scoring =< 0.5 in the gonnet PAM 250 matrix. C) Kyte-Doolittle Hydropathy plot of 
human and mice USP30 made with “EMBOSS Pepwindow” from EMBL-EBI. Window 
size: 10. D) Schematic representation of USP30 anchorage and orientation at the 





















Figure 4.5: Endogenous USP30 localises to mitochondria in SH-SY5Y cells. 
SH-SY5Y cells were transfected with non-targeting siRNA (NT1) and with siRNA 
against USP30 (D3) for 144h (two hit knockdown). A) Representative blot. B) The 
cells were then fixed and probed for USP30 and TOMM20 using Alexa Fluor 488 and 
Alexa Fluor 594-coupled secondary antibodies respectively. The coverslips were 
mounted in mowiol containing DAPI. Images were acquired sequentially using a 3i 
spinning disk confocal microscope with a 63x objective and a sCMOS camera. Scale 
bar: 10μm. Representative images from two experiments. 
 
 USP30 also localises to peroxisomes 
When overexpressing USP30-GFP in U2OS cells, I observed round puncta 
that did not colocalise with TOMM20 (Figure 4.6). I could also detect similar 
structures when looking at endogenous USP30 in the SH-SY5Y cells; although 
some of these were clearly non-specific as they were not affected by USP30 
siRNA. (Figure 4.5). I wondered whether a pool of USP30 was localising to 
another organelle. These non-mitochondrial structures were round and roughly 
the size of fragmented mitochondria. Peroxisomes are single membrane 
bound organelles that fulfill those criteria. Moreover they have an overlapping 
proteome with mitochondria and also share common metabolic functions 
(Islinger et al., 2018; Cipolla and Lodhi, 2017; Schrader et al., 2015; Hartwig 
et al., 2013). Hence, I decided to focus on this candidate. I overexpressed 
USP30 in easily transfectable cells, hTERT-RPE1 and U2OS, and co-stained 
for peroxisomal proteins (Figure 4.7), (see also our published article and 
corresponding commentary: (Marcassa et al., 2018, 2019)).  I stained for 
PMP70, a peroxisomal membrane protein and catalase a peroxisomal matrix 
protein. As matrix proteins are imported during the final step of peroxisome 
maturation, Catalase also gives an indication of the maturation stage of the 
peroxisomes. I observed that USP30-RFP and USP30-MYC positive punctate 
structures co-localised with PMP70 and Catalase respectively. I concluded 
that over-expressed USP30 localises to both mitochondria and peroxisomes. 
Using immunofluorescence, I then verified if endogenous USP30 was also 




Figure 4.6: USP30-GFP localises to mitochondria in U2OS cells. 
U2OS cells were transfected with USP30-GFP for 24h then fixed and stained for 
TOMM20 using an Alexa Fluor 488-coupled secondary antibody. The coverslips were 
mounted using Mowiol mixed with DAPI. Images were acquired sequentially using a 
3i spinning disk confocal microscope with a 63x objective and a sCMOS camera. 































Figure 4.7: A pool of USP30 localises to peroxisomes in hTERT-RPE1 and U2OS 
A) hTRERT-RPE1 cells and B) U2OS cells were transfected with RFP, USP30-RFP, 
pCDNA3.1 and USP30-MYC for 24h then fixed and stained with antibodies targeting 
MYC with Alexa Fluor 488-coupled secondary antibody and/or peroxisomal proteins: 
PMP70 or Catalase with Alexa Fluor 488 and Alexa Fluor 594-coupled secondary 
antibodies respectively. The coverslips were mounted in mowiol containing DAPI. 
Images were acquired sequentially using a 3i spinning disk confocal microscope 
equipped of a sCMOS camera and a 63x objective lens. Scale bar: 10μm. Data from 
a single experiment. 
 
To control for the non-specific punctate staining coming from the USP30 
antibody, I seeded two sets of SH-SY5Y cells, one transfected with non-
targeting siRNA (NT1) and the other with USP30 targeted siRNA (D3) and then 
used PMP70 as a peroxisomal marker (Figure 4.8),(Marcassa et al., 2018). I 
discovered that a pool of endogenous USP30 colocalised with PMP70.  
I then wondered how USP30 was localised to peroxisome. I assessed whether 
it was dependent on its catalytic activity. I transfected hTERT-RPE1 cells with 
either USP30-GFP or with catalytically dead USP30 C77S-GFP and cherry-
SKL (Figure 4.9A). The SKL sequence is the most common peroxisomal 
targeting signal involved in peroxisomal matrix import and can be used to 
target fluorophores to mature peroxisomes. In parallel, I transfected hTERT-
RPE1 with USP30-MYC or USP30 C77S-MYC and probed the fixed cells with 
anti-MYC and Catalase antibodies. I transfected pCDNA3.1 as control for non-
specific MYC staining (Figure 4.8C),(Marcassa et al., 2018). In both sets of 
experiments, I found that catalytically inactive USP30 localised to 
peroxisomes. We thus concluded that USP30 localised to peroxisomes 
independently on its catalytic activity. 
As it is the first time that USP30 has been reported on peroxisomes we went 




Figure 4.8: Endogenous USP30 localises to peroxisomes in SH-SY5Y cells. 
Duplicate samples from the experiment shown in Figure 4.5. SH-SY5Y cells were 
transfected with non-targeting siRNA (NT1) and with siRNA targeting USP30 (D3) for 
144h (two hit knockdown). A) Representative blot (reproduced from figure 4.5). B) 
The cells were then fixed and probed for USP30 and PMP70 using Alexa Fluor 488 
and Alexa Fluor 594-coupled secondary antibodies respectively. The coverslips were 
mounted in mowiol containing DAPI. Images were acquired sequentially using a 3i 
spinning disk confocal microscope with a 63x objective and a sCMOS camera. Scale 
































Figure 4.9: USP30 localises to peroxisomes independently of its catalytic 
activity.  
hTRERT-RPE1 cells were transfected with A) cherry-SKL alone (UNT) or with USP30 
-GFP or USP30 C77S-GFP or C) with pCDNA3.1, USP30-MYC and USP30 C77S-
MYC for 24h. All cells were fixed and for C) probed for MYC and Catalase using Alexa 
Fluor 488 and Alexa Fluor 594-coupled secondary antibodies respectively. All 
coverslips were mounted in mowiol containing DAPI. Images were acquired 
sequentially using a 3i spinning disk confocal microscope with a 63x objective and a 































puncta) per cell using the Fiji’s Analyse Particles plugin (35 cells analysed). 
Representative images from two experiments. 
 
 
4.3 Role of USP30 in SH-SY5Y cells 
 USP30 regulates pexophagy 
As USP30 regulates mitochondrial autophagy, my colleagues and I wondered 
if analogously USP30 could regulate peroxisomal autophagy (pexophagy). 
Supporting this theory, Cunningham et al., had found that pexophagy in 
HEK293 cells was decreased by two-fold when overexpressing for two days a 
PMP34-USP30 chimeric protein, in which the human USP30 DUB domain was 
subcloned downstream of the peroxisomal membrane protein PMP34 to target 
it artificially to peroxisomes (Cunningham et al., 2015). 
As a preliminary study, I assessed whether the overexpression or depletion of 
USP30 would affect peroxisome number or mass. I first used the experiment 
shown in Figure 4.9 to count the number of cherry-SKL positive peroxisomes 
in hTERT-RPE1 cells transfected with wild-type or catalytically inactive 
USP30. Surprisingly, I found that overexpressing USP30, but not its catalytic 
mutant USP30 C77S, reduced by 20% the average number of SKL-cherry 
bearing peroxisomes per cell (Figure 4.9B). On the other hand, depletion of 
USP30 in both U2OS and hTERT-RPE1 cells, did not induce any obvious 
change in abundance of peroxisomal proteins by western blotting (Figure 
4.10).  
In order to measure pexophagy in a direct manner, my colleague Aitor 
Martinez-Zarate generated a pexophagy reporter by flanking the pH sensitive 
Keima fluorophore with a SKL sequence. Similar to mitophagy, during 
pexophagy peroxisomal membrane proteins are ubiquitinated by an E3, such 
as PEX2, and recognised by the LC3-adaptor proteins NBR1 and p62. 
Peroxisomes are then engulfed in autophagosomes and safely disposed in 
lysosomes for degradation (Sargent et al., 2016; Zhang et al., 2015). The 
excitation of the SKL-Keima probe will then shift from 445nm in healthy 
peroxisomes to 561nm in acidic autolysosomes.   
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Figure 4.10: USP30 depletion does not affect peroxisomal protein expression. 
U2OS and hTERT-RPE1 cells were knocked down for 72h with 40nM siRNA targeting 
USP30 (D1 and D3); a non-targeting siRNA was used as a control (NT1). The cells 
were lysed in RIPA and immunoblotted for peroxisomal proteins. Data from a single 
experiment. 
 
My colleague Elena Marcassa measured a two-fold increase in pexophagy 
events in hTERT-RPE1 cells depleted of USP30, either by knockdown or 
knockout (Marcassa et al., 2018). This phenomenon was rescued with the 
reintroduction of wildtype USP30 but not with catalytically inactive 
USP30C77S, indicating that pexophagy is repressed by USP30’s catalytic 
activity. Elena further transfected hTERT-RPE1 overexpressing Keima-SKL 
with ATG7 and USP30-targeting siRNA oligos. She found that the pexophagy 
increase was dependent on ATG7 and consequently dependent on the 
autophagy machinery (Marcassa et al., 2018). 
 
 Regulation of mitophagy in SHSY5Y mito-QC cells by USP30 
Mitophagy has largely been studied in the context of Parkin over-expression 
and harsh depolarisation, but what is the contribution of PINK1, Parkin and 



















































4.3.2.1  Preliminary results indicate that USP30, Parkin and PINK1 
depletion minimally affects basal mitophagy in SH-SY5Y cells. 
 
I made use of the SH-SY5Y mito-QC cells to quantify the number of mitophagy 
events occurring after USP30 depletion (Figure 4.11). After 144h of siRNA 
transfection, I achieved 80-87% of depletion of USP30. The knockdown 
efficiency was increased by seeding two-fold less cells than I previously had. I 
obtained a ~30% rather than 60% confluency on the day of the transfection. I 
did not observe any significant changes between the number of mitolysosomes 
generated with siUSP30 oligos (D1 and D3) and the control siRNA (NT1), 
(Figure 4.11.C). However, I did observe a clear trend towards an increase in 
the number of cells having more than five mitolysosomes. On average, 1.3% 
of the control NT1 transfected cells had more 5 mitolysosomes against 6.7 and 
5.7% of D1 and D3 transfected cells respectively. The average number of 
mitolysosomes in SH-SY5Y mito-QC cells is very low with 84% of the cells 
having zero or one mitolysosome in the absence of a mitophagy trigger. In 
comparison, hTERT-RPE1 and U2OS cells on average have ten 
mitolysosomes per cells under basal conditions. In those cells, Elena observed 
a doubling of the number of mitolysosomes after 72 hours of USP30 depletion 
(Marcassa et al., 2018).  
I had also transfected SH-SY5Y mito-QC cells with siRNAs targeting PINK1 or 
Parkin with or without co-transfection of USP30-targeted siRNA oligos (Figure 
4.12). Neither Parkin nor PINK1 depletion significantly affected the number of 
mitolysosomes present in SH-SY5Y cells (Figure 4.12C-D). Again, when 
looking at the percentage of cells with more than 5 mitolysosomes, I detected 
a small trend towards an increase of mitophagy with USP30 depletion and no 
changes with PINK1 or Parkin depletion (NT1: 6%, D1: 11%, Parkin: 7%, 
PINK1: 7%).  
It is possible that basal mitophagy events are too rare in SH-SY5Y cells to be 
studied by manual image analysis. Moreover, the knockdown efficiency in 
these cells is rather poor and more so in this experiment (47% for Parkin, 69% 
for PINK1 and 59% for USP30; Experiment performed prior optimising the cell 
density); rendering any subtle effect of protein depletion even harder to detect.  




Figure 4.11: USP30 depletion minimally affects basal mitophagy in SH-SY5Y 
cells. 
A) SH-SY5Y mito-QC cells were subjected to a “two hits” transfection protocol over 
144h (72h each) using siRNA oligos targeting USP30 (D1 and D3) or non-targeting 
siRNA (NT1). Images were acquired sequentially using a 3i spinning disk confocal 
microscope with an EMCCD camera and a 63x objective lens. Scale bar: 10μm.  
B) Representative western blot from RIPA lysates. C) USP30 expression was 
normalised to Actin and to NT1. The analysis was performed using ImageStudio. 
D) Graph representing the number of mitolysosomes per cell. The images were 
quantified using the Analyse particle plugin on FIJI. Data from three experiments. 



































































Figure 4.12: PINK1 and PARKIN depletion does not affect basal mitophagy in 
SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were transfected with individual USP30 (D1) and/or 
PARKIN or PINK1-targeting siRNA oligos for 144h. Non-targeting (NT1) oligos were 
used as a control. Images were acquired sequentially using a 3i spinning disk confocal 
microscope with an EMCCD camera and a 63x objective lens. Scale bar: 10μm. B) A 
parallel set of cells was treated for 1h with Antimycin and Oligomycin (AO, 1μM) to 
induce PINK1 accumulation and reveal the knockdown efficiency. The cells were 
lysed in NP40 lysis buffer. C) The relative protein expression of USP30, Parkin and 
PINK1 was quantified using ImageStudio and normalised to Actin. Error bars: mean 
± SD. D and E) The number of mitolysosomes per cell was quantified using the 












































































































































































each cell and per experiment. E) Graph shows the mean number of mitolysosome per 
cell (n=3 experiments). Error bars: mean ± SD. 
 
 
Another potential flaw with this experiment, is the use of the FIS1 targeting 
sequence for the mito-QC probe. FIS1 localises to and regulates the fission of 
both mitochondria and peroxisomes, and thus could principally target the mito-
QC probe to both organelles (Koch et al., 2005). The Ganley lab, reported that 
mito-QC is almost exclusively on mitochondria in SH-SY5Y cells, by 
immunostaining the cells against ATP synthase (Allen et al., 2013). However, 
a few mito-QC punctate which could correspond to peroxisomes did not appear 
in the ATP synthase staining. They also stained MEF and mice mito-QC heart 
tissues against the peroxisomal protein PMP70 and did not detect any overlap 
between PMP70 and mito-QC. I generated a blue peroxisomal probe, 
TagBFP-SKL to verify this hypothesis and transfected this construct into SH-
SY5Y mito-QC cells (Figure 4.13). I found that even though the vast the 
majority of mitoQC localised to mitochondria, a small proportion of it was co-
localising with TagBFP-SKL.  
Elena Marcassa took advantage of the better transfection efficiency and the 
increased levels of basal mitophagy in hTERT-RPE1 and U2OS cells to 
demonstrate that basal mitophagy was unaffected by PINK1 or Parkin 
depletion using both the mito-QC and mt-Keima (targeted to the mitochondrial 
matrix via COX VII’s targeting signal) reporters. Elena also revealed that the 
USP30-dependent enhancement of mitophagy was abolished by PINK1 
depletion but unaffected by Parkin (Marcassa et al., 2018).  
To circumvent the difficulties I had studying basal mitophagy in SH-SY5Y mito-
QC cells, I have generated USP30 knockout cells and characterised USP30-
specific inhibitors to use in combination with mass spectrometry. These will be 
further discussed in Chapter V.  
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Figure 4.13: The mito-QC reporter also localises to peroxisomes. 
SH-SY5Y mito-QC (mCherry-GFP-FIS1101-152) cells were transfected for 48h with 
TagBFP-SKL. The cells were acquired sequentially on a Zeiss LSM 800 confocal. 
Scale bar: 10μm. Representative images from two experiments. 
4.3.2.2 USP30 depletion increases depolarisation induced mitophagy in 
SH-SY5Y cells 
I next assessed whether USP30 was involved in AO or DFP-induced 
mitophagy in cells expressing endogenous Parkin. I transfected SH-SY5Y 
mito-QC cells with USP30-targeting (D1) or non-targeting (NT1) oligos and 
treated them for 24h with AO or DFP (Figure 4.14). USP30 depletion 
significantly increased the number of cells undergoing mitophagy (> 3 
mitolysosomes per cell) in the AO condition (Figure 4.14B). However, USP30 
did not affect DFP-induced mitophagy. We propose that DFP-mediated 
mitophagy is ubiquitin-independent. An additional indication for this is the fact 
that we observed MFN2 ubiquitylated species in SH-SY5Y cells treated with 
AO but not with DFP (Figure 4.14C). My colleague Elena Marcassa also found 
a two-fold increase in the number of mitolysosomes in U2OS mito-QC cells 
treated with DFP for 24h but likewise she could not detect any ubiquitylated 
species of MFN1 after 2, 4 or 24 h of treatment (data not shown).  
Similarly, in hTERT-RPE1-YFP-Parkin, she did not detect ubiquitylated MFN1, 
MFN2, FIS1, TOMM20 nor phospho-ubiquitin, nor PINK1 accumulation 
following 1h, 2h or 6h DFP treatment in comparison to AO induced mitophagy 
(data not shown). This is consistent with the study by Ganley and colleagues, 
who generated the SH-SY5Y mito-QC cells and first described that DFP-
induced mitophagy is independent of PINK1 and Parkin (Allen et al., 2013).   
TagBFP-SKL Cherry-FIS1 GFP-FIS1 MERGE
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Figure 4.14: USP30 depletion sensitises SH-SY5Y mito-QC cells to AO-induced 
mitophagy. 
A) SH-SY5Y mito-QC cells were transfected with either non-targeting (NT1, 40nM) or 
USP30-targeted (D1, 40nM) siRNA oligos for 72h. They were then treated for 24h 
with water (UNT), DMSO, Antimycin and Oligomycin (AO, respectively 1 and 10μM) 
and Deferiprone (DFP, 1mM). Images were acquired sequentially using a 3i spinning 
disk confocal microscope with an EMCCD camera and a 40x objective. Scale bar: 
10μm. B) Graph shows the percentage of cells undergoing mitophagy. A cell having 
more than 3 mitolysosomes is considered as undergoing mitophagy. Analysis: two-
way ANOVA with Bonferroni’s multiple comparison test. **: p < 0.01. Results from 4 
experiments; 110 cells were quantified per experiment. Error bars: mean ± SD. C) 
USP30 knockdown efficiency was assessed by western blotting for each experiment. 
USP30’s expression was normalised to Actin and NT1. D) The experiment in A was 
performed in duplicate and one set was analysed by western blot. E) USP30 
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4.4 Discussion 
 USP30 localises to peroxisomes  
Employing immunofluorescence, I provided the first line of evidence showing 
that a pool of endogenous USP30 was localised at peroxisomes. I also 
demonstrated that overexpressed USP30 colocalises with both PMP70 
(peroxisome membrane) and Catalase (peroxisome matrix). These 
observations were further supported by a density gradient analysis performed 
in HepG2 cells by our colleagues from Markus Islinger’s lab (University of 
Heidelberg, Germany). They found USP30 in both peroxisomal and 
mitochondrial fractions. USP30 migrated across the gradient in a similar 
fashion as to glutathione-S-transferase κ (GSTK1), another protein shared 
between the two organelles (Marcassa et al., 2018). 
I reported that USP30’s localisation to peroxisomes was independent from its 
catalytic activity. Employing USP30 truncation mutants, my colleagues 
Andreas Kallinos and Elena Marcassa assessed whether USP30 had a 
specific peroxisome targeting sequence. They found that the truncated mutant 
USP30(1-53) (TM only) was solely localised to peroxisomes (PMP70) and not 
to mitochondria (TOMM20), whereas USP30(1-68) (TM with its downstream 
polybasic region) was associated with both organelles and USP30∆1-53 was 
diffused in the cytosol. We reasoned that USP30 localisation to peroxisomes 
required the transmembrane domain (35-54 a.a.) and was independent of the 
downstream polybasic region (59-64 a.a.). USP30 has therefore distinct 
targeting motifs for mitochondria and peroxisomes (Marcassa et al., 2018).  
Interestingly, the transmembrane domain of USP30 is preceded by three 
positive residues interspaced by hydrophobic residues (Nakamura and Hirose, 
2008). To test whether those positive charges intervene in USP30’s 
localisation, Andreas Kallinos neutralised them by point mutations as 
described by Nakamura and Hirose (KRmut1),(Nakamura and Hirose, 2008). 
By immunofluorescence assay he observed a reduced co-localisation between 
USP30 KRmut1 and PMP70 in comparison with USP30 and PMP70. This 
could indicate that the basic residues preceding the transmembrane domain 
are involved in the targeting of USP30 to peroxisomes.   
It remains to be elucidated what pathway USP30 follows to be integrated into 
the peroxisomal membrane. There are two main paths for peroxisomal 
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membrane sorting: (1) the direct import route (Class I), used by most 
peroxisomal membrane proteins (PMP), where PEX19 acts as chaperone and 
forms a soluble complex with PMPs and recruits them to peroxisomes by 
binding to PEX3, or (2) the indirect import pathway (Class II) where PMPs 
migrate from the ER to the peroxisome with the help of PEX16 and PEX19 
(Farré et al., 2019; Liu et al., 2016).  
Many proteins shared between peroxisomes and mitochondria are tail 
anchored (TA) proteins, with a C-terminal hydrophobic transmembrane 
domain. Such examples are FIS1, DNM1L, MAVS, MIRO1/2, Bcl-xL, Bcl-2 and 
others (Koch et al., 2005; Dixit et al., 2010; Costello et al., 2017). Those 
proteins can either be produced in the cytosol and get directly targeted to 
peroxisomes via the PEX19-direct pathway or can get integrated into the ER 
via the GET complex and then sorted to peroxisome using the PEX16-indirect 
pathway (Schuldiner et al., 2008; Yagita et al., 2013; Mateja et al., 2015; Liu 
et al., 2016). Characteristics of peroxisomal targeted TA proteins are:  a 
moderately hydrophobic transmembrane domain followed by a highly charged 
tail (Costello et al., 2017). Although, USP30’s transmembrane domain is N-
terminal, it is reminiscent of peroxisomal TA proteins’.  
Shortly after our publication, Riccio et al., suggested that USP30 uses the 
PEX16 dependent pathway to translocate to peroxisomes. They demonstrate 
that overexpressing an ER-targeted PEX16 (sa-PEX16) in COS7 cells 
relocalises overexpressed USP30 and FIS1 but not TOMM20 to the ER; thus 
demonstrating that PEX16 can bind to USP30. Endogenous PEX16 could 
therefore target USP30 to peroxisomes via the ER (Riccio et al., 2019). 
Intriguingly, it has been reported that neutralising the PBR of USP30 (KRmut2) 
results in a ER localised protein (Nakamura and Hirose, 2008). Andreas 
reproduced this experiment and found that USP30 KRmut2 neither co-
localised with PMP70 nor with TOMM20 but did overlap with Calreticulin, a 
protein primarily residing at the ER.  
We sought to assess whether USP30 localisation to peroxisomes was 
dependent on PEX19 by knocking it down in hTERT-RPE1 cells. However, we 
observed by immunofluorescence that PEX19 knockdown resulted in a 
diffused catalase staining. We concluded that depleting cells of PEX19 most 
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likely interfered with peroxisome maturation and thus prevented any further 
analysis. 
MUL1 (also reported as MAPL), another protein shared by mitochondria and 
peroxisomes can be rerouted from mitochondria to peroxisomes via 
mitochondria derived vesicles. Those vesicles are transported to peroxisomes 
by the VPS35-retromer complex (Braschi et al., 2010; Neuspiel et al., 2008). 
We verified if USP30 was using this pathway by knocking down VPS35 in 
hTERT-RPE1. In the absence of VPS35, newly transfected USP30 was still 
distributed on both peroxisomes and mitochondria (Marcassa et al., 2018).  
Finally, a recent study described another route for protein redistribution from 
the mitochondrial network to the peroxisome. Koyano et al., demonstrated that 
upon mitochondrial stress, MARCH5 (also known as MITOL) gets ubiquitylated 
by Parkin, then extracted from mitochondria by the p97/VCP complex, and 
redistributed to peroxisomes via PEX3 and PEX19. They showed that this 
pathway is dependent on PINK1 and Parkin and that the mitochondrial 
localisation is a prerequisite for secondary peroxisome targeting (Koyano et 
al., 2019b). We can rule out this pathway to explain USP30 targeting to 
peroxisome, as Aitor showed that newly transfected USP30 localises to 
peroxisomes in the absence of mitochondria in hTERT-RPE1-YFP-Parkin cells 
treated for 24 h with AO (Marcassa et al., 2018). 
From the current data, it seems that USP30 is either directly recruited from the 
cytosol to the peroxisomes by PEX19 or is targeted to peroxisomes via the ER 
with the help of PEX16, as proposed by Riccio et al.  
 
 USP30 prevents the autophagic degradation of peroxisomes 
We discovered that peroxisomal USP30 was regulating basal pexophagy. 
When Elena depleted USP30 from hTERT-RPE1 cells she measured a two-
fold increase in pexophagy indicating that USP30 was repressing the process 
(Marcassa et al., 2018). She found that this process was PINK1 and Parkin-
independent but we did not identify the key peroxisome substrates for USP30 
nor did we discover the E3 ligase which USP30 opposes in basal pexophagy.  
Counterintuitively, I found that overexpressing catalytically active USP30 
reduced the number of cherry-SKL (matrix) positive peroxisomes per hTERT-
RPE1 cell. USP30 overexpression thus appears to block peroxisome 
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biogenesis or maturation, which are accompanied by the import of newly 
synthesised matrix protein (Farré et al., 2019). USP30 could also directly 
regulate peroxisomal protein import as it was just recently reported to control 
mitochondrial protein import (Phu et al., 2020) (further discussed in Chapter 
V). One other possible explanation could be that pexophagy is actively 
compensated by peroxisome biogenesis. Thus, when pexophagy is inhibited 
by the over-expression of USP30, peroxisome biogenesis would be 
downregulated via negative-feed-forward mechanism to maintain the number 
of peroxisomes per cell relatively stable. One way to assess this would have 
been to compare by immunofluorescence the number of peroxisomes having 
imported newly synthesised cherry-SKL against the total number of 
peroxisome (PMP70 staining), upon USP30 overexpression. In line with this 
hypothesis, Riccio and colleagues found that overexpressing USP30-FLAG in 
HeLa cells did not affect the number of PMP70-labeled peroxisomes. 
Pexophagy can be triggered by hypoxia, oxidative stress or nutrient 
deprivation, which also induce global autophagy, and has been broadly studied 
under those conditions (Eberhart and Kovacs, 2018). Starvation upregulates 
the expression of the peroxisomal E3 RING E3 ligase PEX2, which then 
ubiquitylates peroxisomal proteins such as PEX5 and PMP70 to trigger 
pexophagy (Sargent et al., 2016). ROS triggers the recruitment of the kinase 
ATM to peroxisomes in a PEX5-dependent manner. ATM then supresses 
mTORC1 and phosphorylates PEX5, which gets subsequently ubiquitylated 
and recognised by the adaptor protein p62 causing the autophagosomal 
engulfment of peroxisomes (Zhang et al., 2015).  
PEX2 and PEX5 are also key players in peroxisomal matrix import. PEX5 is 
the carrier for most matrix proteins and PEX2 is an essential component of the 
importomer complex (see review: (Farré et al., 2019)). Interfering with either 
protein would directly affect import of newly synthesised matrix proteins and 
thus impede peroxisomal maturation. Thus, the depletion of endogenous 
PEX2 would give inconclusive results as to its function in basal pexophagy.  
Neither by straightforward western blotting, nor by immunoprecipitation, could 
we observe an increase in basal ubiquitylation of PEX5 in USP30 knockout 
cells (Marcassa et al., 2018). However, Riccio et al. found that in the context 
of nutrient starvation, USP30 depletion increased PEX5 and PMP70 
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ubiquitylation. They further demonstrated that USP30 was opposing PEX2 in 
starvation-induced pexophagy (Riccio et al., 2019).  
USP30 may thus suppress both basal and starvation induced pexophagy and 
deubiquitylate PEX2 substrates. This may then prevent the recruitment of 
pexophagy adaptors such as NBR1 (Riccio et al., 2019; Sargent et al., 2016; 
Deosaran et al., 2013). USP30 is thus the first known DUB to regulate 
pexophagy. 
As mitochondria, peroxisomes are fundamental to the health and proper 
functioning of cells. In mammals, peroxisomes function in many metabolic 
pathways, such as fatty acid oxidation, phospholipid biosynthesis, oxygen and 
reactive nitrogen species degradation, amino acid catabolism and many others 
(Smith and Aitchison, 2013; Wanders and Waterham, 2006). Interestingly, 
mitochondria and peroxisomes are tightly linked together, both functionally and 
physically. They co-regulate fatty acid oxidation, scavenge peroxide and 
reactive oxygen species (Mohanty and McBride, 2013; Wanders, 2013). These 
organelles also share signalling pathways such as antiviral immunity via MAVS 
(Dixit et al., 2010). Recently, it was reported that new peroxisomes are hybrids 
of both ER and mitochondria derived pre-peroxisomes (Sugiura et al., 2017). 
Now we show that they share similar quality control mechanisms, pexophagy 
and mitophagy, both regulated by USP30. 
Impairment of peroxisome homeostasis is involved in severe developmental 
brain disorders classified as peroxisome biogenesis disorders (PBD) and 
single peroxisomal enzymes deficiencies. Although the peroxisome loss 
observed in this disease was first attributed to defective peroxisome 
biogenesis mechanisms, Peter Kim’s group revealed that the most common 
mutation in PBD, PEX1-G843D, resulted in an increase of peroxisome 
degradation by pexophagy (Law et al., 2017). Using various inhibitor of 
autophagy flux, they were able to reverse the peroxisome loss. Once they 
discovered that USP30 was a regulator of pexophagy, they assessed its effect 
in patient derived PEX1-G843D fibroblast and revealed that the 
overexpression of USP30 was able to recover the peroxisomal pool (Riccio et 
al., 2019). 
Peroxisome dysfunctions are also thought to be involved in ageing and in the 
progression of age-related neurodegenerative diseases such as Alzheimer’s 
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disease (Islinger et al., 2018; Trompier et al., 2014). This highlights the need 
to better understand peroxisomal quality control mechanisms such as 
pexophagy and once more point towards USP30 as an interesting drug target.  
 
 USP30 regulates basal and induced mitophagy 
My results on basal mitophagy in SH-SY5Y cells were inconclusive due to the 
poor knockdown efficiency I achieved and the low level of mitophagic flux (= 
low number of mitophagy events per time period per average cell). However, 
it is still interesting to note that reducing the levels of PINK1 and Parkin, for 
which knockdown efficiency was of 69% and 47% respectively, did not 
decrease the number of basal mitophagy events. My colleague Elena 
Marcassa made the same observation in U2OS and hTERT cells (Marcassa 
et al., 2018). This is in agreement with published data showing that PINK1 and 
Parkin depletion had no effect on basal mitophagy in animal models such as 
the mito-QC mouse or the mito-QC and the mt-Keima flies (discussed in 
Chapter VI) (Lee et al., 2018; McWilliams et al., 2018). However, it is also 
interesting that knockdown of ATG7 in U2OS-mitoQC cells did not deplete cells 
of all of their mitolysosomes (Marcassa et al., 2018). Those puncta might 
therefore not originate from the canonical autophagy pathway but could result 
from direct mitochondria-lysosome or mitochondria-endosome fusion. Such 
pathways were described by the Fon and McBride labs. They reported on 
mitochondrial-derived vesicle (MDV) which deliver specific cargoes to 
endosomes and lysosomes. The formation of those MDV was independent on 
DNM1L (DRP1) and on the core autophagy machinery, as it occurred in the 
absence of Atg5, Rab9 or Beclin. Certain MDVs were shown to specifically 
transport oxidised cargoes. The formation of those oxidised cargo-specialised 
MDV was dependent of PINK1 and Parkin (McLelland et al., 2014, 2016; 
Soubannier et al., 2012b, 2012a), (for reviews see: (Roberts et al., 2016; 
Sugiura et al., 2014)).   
In U2OS and hTERT-RPE1 cells, we revealed that USP30 depletion doubled 
the number of mitophagy events occurring basally in a PINK1-dependent but 
Parkin-independent manner (Marcassa et al., 2018). This suggests that 
another E3 ligase might regulate USP30-mediated basal mitophagy. Multiple 
E3 ligases have been found either on mitochondria or interacting with 
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mitochondrial proteins such as ARIH1, HUWE1, MUL1, MARCH5 or FBXO7 
(Burchell et al., 2013; Chen et al., 2017; Di Rita et al., 2018; Koyano et al., 
2019a, 2019b; Strappazzon et al., 2019; Villa et al., 2017; Yun et al., 2014). I 
will be assessing their involvement in mitophagy in Chapter V, using USP30 
knockout SH-SY5Y cells. 
Our current discoveries on basal mitophagy indicate that USP30 opposes 
PINK1 function. The main substrates of PINK1, outside of Parkin, are ubiquitin 
moieties on outer mitochondrial membrane proteins (Kane et al., 2014; 
Kazlauskaite et al., 2014; Koyano et al., 2014; Ordureau et al., 2014). Hence, 
one could speculate that USP30 removes phospho-ubiquitin. However, USP30 
has very low affinity for phospho-ubiquitin and distal phosphorylation of 
ubiquitin chains prevents USP30 hydrolysis (Gersch et al., 2017; Wauer et al., 
2015a). We therefore hypothesise that USP30 acts upstream of PINK1 by 
deubiquitylating its substrates, this would prevent the ubiquitin-mediated 
recruitment of autophagy adaptor proteins (Heo et al., 2015; Richter et al., 
2016), as well as the phospho-ubiquitin-mediated recruitment and activation of 
Parkin (Gladkova et al., 2018; Sauvé et al., 2018; Okatsu et al., 2015b).  
 
 Concluding remarks 
In this chapter, I have described a dual role for USP30 in selective autophagy: 
USP30 regulates both mitophagy and pexophagy. Its role in mitophagy will be 
further studied and discussed in Chapter V with the generation and 




Chapter 5: A selective inhibitor and knock-out 
cells enable the identification of new players 




In Chapter IV, I described that USP30 regulates both mitophagy and 
pexophagy. However, a poor knockdown efficiency in SH-SY5Y cells hindered 
most experiments. I therefore generated USP30 knockout SH-SY5Y cells 
using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). 
To strengthen the results obtained with the knockout cells, I also utilised and 
characterised novel USP30 inhibitors. I employed those tools in proteomics 
and mitochondrial fractionation experiments to find novel substrates of USP30. 
I confirmed that TOMM20 was one of USP30’s main substrates and that 
USP30 targets most of PRKN’s OMM substrates. Potential substrates include 
the ribosomal protein RPS20, which is ubiquitylated during ribosome quality 
control and proteins controlling neural structure, function and differentiation. 
As described by the Harper and Bingol labs, I noticed that USP30’s activity 
was mainly focussed on the mitochondrial protein import complexes, TOM and 
VDAC complexes, and detected enhanced ubiquitylation of a few matrix and 
IMS proteins (GRSF1, HSPD1, HSPE1, MDH2, MTCH2, NDUFB5, PRDX3). 
This suggests that USP30 has a role in mitochondrial protein import via the 
TOM and VDAC complexes (Ordureau et al., 2020; Phu et al., 2020). Finally, 
I found that pUb levels are enhanced in USP30 KO cells which fits with a model 
whereby USP30 activity limits PINK1 substrate availability. 
In this Chapter, I will first describe the CRISPR-Cas9 system I have employed 
to produce USP30 knockout cells. I will then characterise two USP30 inhibitors 




5.2 Generation and description of USP30 knockout SH-SY5Y cells 
 Generation of USP30 knockout SH-SY5Y cells using the CRISPR-
Cas9 system 
 
5.2.1.1 Gene editing using the CRISPR/Cas9 system  
CRISPR were first discovered in Archea and bacteria (Ishino et al., 1987; 
Mojica et al., 1993). They were described as short base repeats separated by 
spacers. In 2005, scientists finally uncovered the role of the CRISPR repeats: 
they function as an immune adaptive response against virus and plasmid 
infection (Mojica et al., 2005; Pourcel et al., 2005).  
The CRISPR system is an elegant tool to specifically target virus invasion. 
Following viral infection, bacteria and archaea integrate segments of viral 
nucleic acid into their genome. They then use those sequences to later 
recognise the virus and efficiently destroy viral DNA. This system requires 
CRISPR-associated genes (Cas) that encode proteins such as nucleases or 
helicases, which orchestrate the DNA cleavage (Rath et al., 2015). 
This sophisticated system has been adapted for genome editing; in 2013, the 
Zhang lab described a three-component system composed of a CRISPR RNA 
(crRNA), a transactivating crRNA (tracrRNA) and the Streptococcus pyogenes 
Cas9 (SpCas9 or Cas9) endonuclease. The crRNA is a guide sequence, which 
directs the Cas endonuclease to the target genomic DNA. In the original 
bacteria, the tracrRNA enables the processing of the pre-crRNA into its ~20nt 
mature form. In this system, the tracrRNA is required for correct cleavage by 
SpCas9; it is thought to serve as a scaffold sequence for Cas9 binding (Cong 
et al., 2013; Ran et al., 2013). The crRNA and tracrRNA can be fused and the 
resulting RNA is termed single-guide RNA (sgRNA). The crRNA guide 
sequence has to be directly followed by a Proto-spacer adjactent motif (PAM). 
This short motif is essential for the targeting of the Cas9-crRNA complex to 




Figure 5.1: Schematic representation of a Cas9 nuclease targeted by its sgRNA. 
The S. pyogenes Cas9 nuclease (green) is targeted to genomic DNA by its single-
guide RNA (sgRNA). The sgRNA is composed of a 20bp guide sequence (or crRNA, 
blue), that directs the Cas9 to the target DNA region (overlined in blue), and of a 
scaffold sequence (or tracrRNA, purple) that enable the Cas9/sgRNA binding. The 
3bp PAM sequence (red) adjacent to the target region is required for nuclease activity. 
Cas9 cleaves both strands of the target DNA ~3bp upstream of the PAM sequence. 
Figure adapted from Jinek at al., 2012 and Ran et al., 2013. 
 
Currently, SpCas9 is the most commonly employed Cas endonuclease for 
genome editing. Indeed, SpCas9 only requires a 3 nucleotide PAM: NGG. This 
DNA endonuclease contains two nuclease domains, HNH and RuvC. These 
domains respectively cleave the target- and its antiparallel-DNA strand, to 
create Double Strand Breaks (DSBs) (Gasiunas et al., 2012; Jinek et al., 
2012). These DSBs, trigger two main repair pathways:  
- The Non-homologous end joining repair system (NHEJ)  
- The homology directed repair system (HDR) 
 
Most DSBs are repaired by the error prone NHEJ system. This repair 
mechanism directly ligates DNA strands and often causes stochastic insertions 
or deletions (indels). These indels are of interest when generating knockouts 
as it causes non-reversible alteration of the gene of interest. 
Unlike NHEJ, HDR is highly specific but requires a DNA template to repair 
DBS. Thus, this system can be used to generate knock-in cells during S-phase 

















5.2.1.2 Targeting Cas9 to USP30’s catalytic cysteine 
To knockout USP30 in SH-SY5Y cells, I employed Zhang’s three component 
system. I used two sgRNA (sgUSP30-1: 5’-AGTTCACCTCCCAGTACTCC-
3’and sgUSP30-2: 5’-TGAAAGCAGGACAGGCAGAC -3’) designed by Dr JR 
Liang. These sgRNA target USP30’s USP domain, at exon 3, in the direct 
vicinity of the catalytic cysteine (C77), (Figure 5.2). 
The DSB should then trigger the NHEJ repair pathway and produce indels or 
a frameshift that will lead to an inactive DUB or cause misfolding and 




Figure 5.2: Alignment of USP30-targeted sgRNA#1 and #2 with the sequence 
and exons of USP30 isoform 1. 
Schematic representation of the exons of USP30 isoform 1 aligned with the protein 
domains. The catalytic triad, composed of C77, H452 and S477 is highlighted in bold. 
Important features of the protein are annotated: the transmembrane domain (yellow), 
the polybasic region (red) and the USP domain (orange). The regions targeted by 













I employed two plasmids from the Zhang lab to transfect the sgRNAs into SH-
SY5Y cells: pX330 and pX458 (Figure 5.3). pX330 contains two cassettes, 
one encoding for the sgRNA and the other for the Cas9 endonuclease. The 
Cas9-sgRNA complex is sent to the nucleus by the two nuclear localization 
signals (NLS) flanking the Cas9. The sgRNA cassette has an insertion site for 
the guide crRNA and an invariant scaffold tracrRNA (Figure 5.3A). The 
Morrison lab inserted a puromycin resistance cassette at the 3’end of the Cas9 
sequence to select for positively transfected cells (Prof Ciaran Morrison, NUI 
Galway) (Figure 5.3B). pX458 is a variant of the pX330 plasmid that has an 
EGFP cassette after the Cas9 sequence (Figure 5.3C). The pX330-puroR and 
pX458 plasmids containing either sgUSP30-1 or sgUSP30-2 were generated 




Figure 5.3: Schematic representation of Cas9/sgRNA plasmids used to generate 
USP30 knockout SH-SY5Y cells. 
The two plasmids used to knockout SH-SY5Y cells, B) pX330-puro and C) pX458, 
were made from A) pX330. pX330 was generated by the Zhang Lab and is formed of 
two cassettes, one encoding for the sgRNA (blue and purple line) and the other for 
the S.pyogenes Cas9 nuclease (light green). The sgRNA cassette has an insertion 
site for the guide RNA sequence (blue) that is followed by the sgRNA scaffold 
sequence (purple). B) pX330-puro contains a puromycin resistance cassette at the 3’ 
end of the Cas9 sequence. C) pX458 has an additional EGFP cassette following the 
Cas9.  
Figure adapted from Ran et al., 2013. Abbreviations: U6: U6 promoter; CBh: CMV 
enhancer + chicken β-actin promoter; NLS: nuclear localisation signal of SV40; 
SpCas9: S.pyogenes Cas9; 2A: 2A self-cleaving peptide sequence from Thosea 



















5.2.1.3 Generating USP30 knockout SH-SY5Y and SH-SY5Y mito-QC 
clones.  
Ahead of using the pX330-puroR plasmids to knockout USP30, I employed a 
colorimetric assay to determine the optimal puromycin concentrations required 
to induce cell death in the non-transfected cells (Figure 5.4). I found that 1.5 
µg.ml-1 of puromycin was sufficient to deplete 95% non-resistant cells within 
48 hours. Lower doses, such as 1 or 1.25 µg.ml-1, led to the loss of 75-80% of 
the population (Figure 5.5A). With this assay, I also showed that co-treating 
with 500µg.ml-1 of hygromycin did not compromise the cells’ sensitivity to 
puromycin (Figure 5.4B). 
 
 
Figure 5.4: Puromycin and hygromycin titration in SH-SY5Y mito-QC cells. 
SH-SY5Y mito-QC cells were grown in 96 well plates and treated with increasing 
concentrations of puromycin. A) SH-SY5Y mito-QC cells were treated for 24h or 48h 
with puromycin. B) SH-SY5Y mito-QC cells were co-treated for 48h with 500μg.ml-1 
hygromycin and indicated concentrations of puromycin. The cell viability was 
assessed using The CellTiter 96® AQueous One Solution Cell Proliferation Assay, a 
colorimetric analysis. The graphs represent the percentage of cell surviving plotted 
against puromycin concentration. Error bar = SD, 4 technical replicates.  
A
B
































I transfected SH-SY5Y mito-QC cells with pX330-puroR-sgUSP30#1 and 2 
and used pX458-sgUSP30#1 and 2 in SH-SY5Y cells (Figure 5.5).  
The mito-QC construct is associated with a hygromycin resistance cassette 
(Allen et al., 2013). As I was aiming to retain this construct in SH-SY5Y mito-
QC cells during the knockout process, I performed three distinct experiments 
with the following transfection conditions:  1- Transfection of pX330-puroR 
followed by a 72h hygromycin and puromycin treatment. 2- Transfection of 
pX330-puroR followed by a 72h puromycin treatment. 3- 24h pre-treatment 
with hygromycin followed by the transfection of pX330-puroR and then 
combined puromycin and hygromycin treatment for 72h (Figure 5.5A). I 
treated the cells with puromycin concentrations ranging from 0.5 to 1.5 µg.ml-
1 in all three conditions. Once the non-transfected cells had died, I diluted the 
surviving cells into 10cm dishes to promote the growth of individual colonies. 
As soon as the colonies were distinguishable by eye and still well separated, I 
picked single colonies and expanded them for screening. 
 
In a separate approach, I transfected SH-SY5Y cells with pX458-sgUSP30 for 
24h, then selected the GFP positive cells by flow cytometry using the FACS 
AriaIII (central FACS facility on the University of Liverpool campus, operated 
by Sandra Cachinho) (Figure 5.5B).  
Under the guidance of Sandra Cachinho, I determined the gates to solely 
select alive and single cells and to exclude untransfected cells (Figure 5.6). 
The pool of living cells was visualised using granulometry measures, which is 
determined with Side Scatter values-Area (SSC-A) and Forward Scatter 
values-Area (FSC-A) (Figure 5.6A, D and H). Singlets were discriminated 
from cell aggregates by their width and height; measures that are performed 
with the FSC-W (weight) and FSC-H (height) (Figure 5.6B, E, I). Finally, using 
a FITC laser (Ex/Em: 488nm/502-560), I determined the background emission 
produced by untransfected cells (Figure 5.6C-D, F-G, J-K). Using those 
settings, I determined that ~13% of the population was efficiently transfected 
with both pX458-sgUSP30#1 and 2 (Figure 5.6L). The EGFP+ cells were 







Figure 5.5: USP30 knock-out procedure in SH-SY5Y mito-QC and SH-SY5Y cells. 
A) SH-SY5Y mito-QC cells were seeded in 6-well plates then transfected with the 
pX330-puro sgUSP30#1 and #2 plasmids for 24h. The transfected cells were then 
split into 10cm dishes and positively selected using a range of puromycin 
concentrations (from 0.5 μg.ml-1 to 1.5 μg.ml-1) for 72h. B) SH-SY5Y cells were seeded 
into 10cm dishes and then transfected with the pX458 sgUSP30#1 and #2 for 24h. 
The successfully transfected cells expressed EGFP and were selected by FACS. This 
EGFP+ population was single cell diluted into 96 well plates.The marks and crosses 
indicate whether the process led to the generation of viable knockout clones. 
  
Pick clones
Seed SH-SY5Y mito-QC cells
Tranfect
pX330-puro sgUSP30










FACS sort EGFP+ cells












Figure 5.6: Sorting of CRISPR transfected SH-SY5Y cells by flow cytometry. 
SH-SY5Y cells untransfected (UNT) or transfected with either pX458-sgUSP30#1 
(sgRNA#1) or pX458-sgUSP30#2 (sgRNA#2) were sorted by flow cytometry. 
Untransfected SH-SY5Y cells were used as a negative control. Only living, single and 
GFP+ cells were selected for further single cell dilution. A, D, H) The live cells were 
selected by granulometry, using the Side Scatter values - Area (SSC-A) and by size, 
employing the Forward Scatter values - Area (FSC-A). B, E, I) Further on, singlets 
were selected depending on their width and height: FSC-W (width) and FSC-H 
(height). C-D, F-G, J-K) Finally, GFP+ cells (annotated as FITC-A) were sorted using 
a 488nm laser. L) The percentage of live cells, singlets and GFP+ (FITC+) are 
represented in the above table.  
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5.2.1.4 Western blot screen of USP30 knockout clones 
All selected clones were expanded into six well plates and lysed for a western 
blot screen. No SH-SY5Y mito-QC clone survived from condition 1 
(transfection then combined treatment with puromycin and hygromycin). 
Colonies from condition 3 (pre-treatment with hygromycin and transfection 
then puromycin + hygromycin treatment), only grew in low puromycin 




Figure 5.7: Western blot screen for SH-SY5Y mito-QC USP30 knockout cells. 
SH-SY5Y mito-QC cells were transfected with two sgRNA targeting USP30: sgUSP30#1 
(sg#1) and sgUSP30#2 (sg#2). A-C) Condition 2: Following transfection, SH-SY5Y mito-
QC cells were maintained under puromycin selection (0.5-1μg.ml-1), for 72h, to select for 
positively transfected cells. C) Three passages later, fresh lysates of KO2, KO7, KO10 and 
KO11 were immunoblotted against USP30. D-F) Condition 3: SH-SY5Y mito-QC cells were 
maintained in hygromycin (500μg.ml-1) for 24h prior transfection. Following transfection, 













































































































































































































































































































































































Condition 3: Putomycin and hygromycin selectionCondition 2: Puromycin selection
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A total of 13 SH-SY5Y mito-QC clones survived the selection process of 
condition 2 (Puromycin only selection) (Figure 5.7A-C). In the first round of 
immunoblotting, 5 clones appeared to have lost USP30: Clone#2, 5 and 7 
(sgUSP30#1) and Clone#11 and 14 (sgUSP30#2) (Figure 5.7A-B). After three 
passages, only Clone#7 (KO7) and Clone#11 (KO11) remained free of USP30 
signal (Figure 5.7C).  
 
SH-SY5Y cells transfected with pX458-sgUSP30 plasmids grew very slowly 
and poorly recovered from the FACS sorting. I previously observed that SH-
SY5Y cells tend to grow slowly when seeded at a low confluency. This is 
possibly due to a lack of some growth factors or metabolites secreted by the 
nearby cells. To counter this issue, I decided to use a 1:4 mix of condition 
media in full media. However, even then, out of the four 96 well plates only 9 
clones survived and proliferated. Immunoblotting showed that Clone-C and D 
(KOC and KOD, sgUSP30#1) were depleted of USP30 (Figure 5.8). 
 
 
Figure 5.8: Western blotting screen for USP30 knocked-out SH-SY5Y clones. 
SH-SY5Y cells were transfected with two sgRNA targeting USP30 (sgUSP30#1 and 
#2). Six sgUSP30#1 and three sgUSP30#2 transfected clones were expanded and 

































































































5.2.1.5 Sequencing of USP30 knockout clones 
I next undertook genomic sequencing to see what mutations were suffered by 
KOC, KOD, KO7 and KO11.  
I extracted genomic DNA from each clone and amplified exon 3 by PCR using 
the following sets of primers: 2225/2226 (KO11), 2227/2228 (KO11) & 
2229/2230 (KO7, KOC and KOD). I inserted the PCR products into pCR4-
TOPO plasmids and transformed them into TOP10 bacteria. I picked 6-10 
colonies per clone and sets of primer. I extracted the plasmid DNA and 
checked whether it contained an insert by a diagnostic restriction digest with 
EcoRI (two sites for this enzyme flank the insertion site).  All plasmids positive 
for this exon 3 insert were sent for Sanger sequencing at the Dundee’s DNA 
Sequencing and Services Unit.  
 
The alignment of the sequencing results with the USP30 exon 3 sequence 
highlights the Indels produced by the NHEJ repair machinery, allowing me to 
predict the resulting frameshifts and early stop codons (Figure 5.9). All 
sequences had Indels in the exon 3 sequence coding for a section of the USP 
domain and would result in frameshifts and premature stop codons. Such 
truncations in a folded domain region of a protein have a high likelihood to give 
rise to non-functional and misfolded proteins that are degraded by the 
proteasome (Shi et al., 2015), (Figure 5.10).  
The USP30 gene is located on chromosome 12 at location 12q24.11; this 
region shows no chromosomal abnormalities and is present on only two alleles 
in SH-SY5Y cells (Spengler et al., 2002; Yusuf et al., 2013). KOC, KOD and 
KO11 have distinct mutations on each allele whilst I only detected a single 




Figure 5.9: Alignment a KO11 exon 3 variant with USP30’s wildtype exon 3. 
USP30 exon 3 of SH-SY5Y and SH-SY5Y mito-QC knockout cells (here KO11) were 
sequenced and the results aligned with their wild type sequence. A) KO11 nucleotide 
sequence (Seq_2) aligned with wildtype USP30 exon 3 (Seq_1) using SerialCloner. 
The position of the catalytic cysteine C77 (orange), sgUSP30#1 (blue) and 
sgUSP30#2 (green) are annotated on the figure. B) Description of the deletion 
observed in A and prediction of the resulting mutated protein sequence compared 
with wildtype USP30 amino acid sequence. The USP domain is highlighted in yellow 
and the catalytic triad (C77, H452, S477) is coloured in orange. In dark red are 
annotated the predicted amino acids produced by the frameshift. The stars (*) 
represent stop codons. 
  
Seq_1  1     ------------------------------GTGCCTGGCCTTGTTAATTTAGGGAACACC  30 
                                           |||||||||||||||||||||||||||||| 
Seq_2  449   AGTCCTGCAGGTTTAAACGAATTCGCCCTTGTGCCTGGCCTTGTTAATTTAGGGAACACC  390 
 
 
Seq_1  31    TGCTTCATGAACTCCCTGCTACAAGGCCTGTCTGCCTGTCCTGCTTTCATCAGGTGGCTG  90 
             ||||||||||||||||||||||||||||||||        |||||||||||||||||||| 
Seq_2  389   TGCTTCATGAACTCCCTGCTACAAGGCCTGTC--------CTGCTTTCATCAGGTGGCTG  338 
 
 
Seq_1  91    GAAGAGTTCACCTCCCAGTACTCCAGGGATCAGAAGGAGCCCCCCTCACACCAGTATTTA  150 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  337   GAAGAGTTCACCTCCCAGTACTCCAGGGATCAGAAGGAGCCCCCCTCACACCAGTATTTA  278 
 
 
Seq_1  151   TCCTTAACACTCTTGCACCTTCTGAAAGGTATCTAGATGGGAATTTCAAGGGAATTATGT  210 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  277   TCCTTAACACTCTTGCACCTTCTGAAAGGTATCTAGATGGGAATTTCAAGGGAATTATGT  218 
 
 
Seq_1  211   ACCTTTTCAAAGAAGTCCAGATGACAGAGACTCTTATAACAAAGAGTTAATACCTTATTG  270 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  217   ACCTTTTCAAAGAAGTCCAGATGACAGAGACTCTTATAACAAAGAGTTAATACCTTATTG  158 
 
 
Seq_1  271   TAGGAAAAGATCATACAGATCATTATGAATAAACAACACCAAGAGCCCAATAGATACAAA  330 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  157   TAGGAAAAGATCATACAGATCATTATGAATAAACAACACCAAGAGCCCAATAGATACAAA  98 
 
 
Seq_1  331   CAAGTATTTTTTAAAAATCAAAGATGGAGGCCGGGTGCAGTGGCTCATGCCTG-------  383 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||        
Seq_2  97    CAAGTATTTTTTAAAAATCAAAGATGGAGGCCGGGTGCAGTGGCTCATGCCTGAAGGGCG  38 
Alignment of Sequence_1:  [PCR_UP_product_exon3.xdna] with  Sequence_2: [11.1 C-M13 
Fwd-130917-07-39.seq.xdna] :
A
Mutation: 8nt deletion, position 262-269aa
















Figure 5.10: Details of the mutations suffered by SH-SY5Y and SH-SY5Y mito-
QC USP30 knockout clones. 
A) USP30 was deleted in SH-SY5Y mito-QC and SH-SY5Y cells using two sgRNAs, 
sgRNA#1 (blue & underlined) and sgRNA#2 (orange & underlined). The genomic 
DNA of USP30 knockout clones was extracted and the edited region was amplified 
by PCR. The PCR product was ligated into a plasmid vector, transformed into 
competent cells and multiple bacterial colonies were selected and analysed by 
sequencing. The mutation suffered per allele and per clone is highlighted in bold red. 
The catalytic cysteine C77 is highlighted in green. TSS: Transcription start site. B) 
The table summarises the sequencing results obtained from SH-SY5Y (KOC and 
KOD) and SH-SY5Y mito-QC (KO7 and KO11) USP30 KO clones. The editing 
observed for each clone is reported in the mutation column and the resulting expected 
protein is described in the protein section. Plasmids extracted from between 5 and 13 
colonies of competent cells were sequenced per knockout clone. The frequency of 




Reference 1   GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTACTCCAGGGATCAG TSS +261 
KOC-allele 1  GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTACTTCCAGGGATCAG    +1bp 
KOC-allele 2  GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTACCTCCAGGGATCAG    +1bp 
 
Reference 1   GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTACTCCAGGGATCAG TSS +261 
KOD-allele 1  GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTAC-------ATCAG     -7nt 
KOD-allele 2  GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGT-------------G    -13nt 
 
Reference 1   GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTACTCCAGGGATCAG TSS +261 
KO7-alleles   GCCTGTCCTGCTTTCATCAGGTGGCTGGAAGAGTTCACCTCCCAGTACGATCCAGGGATCAG   +2bp 
 
Reference 2   TGCTTCATGAACTCCCTGCTACAAGGCCTGTCTGCCTGTCCTGCTTTCATCAGGTGGCTG TSS +228         
KO11-allele 1 TGCTTCATGAACTCCCTGCTACAAGGCCTGTC--------CTGCTTTCATCAGGTGGCTG     -8bp 
KO11-allele 2 TGCTTCATGAACTCCCTGCTACAAGGCCTGTCTTGCCTGTCCTGCTTTCATCAGGTGGCTG    +1bp 
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5.2.1.6 Loss of the mito-QC construct in KO7 and KO11 cells 
 
5.2.1.6.1  Fluorescence and confocal microscopy characterisation of 
KO7 and KO11. 
In parallel of the sequencing process, I assessed the mito-QC USP30 KO 
clones by live cell epifluorescence and confocal microscopy and compared 
them with the parental cell line (Figure 5.11). All cells were morphologically 
similar to the parental cells, However, only 10-20% of KO7 and KO11 cells 
were expressing mito-QC. In an attempt to enrich the small percentage of 
mitoQC expressing USP30 KO cells, I treated the clones with 500µg.ml-1 
hygromycin for 7 days, then lysed and immunoblotted the selected cell against 
USP30 (Figure 5.12). All hygromycin selected cells were expressing USP30. 
Most likely, KO7 and KO11 were mixed populations containing both USP30 
KO cells that are mitoQC negative as well as a small percentage of wildtype 
cells expressing mito-QC.  
I decided to single cell dilute the original KO11 and KO7 “clones” to separate 
the USP30 wildtype from USP30 knockout cells.  
However, post-single cell dilution, the cells didn’t divide and ended up dying. 
As I had previously observed with single the cell dilution by flow cytometry, SH-
SY5Y cells are very sensitive to cell confluency and fail to expand when grown 
in isolation.  
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Figure 5.11: USP30 knockout clones 7 and 11 (KO7, KO11) only partially express 
mito-QC. 
A) Following USP30-targeted sgRNA transfection, six clones were imaged by 
fluorescence microscopy on a Nikon Ti-Eclipse microscope and compared with the 
parental SH-SY5Y mito-QC cell line. mCherryFIS1 Ex/Em: 561/610; GFP Ex/Em: 
488/507; BF: brightfield. 20X Objective lens. Scale bar: 50μm. B) Clone#10 (WT1), 
Clone#7 (KO7) and Clone#11 (KO11), were grown on IDIBI dished and imaged using 
a 3i spinning disk confocal. TOP panel: Brightfield images of control cells WT1 and 
USP30 knockout clones KO7, KO11 cells. BOTTOM panel: Corresponding merge 


























Figure 5.12: Hygromycin selection of mito-QC expressing KO7 and KO11 cells. 
A) “KO7” and B) “KO11” mixed populations were treated with 500μg.ml-1 Hygromycin 
for 7 days to select for mito-QC expressing cells. The resulting pools were lysed and 




5.2.1.6.2 Negative FACS sorting of mito-QC negative cells in KO7 and 
KO11 mixed clones 
As a last resort to obtain a clonal population of USP30 KO cells, I decided to 
use flow cytometry to negatively sort the mito-QC positive cells (FACS sorting 
performed by Christopher Law). We used a mix of wildtype SH-SY5Y mito-QC 
and SH-SY5Y cells to discriminate between the background autofluorescence 
of SH-SY5Y cells and Cherry+ signal using a PE-TxRed specific laser 
(Ex/Em:561/610-620 nm) on the FACS AriaIII instrument (Figure 5.13). Side 
scatter and forward scatter measurements (SSC and FSC) permitted to select 
live and singlet cells (Figure 5.13 A-B, D-E, H-I). 
The mCherry-positive cells present in KO7 and KO11 populations were 
discarded and the mCherry-negative cells were maintained as a pool, 
expanded and screened by western blotting (Figure 5.13C, F-G, J-L). The 
FACS sorted KO7 cells were still expressing low levels of USP30 (Figure 
5.13K). However, KO11 appeared to be cleared from USP30 expressing cells 
(Figure 5.13G).  
For most of the following experiments I have therefore mainly been using 
KO11, KOC and KOD, which derive from two different parent lines, but neither 
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Figure 5.13: Negative FACS sorting of mito-QC positive cell in KO7 in KO11 
mixed populations. 
SH-SY5Y cells stably expressing mito-QC from KO7 and KO11 cells were sorted by 
flow cytometry. A-C) FACS sorting gates were previously set using the parental SH-
SY5Y MGFIS cell line. A, D, H) Live cells were selected by granulometry, using the 
Side Scatter values - Area (SSC-A) and by size, employing the Forward Scatter 
values - Area (FSC-A). B, E, I) Singlets were selected depending on their width and 
height: FSC-W (width) and FSC-H (height). C, F, J) Finally, gates were set to 
discriminate between mito-QC-positive (mCherry[+]) and mito-QC-negative 
(mCherry[-]) cells using a PE-TxRed laser (Ex:561nm). G, K) Following FACS sorting, 
G) KO7 and K) KO11 mCherry- cells were lysed and analysed by western blotting. 
The lysates were probed against USP30. L) The percentage of live cells, singlets, 

























































































































































































 Identifying USP30 substrates and function 
5.2.2.1 Mitochondria fission and fusion dynamics 
Hirose and Nakamura were the first to identify USP30 as a mitochondrial DUB 
and proposed that it functions in mitochondrial dynamics (Nakamura and 
Hirose, 2008). They reported that knocking-down USP30 promotes the fusion 
of the mitochondrial network in HeLa cells. Hirose and Nakamura were 
however not able to explain the mechanism underlying the USP30-induced 
elongation of mitochondria as they found no changes in fusion proteins (MFNs, 
OPA1) or fission proteins (FIS1, DNM1L). Later, Yue and colleagues made 
use of a non-selective inhibitor, S3, that induces mitochondrial fission, 
enhances non-degradative ubiquitylation of MFNs and could bind catalytically 
active USP30. From these observations, they suggested that USP30 
deubiquitylates the fission factors MFN1 and MFN2 to promote fission, without 
affecting their stability (Yue et al., 2014).  
Neither of the two studies have studied the effect of USP30 deletion on the 
mitochondrial network. To assess this, I fixed and stained SH-SY5Y and KO11 
cells against the outer mitochondrial protein TOMM20 (Figure 5.14). I 
measured the number of fragmented mitochondria, the number of branched 
mitochondria (networks), and the number and length of branches for each 
network using MiNA, a FIJI plugin. USP30 knockout did not increase the 
number of networks, nor the number of branches, nor did it affect the branches’ 
length (Figure 5.14D-F). In the contrary, if anything I noted a trend towards an 
increase of the number of fragmented mitochondria (dots and unconnected 
rods) and towards a reduction of the mitochondrial mass (Mitochondria 
footprint) (Figure 5.14B-C). In parallel, I determined by immunofluorescence 
whether USP30 knockout could result in a decrease in the peroxisome pool by 
raising basal pexophagy (Figure 5.15). Using the Fiji plug-in ‘Analyse Particle’, 
I found that both KO11 and SH-SY5Y cells had on average 110 peroxisomes 
per cell in one confocal slice (0.34 µM). Similarly, my colleague Elena 
Marcassa found that neither the mitochondrial nor the peroxisomal networks 




Figure 5.14: The mitochondrial network is unaffected by USP30 depletion in SH-
SY5Y cells. 
A) SH-SY5Y and KO11 cells were fixed and stained by immunofluorescence for the 
mitochondrial protein TOMM20. Images were taken using a 3i spinning disk confocal. 
Objective lens: 63X. Scale bar: 10μm. B, C, D, E and F) Images were analysed using 
the MiNA plug-in on FIJI; 20 cells were quantified per cell line. B) Mitochondrial 
footprint: Total area of the cell occupied by the TOMM20 signal. C) Number of 
unbranched mitochondria (punctate and rods) per cell. D) Number of branched 
mitochondria (networks) per cell. E) Mean number of branches per network and per 



















































































































Figure 5.15: The peroxisomal network is not affected by USP30 depletion. 
A) SH-SY5Y cells and KO11 cells were fixed and stained by immunofluorescence for 
PMP70, a peroxisomal proteins. The images were taken with 3i a spinning disk 
confocal. Objective lens: 63X. Scale bar: 10μm. B) The images were analysed using 
Analyse particle, a FIJI plugin. The graph represents the number of peroxisomes per 
cell (from a single confocal plane) and per cell line. Each dot represents a single cell. 
Error bars: mean ± SD. Data from a single experiment. 
 
5.2.2.2 Mitochondrial metabolism 
I then wondered if USP30 could affect the mitochondrial metabolism and 
energy production. I decided to measure ATP synthesis in oxidative or 
glycolytic conditions. I employed a chemiluminescence assay, the CellTitre-
Glo assay, in which luciferase’s luminescence is directly proportional to the 
ATP concentration (Figure 5.16). To block oxidative phosphorylation 
(OXPHOS), I treated the cells with an inhibitor of Complex V of the respiratory 
chain, Oligomycin A, for 30 minutes at 10µM. Both the parental lines, SH-SY5Y 
and SH-SY5Y mito-QC, and the USP30 knockout lines, KOC, KOD and KO11, 
could efficiently compensate for inhibition of OXPHOS. The cells were 
producing 96% ± 0.02 of their ATP production capacity. To test for the cells’ 
dependency on glycolysis for ATP production, I supplemented the media with 
50mM 2-Deoxyglucose (2-DG). 2-DG is a glucose molecule which lacks the 2-
hydroxyl group and acts as a competitive inhibitor of glycolysis via Hexokinase 
2. Indeed, the resulting 2-deoxyglucose-6-phosphate cannot be utilized by 
phosphoglucose isomerase (Wick et al., 1957). With 2-DG, the ATP production 






























machinery was not sufficient to fully compensate for glycolysis inhibition. In the 
knockout cells the results were less clear. KOC cells were more glycolytic, with 
2-DG their ATP synthesis dropped by 73%; KOD cells reacted just as the 
parental lines, their ATP production was decreased to 50%; KO11 cells were 
less sensitive to glycolysis inhibition than the parental lines, OXPHOS could 
compensate for 67% of ATP generation in those cells.  
The differences observed are likely to be due to clonal variation rather than a 
direct effect of USP30 knockout. Andreas Kallinos’ findings in RPE1 and 
HCT116 cells support this hypothesis. In HCT116, the loss of USP30 does not 
affect ATP production and in RPE1 cells he observed a variable response that 




Figure 5.16: USP30 knockout and wildtype SH-SY5Y cells are dependent on 
their glycolytic metabolism to produce ATP. 
ATP produced by the parental cell lines (SH-SY5Y and SH-SY5Y mito-QC cells) and 
SH-SY5Y USP30 KO cells (KOC, KOD and KO11) was assessed using the CellTitre- 
Glo assay. Cells were treated with Oligomycin (Oligo., 10μM), 2-Deoxyglucose (2-
DG, 50mM) or a combination of both for 30 min then lysed. This assay employs 
luciferase, an enzyme which produces luminescence directly proportional to the ATP 
concentration. The graph represents the chemiluminescence measurements 
normalised to the untreated conditions. Results from 2 experiments. Error bars: mean 



































5.2.2.3 Mitophagy: TOMM20- and pS65-Ubiquitylation 
In Chapter IV, I described that USP30 knockdown increases AO-induced 
mitophagy. In this chapter, I will be assessing USP30 substrates involved in 
mitophagy. I started by measuring the levels of expression of the major 
mitophagy regulators, PINK1 and Parkin, in SH-SY5Y Mito-QC cells 
transfected with sgUSP30 (prior to the FACS sorting of KO7 and KO11) 
(Figure 5.17). I found that neither PINK1 accumulation nor Parkin general 
expression levels were affected by USP30 deletion in KO7 and KO11 clones 
in response to depolarisation. Similarly, I did not observe a variation in PINK1 
accumulation in the SH-SY5Y knockout KOD cell line (Figure 5.18E). In SH-
SY5Y KOC, PINK1’s accumulation was slightly reduced at the 8h time point 
compared to WT SH-SY5Y cells (~25% less). Unlike KOD, KOC also appeared 
to have twice more ubiquitylated FIS1 species than the control cells (Figure 
5.18D-E). However, the only striking and consistent phenomenon occurring in 
USP30 KO clones was the appearance of TOMM20 ubiquitylated species 
upon AO stimulation (4h and 8h AO) (Figure 5.18C). 
 
 
Figure 5.17: Antimycin and Oligomycin time course in SH-SY5Y USP30 wildtype 
and knockout cells.  
SH-SY5Y, parental SH-SY5Y mito-QC, clone#8 (WT8), clone#7 (“KO7”), Clone#11 
(“KO11”) were treated with Antimycin A and Oligomycin A (AO, 1μM each) for 1, 6 
and 24h to trigger mitophagy. The cells were then lysed in NP40 buffer and 


























































































































Figure 5.18: Antimycin and Oligomycin time course in SH-SY5Y USP30 wildtype 
and knockout cells. 
SH-SY5Y, KOC and KOD were treated with Antimycin A and Oligomycin A (AO, 1μM 
each) for 4 and 8h to depolarise mitochondria. A) The cells were then lysed in NP40 
buffer and immunoblotted. The lysates were probed for proteins involved in 
mitophagy. Quantification of B) Ub-MFN2, C) Ub-TOMM20, D) Ub-FIS1 over their 
non-ubiquitylated form and normalised to SH-SY5Y 8h AO or C) to KOD 8h AO. E) 
Bar charts representing total PINK1 normalised over Actin then to SH-SY5Y 8h AO. 











































































































































































In mitochondria enriched samples, TOMM20 ubiquitylation is detected in all 
KO clones (KOC, KOD and KO11) following 1h AO treatment (Figure 5.19, 
5.20.1). Those samples also suggest that USP30 knockout cells have slightly 
higher detectable levels of TOMM20 ubiquitylation without depolarisation 
(Figure 5.19A-B, 5.20.1A-B).  
Interestingly, the ubiquitylation of TOMM20 forms close doublets (indicated by 
red arrows). The upper band of the doublet could correspond to modified 
ubiquitin species, such as phosphorylated ubiquitin. When further depolarising 
mitochondria for 4h, the TOMM20-ubiquitylation doublet is enhanced 3-fold 
and a new ubiquitin band appears in the KO samples ~14kDa above TOMM20 
(Figure 5.21). In the experiment performed in whole cell lysate, I did not 
measure a further increase of ubiquitylation upon 8h depolarisation, however 
this was not assessed in the mitochondria enriched fractions (Figure 5.18). 
Again, those changes in ubiquitylation pattern were not accompanied by a 
greater accumulation of PINK1 on mitochondria nor by a differential 
recruitment of Parkin to mitochondrial fraction (5.19A, 5.20.1C-D, 5.21E). 
Interestingly, although PINK1 is unaffected, the levels of phospho-Ser65 
Ubiquitin (pS65-Ub) are increased in the USP30 knockout fractions (Figure 
5.20.2 and 5.21). To determine the molecular weight range of the proteins 
differently phospho-ubiquitylated in response to USP30 knockout, I generated 
line graphs using Fiji in two separate experiments. These line graphs represent 
the intensity of pS65-Ub along the smear (From the top of the band ~ 300kDa 
to the bottom at ~0kDa) (Figure 5.20.2D-G).  
The maximum intensity peaks of those graphs were at ~300kDa and masked 
any variation of pS65-Ub at lower molecular weight (Figure 5.20.2B). I noticed 
that pS65-Ub was clearly stronger in KOD and KO11 below 76kDa. I therefore 
generated line graphs in that segment of the blot (Figure 5.20.2E, G). Those 
graphs revealed that the levels of pS65-Ub-proteins ranging between 76 and 
38kDa were specifically increased in KOD and KO11 after 1h AO. The overall 
pS65-Ub intensity signal in the 0-76kDa range was increased by ~50% in the 
knockout lines (Figure 5.20.2C). After 4h AO, smaller proteins (<38kDa) were 
differentially pS65-Ubiquitylated in KOD and KO11 (Figure 5.21H, K). Proteins 
such as TOMM20 and FIS1 would fall in that second category.   
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Figure 5.19: Mitochondria fraction: USP30 depletion increases TOMM20 
ubiquitylation. 
SH-SY5Y, KOC and KOD cells were treated with 1μM Antimycin A and Oligomycin A 
(AO) for 1h. The cells were then homogenised in HIM buffer. The nuclei were span 
down at 600g to collect the Post Nuclear Supernatant (PNS). The PNS was span a 
second time at 7,000g. The resulting pellet was labelled as Mitochondrial Fraction 
(MF) and the supernatant as Post Mitochondrial Supernatant (PMS). A) All fractions 
were ran on a 20 well gel for western blotting. B) The mitochondrial fraction was 
resolved on a 10-well gel. The lysates were probed for mitophagy substrates and 
regulators. The black arrows indicate the unmodified TOMM20 band; the red arrows 
point towards ubiquitylated-TOMM20. C) Quantification of (B) mitochondrial Ub-















































































































































































Figure 5.20.1: USP30 depletion increases TOMM20 ubiquitylation and phospho-
ubiquitylation of medium-sized proteins. 
SH-SY5Y, KOD and KO11 cells were treated with 1μM Antimycin A and Oligomycin 
A (AO) for 1h. The cells were then homogenised in HIM buffer. The nuclei were span 
down at 600g to collect the Post Nuclear Supernatant (PNS). The PNS was span a 
second time at 7,000g. The resulting pellet was labelled as Mitochondrial Fraction 
(MF) and the supernatant as Post Mitochondrial Supernatant (PMS). A) All fractions 
were immunoblotted against proteins involved in mitophagy. The black arrows 
indicate the unmodified TOMM20 band; the red arrows point towards ubiquitylated- 
TOMM20. B) Quantification of mitochondrial Ub-TOMM20 ratioed over non-
ubiquitylated TOMM20 and normalised to KO11 1h AO. Bar charts representing total 
C) PINK1 or D) Parkin localised at the mitochondrial fraction and normalised to SH-
SY5Y 1h AO. n=2. 
  
: 1h AO





































































































































































































Figure 5.20.2: USP30 depletion increases TOMM20 ubiquitylation and phospho-
ubiquitylation of medium-sized proteins. 
SH-SY5Y, KOD and KO11 cells were treated with 1μM Antimycin A and Oligomycin 
A (AO) for 1h. The cells were then homogenised in HIM buffer. The nuclei were span 
down at 600g to collect the Post Nuclear Supernatant (PNS). The PNS was span a 
second time at 7,000g. The resulting pellet was labelled as Mitochondrial Fraction 
(MF) and the supernatant as Post Mitochondrial Supernatant (PMS). A) All fractions 
were immunoblotted against pUb. B) Quantification of total mitochondrial pUb 
normalised to SH-SY5Y 1h AO. C) Bar chart representing the pUb signal measured 
below 76kDa and normalised to SH-SY5Y 1h AO. D and F) Line graph of the pUb 
signal measured in the mitochondrial fraction of two separate experiments. E and G) 
Line graph of pUb signal found below 76kDa. The 76kDa and 38kDa limits are 
respectively represented as a red and green dashed line. N=2.  
: 1h AO
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Figure 5.21: Mitochondria fraction: USP30 depletion increases phospho-
ubiquitylation of low molecular weight proteins. 
SH-SY5Y, KOD and KO11 cells were treated with 1μM Antimycin A and 1μM 
Oligomycin A (AO) for both 1h and 4h. The cells were then homogenised in HIM 
buffer. The Post Nuclear Supernatant (PNS), Post Mitochondrial Supernatant (PMS) 
and Mitochondrial Fraction (MF) were obtained by differential centrifugation. A) The 
fractions were immunoblotted against proteins involved in mitophagy. The black 
arrows indicate the unmodified TOMM20 band; the red arrows point towards 
ubiquitylated-TOMM20. B, C and D) Ubiquitylated-TOMM20, -FIS1 and -MFN2 from 
the MF were quantified using ImageStudio, ratioed to their unmodified form and 
normalised to SH-SY5Y 4h AO or to B) KO11 4h AO. E) The intensity of the PINK1 
band from the MF was also measured and normalised to SH-SY5Y 4h AO. F) Total 
phospho-ubiquitin signal, phospho-ubiquitin signal running G) below 76kDa or H) 
below 35kDa was detected and normalised to SH-SY5Y 4h AO. I, J and K) Line graph 
of the entire mitochondrial pUb smear and, in orange, line graph of the pUb bands 
running below 76kDa. The 76kDa and 38kDa limits are respectively represented as a 
red and green dashed line. 
 
I then assessed, by immunofluorescence, whether I could observe enhanced 
pS65-Ub accumulation at mitochondria in USP30 KO cells. I depolarised SH-
SY5Y and KOD cells with AO for 4h, fixed and stained them for TOMM20 and 
pS65-Ub (Figure 5.22A). Without AO, the antibody signal of pS65-Ub is low 
and rather ubiquitous, with the exception of a strong centrosomal-like staining. 
My colleague Andreas demonstrated that the centrosomal staining was 
retained even after PINK1 knockdown and was thus non-specific, caused by 
unknown cross-reactivity. 
Following AO-treatment, I observed puncta of pS65-Ub that partially 
colocalised with TOMM20, which identifies the now fragmented mitochondrial 
network (Figure 5.22A). I manually counted the number of cells with pS65-Ub 
concentrated on mitochondrial membranes and found that there was higher 
percentage of KOD and KO11 cells with mitochondrial pS65-Ub (~15%) than 
SH-SY5Y cells (~3%) (Figure 5.22B-C). Ideally, these conditions would have 
been compared with PINK1 knockdown to validate the specificity of the 
mitochondrial pS65-Ub staining. 
 
This variation of pS65-Ub could be the result of a global increase in ubiquitin. 
To verify this, I probed mitochondrial fractions with the VU-1 antibody 
(LifeSensors), which recognises free ubiquitin and poly-ubiquitin of all chain 
types, including K6-chains which are the proposed substrate of USP30 



























































































Figure 5.22: USP30 knockout increases pUb accumulation on mitochondria 
following depolarisation. 
SH-SY5Y, KOD and KO11 cells were treated with 1μM Antimycin and 10μM 
Oligomycin (AO) for 4h. The cells where then fixed with PFA and co-stained with anti-
pUb and anti-TOMM20 antibodies. The coverslips were mounted using mowiol mixed 
with DAPI. A) Images were taken with a spinning disk confocal microscope. Scale 
bar: 10μM. B) The number of cells with pUb aggregates overlapping with TOMM20 
were manually counted and plotted over the total number of cells. Analysis: one-way 
ANOVA with Tukey’s multiple comparison test. *: p < 0.05. Results from 3 
experiments; 200 cells were quantified in total. Error bars: mean ± SD. C) 
Representative images depicting pUb re-localisation following AO treatment. The 
















In AO treated cells, total ubiquitin is increased by 25%, irrespective of the 
USP30 status, in the high molecular weight range (>76kDa) (Figure 5.23D).  
MIRO1 (72kDa), MFN1 (84kDa) or MFN2 (86kDa) are ubiquitylated early on 
during mitophagy, although lower molecular weight proteins that are modified 
with long ubiquitin chains may also contribute to this ubiquitin smear (Figure 
5.18-5.19, 5.21-5.23).  
As USP30 preferentially deubiquitylates K6-chains, I also made use of a highly 
specific K6-affimer. (Figure 5.23E) (Gersch et al., 2017; Michel et al., 2017). 
Affimers are small (12kDa) engineered binding proteins used as alternatives 
to antibodies. They are derived from sequences of cystatins and consist of an 
α-helix and four antiparallel β-sheets. Two surface loops linking the β-sheets 
can be randomised and produce affimer libraries with substrate specificity 
(Tiede et al., 2014, 2017). I made use of a K6-affimer linked to a GFP tag and 
thus detected it with a GFP antibody (Figure 5.23E). 
As I used the parental SH-SY5Y mito-QC line as a control, the GFP antibody 
also detected the mito-QC probe. This reporter contains mCherry (26.7 kDa), 
EGFP (26.9 kDa) and FIS1101-152 (5.26 kDa) and therefore the full-length 
construct runs approximatively at 60kDa. Multiple lower molecular weight 
fragments of the probe were also apparent and made it difficult to interpret the 
signal above 76 kDa (Figure 5.23A, E). There is also an apparent mono-Ub 
form of the mito-QC probe that is enhanced with AO-mediated depolarisation 
(red arrow). FIS1 is known to be ubiquitylated by Parkin at K25 but also at 
K108, amongst other lysines, during mitophagy (Ordureau et al., 2020; Rose 
et al., 2016). It is possible that the FIS1101-152 fragment of mito-QC gets 
ubiquitylated. 
Just as for total ubiquitin, AO elevated by 20% the amount K6-chains in the 
high molecular weight range of mitochondrial fractions (Figure 5.23E). 
Interestingly, USP30 knockout did not promote an increase of those high 
molecular weight range K6-chains. This could indicate that USP30 has only 
selective substrates, such as TOMM20, rather than globally deubiquitylating 
mitochondria. USP30’s substrates could also be modified by other chain types 
or monoubiquitin. Another hypothesis would be that another deubiquitylase is 
compensating for the loss of USP30.  
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Those results would be in agreement with the model we have presented in 
Chapter IV, in which USP30 acts upstream of PINK1 to limit the availability of 
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Figure 5.23: Mitochondria fraction: USP30 depletion does not affect the 
unmodified mitochondrial ubiquitin pool. 
SH-SY5Y mito-QC (annotated as SH-SY5Y) and KO11 cells were treated with 1μM 
Antimycin A and 1μM Oligomycin A (AO) for 1h. The cells were then homogenised in 
HIM buffer. The Post Nuclear Supernatant (PNS), Post Mitochondrial Supernatant 
(PMS) and Mitochondrial Fraction (MF) were obtained by differential centrifugation. 
A) The fractions were immunoblotted against proteins involved in mitophagy, ubiquitin 
and K6-ubiquitin chains. The general ubiquitin antibody VU-1 recognises free 
ubiquitin, K48-, K63-, K11- and linear- ubiquitin chains. The K6 affimer (Anti di-
Ubiquitin K6 Affimer (K6-29) - 7X His and GFP tags) was detected using a GFP 
antibody. The GFP antibody also recognises the mito-QC probe, which runs at 
58.9kDa; the arrows indicate mito-QC and possible cleaved forms of the probe. B and 
C) Mitochondrial PINK1 and Parkin were quantified using ImageStudio and 
normalised to SH-SY5Y mito-QC 1h AO. D) Quantification of total Ub (VU-1) bands 
running between 0-76kDa or 76-300kDa normalised to SH-SY5Y mito-QC DMSO. E) 
Mitochondrial K6 chains were measured above 76kDa and normalised to SH-SY5Y 
mito-QC DMSO. Data from a single or two (VU-1 and Parkin blots) experiments. Error 
bars: mean ± SD. 
  Identifying new E3 ligases opposing USP30 in mitophagy 
We have been hypothesising that USP30 deubiquitylates mitochondrial 
proteins upstream of PINK1 and PRKN. This model implies that there are 
priming E3(s) ligase(s) at mitochondria which decorate the OMM with ubiquitin 
upstream of PARKN (Figure 5.24). MARCH5, MUL1, RNF185 could be 
potential candidates as they are E3 ligases possessing transmembrane 
domains which anchor them to the OMM (Figure 5.25). Moreover, those E3 
ligases have also been reported to regulate canonical or non-canonical 
pathways of mitophagy as well as other mitochondrial quality control pathways, 
mitochondria dynamics and innate immunity (Table 5.1 and 5.2) (Chen et al., 
2017; Koyano et al., 2019a; Li et al., 2015; Puri et al., 2019a, 2019b; Rojansky 
et al., 2016; Tang et al., 2011; Yun et al., 2014), Cytoplasmic and ER E3 
ligases, such as FBXO7, ARIH1, HUWE1, AMFR, SMURF1, SIAH1 and 
TRAF2 have also been reported to regulate mitophagy (Figure 5.25, Table 
5.1) (Burchell et al., 2013; Di Rita et al., 2018; Fu et al., 2013; Joshi et al., 
2018; Leboucher et al., 2012; Orvedahl et al., 2011; Strappazzon et al., 2019; 
Szargel et al., 2016; Villa et al., 2017; Yang et al., 2015).  
I decided to focus on MARCH5, HUWE1, FBXO7 and MUL1 and chose to look 
at ubiquitylation of TOMM20 and pS65-Ub as a read-out. According to our 
model, depleting the priming E3 ligase(s) should reduce the availability of 
putative trigger ubiquitin sites, such as TOMM20 ubiquitylation, for the PINK1-
Parkin feedforward loop and therefore diminish the initial phospho-ubiquitin 
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Figure 5.24: Model detailing the respective function of priming and amplifying 
E3 ligases during mitophagy. 
Unidentified E3 priming ligases ubiquitylate putative trigger OMM proteins (namely 
proteins of the TOMM complex) at PINK1’s reach. PINK1 can then phosphorylate 
those seed ubiquitin moieties and initiate the feedforward process by recruiting 
amplifying E3 ligases such as Parkin. The amplifying E3 enhance the ubiquitin signal 
and autophagy adaptors (NDP52, OPTN, TAX1BP1, p62) bring the autophagosomes 
to the ubiquitylated mitochondria. 
 
 
Figure 5.25: Example of alternative ubiquitin E3 ligases. 
Here are represented ubiquitin E3 ligases with a reported role on mitochondria and/or 
in mitophagy. HECT (HUWE1) and RING domains (all others) are shown in green, 


























































Table 5.1 : A not exhaustive alphabetical list of E3 ligases, other than Parkin, 
associated with mitophagy. 
(In brackets are shown those E3 ligases with a less robust literature linking their 








Mitophagy pathway Reference 





(Villa et al., 2017) 
FBXO7 SCF PARK15 
Cytoplasm, 
Mitochondria 
Promotes Parkin recruitment 








May regulate PINK1 via Myc 
(Dadson et al., 










recruitment (“seed Ub”) 
(Chen et al., 
2017; Koyano et 








ULK1 dependent and 
Selenite induced; 
Gemcitabine-induced via 
PINK1 stabilisation and 
Parkin independent; inhibits 
Parkin dep. (MFN2) in 
neurons; paternal mt with 
Parkin 
(Igarashi et al., 
2020; Li et al., 
2015; Puri et al., 
2019b; Rojansky 
et al., 2016; Yun 







(Fu et al., 2013), 
preprint: (Joshi et 
al., 2018) 




(Tang et al., 
2011) 





(Independent of SMURF1 
E3 ligase activity) 
(Orvedahl et al., 
2011) 






(Szargel et al., 
2016) 
(TRAF2) RING TRAP3 Cytoplasm 
Parkin mitophagy in 
cardiomyocytes 
(Yang et al., 
2015) 
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Table 5.2: Mitochondria localised E3 ligases and associated functions (other 
than mitophagy). 
mt: mitochondria; Ub: ubiquitin; TM: transmembrane domain; MDV: Mitochondrial-
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(Karbowski et al., 2007; 
Koyano et al., 2019b; 
Nakamura et al., 2006; 
Park et al., 2020; 
Sugiura et al., 2013; 
Takeda et al., 2019; 
Yonashiro et al., 2006; 











and DNM1L -SUMO 
mediated fission and 
ER-mt tethering 
(Braschi et al., 2009, 
2010; Doiron et al., 
2017; Li et al., 2008; 
Neuspiel et al., 2008; 
Prudent et al., 2015; 
Puri et al., 2019b) 
FBXO7 SCF PARK15 
Cytoplasm, 
Mitochondria 
TOMM20 is a substrate 
of FBXO7 
(Teixeira et al., 2016) 
RNF185 RING - 
Mitochondria?, 
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I employed SH-SY5Y and KOD cells and transfected them with E3 ligase-
targeting siRNA oligos for 96h. I then treated the cells for 4h with AO (1µM 
each) to trigger the generation of pS65-Ub and Ub-TOMM20. (Figure 5.26-
5.29) 
 
I first knocked-down the canonical mitophagy E3, Parkin, and the kinase 
PINK1 as a positive control (Figure 5.26). AO-mediated depolarisation 
induced the ubiquitylation of MFN2 and FIS1 and raised pS65-Ub levels in both 
SH-SY5Y and KOD cells (Figure 5.26A). Ub-TOMM20 was only increased in 
KOD cells following AO treatment (Figure 5.26C). PINK1 and Parkin 
knockdown drastically reduced the levels of pS65-Ub and ubiquitylation of 
MFN2, FIS1 and TOMM20 (Figure 5.26B-E). As expected, PINK1 and Parkin 
are the core regulators of AO-induced ubiquitylation of OMM proteins. 
Interestingly, Parkin knockdown did not completely abolish pS65-Ub, with ~35% 
of residual pS65-Ub signal remaining in Parkin depleted cells whereas PINK1 
knockdown suppressed all but ~13% of the pS65-Ub signal (Figure 5.26B). This 
provides first evidence for the existence of a priming E3 ligase or an alternative 
amplifying E3 ligase to Parkin involved in PINK1-dependant mitophagy. 
Likewise, ubiquitylation of FIS1, MFN2 and TOMM20 is more sensitive to 
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Figure 5.26: PINK1 and Parkin regulate the ubiquitylation of TOMM20 and other 
outer-mitochondrial proteins. 
SH-SY5Y (SH) cells and SH-SY5Y USP30-knockout cells (KOD) were transfected for 
96h with 40nM of non-targeting siRNA oligo (NT1) or PINK1- and Parkin-targeting 
siRNA oligos. The cells were treated for 4h with 1μM of Antimycin and Oligomycin 
(AO) then lysed in NP40 lysis buffer containing phosStop. A) The lysates were 
immunoblotted against mitochondrial proteins. Quantification of B) pUb, F) TOMM20, 
G) MFN2 and H) FIS1 normalised over Actin then to SH-SY5Y AO NT1 or G) to SH-
SY5Y AO PINK1. Bar charts representing C) Ub-TOMM20, D) Ub-MFN2, E) Ub-FIS1 
over their non-ubiquitylated form and normalised to SH-SY5Y AO NT1 or C) to KOD 




HUWE1 is one of the E3 ligases which has been reported to regulate 
mitophagy and that could act as a priming E3 ligase (Table 5.1). HUWE1 was 
found to be recruited from the cytosol to mitochondria upon AO treatment in 
HeLa cells (Di Rita et al., 2018; Strappazzon et al., 2019). Once at 
mitochondria, HUWE1 binds to both the LIR containing protein AMBRA1 and 
to MFN2, stimulates AMBRA1 phosphorylation by IKKα and MFN2 
ubiquitylation, which promotes AMBRA1-mediated mitophagy in the absence 
of Parkin (Di Rita et al., 2018). Another study described that following cellular 
stress caused by Doxorubicin, HUWE1 was recruited to mitochondria and 
mediated MFN2 ubiquitylation leading further to mitochondrial fragmentation 
(Leboucher et al., 2012).  
I used siRNA to knock-down HUWE1 in WT and USP30 KO SH-SY5Y cells to 
test whether HUWE1 opposes USP30 during mitophagy (Figure 5.27, 5.28, 
5.29). Surprisingly, HUWE1 knockdown did not affect the levels of MFN2 
ubiquitylation. On average HUWE1 KD had little to no effect on pUb, I only 
measured a negligible decrease of pUb in WT cells (~10%), (Figure 5.27B, D, 
5.28 and 5.29).  
However, depleting HUWE1 decreased TOMM20 mono-ubiquitylation by 
approximately 25% in KOD cells, whilst FIS1 ubiquitylation was unaffected in 
either cell line (Figure 5.27C, E, 5.28, 5.29). This suggests that HUWE1 may 
contribute to the ubiquitylation of TOMM20 in response to AO and thus 




Figure 5.27: HUWE1 and MARCH5 oppose USP30-mediated deubiquitylation of 
TOMM20. 
SH-SY5Y (SH) cells and SH-SY5Y USP30-knockout cells (KOD) were transfected for 
96h with 40nM of non-targeting siRNA oligo (NT1) or HUWE1- and MARCH5-
targeting siRNA oligos. The cells were treated for 4h with 1μM of Antimycin and 
Oligomycin (AO) then lysed in NP40 lysis buffer containing phosStop. A) The lysates 
were immunoblotted against mitochondrial proteins. B) Quantification of pUb was 
normalised over Actin and further to SH-SY5Y AO NT1. C) Bar chart representing Ub-
TOMM20 over non-ubiquitylated TOMM20 and normalised to KOD OA NT1. D-E) 
Average quantitation of D) pUb and E) Ub-TOMM20 from experiments shown in 











































































































































































































































































































HUWE1 is a well-known regulator of the transcription factor and proto-
oncogene c-Myc (Adhikary et al., 2005; Zhao et al., 2008). Dadson and 
colleagues suggested that deletion of HUWE1 in mouse heart correlated with 
reduced PINK1 expression possibly through stabilisation c-Myc (Dadson et al., 
2017). Interestingly, in SH-SY5Y cells, HUWE1 KD did not affect PINK1 
stability (Figure 5.27-5.29). However, This neuroblastoma line has a c-Myc 
amplification that might make it less sensitive to HUWE1 to that regard 
(Zimmerman et al., 2018). 
 
MARCH5 
MARCH5 has four predicted carboxyl terminal transmembrane spanning 
domains, is localised on mitochondria and was first studied for its role in 
mitochondrial dynamics (Karbowski et al., 2007; Nakamura et al., 2006; 
Yonashiro et al., 2006). More recently, Quan Chen’s group reported that 
MARCH5 is involved in fine tuning of hypoxia-induced mitophagy by mediating 
the ubiquitylation and proteasomal degradation of FUNDC1, a receptor of 
hypoxia-induced mitophagy in HeLa cells (Chen et al., 2017) (Table 5.1). 
I found that knocking down MARCH5 decreased the overall levels of pS65-Ub 
by ~35% in both USP30 WT and USP30 KO SH-SY5Y cells treated with AO 
(Figure 5.27A-B). MARCH5 depletion also appeared to result in 30% less 
TOMM20’s ubiquitylation in KOD cells (Figure 5.27C-D). Although this 
experiment seems to indicate that MARCH5 is involved in AO-induced 
mitophagy, it would need to be repeated to be conclusive.  
 
MUL1 
MUL1 had already been linked to several mitophagy pathways such as 
selenite-induced and gemcitabine-induced mitophagy or the elimination of 
paternal mitochondria in mouse embryo (Igarashi et al., 2020; Li et al., 2015; 
Rojansky et al., 2016). It is also present at mitochondrial-associated vesicles, 
regulates innate immunity at mitochondria (MAVS pathways) and controls 
mitochondrial fusion and fission dynamics (Braschi et al., 2009, 2010; Doiron 




















































































































































































































































































Figure 5.28: MUL1 counteracts the loss of TOMM20 in SH-SY5Y cells. 
SH-SY5Y (SH) cells and SH-SY5Y USP30-knockout cells (KOD) were transfected for 
96h with 40nM of non-targeting siRNA oligo (NT1) or HUWE1- and MUL1-targeting 
siRNA oligos. The cells were treated for 4h with 1μM of Antimycin and Oligomycin 
(AO) then lysed in NP40 lysis buffer containing phosStop. A and E) The lysates were 
immunoblotted against mitochondrial proteins. Quantification of B) pUb and D) 
TOMM20 normalised over Actin and further to B) SH-SY5Y AO NT1 or D) SH-SY5Y 
DMSO NT1. C) Bar chart representing Ub-TOMM20 over non-ubiquitylated TOMM20 
and normalised to KOD OA NT1. Average of (A) and (E). pUb was only quantified for 

















































































I observed that MUL1 depletion correlated with reduced TOMM20 expression 
(29% reduction) independently on depolarisation (Figure 5.28D). However, 
when reported to the levels of unmodified TOMM20, the ubiquitylation of 
TOMM20 itself did not seem affected by the MUL1 loss (Figure 5.28C). pS65-
Ub was also decreased by ~20% following MUL1 knockdown in WT SH-SY5Y 
cells (Figure 5.28B). It was less clear in KOD cells whether siMUL1 had 
reduced the levels of pS65-Ub as the lane was underloaded. The normalisation 
to actin suggested that it did not (Figure 5.28A-B). 
From these western blot analyses, it seems that MUL1 stabilises TOMM20. 
 
FBXO7 
Mutations in the gene coding for FBXO7 have been found associated with 
early-onset forms of PD (Di Fonzo et al., 2009; Paisán-Ruiz et al., 2010; 
Shojaee et al., 2008).  It is a member of the SKIP1-CUL1-F-box E3 ligase 
complex and was reported to regulate CCCP-induced mitophagy in 
mammalian cells over-expressing Parkin (Burchell et al., 2013). Burchell and 
colleagues showed that FBXO7 interacts with Parkin and PINK1 and that the 
knockdown of FBXO7 decreased Parkin’s translocation to mitochondria as well 
as mitochondria degradation, following CCCP treatment. Moreover, they 
reported that Fbxo7 overexpression rescues motor function in Parkin mutant 
Drosophila (Park25). Heike Laman and David Komander’s group jointly 
revealed, using protein arrays and in vitro ubiquitylation reactions, that 
TOMM20 is a substrate of FBXO7 (Teixeira et al., 2016). 
 
I found that knocking down FBXO7 neither affected the levels of pS65-Ub nor 
did it impact the degree of ubiquitylation of OMM proteins (MFN2, FIS1 and 
TOMM20), nor the stability of TOMM20 (Figure 5.29A-E). 
Knocking down FBXO7 did not enhance (neither decrease) the percentage of 
cells undergoing mitophagy in AO treated cells. Nor did it affect the enhanced 
mitophagy seen in USP30 deleted cells, suggesting that FBXO7 is not the 
priming E3 (Figure 5.30). I studied a duplicate of this experiment by western 
blotting and measured no changes in the ubiquitylation status of OMM proteins 




Figure 5.29: FBXO7 depletion does not affect the ubiquitylation of outer 
mitochondrial membrane proteins. 
SH-SY5Y (SH) cells and SH-SY5Y USP30-knockout cells (KOD) were transfected for 
96h with 40nM of non-targeting siRNA oligo (NT1) or HUWE1- and FBXO7-targeting 
siRNA oligos. The cells were treated for 4h with 1μM of Antimycin and Oligomycin 
(AO) then lysed in NP40 lysis buffer containing phosStop. A) The lysates were 
immunoblotted against mitochondrial proteins. Quantification of B) pUb, D) TOMM20 
and E) PINK1 normalised over Actin and further to SH-SY5Y AO NT1. C) Bar chart 
representing Ub-TOMM20 over non-ubiquitylated TOMM20 and normalised to KOD 
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Figure 5.30: FBXO7 depletion does not affect AO-induced mitophagy in SH-
SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were transfected for 72h with 40nM siRNA targeting 
USP30 (D1), FBXO7 or non-targeting siRNA (NT1). The cells were then depolarised 
for 24h with 1M Antimycin A and 10μM Oligomycin A (AO). The cells were imaged on 
a spinning disk confocal microscope using a 40X objective lens. Scale bar: 10μm. B) 
Representative western blot figure showing the knockdown efficiency of FBXO7 and 
USP30. C) Cells with more than 3 mitolysosomes were considered are undergoing 
mitophagy. The cells were manually counted. D) A separate experiment was 
performed without AO treatment. Error bars: mean ± SD. 
  
NT1 D1


























































































































Cullin Ring Ligases CRLs  
ARIH1 is a cytosolic RING-between-RING (RBR) E3 ligase, like Parkin, which 
was found to be recruited to mitochondria and to promote PINK1-dependent 
mitophagy in depolarised cells lacking Parkin (Villa et al., 2017). This E3 ligase 
shares the same E2 ligase as Parkin, UBCH7, and works in cooperation with 
Cullin-RING ligases (CRLs) (Wenzel et al., 2011). ARIH1 acts as a priming E3 
ligase, adding monoubiquitin on specific CLR substrates for subsequent 
ubiquitin chain elongation by CLRs (Scott et al., 2016). I thus thought that it 
would be interesting to assess whether inhibiting CLRs function would affect 
mitophagy. 
These multi-subunit E3 ubiquitin ligases are activated through neddylation of 
their Cullin subunit (Lydeard et al., 2013). I used MLN492, an inhibitor of the 
Nedd8 E1 activating enzyme (NAE) to indirectly inhibit CRLs. 
I characterised the effect of CRLs inhibition by western blotting (Figure 5.31). 
I found that treating SH-SY5Y cells with 1µM MLN492 for 30min was sufficient 
to fully de-neddylate cullins (Figure 5.31A). I then assessed the involvement 
of CLRs in AO-induced mitophagy. I found that inhibiting CLRs using MLN492 
did not reduce AO-induced ubiquitylation of OMM proteins: Ub-MFN2, Ub-
MFN1, Ub-MIRO1, Ub-FIS1, Ub-VDAC and Parkin auto-Ub remained stable 
(Figure 5.31B-C). However, in a parallel imaging experiment of SHSY5Y mito-
QC cells, I observed that inhibition of Cullins (with 1 µM MLN492 for 24h) 
induced a potent activation of basal mitophagy (55.3 ± 6.1% of cells 
undergoing mitophagy compared to 2.3 ± 2.3% in DMSO treated cells) which 
was in fact significantly higher than AO-induced mitophagy (34.0 ± 6.2%). Co-
treating the cells with AO and MLN492, did not further enhance mitophagy 
significantly (68.7±14.5 %) (Figure 5.31D-E).  
Surprisingly, I observed that inhibition of CRL is sufficient to trigger potent 
mitophagy. A preliminary experiment suggests that it is not dependent on 
FBXO7 inhibition (3% of cells undergoing mitophagy in FBXO7 knockdown 
cells compared to 1% of control cells) (Figure 5.30D). MLN492-induced 
mitophagy was not accompanied by the ubiquitylation of common mitophagy 
substrates such as MFN2, MFN1, MIRO1 or FIS1 which could indicate that it 
is not dependent on ubiquitylation. It would be important to assess whether 
this mitophagy peak reflects a global induction of autophagy.   
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Figure 5.31: FBXO7 depletion does not affect AO-induced mitophagy in SH-
SY5Y mito-QC cells. 
A) SH-SY5Y cells were treated with 1μM MLN4924 up to 4h and lysed in NP40 buffer. 
The lysates were probed for cullin 3 (CUL3), a component of Cullin-RING E3 ubiquitin 
ligases complexes and substrate of neddylation. B and C) SH-SY5Y mito-QC cells 
were pre-treated with 1μM MLN4924 for 30min then treated for 4h with 1μM Antimycin 
A, 10μM Oligomycin A (AO) with/without 1μM MLN (1μM). The cells were lysed and 
immunoblotted against common mitophagy players. D) SH-SY5Y Mito-QC were 
treated as in B, C) and imaged live on a spinning disk confocal using a 40X objective 
lens. Scale bar 10μM. n=2 (Exp#1 and 3: 24h treatment only, Exp#2: 4h vs 24h 
treatment). E) The number of cells undergoing mitophagy (> 3 mitolysosomes) was 
counted manually and reported on this graph. Analysis: One-way ANOVA with 
Tukey’s multiple comparison test. *: p < 0.05   
















































































































































5.3  Characterisation of USP30 inhibitors  
 
As reported in the Introduction chapter, a subset of hereditary and early-onset 
forms of PD are caused by loss of function mutations targeting PINK1 and 
Parkin (Corti et al., 2011; Deas et al., 2009; Kitada et al., 1998; Valente et al., 
2004). Parkin inactivation was also reported in sporadic PD and correlates with 
Parkin post translational modification resulting from dopaminergic, oxidative 
and nitrosative stress (Dawson and Dawson, 2014; LaVoie et al., 2005, 2007; 
Wong et al., 2007). A widespread hypothesis is that defects in mitophagy 
underly neurodegeneration in PD. Hence, efforts have been put into finding 
means of activating mitophagy as a therapeutic approach. This includes the 
development of PINK1 and Parkin activators as well as USP30 inhibitors (Miller 
and Muqit, 2019).  
We have previously shown, with others, that USP30 depletion increases both 
induced and basal mitophagy in human cell lines (Chapter III and IV), (Bingol 
et al., 2014; Cunningham et al., 2015; Liang et al., 2015; Wang et al., 2015; 
Marcassa et al., 2018).  
The Bingol lab has further shown that Usp30 knockdown was able to rescue 
PD-pathogenic phenotypes in PINK1 and Parkin mutant Drosophila (Bingol et 
al., 2014). These observations suggest that inhibiting USP30 could rescue 
pathogenic defects caused by the slow accumulation of damaged 
mitochondria in humans affected by PD. 
 
I have had the chance and the opportunity to participate in the characterision 
of a first generation of highly selective USP30 inhibitor (Rusilowicz-Jones et 
al., 2020). USP30 is a good target for the development of inhibitors as CRISPR 
essentiality screens show that its depletion is well tolerated across a broad 
range of cell lines (Lenoir et al., 2018; Meyers et al., 2017). As USPs are 
cysteine proteases, multiple groups have aimed at targeting the reactive 
cysteine to produce potent inhibitors, as exemplified by USP7 inhibitors 
(Pozhidaeva et al., 2017; Reverdy et al., 2012; Turnbull et al., 2017). 
Cyanopyrrolidines have been reported to inhibit cysteine proteases, notably 
cathepsin C and DUBs such as UCHL1, USP7 and USP30 (Bashore et al., 
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2020; Krabill et al., 2020; Lainé et al., 2011), (Patents: WO2014041111A1, 
WO2016156816, WO2018060742A1, EP3433246A1). 
We introduce here two new USP30 N-cyano pyrrolidines compounds 
inhibitors. 
 
 First generation inhibitor 
We have been working in collaboration with FORMA Therapeutics/Celgene to 
characterise new USP30 inhibitors.  The first experiments I have performed 
used a first-generation version of the FT385 inhibitor (hereafter referred to as 
USP30i) (Rusilowicz-Jones et al., 2020). Together with Aitor Martinez-Zarate, 
I assessed the effect of USP30i mediated inhibition of USP30 in cells with 
endogenous or over-expressed Parkin.  
 
5.3.1.1 USP30i in cells over-expressing Parkin 
Using YFP-Parkin overexpressing hTERT-RPE1 cells, I tested whether 
USP30i would phenocopy USP30 knockdown and prevent the deubiquitylation 
of USP30 substrates such as TOMM20. I treated the cells with increasing 
USP30i concentration (0.5-5µM) for 4h with or without AO-mediated 
depolarisation (Figure 5.32). In the absence of a depolarising trigger, 
TOMM20 ubiquitylation was not affected by USP30i. Treating the cells for 4h 
with AO clearly induced the ubiquitylation of TOMM20 and this was further 
increased by up to 1.6-fold when USP30i was included (Figure 5.32B).  
 
It has previously been reported that knocking-down or inhibiting USP30 
promotes fusion of the mitochondrial network in HeLa and mouse embryonic 
fibroblasts (MEF) cells, respectively (Nakamura and Hirose, 2008; Yue et al., 
2014). Yue and colleagues had further shown that USP30 inhibition using the 
non-selective small inhibitor 15-oxospiramilactone, had the ability to revert the 
mitochondrial fragmentation in MFN1 or MFN2 KO MEF cells (Yue et al., 
2014). In contrast, I did not observe a mitochondria hyperfused phenotype in 
hTERT-RPE1-YFP-Parkin cells (TOMM20 staining) following USP30i-
meditated inhibition of USP30 (Figure 5.33).  
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I next moved onto cells that do not express Parkin or express endogenous 
Parkin and visualised mitophagy live in these cells. The mitochondrial network 
of those cells was unchanged with USP30i treatment. 
 
 
Figure 5.32: USP30 inhibition by USP30i induces ubiquitylation of TOMM20 in 
hTERT-RPE1-YFP-Parkin RPE1 cells. 
A) hTERT-RPE1-YFP-Parkin cells were depolarised with 1μM Antimycin A and 1μM 
Oligomycin A (AO) and co-treated with a range of concentrations of USP30i (0-5μM) 
for 4h. The cells were then lysed in RIPA buffer and immunoblotted. B) Graph 
representing ubiquitylated TOMM20 ratioed to unmodified-TOMM20 and normalised 
to the 4h AO condition. Data shown are the average of three independent 







































Figure 5.33: USP30i does not affect the mitochondrial network of hTERT-RPE1-
YFP-Parkin cells. 
hTERT-RPE1-YFP-Parkin cells treated with 5μM USP30i for 1, 8 and 10h. The cells 
where then fixed with PFA and stained with an anti-TOMM20 antibody. The coverslips 
were mounted using mowiol mixed with DAPI. The cells were imaged live on a 3i 
spinning disk confocal equipped of an sCMOS camera and using a 63X objective lens. 
















5.3.1.2 USP30i in cells with endogenous Parkin expression 
I employed the mito-QC probe to measure mitophagy in U2OS cells, kindly 
provided by Ian Ganley (MRC-PPU, Dundee), following USP30 inhibition.  
Using these same cells, my colleague Elena Marcassa had previously shown 
that basal mitophagy is enhanced following 72 h of knockdown (Marcassa et 
al., 2018). In order to mirror those conditions, I first treated those cells for 72h 
with USP30i (0.5-10µM) (Figure 5.34). Treatment with 5µM and 10µM USP30i 
increased the number of mitolysosomes, by 1.6 and 1.7-fold respectively, and 
increased the mitolysosomes area by 1.5 and 2.6 times (Figure 5.34B, C and 
D).  
This enhancement of basal mitophagy events upon USP30 inhibition was also 
apparent for a shorter exposure time (24h). The number of mitolysosomes was 
multiplied 1.4-fold and their area was doubled with 5µM USP30i (Figure 
5.35A-D). I thus concluded that in U20S cells, USP30i phenocopies USP30 
KD by triggering mitophagy. The mitolysosome swelling was however only 
observed with the inhibitor and should be assessed with other inhibitors to 
verify the specificity of that response. Mitolysosome swelling could indicate 
that the autophagosomes have incorporated multiple mitochondrial fragments 
or larger fragments.  
 
I then observed the impact of USP30 inhibition in SH-SY5Y cells stably 
expressing the mito-QC probe (Figure 5.35E-H). I found that at concentrations 
above 2.5µM, USP30i induced cell death in SH-SY5Y mito-QC cells (data not 
shown). SH-SY5Y mito-QC cells treated with the vehicle (DMSO) alone 
showed very few mitolysosomes, only 0.69 per cell on average with ~ 65% of 
cells having no mitolysosomes. In SH-SY5Y mito-QC cells treated for 24h with 
USP30i, I measured a trend towards an increase of both the number of 
mitolysosomes per cell and of the mitolysosome area (Figure 5.35F-H). On 
average, the number of mitolysosomes was multiplied by 5.8±5.5 (1µM 
USP30i) and by 5.1 ±5.1 (2.5 µM USP30i). However, only few cells were 
showing signs of mitophagy (45% and 40% of cells still had no mitolysosomes 
with 1 and 2.5µM USP30i respectively). Thus, in SH-SY5Y cells, USP30i also 




Figure 5.34: USP30 inhibition induces mitophagy in U2OS mito-QC cells. 
A) U2OS mito-QC cells were treated with the USP30i inhibitor for 72h at indicated 
concentrations. The cells were imaged live on a spinning disk confocal microscope 
using a 63X objective lens. Scale bar: 10μm. B) The number of dots per cell was 
quantified using Analyse particle on Fiji. C) Graph categorising the cells by no. of 
mitolysosomes. D) Mean mitolysosome area per condition. Error bars: mean ± SD. 
Data from a single experiment. 
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Figure 5.35: USP30 inhibition by USP30i induces mitophagy in U2OS mito-QC 
cells. 
A) U2OS mito-QC cells or E) SH-SY5Y mito-QC cells were treated with USP30i for 
24h at the indicated concentrations. The cells were imaged live on a spinning disk 
confocal using a 63X objective lens. Scale bar: 10μm. B and F) The number of 
mitolysosomes per cell was quantified using Analyse particle on Fiji. C and G) The 
average mitolysosome area was assessed with Analyse particle. (In (C) The 
mitolysosome area was analysed for Exp#1 only). D and H) Graph categorising the 
cells by no. of mitolysosomes; the values are normalised to the total number of cells. 
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SH-SY5Y cells can be differentiated into neuron-like cells with retinoic acid 
(RA) and 12-O-tetradecanoly-phorbol-13-acetate (TPA) dopaminergic-like 
neurons (Kovalevich and Langford, 2013; Presgraves et al., 2004). I thus 
assessed whether I could monitor mitophagy in differentiated cells. 
Following sequential 72h treatments with RA then TPA, I obtained a mixed 
population of undifferentiated (~90%) and differentiated (~10%) SH-SY5Y 
mito-QC cells with prominent neurite like extensions (Figure 5.36). I treated 
those cells with DMSO or 2.5µM USP30i for 48h and imaged 5 cells with a 
typical neuron-like appearance per condition for 5min. Overall, the 
differentiated cells had a dense mitochondrial network in the perinuclear area 
with elongated filamentous mitochondria extending into the neurites. The 
mitolysosomes were typically located in the perinuclear area. Although the 
efficiency of differentiation was too low to gain definitive answers, based on 
this small sample, I had the impression that USP30i treated cells had a more 
fused mitochondrial network and more mitolysosomes. 
 
In an attempt to improve the efficiency of differentiation, I adopted an 
alternative protocol optimised by Heather Mortiboys (SITraN, Sheffield). SH-
SY5Y cells are grown in neurobasal medium mixed with N2 supplement and 
treated for 7 days with 10µM RA. I tested this protocol in SH-SY5Y, SH-SY5Y 
mito-QC, KOC, KOD and KO11 cells and found that only the KO11 line 
survived the procedure (Figure 5.37). The KO11 cells appeared differentiated 
with elongated cellbodies and extended neurites.  
One possible cause for cell death (RA protocol) and low differentiation rate (RA 
+ TPA) is the passage number of the cells I used. I inherited of late passage 
SH-SY5Y cells (p20 and p25) and stable SH-SY5Y mito-QC cells that are most 
likely older than p15. ECACC report that SH-SY5Y cells start to lose their 
neuronal characteristics and potential to differentiate with passages; they 
recommend maintaining SH-SY5Y cells below passage number 20. Others 
suggest maintaining SH-SY5Y cells below passage 15 when wanting to 
differentiate them. "Older" cell populations will be enriched in a subset of 
epithelial-like SH-SY5Y cells that cannot differentiate into neurons and which 
undergo cell death during the differentiation process (Shipley et al., 2016). 
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I did not further pursue the experiments with USP30i as we received in the 
meantime a more potent and specific USP30 inhibitor (FT385).  
 
 
Figure 5.36: Differentiation of SH-SY5Y mito-QC cells into dopaminergic-like 
neurons using RA and TPA. 
SH-SY5Y mito-QC cells were treated sequentially with 10μM retinoic acid (RA) for 
72h and 12-O-tetradecanoyl-phorbol-13-acetate (TPA) for 72h. Subsequently the 
cells were incubated with 2.5μM USP30i for 48h and then imaged using a 3i spinning 
disk confocal equipped of an EMCCD camera and using a 63X objective lens. Scale 
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Figure 5.37: Differentiation of SH-SY5Y cells into dopaminergic-like neurons 
using RA and neurobasal medium. 
SH-SY5Y, SH-SY5Y mito-QC, KOC, KOD and KO11 cells were incubated with 10μM 
retinoic acid (RA) for 7 days in neurobasal medium and subsequently imaged using a 
NIKON epifluorescence microscope with a 10X objective lens. Scale bar: 100μm. 
Representative images from two experiments. 
 
  












  Second generation inhibitor: FT385 
We received another inhibitor, FT385, which arose from further development 
of the first-generation inhibitor (USP30i) and based on the same scaffold. Both 
inhibitors are N-cyano pyrrolidine compounds. The characterisation of the 
FT385 USP30 inhibitor is published in Rusilowicz et al. (Rusilowicz-Jones et 
al., 2020). The Chemical and biochemical characterisation of the inhibitor was 
performed at FORMA Therapeutics (Watertown, MA, USA) and by 
collaborators in Oxford (Target Discovery Institute, University of Oxford). 
The half maximal inhibitory concentration of FT385 (IC50) for USP30 was ~1nM 
compared to ~90nM for USP30i using ubiquitin-rhodamine as a fluorogenic 
substrate.  
The specificity of FT385 towards USP30 was further assessed by screening in 
vitro its inhibitory activity across a large panel of DUBs and using ubiquitin-
rhodamine 110 as a substrate (DUB profiler screen, Ubiquigent, Dundee, UK), 
(Rusilowicz-Jones et al., 2020). At 2nM FT385 specifically inhibited USP30’s 
activity (activity decreased by 58%) without affecting any other DUBs in the 
panel. At 20nM, FT385 fully inhibited USP30’s activity (activity decreased by 
97%) and partially inhibited USP6 (42% decrease in activity). Strikingly, even 
at the highest concentration measured (200 nM), FT385 did not affect any of 
42 other DUBs tested. 
USP6 is localised at the plasma membrane has been studied in the context of 
trafficking and tumorigenesis (Martinu et al., 2004; Urbé et al., 2012; Funakoshi 
et al., 2014). It is however restricted to very few tissues, including testis and 
skeletal muscles (The Human Protein Atlas v19.3), (CCLE, Broad 
Institute),(Barretina et al., 2012; Uhlén et al., 2015). We did not detect USP6 
in any of our proteomic studies, neither was it identified by our colleagues in 
Oxford in their analysis of a variety of cells lines nor was it detected in recent 
high coverage DUB screens employing ubiquitin Activity based probes (ABP) 
assays, (Hewings et al., 2018; Pinto-Fernández et al., 2019). 
 
FT385 is thus a highly selective and potent inhibitor of USP30. The chemical 
characterisation of this compound further reveals that it binds covalently to 
USP30 (Rusilowicz-Jones et al., 2020). 
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5.3.2.1  FT385 efficiently binds to USP30 
Assisted by my colleague Emma Rusilowicz-Jones, I tested the specificity of 
FT385 and assessed the optimal concentration necessary to inhibit USP30 
using an ABP assay (Figure 5.38). These assays are used to study enzymatic 
activity. The probes covalently bind to active site residues of the enzyme 
(Niphakis and Cravatt, 2014; Sanman and Bogyo, 2014). The ABP usually 
consists of a reactive group (also known as warhead) that reacts with the active 
site, a recognition element that is responsible of target selectivity and a 
reporter tag (ex: HA) (Hewings et al., 2017). ABPs developed against DUBs of 
the cysteine protease family target the catalytic cysteine nucleophile using an 
electrophilic reactive group. Common reactive groups used against cysteine 
protease DUBs include vinyl sulfones (VS), vinyl methyl ester (VME) and 
propargyl amide (PA), (Hewings et al., 2017). 
The Ubiquitin-propargylamide (Ub-PA) activity probe is a so-called suicide 
substrate composed of full-length ubiquitin, which serves as the recognition 
element, and a PA reactive group that replaces the C-terminal GlyGly of 
ubiquitin. I used the competition between FT385 and Ub-PA for USP30’s 
catalytic cysteine to determine target engagement and assess the optimal 
FT385 concentrations to use for experiments in SH-SY5Y cells. 
I treated SH-SY5Y cells for 4h with FT385 at concentrations ranging from 5 to 
625nM and with 500nM of an unrelated compound as a control (CTRL). I then 
homogenised the cells, incubated the PNS with the Ub-PA probe for 15min 
and analysed the samples by western blotting using a USP30 antibody (Figure 
5.38). Two USP30-antibody reactive bands can be detected in this experiment: 
Ub-PA bound USP30 (65 kDa) and Ub-PA unbound USP30 (56kDa). As a 
covalent USP30 inhibitor is expected to prevent the binding of the probe, the 
Ub-PA unbound band indirectly reflects the proportion of USP30 bound to 
FT385.  
When the cells were treated with DMSO, 85% of USP30 in the PNS was able 
to bind to the Ub-PA probe. For cells treated with 625µM FT385, this Ub-PA 
bound portion decreased to 24%. I found that 125nM FT385 was an optimal 
concentration to efficiently inhibit USP30 in SH-SY5Y cells: only 33% of USP30 
was bound to Ub-PA, indicating that there was approximatively 67% of USP30 
inhibited by FT385. 
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Based on the Ub-PA and the Ubiquigent DUB profiler assay, I decided to adopt 
FT385 concentrations ranging between 100 and 200nM, as those 
concentrations were sufficient to observe target engagement without 




Figure 5.38: FT385 efficiently binds to USP30 
Ubiquitin-propargylamide (Ub-PA) probe engagement assay. SH-SY5Y cells were 
treated for 4h with 0-625nM of the USP30 inhibitor FT385 or with 500nM of an 
unrelated control compound (CTRL). The cells were then homogenised in HIM buffer 
mixed with TCEP and the nuclei pelleted at 600g to collect the Post Nuclear 
Supernatant (PNS). The PNS was incubated with the Ub-PA activity probe at a 1:100 
w/w probe to protein ratio for 15min and 37°C. The homogenates were then 
immunoblotted for USP30 and Actin. The percentage of bound and unbound USP30 











































5.3.2.2 FT385 promotes TOMM20 ubiquitylation and pS65 Ubiquitylation 
 
The USP30 substrates that I was able to detect directly by western blotting in 
USP30 KO cells were TOMM20 and pS65-Ub (Figure 5.18-22). I therefore 
decided to monitor the effect of FT385 on these proteins in the absence and 
presence of AO over a 24 h timecourse. I treated SH-SY5Y mito-QC cells with 
a combination of FT385 (100nM) and AO (1µM, each), and compared these 
directly to AO treated USP30 KO cells (KO11) (Figure 5.39). In agreement 
with the data shown in section 2.2.3 (Chapter V), I observed the accumulation 
of TOMM20-ubiquitylated species in response to AO specifically in USP30 KO 
cells (2.5- and 3.5-fold increase at 4h and 8h AO respectively compared to 
DMSO).  
Although more subtle than USP30 deletion, inhibiting USP30 also enhanced 
the ubiquitylation of TOMM20 in SH-SY5Y cells (up to 2.1-fold increase at 8h) 
(Figure 5.39B-C). Unlike for TOMM20, the AO-induced ubiquitylation of 
MIRO1 and Parkin appeared unaffected by either USP30 KO or USP30 
inhibition (Figure 5.39B, D).  
 
Although those results seemed encouraging, the TOMM20 ubiquitylating 
pattern was hard to see in whole cell lysates. I thus decided to confirm those 
observations in mitochondrial enriched fractions. 
 
I first treated SH-SY5Y cells for 24h with 100nM FT385 and looked at early 
ubiquitylation events (Figure 5.40). Following 1h depolarisation, I observed a 
consistent ubiquitylation of MFN2 across WT, FT385-treated WT and KO11 
cells. However, only KO11 cells showed increased Ub-TOMM20.  
I then wondered if a longer FT385 treatment would promote TOMM20 
ubiquitylation. I treated SH-SY5Y cells for 72h with FT385 and 1h with AO 





Figure 5.39: AO and FT385 time course in SH-SY5Y mito-QC and KO11. 
SH-SY5Y mito-QC and KO11 cells were treated for 1-24h with Antimycin A and 
Oligomycin A (1μM each); a set of SH-SY5Y mito-QC cells was co-treated with 100nM 
FT385 (USP30i) for 24h. The cells were lysed in NP40. A) Schematic representation 
of the treatment. B) The lysates were immunoblotted and probed against mitophagy 
proteins. The black arrows indicate the unmodified protein bands; the red arrows point 
towards ubiquitylated-proteins. Graphs representing C) Ub-TOMM20 and D) Ub-
MIRO1 ratioed to unmodified TOMM20 or MIRO1 respectively and normalised to C) 
24h AO KO11 or D) 24h AO SH-SY5Y mito-QC. Data from a single experiment. 
 
  



































































































Figure 5.40: Assessing TOMM20-ubiquitylation upon 1h AO and 24h USP30 
inhibition with 100nM FT385 or USP30 KO. 
SH-SY5Y mito-QC and KO11 cells were treated with Antimycin A and Oligomycin A 
(AO, 1μM each) for 1h; a set of SH-SY5Y mito-QC cells was pre-treated with 100nM 
FT385 for 24h. The cells were then homogenised in HIM buffer. The Post Nuclear 
Supernatant (PNS), Post Mitochondrial Supernatant (PMS) and Mitochondrial 
Fraction (MF) were obtained by differential centrifugation. The fractions were 
immunoblotted against proteins involved in mitophagy. The black arrows indicate 


























































































Figure 5.41: Assessing TOMM20-ubiquitylation upon 1h AO and 72h USP30 
inhibition with 100nM FT385 or USP30 KO. 
SH-SY5Y mito-QC and KO11 cells were treated with Antimycin A and Oligomycin A 
(AO, 1μM each) for 1h; a set of SH-SY5Y mito-QC cells was pre-treated with 100nM 
FT385 for 72h. The cells were then homogenised in HIM buffer. The Post Nuclear 
Supernatant (PNS), Post Mitochondrial Supernatant (PMS) and Mitochondrial 
Fraction (MF) were obtained by differential centrifugation. The fractions were 
immunoblotted against proteins involved in mitophagy. The black arrows indicate 








































































































I next increased the depolarisation length to 4h. Cells were treated for 24h with 
100nM FT385 and 4h AO (Figure 5.42). Once again, this treatment 
combination did not lead to TOMM20-ubiquitylation. Interestingly, I had made 
use of late passage KOD cells which had accumulated wildtype USP30 
expressing cells (50% of residual USP30) and I could still detect TOMM20 
ubiquitylation. Remarkably, with 4h AO I could also detect TOMM22 
ubiquitylation in KOD and KO11 cells only. FIS1’s ubiquitylation was also 
enhanced in KOD and KO11 – similar to my previous observations in Figure 
5.28. These blots indicate that FIS1 and TOMM22 are substrates of USP30. 
 
Finally, I treated SH-SY5Y cells for 24h with both 100nM FT385 and the 
depolarisation cocktail, AO (Figure 5.43). Under those conditions, I did 
observe a TOMM20 ubiquitylation band in the FT385 treated cells. I failed to 
reproduce this observation with a second batch of the inhibitor. However 
subsequent experiments by my colleague Andreas Kallinos using this time 
200nM of FT385 for 24h with 4h AO consistently enhanced Ub-TOMM20 in 
SH-SY5Y cells (Rusilowicz-Jones et al., 2020). 
Supporting these observations, Emma Rusilowicz-Jones reported that 200nM 
FT385 enhanced AO-induced ubiquitylation of TOMM20 in hTERT-RPE1-




Figure 5.42: Assessing TOMM20-ubiquitylation upon 4h AO and 24hh USP30 
inhibition with 100nM FT385 or USP30 KO. 
SH-SY5Y, KOD and KO11 cells were treated with Antimycin A and Oligomycin A (AO, 
1μM each) for 4h; a set of SH-SY5Y cells was pre-treated with 100nM FT385 for 24h. 
The cells were then homogenised in HIM buffer. The Post Nuclear Supernatant 
(PNS), Post Mitochondrial Supernatant (PMS) and Mitochondrial Fraction (MF) were 
obtained by differential centrifugation. The fractions were immunoblotted against 
proteins involved in mitophagy. The black arrows indicate unmodified-proteins; the 

































































































Figure 5.43: 24h FT385 increases TOMM20 ubiquitylation with 24h AO; 
reproducing the effect of USP30 knockout in SH-SY5Y cells. 
SH-SY5Y mito-QC and KO11 cells were treated with Antimycin A and Oligomycin A 
(AO, 1μM each) for 24h; a set of SH-SY5Y mito-QC cells was co-treated with 100nM 
FT385 for 24h. The cells were then homogenised in HIM buffer. The Post Nuclear 
Supernatant (PNS), Post Mitochondrial Supernatant (PMS) and Mitochondrial 
Fraction (MF) were obtained by differential centrifugation. The fractions were 
immunoblotted against proteins involved in mitophagy. The black arrows indicate 





























































































5.3.2.3 FT385 enhances pS65-ubiquitin deposition at mitochondria 
I next went on to analyse the effect of USP30 inhibition on the rate of pS65-
ubiquitylation by western blotting (Figure 5.44). To do so I re-probed the 
samples from Figure 5.40, 5.42 and 5.43 with a pS65-Ub specific antibody. 
pS65-Ub was predominantly seen on mitochondria which is consistent with 
PINK1 accumulating on the mitochondria fraction in Figure 5.42.  
To specifically determine at what molecular weight the pS65-Ub smear 
fluctuates, I used line graphs, which quantify the pS65-Ub band intensity 
across the whole smear. 
Mitochondrial depolarisation (1h AO) induced a strong accumulation of pS65-
Ub in the mitochondrial fractions (Figure 5.44 A-B, G). Most pS65-Ub-
modified proteins run in the higher molecular weight range (76-150kDa) and 
were not affected by USP30 inhibition or deletion. There was however a slight 
increase of pS65-Ub in the KO11 line graph below 76kDa. With 4h AO, the 
integrated intensity of the pS65-Ub signal was increased in KOD and KO11 
cell lines (Figure 5.44C-D, H). Unlike USP30 KO, FT385 only slightly 
increased the number of pS65-Ub proteins compared to control cells. 
However, when treating SH-SY5Y cells for 24h with AO and FT385, the 
amount of pS65-Ub-proteins was clearly increased (Figure 5.44E-F, I).  
 
As seen for TOMM20 ubiquitylation, USP30 inhibition with 100nM FT385 had 
a more subtle effect on pS65-Ub than knocking-out USP30.  
In the USP30KO cells, I was able to detect increased TOMM20 ubiquitylation 
and pSer65-Ub already at 1h AO and 4h respectively. In contrast, with 100nM 
of the inhibitor it was only with 24h AO and FT385 that I measured an 
enhancement of both TOMM20 ubiquitylation and pSer65-Ub compared to 
control cells. This inhibitor concentration might have been slightly suboptimal 
as Andreas has reported that 200nM FT385 completly reproduced the effect 
of USP30 KO on TOMM20 ubiquitylation and pS65-Ub accumulation 





















































































































































































































































































































































































Figure 5.44: FT385 increases AO-mediated pS65-Ub of mitochondrial proteins. 
SH-SY5Y, KOD and KO11 cells were treated with Antimycin A and Oligomycin A (AO, 
1μM each) for A) 1h, C) 4h or E) 24h; a set of SH-SY5Y cells was A and C) pre-
treated with or E) co-treated with 100nM FT385 for 24h. The cells were then 
homogenised in HIM buffer. The Post Nuclear Supernatant (PNS), Post Mitochondrial 
Supernatant (PMS) and Mitochondrial Fraction (MF) were obtained by differential 
centrifugation. A, C and E) The fractions were immunoblotted against pS65-Ub. B, D 
and F) Mitochondrial pS65-Ub bands were quantified and normalised to KO11 AO. 
G, H, I) Line graphs of the mitochondrial pUb signal and, in orange, line graph of the 
pUb bands running below 76kDa. The 76kDa and 35kDa limits are respectively 
represented as a red and green dashed line. A, B, G) Same lysates as in Figure 5.40; 











































5.3.2.4 FT385 enhances basal mitophagy 
Finally, I decided to verify if FT385 promoted mitolysosome formation in SH-
SY5Y cells. Indeed, in section 3.1.2 (Chapter V), I showed that treating U2OS 
mito-QC cells with 5µM of the USP30 inhibitor USP30i was sufficient to induce 
mitophagy and promote the swelling of mitolysosomes (Figure 5.34 and 
5.35A-D). Alas, such concentrations were toxic for SH-SY5Y cells and treating 
SH-SY5Y mito-QC with lower doses of USP30i (2.5µM) only provoked a subtle 
and insignificant increase in the number of mitolysomes (Figure 5.35E-H). I 
wondered if a more potent and specific inhibitor such as FT385 which can be 
used at submicromolar doses could induce mitophagy in SH-SY5Y cells 
without triggering cell death. I used SH-SY5Y mito-QC cells and treated them 
for 24h with DMSO, FT385 (100nM) with or without Antimycin (1µM) and 
Oligomycin (Low: 1µM or High: 10µM) (Figure 5.45).  
AO-“Low” (AO-L, 1µM each) can trigger the ubiquitylation of OMM proteins but 
isn’t sufficient to visibly enhance basal mitophagy within 24h in SH-SY5Y cells. 
I thus tested whether FT385 could enhance basal mitophagy by itself or 
enhance basal mitophagy in “pre-stressed” cells (AO-Low) or enhance AO-
induced mitophagy (“AO-High”, 1µM and 10µM respectively). 
On its own, FT385 neither promoted mitolysosome formation nor did it raise 
the area of mitolysosomes (Figure 5.45 B-E). AO-“Low” (AO-L, 1µM each) 
was insufficient to facilitate mitophagy and co-treating with FT385 had no 
effect. Only AO-“High” (AO-H, 1µM and 10µM respectively) triggered 
mitochondria engulfment into mitolysosomes (5.45B, 5.46B). Combining AO-
“high” and FT385 treatments did not further increase mitolysosome formation 
nor did it affect mitolysosome area (Figure 5.45B-C, 5.46A-E). I finally 
compared USP30 inhibition and USP30 knockdown and confirmed that unlike 
knocking-down USP30, inhibiting USP30 for 24h with 100nM FT385 did not 
accelerate AO-induced mitophagy (Figure 5.47 and 4.14).  
The western blotting experiments seemed to indicate that 100nM is a 
suboptimal concentration of FT385 to induce TOMM20 ubiquitylation and 
pS65-Ub, as it delayed the occurrence and the strength of those events 
compared to USP30 KO. 
To observe mitophagy events downstream of USP30 inhibition it seemed 
necessary to either extend or increase the concentration of the FT385 
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treatment in SH-SY5Y mito-QC. Francesco Barone and Katy McCarron, PhD 
students in the Clague-Urbé lab, decided to test this hypothesis and measured 
mitophagy in SH-SY5Y mito-QC cells treated with 200nM and 500nM FT385 
for 96h (Rusilowicz-Jones et al., 2020). They further adopted a semi-
automated method to quantify mitophagy which has been recently been 
introduced by the Ganley lab (Montava-Garriga et al., 2020). Using these 
parameters, they found that USP30 inhibition with FT385 alone significantly 
enhanced basal mitophagy. The number of mitolysosomes per cells was 
increased by 1.7- and 2-fold when cells were treated for 96h with 200 and 
500nM FT385 respectively. 
 
We have thus shown that USP30 inhibition enhances depolarisation induced- 
TOMM20 ubiquitylation and pS65 ubiquitylation and increases basal 
mitophagy in SH-SY5Y cells. Thus, this new compound recapitulates the 






Figure 5.45: USP30 inhibition using 100nM FT385 is not sufficient to enhance 
mitophagy in SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were treated with DMSO, Antimycin A and “low” 
Oligomycin A (1μM each, AO-L), Antimycin A and “high” Oligomycin A (1μM and 10μM 
respectively, AO-H) for 24h. A set of cells were co-treated with 100nM FT385 for 24h. 
The cells were then imaged live on a spinning disk confocal using an EMCCD camera 
and a 63X objective lens. Scale bar: 10μm. B) The number of mitolysosomes and C) 
the mitolysosome area were quantified using Analyse Particles on Fiji. D) Cells having 
more than 3 mitolysosomes were considered as undergoing mitophagy. E) The cells 
were categorised depending on the number of mitolysosomes they contained. The 
graph represents the percentage of cells per category. Dashed lines represent AO 
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Figure 5.46: USP30 inhibition using 100nM FT385 is not sufficient to enhance 
mitophagy in SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were treated with DMSO, FT385 (100nM) and/or 
Antimycin A and Oligomycin A (1μM and 10μM respectively, AO) for 24h. A set of 
cells were co-treated with 100nM FT385 for 24h. The cells were then imaged live on 
a spinning disk confocal using an sCMOS camera and a 40X objective lens. Scale 
bar: 10μm. B) The number of mitolysosomes and E) the mitolysosome area were 
quantified using Analyse Particles on Fiji. C) Cells having more than 3 mitolysosomes 
were considered as undergoing mitophagy. D) The cells were categorised depending 
on the number of mitolysosomes they contained. The graph represents the 
percentage of cells per category. Dashed lines represent AO conditions. Analysis: 
one-way ANOVA with Tukey’s multiple comparison test. *: p < 0.05. Results from 4 
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Figure 5.47: USP30 knockdown but not inhibition with 100nM FT385 amplifies 
AO-induced mitophagy in SH-SY5Y mito-QC cells. 
A) SH-SY5Y mito-QC cells were transfected for 72h with USP30-targeted (D1) or non-
targeting (NT1) siRNA oligos. The cells were then treated for 24h with Antimycin A 
and Oligomycin A (1 and 10μM respectively); a set of untransfected SH-SY5Y mito-
QC cells were co-treated with DMSO or 100nM FT385 for 24h. The cells were then 
imaged live on a 3i spinning disk confocal using an EMCCD camera and a 40X 
objective lens. Scale bar: 10μm. B) The number of mitolysosomes and E) the 
mitolysosome area were quantified using Analyse Particles on Fiji. C) The cells were 
categorised depending on the number of mitolysosomes they contained. The graph 
represents the percentage of cells per category. Dashed lines represent AO-treated 
conditions. D) Cells having more than 3 mitolysosomes were considered as 




5.4  Identifying USP30 substrates using SILAC based proteomics  
To have a more global view on USP30 substrates and in hope of finding 
biomarkers for testing the efficacy of compounds against USP30 in pre-clinical 
models, I carried out Mass Spectrometry experiments on SH-SY5Y cells, with 
the help of Emma Rusilowicz-Jones. I used triple SILAC labelling in order to 
simultaneously analyse WT, USP30 KO cells and USP30 inhibitor treated 
cells. I analysed these cells’ proteomes as well as their ubiquitylomes. Trypsin 
digestion of ubiquitylated proteins leaves a GlyGly residual peptide still 
covalently attached to the modified lysine (KGG). This remnant induces a 
characteristic 114.1 Da mass shift that is detected by mass spectrometry 
(Peng et al., 2003). The samples used for ubiquitylomics were further enriched 
for ubiquitylated peptides by immunoprecipitation using a KGG specific 
antibody. This technique has already successfully been used to identify Parkin 
substrates (Sarraf et al., 2013; Rose et al., 2016). 
Deleting or inhibiting USP30 was expected to result in an increase of USP30 
substrate ubiquitylation or to promote the degradation of USP30 substrate that 
are modified with degradative ubiquitin labels. 
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  Depolarisation treatment optimisation 
I labelled SH-SY5Y cells with “Light” Amino acids (Arg0, Lys0, Pro0; hereafter 
referred to as SHSY5Y-L), KO11 cells with “Medium” Amino acids (Arg6, Lys4, 
Pro0; hereafter referred to as KO11-M) and SH-SY5Y and KOD cells with 
“Heavy” Amino acids (Arg10, Lys8, Pro0; hereafter referred to as SH-SY5Y-H 
and KOD-H). The cells were labelled until over 99% of proteins had 
incorporated the labels (see method sections 1.4.2 and 1.4.3 (Chapter I)). Prior 
to mass spectrometry experiments, we determined the optimal Oligomycin and 
Antimycin concentrations required to induce ubiquitylation and degradation of 
mitochondrial proteins in the SILAC labelled SH-SY5Y, KOD and KO11 cells 
(Figure 5.48).  
One major difference between our standard media used in all previous 
experiments and the SILAC media used for the proteomics experiments is the 
serum, which in the case of the SILAC media has to be dialysed to remove all 
amino acids. In addition, the medium is also filtered which in principle could 
remove additional constituents that in standard medium contribute may 
"adsorb and quench" some of the depolarising drugs used to induce mitophagy 
(Soutar et al., 2019). Moreover, from our experience, SILAC labelled SH-SY5Y 
cells grow slower and might be more sensitive to AO. Therefore, we first 
determined the optimal AO concentration to use for SILAC based proteomic 
experiments. 
I treated SH-SY5Y-L, KO11-M and KOD-H for 4h with Antimycin (0.1 or 1µM) 
and Oligomycin (0.1 or 1µM) (Figure 5.48). The cells appeared healthy in all 
conditions. Across the board, the combination of 1µM Antimycin and 1µM 
Oligomycin promoted the strongest pS65-Ub smear and Ub-FIS1 band in all 
cell lines; lower AO concentrations (0.1µM each) were sufficient to optimally 
ubiquitylate MFN2. I made use of 1µM of Antimycin and Oligomycin in the 






Figure 5.48: AO-treatment optimisation for SILAC based quantitative mass 
spectrometry. 
SH-SY5Y, KOD and KO11 cells were labelled using SILAC amino acids (L = light, M 
= medium and H = heavy). The cells were then treated for 4h with Antimycin A and 
Oligomycin A at the indicated concentrations and lysed in NP40. The samples were 
finally probed for pS65-Ub and mitochondrial proteins (MFN2, FIS1). 
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  Proteome and ubiquitylome experiment description 
5.4.2.1 Proteome and ubiquitylome analysis of USP30 KO versus USP30 
inhibition following 24h depolarisation  
In the first set of mass spectrometry experiments SH-SY5Y-H cells were 
treated with 200nM FT385 and both SH-SY5Y-L and KO11-M with DMSO for 
24h. These cells were either co-treated with AO (1µM each) or DMSO (Figure 
5.49). The samples were processed for proteomic and ubiquitylomic analysis 
by Emma Rusilowicz with the help of Adan Pinto in the lab of Benedikt Kessler 
(Oxford, UK). We analysed the proteomics data files obtained from the mass 
spectrometer using MaxQuant (version 1.6.7.0), (Tyanova et al., 2016b). We 
identified 6,423 peptides and 9,536 KGG-modified peptides from 2,915 
proteins. Statistical analysis was performed using Perseus to determine the 
outliers (Significance B, p< 0.05), (Appendix 1 and 2), (Tyanova et al., 2016a). 
 
 
Figure 5.49: Schematic flow chart of SILAC based quantitative mass 
spectrometry performed on USP30 KO and USP30 inhibited SH-SY5Y cells. 
SH-SY5Y and KO11 cells were labelled using SILAC amino acids as shown (L = light, 
M = medium and H = heavy). The cells were then treated for 24h with DMSO or 
Antimycin A and Oligomycin A (AO; 1μM each) and/or 200nM FT385 as indicated. 




























5.4.2.2 Proteome and ubiquitylome analysis of USP30 mitochondrial 
substrates following 4h depolarisation. 
We next performed a second series of mass spectrometry experiments in 
which we compared KO11 with KOD cells, that had been made with two 
independent sgRNA, to control for clonal variability (Figure 5.50). These 
experiments were performed in collaboration with Matthias Trost’s group 
(Newcastle, UK). In whose lab the samples were run on an Orbitrap Fusion 
Lumos. 
In our previous experiments we had depolarised cells for 24h as our focus was 
on detecting proteins that may be lost due to enhanced degradation in the 
absence of USP30 activity and which may serve as future biomarkers to help 
validate USP30 inhibitors in a translational setting. Here we wished to focus 
on the more immediate effects of USP30 loss on protein ubiquitylation whether 
this is linked to protein degradation or not.  
We thus only treated the cells for 4h with Antimycin A and Oligomycin A. This 
time point had previously been established as optimal to observe the 
ubiquitylation of FIS1, TOMM20 and other suspected USP30 substrates 
(Figure 5.21). Finally, as USP30 is an OMM protein, for the ubiquitylome 
analysis only we fractionated our samples to obtain mitochondria enriched 
samples in the hope of enriching our dataset with mitochondrial USP30 
substrates. We identified 7,372 peptides in the total proteome and 940 KGG-
modified peptides from 541 proteins in the mitochondria enriched fractions 




Figure 5.50: Schematic flow chart of SILAC based quantitative mass 
spectrometry performed on two USP30 KO clones. 
SH-SY5Y, KO11 and KOD cells were labelled using SILAC amino acids as shown (L 
= light, M = medium and H = heavy) and then treated for 4h with Antimycin A and 
Oligomycin A (AO; 1μM each). The cells were either lysed for total proteome analysis 
or further processed by subcellular fractionation to obtain mitochondrial fractions for 
ubiquitylome analysis. 
 
 Proteome analysis 
5.4.3.1 In the absence of depolarisation agents 
I started by observing the changes in the global proteome occurring after 
inhibiting USP30 for 24h without depolarisation agents, for which we had two 
replicate experiments (Figure 5.51).  
TOMM7, a component of the TOM complex, was the only significantly 
downregulated protein in both FT385 replicates and TOMM7 levels were 
similarly decreased in KO11 cells (Figure 5.52A). 
Aside from reducing TOM7 availability, blocking USP30’s deubiquitylating 
activity mainly affected three pathways:  there was a significant upregulation 
of a) proteins promoting cell cycle progression (significantly upregulated: 
CKS1B, CDK1, GSG2; high fold change but not significant: in CKS2, NUF2), 
b) proteins involved in DNA replication or mRNA translation (significantly 
upregulated: DUT, LIG1, RBM3, C14orf142; high fold change but not 
L M H
SH-SY5Y KO11 KOD










significant: POLE), c) proteins involved in neuronal differentiation or function 
(significantly upregulated: NRP1), including neuroendocrine secretory granule 
proteins (significantly upregulated: CHGB, CYB561) and down regulation of a 
histone demethylase which participates in the transcriptional repression of 
neuronal genes (KDM5C).  
 
 
Figure 5.51: Scatter plots from the proteome analysis of USP30 KO or inhibited 
samples in the absence of depolarisation agents. 
A-C) Scatter plots depicting the protein intensity (Log10; y-axis) over the fold change 
in the proteome of DMSO treated cells ± FT385 or USP30 KO (KO11) (Log2; x-axis). 
Proteins in red have a significance B score of p<0.05, proteins in grey have a 
significance B score of p>0.05. D) Scatter plots depicting fold change in the proteome 
of DMSO treated cells ± FT385 of experiment A (Log2; y-axis) over experiment D 
(Log2; x-axis). Proteins with a Log2 ratio <-0.585 are shown in red and proteins with 
a Log2 ratio >0.585 are shown in green. Proteins with hollow circles have a 
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Figure 5.52: Heatmaps of proteins affected by USP30 KO and USP30 inhibition 
independently of depolarisation. 
A) Heatmap depicting the fold change in the proteome of DMSO treated cells ± FT385 
or ± USP30 KO. B) Heatmap depicting a consistent fold change in the proteome of 
USP30 KO or USP30 inhibitor treated cells independently of depolarisation. All three 
sets of proteome analyses are included (DMSO, 24h and 4h). Proteins with a Log2 
ratio <-0.585 are in shades of red and proteins with a Log2 ratio >0.585 are in shades 
of blue. Proteins with a plus sign have a significance B score of p<0.05. Proteins are 
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Figure 5.53: Scatter plots from the proteome analysis of USP30 KO or inhibited 
samples treated with AO for 24h. 
A-D) Scatter plots depicting the protein intensity (Log10; y-axis) over the fold change 
in the proteome of AO treated cells ± FT385 or USP30 KO (KO11) (Log2; x-axis). 
Proteins in red have a significance B score of p<0.05, proteins in grey have a 
significance B score of p>0.05. E-F) Scatter plots depicting fold change in the 
proteome of AO treated cells ± E) FT385 or F) USP30 KO of experiment B (Log2; y-
axis) over experiment C (Log2; x-axis). Proteins with a Log2 ratio <-0.585 are in red 
and proteins with a Log2 ratio >0.585 are in green. Proteins with hollow circles have 
a significance B score of p<0.05, proteins with a solid circle have a significance B 
score of p>0.05. G) Scatter plots depicting the average fold change (Experiment B 
and C) in the proteome of AO treated cells ± FT385 (Log2; y-axis) over AO treated 
cells ± KO11 (Log2; x-axis). Mitochondrial and peroxisomal proteins are shown in 





Figure 5.54: Scatter plots from the proteome analysis of USP30 KO samples 
treated with AO for 4h. 
A-B) Scatter plots depicting the protein intensity (Log10; y-axis) over the fold change 
in the proteome of AO treated cells ± USP30 KO (KO11 or KO11) (Log2; x-axis). 
Proteins in dark red, red and pink have a significance B score of p<0.005, p<0.01 and 
p<0.05, respectively. Proteins in grey have a significance B score of p>0.05. C) 
Scatter plot depicting fold changes in the proteome of 4h AO treated cells ± USP30 
KO with KOD (Log2; y-axis) over KO11 (Log2; x-axis). Proteins with a Log2 ratio <-
0.585 are in red and proteins with a Log2 ratio >0.585 are in green. Proteins with 
hollow circles have a significance B score of p<0.05, proteins with a solid circle have 
a significance B score of p>0.05. D) Scatter plot in (C) with mitochondrial and 
peroxisomal proteins shown in orange and purple respectively. 
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5.4.3.2 Cross comparison of proteome datasets 
5.4.3.2.1 Mitochondrial and peroxisomal proteomes 
In SH-SY5Y cells treated with AO (4h and 24h), I did not measure any global 
changes in the mitochondrial and peroxisomal mass upon deletion or inhibition 
of USP30 (Figure 5.53G, 5.54D). 
 
5.4.3.2.2 Proteins involved in neuronal structure and function 
A cross comparison of proteome datasets revealed consistent changes in 
neuronal proteins (Figure 5.52B, 5.53, 5.54). I observed changes in neuronal 
components (CNTNAP2, LPPR4, NES, NRP1), synapse constituents 
(CNTNAP4, CAMD2, MPP2, SYT1, SNAP25, NPTX2), elements of synaptic 
vesicles and neurotransmitter release (CHGA, CHGB SNAP25, SLC6A2, 
NPY, CNTNAP4, SLC18A1, SNCA, SCG2), in dopamine production (DDC, 
QDPR, PAM), and in neuronal differentiation and survival proteins (CNTFR, 
SLIT1, CSRP1).  
In addition to this striking increase in individual neuronal marker proteins, 
multiple components of signalling pathways that play a key role in neuronal 
differentiation, such as the SLIT/ ROBO pathway, were also affected (Figure 
5.52B, 5.53, 5.54). The protein abundance of the slit guidance ligand 1 (SLIT1) 
was significantly reduced in both USP30 KO lines and one of the SLIT 
receptors, ROBO2, was conversely significantly more abundant in KO11 and 
FT385 treated cells.  
 
5.4.3.2.3 Cytoskeleton 
Multiple cytoskeleton proteins were upregulated across USP30 KO proteomes. 
This include microtubule proteins (TUBA4A, MAP7, CEP44), and other 
cytoskeleton interacting proteins (MSN, CD9, TIAM1, CDC42EP4). 
Conversely, the myosin MYO5C and the intermediate filaments VIM were 
significantly downregulated (Figure 5.52B, 5.53, 5.54).  
Vimentin (VIM) is highly abundant in mesenchymal cells and involved in 
epithelial to mesenchymal transition (EMT) and thus is a common marker of 
EMT (Liu et al., 2015). Conversely a loss of vimentin, seen here in the USP30 
KO cells, may be indicative of the opposite process, mesenchymal to epithelial 
transition (MET). During EMT, epithelial cells lose their cell adhesion 
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properties and gain the ability to migrate and invade. This process is 
particularly important during metastasis. Cell scattering assays mimic the 
cancer cell dispersal occurring during EMT and metastasis. Interestingly, Ricky 
Buus, a former lab member, had picked up USP30 in a siRNA-based DUB 
screen as necessary for HGF-mediated A549 cell scattering. Similarly, USP30 
depletion prevented HGF-Dependent wound healing in A549 cells, another 
process commonly upregulated in response to EMT (Buus et al., 2009). 
Furthermore, our lab has previously discovered that knocking down USP30 
also interferes with anchorage independent cell growth, another hallmark of 
cancer cells (unpublished data; personal communication, Monika Faronato, 
Sylvie Urbé and Michael Clague). Collectively these result points towards a 
role of USP30 in EMT and metastasis. 
 
5.4.3.2.4 Proteins reacting in opposite fashion to USP30 inhibition and to 
USP30 deletion. 
Some proteins reacted in an opposite fashion in response to treatment with 
the FT385 USP30 inhibitor compared to USP30 deletion. As an example, 
MAGEA10, which is a protein of unknown function, was one of the most highly 
upregulated proteins after 24h FT385 treatment in DMSO treated cells but 
conversely was significantly decreased in KO11 cells (Figure 5.51, 5.52, 5.53, 
5.54). I could confirm the decrease in the KO cells by western blotting, while I 
did not detect an obvious change in WT and FT385 treated cells (Figure 
5.55A-B). 
This discrepancy between inhibition and deletion of USP30 could be explained 
by the fact that the catalytically inhibited deubiquitylase still retains the ability 
to interact with other proteins. The half-life of a protein can be extended when 
it is part of a complex due to its scaffolding function (McShane et al., 2016). 
USP30 and MAGEA10 could be part of a complex. In USP30 knockout cells, 
singled out MAGEA10 may therefore get degraded quicker. 
Proteins specifically upregulated or downregulated by FT385 and unaffected 




The presence of certain proteins in mass spectrometry datasets needs to be 
interpreted with caution. Some constituents of fetal bovine serum (FBS), such 
as albumin or secreted protein, will be detected by the mass spectrometer. 
These proteins won’t be labelled, and therefore will be associated with 
decreased ratios in “medium-” and “heavy-” labelled conditions.  Some of those 
proteins have conserved sequences between human and bovine and will thus 
be detected as "hits". Retinol binding protein 4 (RBP4) is a protein consistently 
destabilised by USP30 inhibition and USP30 knockout across proteomes and 
therefore appears as a major USP30 substrate (Figure 5.51, 5.53). However, 
RBP4 is a protein found in serum and which is secreted by the liver, adipose 
tissues and macrophages to permit the circulation of retinol (Atawia et al., 
2019). Aligning the amino-acid sequence of bovine and human RBP4, I found 
that 96% of the protein sequence was conserved between both species 
(Figure 5.56). Moreover, the amino acid sequences of most peptides detected 
in both proteome analyses are conserved across both species. One peptide 
does align with the human protein selectively but has only been detected once. 




Figure 5.55: Western blot analysis of MAGEA10 protein levels in USP30 
inhibited and KO cells. 
A-B) SH-SY5Y, KOD and KO11 cells were treated with Antimycin A and Oligomycin 
A (AO, 1μM each) for A) 24h or B) 1 and 4h, and A) a set of SH-SY5Y cells was co-
treated with 100nM FT385 for 24h. The cells were then homogenised in HIM buffer. 
The Post Nuclear Supernatant (PNS), Post Mitochondrial Supernatant (PMS) and 
Mitochondrial Fraction (MF) were obtained by differential centrifugation. A-B) The 









































































































































Figure 5.56: Human and bovine RBP4 protein alignment. 
A) Amino-acid sequences of human and bovine RBP4. B) The amino acid sequences 
of human and bovine RBP4 were aligned using Serial Cloner (v2.6.1). The RBP4 
peptides sequences detected in the mass spectrometry analysis are highlighted in 
yellow. C) Amino acid sequences of the three RBP4 peptides which were detected in 






>sp|P02753|RET4_HUMAN Retinol-binding protein 4 OS=Homo sapiens 






>tr|Q32L14|Q32L14_BOVIN Retinol-binding protein OS=Bos taurus 





Alignment of Sequence_1:  [HUMAN RBP4, Protein Sequence #1] with  Sequence_2: 
[BOVINE RBP4 Protein Sequence Window #2] 
Similarity : 193/201 (96.02 %)
Seq_1  1     MKWVWALLLLAALGSGRAERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIV  60
             | |||||:||||||| |||||||||||||||||||||| |||||||||||||||||||||
Seq_2  1     MEWVWALVLLAALGSARAERDCRVSSFRVKENFDKARFAGTWYAMAKKDPEGLFLQDNIV  60
Seq_1  61    AEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGND  120
             |||||||:|:|:||||||||||||||||||||||||||||||||||||||||||||||||
Seq_2  61    AEFSVDENGHMCATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGND  120
Seq_1  121   DHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLA  180
             |||| |||| | ||||||||||||||||||||||| |||:|::||:||||||||:|||||
Seq_2  121   DHWIIDTDYETFAVQYSCRLLNLDGTCADSYSFVFARDPSGFSPEVQKIVRQRQDELCLA  180
Seq_1  181   RQYRLIVHNGYCDGRSERNLL  201
             |||||| |||||||:||||:|
Seq_2  181   RQYRLIPHNGYCDGKSERNIL  201
RBP4 peptides detected:
LLNNWDVCADMVGTFTDTEDPAKFK; QRQEELCLAR; VKENFDK; VKENFDKAR 
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 Ubiquitylome analysis 
I then measured the effect of USP30 KO or inhibition on protein ubiquitylation 
in SH-SY5Y cells (Figure 5.57, 5.58). A change in the ratio of ubiquitylated 
peptides between WT and USP30 KO or USP30 inhibited cells can either 
genuinely result from a change in the ubiquitylation status or simply reflect 
changes in protein abundance. I therefore analysed the proteomes and 
ubiquitylomes side by side to determine bona fide USP30 substrates for which 
we would expect to see either an increase in ubiquitylated species with no 
changes at the proteome level or a decrease in both proteome and 
ubiquitylome datasets. SYT1 K105 was an example of a ubiquitylated peptides 
enriched in all KO11 and FT385 datasets that was also significantly increased 
in the proteome.  
 
5.4.4.1 Total ubiquitylome (24h AO) 
In SH-SY5Y cells treated with AO for 24h, the deletion or inhibition of USP30 
primarily enhanced the ubiquitylation of the Voltage-Dependent Anion Channel 
(VDAC) subunits (VDAC1, VDAC2 and VDAC3) located at the OMM, whilst 
the few TOMM subunit ubiquitylation events detected in this dataset were 
unaffected by USP30 loss (Lysines detected: TOMM70 (K168, K170, K178); 
TOMM40 (K175), TOMM22 (K141)). (Figure 5.57). GAPDH, another predicted 
mitochondria-localising protein, was ubiquitylated at K196 in the absence of 
USP30 activity.  
USP30 deletion or inhibition also enhanced the ubiquitylation of ribosomal 
proteins (RPS20, RLP19, HNRNPDL), histones (H3F3B and HIST1H2BD), 
amino acid transporters (SLC1A5, SLC29A1, SLC7A5), neuronal proteins 
(KIDINS220, NOVA2, SYNGR2, TMEM230, TMEM230) and proteins involved 
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Figure 5.57: Scatter plots from the ubiquitylome analysis of USP30 KO and 
USP30 inhibited samples treated with AO for 24h. 
A-D) Scatter plots depicting the peptide intensity (Log10; y-axis) over the fold change 
in the ubiquitylome of AO treated cells ± FT385 or ± USP30 KO (KO11) (Log2; x-axis). 
Proteins in red have a significance B score of p<0.05, respectively. Proteins in grey 
have a significance B score of p>0.05. E-F) Scatter plots depicting fold change in the 
ubiquitylome of 24h AO treated cells ± E) USP30 KO or F) FT385 of experiment B 
(Log2; y-axis) over experiment C (Log2; x-axis). Proteins with a Log2 ratio <-1 are in 
red and proteins with a Log2 ratio >1 are in green. Proteins with hollow circles have a 
significance B score of p<0.05, proteins with a solid circle have a significance B score 
of p>0.05. G) Heatmap depicting the fold change in the ubiquitylome and proteome 
of USP30 KO (KO11) and USP30 inhibited cells treated with 24h AO. Ubiquitylome: 
peptides with a Log2 ratio <-0.75 are in shades of red and proteins with a Log2 ratio 
>0.75 are in shades of blue. Proteome: Proteins with a Log2 ratio <-0.585 are in 
shades of red and proteins with a Log2 ratio >0.585 are in shades of blue. Peptides 
with a plus sign have a significance B score of p<0.05. Proteins are grouped by 



























































































































































































































































































































KO11-AO/AO Ratio  M/L normalized LOG2





















































Significance B (p > 0.05)
KO11
Ubiquitylome
KOD-AO/AO Ratio  H/L normalized LOG2


















































































































































































































































































































































































































































Figure 5.58: Scatter plots and heatmaps from the ubiquitylome analysis of 
USP30 KO samples treated with AO for 4h. 
A-B) Scatter plots depicting the peptide intensity (Log10; y-axis) over the fold change 
in the ubiquitylome of AO treated cells ± USP30 KO (KO11 or KOD) (Log2; x-axis). 
Proteins in red have a significance B score of p<0.05, respectively. Proteins in grey 
have a significance B score of p>0.05. C) Scatter plot depicting fold changes in the 
ubiquitylome of 4h AO treated cells KOD (Log2; y-axis) over KO11 cells (Log2; x-
axis). Proteins with a Log2 ratio <-1 are in red and proteins with a Log2 ratio >1 are 
in green. Proteins with hollow circles have a significance B score of p<0.05, proteins 
with a solid circle have a significance B score of p>0.05. D-E) Heatmap depicting the 
fold change in the ubiquitylome and proteome of 4h AO treated KOD and KO11 cells. 
D) Decreased and E) increased fold change. Proteome: Proteins with a Log2 ratio <-
0.585 are in shades of red and proteins with a Log2 ratio >0.585 are in shades of blue. 
Ubiquitylome: peptides with a Log2 ratio <-1 are in shades of red and proteins with a 
Log2 ratio >1 are in shades of blue. Peptides with a plus sign have a significance B 




5.4.4.2 Mito-ubiquitylome (4h AO) 
The mito-ubiquitylome revealed additional mitochondria localised substrates 
of USP30 (Figure 5.58). Many of those proteins are localised at the OMM such 
as GDAP1, which has six lysines significantly more ubiquitylated upon USP30 
loss and inhibition (K19, K172, K173, K188, K195 and K203) and members of 
the TOM complex. USP30’s deubiquitylating activity towards the TOM complex 
was not restricted to TOMM20. Most of the TOM core complex components 
except for TOMM6, which has no lysines, and TOMM7 were significantly more 
ubiquitylated.  
Intriguingly, although USP30 localises at the OMM, USP30 deletion in both 
clones led to a significant increase in the ubiquitylation of IMM and matrix 
proteins. These include chaperone proteins (HSPD1, HSPE1), OXPHOS 
proteins (NDUFB5), Krebs cycle enzymes (MDH2), peroxidases (PRDX3), 
proteins regulating mitochondrial mRNA translation (GRSF1) and 
mitochondrial carriers (MTCH2). In contrast some other, IMM and matrix 
proteins, TIMM complex and OXPHOS components, had lysines which were 
>8-fold less ubiquitylated in KO11 (significant) and KOD (not significant).  
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5.4.4.3 Cross-comparison of ubiquitylome 
The VDAC proteins were a consistent hit across depolarised KOD, KO11 and 
FT385 cells (Figure 5.59 and 5.60). USP30 appears to specifically 
deubiquitylate K20, K53, K109, K266 in VDAC1, K120 in VDAC2 and both K20 
and K54 in VDAC3. On average USP30 deletion or inhibition induced a 1.5 to 
7-fold increase in these ubiquitylated lysines across the board. The OMM 
protein, synaptojanin 2-binding protein (SYNJ2BP), was another hit with K48 
and K64 ubiquitylation being increase by 4-fold on average. The other four hits 
were the pro-fission protein GDAP1 (K203, ~4-fold increase), the OMM protein 
PTRH2 (K48, ~2.6-fold increase), the monoamine neurotransmitter transporter 
SLC18A2 (K491, ~2.5-fold increase) and the peroxisomal protein ABCD3 (also 
known as PMP70, ~1.7-fold increase). 
 
5.4.4.4 Substrates in common with Parkin 
USP30 KO in both clones  and FT385 enhanced the ubiquitylation of multiple 
OMM proteins, all of which have been reported as substrates of the E3 ligase 
Parkin (VDAC1/2/3, TOMM5/20/22/40/70, GDAP1, …) (Figure 5.60) (Heo et 
al., 2019; Ordureau et al., 2018; Rose et al., 2016; Sarraf et al., 2013). Our lab 
had previously reported in Drosophila, that porin (VDAC1, 2 and 3 in 
mammals) was amongst the most ubiquitylated proteins in Drosophila neurons 
overexpressing Parkin, second to MitoNEET (the Drosophila homolog of 
human CISD1 and CISD2), (Martinez et al., 2017). In a small proteomic study 
performed in HeLa depolarised with CCCP by Richard Youle’s lab,  GDAP1 
emerged as the second most destabilised protein following Parkin 
overexpression (Narendra et al., 2012).  
Comparing the ubiquitylation sites affected by USP30 in our mass 
spectrometry experiments (of hit proteins) with those reported to be substrates 
of Parkin, indicated that roughly 2/3 of those sites are substrates of both 
USP30 and Parkin (Figure 5.60), (Sarraf et al., 2013; Bingol et al., 2014; 
Ordureau et al., 2018, 2020). This confirms that USP30 is the bona fide 
deubiquitylating enzyme which opposes Parkin in the canonical PINK1-Parkin 
pathways of mitophagy. USP30 did, however, have specific ubiquitylations 
sites on VDAC2 (K121, K277), VDAC3 (K111), TOMM5 (K10), TOMM22 
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(K27), TOMM40 (K14), TOMM70 (K188), SYNJ2BP (K48) and ABCD3 (K260) 





Figure 5.59: Heatmaps of ubiquitylation sites consistently affected by USP30 
KO and USP30 inhibition across experiments. 
Heatmap depicting the fold change in the ubiquitylome and proteome of USP30 KO 
(KO11 and KOD) and USP30 inhibited cells across all datasets. Ubiquitylome: 
peptides with a Log2 ratio <-0.75 are in shades of red and proteins with a Log2 ratio 
>0.75 are in shades of blue. Proteome: Proteins with a Log2 ratio <-0.585 are in 
shades of red and proteins with a Log2 ratio >0.585 are in shades of blue. Peptides 









































































































































































































































Figure 5.60: Schematic representation of USP30’s deubiquitylation sites. 
Schematics depicting VDACs, TOMMs , GDAP1, SYNJ2BP, PTRH2 and ABCD3’s 
ubiquitylated peptides detected in the ubiquitylome (24h AO) and mito-ubiquitylome 
(4h AO) experiments. Peptides are described as significantly increased if they have a 
significance B score of p<0.05. The peptides which have been characterised as 
USP30 and/or Parkin substrates in other mass spectrometry analysis are outlines in 
black and/or highlighted in yellow, respectively. (Data compared with Sarraf et al., 
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In this Chapter, I have introduced USP30 KO SH-SY5Y cell lines, 
characterised novel USP30 targeted inhibitors and further studied and 
discussed novel pathways regulated by USP30. 
 
 TOMM20-ubiquitylation and pS65-ubiquitin deposition at 
mitochondria 
I successfully generated USP30 KO SH-SY5Y lines with two distinct sgRNA 
(KOD with sgRNA#1 and KO11 with sgRNA#2). By western blotting and 
subcellular fractionation, I showed that USP30 deletion enhanced both basal 
and AO-induced ubiquitylation of TOMM20 in SH-SY5Y cells expressing 
Parkin endogenously. This was in agreement with Amos’s findings which 
describe that USP30 knockdown enhances the ubiquitylation of TOMM20 in 
response to CCCP in hTERT-RPE1-YFP-Parkin cells (Liang et al., 2015). Our 
ubiquitylomic experiment performed on mitochondrial fractions revealed that 
USP30 deletion significantly upregulated TOMM20’s ubiquitylation at K35 by 
over 4-fold. TOMM20 was unique in the sense that it was the only Parkin 
substrate for which I saw consistently a clear increase in ubiquitylation with 
USP30 deletion in western blot assays.  
 
Using a combination of microscopy and western blotting, I showed that 
pSer65-ubiquitin accumulates substantially on mitochondria of USP30 KO cell 
lines upon AO depolarisation (Rusilowicz-Jones et al., 2020). While writing our 
manuscript, Ordureau and colleagues also reported what they referred to as a 
modest acceleration of pS65-Ub accumulation in USP30-/- iNeurons but only 
when using a low concentration of AO (0.5µM each against 1µM each in our 
western blot experiments). Their initial experiments employed much higher 
concentrations of AO (10µM Antimycin + 5µM Oligomycin), which masked any 
effect of USP30 deletion on the levels of pSer65-Ub (Ordureau et al., 2020). 
Interestingly, this increase in pS65-Ub does not correlate with enhanced 
Parkin or PINK1 levels and furthermore phosphorylated ubiquitin is a poor 
substrate for USP30 (Wauer et al., 2015a; Gersch et al., 2017). We thus 
believe that USP30 acts upstream of PINK1 to fine tune mitophagy. 
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 E3 ligases opposing USP30 
I have searched for new E3 ligases that could oppose USP30 and prime 
mitochondria with ubiquitin prior to Parkin recruitment during AO-induced 
mitophagy. My preliminary results suggested that both HUWE1 and MARCH5 
ubiquitylate TOMM20 and are involved in ubiquitylation prior to PINK1 
phosphorylation (decreased pS65-Ub and Ub-TOMM20 with HUWE1 and 
MARCH5 knockdown).  
 
Consistent with these observations, the cytosolic E3 ubiquitin ligase HUWE1, 
was reported to be involved in AMBRA1-mediated mitophagy (Di Rita et al., 
2018; Strappazzon et al., 2019). The Cecconi group have shown that targeting 
AMBRA1 to mitochondria (AMBRA1Acta overexpression) induced mitophagy in 
HeLa cells (Strappazzon et al., 2015). In their 2018 paper, they described that 
HUWE1 binds to both the mitophagy receptor AMBRA1 and to MFN2, 
promotes the activation of AMBRA1 (positive regulation of AMBRA1-S1014 
phosphorylation), and further enables the ubiquitylation and degradation of 
mitochondria in cells overexpressing AMBRA1Acta and lacking Parkin (Di Rita 
et al., 2018).  
Interestingly, both HUWE1 and USP30 are key modulators of cellular K6-
linked ubiquitin chains and could therefore oppose each other in the regulation 
of mitochondrial ubiquitylation (Cunningham et al., 2015; Gersch et al., 2017; 
Michel et al., 2017). Remarkably, Elena Marcassa has observed in U2OS mito-
QC cells that enhancement of basal mitophagy by USP30 depletion is 
abolished by HUWE1 knockdown (unpublished data- Elena Marcassa). 
 
On the other hand, Koyano and colleagues have suggested that MARCH5 
(also known as MITOL) adds the “seed” ubiquitin onto mitophagy substrates 
prior to Parkin recruitment. They described that MARCH5 knockdown and 
knockout delayed the recruitment of Parkin to mitochondria and reduced the 
ubiquitylation of mitochondrial proteins, such as TOMM20 and CISD1 in Parkin 
overexpressing cells following CCCP treatment (Koyano et al., 2019a).  
A recent study by the Bingol lab disclosed that USP30 and MARCH5 fine tune 
protein import at the TOM complex (Phu et al., 2020). This finding stemmed 
from the observation that many of USP30 substrates they found by mass 
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spectrometry were IMM or matrix proteins in USP30 inhibited or USP30 KO 
HEK293 cells (Phu et al., 2020). 
In agreement with this, our ubiquitylomics studies also described that matrix 
and IMS proteins such as MDH2, MTCH2, GRSF1, HSPD1, HSPE1, NDUFB5 
or PRDX3 are more ubiquitylated in USP30 KO cells (Rusilowicz-Jones et al., 
2020). Similarly, ubiquitylomics performed in USP30 KO iNeurons show 
increased ubiquitylation of proteins targeted to the mitochondrial matrix such 
as Citrate Synthase or subunits of Complex I, IV and V, using USP30 KO 
iNeurons (Ordureau et al., 2020).  
Phu and colleagues employed a mitochondrial ‘import assay” based on a split 
GFP system, the MTS-Scarlett-GFP(1-10) split probe with DOX induced 
GFP(11) fused to any import substrate, to assess USP30’s involvement in 
protein import. Using USP30 KO HEK293 and siRNA targeting MARCH5, they 
showed that MARCH5 ubiquitylates proteins getting imported to send them for 
proteasomal degradation whilst USP30 deubiquitylates them to permit their 
import (Phu et al., 2020). Likewise, Wade Harper’s group observed an increase 
in the ubiquitylation of IMM and matrix protein (citrate synthase and subunits 
of CI, CIV and CV of the electron transport chain) in USP30 KO iNeurons. 
However, they found that neither knocking out MUL1 nor MARCH5 in USP30 
KO iNeurons suppressed the ubiquitylation of citrate synthase (Ordureau et 
al., 2020).  
Interestingly I have also found that HSPE1 and HSP60, chaperones involved 
in protein import and protein folding, were also more ubiquitylated USP30 KO 
cells. However, those proteins were also found to be ubiquitylated by Parkin. 
HSPE1 and HSP60 ubiquitylation thus maybe relates more to mitophagy 
induction rather than protein import (Rose et al., 2016). 
 
 
 FT385 is a highly specific and potent USP30 inhibitor 
I have introduced two novel cyano-pyrrolidines inhibitor targeting USP30: 
USP30i and FT385. 
The USP30i compound inhibitor was able to augment basal mitophagy by 1.6 
and 1.7-fold and increased the mitolysosomes area in U2OS cells (5-10µM). 
However, in SH-SY5Y cells at 5µM, USP30i induced cell death and lower 
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USP30i doses showed only subtle effects (small trend towards an increase of 
mitolysosomes and mitolysosome area).  
The FT385 compound emerged as a highly specific and potent USP30 inhibitor 
(USP30 IC50: 1 nM against 90nM for USP30i) (Rusilowicz-Jones et al., 2020). 
By western blot analysis, FT385 phenocopied USP30 knockdown and 
knockout in SH-SY5Y cells, increasing AO-induced TOMM20 ubiquitylation 
and pS65-Ub accumulation at mitochondria. Further characterisation by Emma 
Rusilowicz-Jones in hTERT-RPE1-YFP-Parkin cells, revealed that FT385-
mediated inhibition of USP30 increases AO-induced TOMM20-ubiquitylation 
to the same extent as USP30 deletion. Treating USP30 KO cells with FT385 
did not further augment TOMM20 ubiquitylation, indicating that it is an on-
target effect of FT385 (Rusilowicz-Jones et al., 2020). Remarkably FT385 also 
phenocopied USP30 KO by ubiquitylomics, proving for the first time that these 
ubiquitylation events are regulated by USP30’s catalytic activity. FT385 
confirmed that VDAC1, 2 and 3 are genuine substrates of USP30 and led me 
to identify SYNJ2BP as a novel USP30 substrate.  
Treating SH-SY5Y cells for 24h with 100nM FT385 was insufficient to either 
enhance AO-induced mitophagy or augment basal mitophagy. However, Katy 
McCarron and Francesco Barone showed that treating these cells with 200nM 
FT385 for 96h significantly enhanced basal mitophagy by 1.7-fold (Rusilowicz-
Jones et al., 2020). Through the pharmacological inhibition of USP30, with 
USP30i and FT385, we have thus confirmed that USP30 regulates basal 
mitophagy. 
 
Other USP30 inhibitors have been published but were less potent with >60-
fold higher USP30 IC50 and/or used in mammalian cells at micromolar doses 
(2-5µM vs 100-200nM with FT385). These inhibitors were also not as selective 
or not tested for specificity (Yue et al., 2014; Kluge et al., 2018; Stockley et al., 
2018; Phu et al., 2020).  
Congruent with our data, another USP30 inhibitor, MF-094 (USP30 IC50: 
120nM), was shown to enhance the decay of BrdU labelled mtDNA in 
postmitotic C2C12 mice myotubes cells which indirectly suggests an increase 
in mitochondrial degradation (Kluge et al., 2018).  
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I did not observe any distinct fusion of the mitochondrial network with FT385 
in SH-SY5Y cells unlike that reported by Yue and colleagues with the 15-
oxospiramilactone USP30 inhibitor in MEF cells, (Yue et al., 2014). Neither 
FT385 treated, nor USP30 knocked-down nor KO SH-SY5Y cells had 
mitochondria which were more elongated than wildtype cells. Similar 
observations were made by Andreas, Elena, Aitor and Emma which had 
respectively generated USP30 knockout lines in HCT116, RPE1 and U2OS 
cells.  
While our manuscript was in preparation, Bingol’s group published a 
complementary study describing the effect of USP30 inhibition on HEK293 
cells by mass spectrometry (Phu et al., 2020). They focussed their study on 
constitutive conditions (no depolarisation) and made use of a much higher 
inhibitor concentration (5µM). They obtained a 2-fold deeper total ubiquitylome 
coverage than ours, which contained a much higher number of hit proteins 
belonging to the IMM and mitochondrial matrix. Their publication was thus 
focussed on the regulation of mitochondrial protein import by USP30. 
However, the few OMM hit proteins they found coincide with our results, with 
proteins such as GDAP1 and TOMM20 being more ubiquitylated with USP30 
inhibition. 
 
 Biomarkers for USP30 deletion or inhibition  
I had aimed at using the total proteomes to find supplementary biomarkers 
characteristic of USP30 inhibition and deletion. Despite having large proteome 
coverages, 6,423 peptides (24h AO total proteome) and 7,372 peptides (4h 
AO total proteome), I only found few proteins that similarly responded to 
USP30 deletion and inhibition. There were no apparent changes in the global 
mitochondrial or peroxisomal proteomes. This was consistent with my 
observations by immunofluorescence in KO11 cells where I had seen no global 
changes in the number of peroxisomes nor in the total mitochondrial mass. 
Similar observations were made by my colleague Elena Marcassa in RPE1 
cells. It thus appears that in cells expressing no or endogenous Parkin, basal 
and induced mitophagy events occur at relatively a low rate, such that they 




In the absence of mitochondrial depolarisation, TOMM7 was the only 
significantly downregulated protein in both FT385 replicates and KO11 cells. 
TOMM7 was similarly downregulated upon depolarisation but was not 
detected in all replicates. 
This OMM protein is part of the TOM complex and has recently been described 
as a major regulator of the PINK1-Parkin pathway of mitophagy. In a CRISPR 
knockout screen for proteins that accelerate or decelerate mitophagy, TOMM7 
KO stood out as major decelerator ranking 21st out of 1998 proteins with PINK1 
KO ranking first. TOMM7 depletion restrained depolarisation-mediated 
degradation of OMM and IMM proteins as well as mitolysosome formation in 
mouse myoblasts overexpressing Parkin (Hoshino et al., 2019). Similarly, 
TOMM7 was highlighted as a “critical mitophagy gene” in a mitophagy flux 
screen using HFT cells overexpressing Parkin and mt-Keima (Heo et al., 
2019). Youle and colleagues had been the first to identify TOMM7 as a 
regulator of Parkin translocation upstream of mitophagy in a RNAi and 
microscopy screen performed in HeLa cells stably expressing GFP-Parkin 
(Hasson et al., 2013). They then showed that upon depolarisation, TOMM7 
tethers PINK1 to the OMM to promote its stabilisation and initiates mitophagy 
(Hasson et al., 2013; Sekine et al., 2019).  
Loss of TOMM7 in the USP30 KO cells would then be predicted to lead to 
reduced PINK1 stabilisation and reduced mitophagy, which is opposite to my 
findings. I also did not observe a decrease in PINK1 stabilisation in any of my 
previous western blot experiments.  
Our analysis only relies on three TOMM7 peptides, which is not surprising as 
TOMM7 is a small protein (6kDa). We could not further confirm this observation 
as we did not detect it neither in our second set of proteomic analysis (4h AO) 
nor by western blot analysis. 
 
 Pathways upregulated by USP30 deletion or inhibition 
5.5.5.1 Cell cycle 
In basal conditions, USP30 inhibition led to the upregulation of several cell 
cycle components: cyclin-dependent kinases (CDK1), positive regulators of 
cyclin-dependent kinases (CKS1B, CKS2), a mitosis-specific kinase of histone 
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3 (GSG2) and to the downregulation of a cyclin inhibitor CDKN1C (only with 
FT385). However, these cell cycle components did not respond to USP30 KO 
in a consistent manner. 
These observations were of interest as Parkin is a master regulator of the cell 
cycle. Parkin has been reported to negatively regulate the stability of G1/S 
phase cyclins D and E, and this E3 ligase is also a target of the p53 tumor 
suppressor, which is involved in stress responses such as cell cycle arrest or 
apoptosis (Staropoli et al., 2003; Gong et al., 2014; Zhang et al., 2011). Pink1 
and Parkin are both tumour suppressors that were shown to genetically 
interact with the cell cycle regulatory proteins Cdk1, Cdk2 and Cdc25 in 
Drosophila and to inhibit mitosis during mitophagy (Sarraf et al., 2019). 
Pickrell’s group propose that TBK1 mediates this mitotic arrest (Sarraf et al., 
2019). Upon depolarisation, PINK1 and Parkin recruit the centrosomal kinase 
TBK1 to damaged mitochondria in order to promote the tethering of autophagy 
receptors to the autophagosome (Heo et al., 2015; Lazarou et al., 2015; Moore 
and Holzbaur, 2016; Richter et al., 2016). While at mitochondria, TBK1 is 
restricted from its function at centrosomes leading to a cell cycle arrest at the 
G2/M phase (Pillai et al., 2015; Sarraf et al., 2019). A mass spectrometry 
experiment performed in HeLa cells revealed that TBK1 was ubiquitylated by 
Parkin at K60 during mitochondrial depolarisation (Rose et al., 2016). In SH-
SY5Y cells, I did not measure any further ubiquitylation of TBK1 in the absence 
or inhibition of USP30, however I did not detect the peptide containing the K60 
residue.  
As the upregulation of cell cycle proteins was mainly reproducible in FT385 
treated cells, I concluded that it was most likely an off-target response. 
 
5.5.5.2 Neuronal potential 
Our proteomic analyses suggest that USP30 could be involved in regulating 
the neuronal potential of SH-SY5Y cells. I observed both the significant 
upregulation and downregulation of neuronal components, synapse 
constituents, elements of synaptic vesicles and proteins regulating neuronal 
migration, differentiation or survival. Remarkably, neuropilin-1 (NRP1, 
upregulated) involved in neuronal migration, the neurotransmitter transporter 
SLC18A1 (upregulated) and neuropeptide-Y (NPY, downregulated) were also 
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hits in two repeat proteome experiments performed by Emma Rusilowicz-
Jones in AO treated (4h) -KOD and KO11 cells (Rusilowicz-Jones et al., 2020). 
Unfortunately, these repeat experiments had a smaller peptide coverage 
(~5,500 peptides each against 7,372 peptides) and did not detect the other 
neuronal peptides.  
 
The protein abundance of the slit guidance ligand 1 (SLIT1) was significantly 
reduced in both KOD and KO11 cells and one of SLIT1’s receptor, ROBO2, 
was conversely significantly more abundant in KO11 and FT385 treated cells. 
SLIT proteins are known to bind ROBO receptors and regulate various 
processes from axon repulsion during brain development to angiogenesis 
(review: (Blockus and Chédotal, 2016)). In particular, SLIT1 and SLIT2 were 
reported to act as chemorepellent and specifically bind to ROBO1/2 ligands 
during as axon guidance  (reviews: (Bisiak and McCarthy, 2019; Tong et al., 
2019; Blockus and Chédotal, 2016)). SH-SY5Y cells are derived from 
neuroblastoma cells and have typically two morphologies: neuroblast-like and 
epithelial-like. Neuroblast-type SH-SY5Y have maintained neuronal functions 
such as tyrosine hydroxylase and dopamine-β-hydroxylase activity 
(Kovalevich and Langford, 2013).  
As described earlier, SH-SY5Y cells can also be differentiated into neuron-like 
cells. Differentiated SH-SY5Y cells typically express mature neuronal markers 
(synaptophysin (SYP), RBFOX3, DLG1, ENO2), differentiation promoting 
genes (NEUROD1, NEUROD6), TH, dopamine transporter (SLC6A3), 
dopamine receptors (DRD2, DRD3) and vesicular monoamine transporters 
(VMATs: SLC18A1 and SLC18A2) (Cheung et al., 2009; Constantinescu et al., 
2007; Kovalevich and Langford, 2013; Lopes et al., 2010). In my proteome 
analyses, SLC18A1 was upregulated across all conditions, SYP was 
upregulated in two KO11 samples (KO11 DMSO and KO11 4h AO), ENO2 
was upregulated in only one KO11 sample (24h AO), DLG1 was unchanged 
and none of the other markers were detected.  
Visually, SH-SY5Y cells treated with FT385 for 24h or USP30 KO did not 




From these proteomic data, it appears that USP30 deletion and inhibition 
elevates this neuronal potential, indicating that USP30 might play a negative 
regulatory role in neuronal development or differentiation. 
 
 Characterising USP30’s favoured deubiquitylation sites 
5.5.6.1 Peroxisomal proteins  
We have shown that USP30 localises at peroxisomes and decelerates basal 
pexophagy in mammalian cells (Marcassa et al., 2018). This is in agreement 
with studies from the Kim lab, which describe, using immunoprecipitation 
assays, that USP30 opposes starvation induced pexophagy by opposing 
PEX2-mediated ubiquitylation of PEX5 and PMP70 in HEK293 cells 
overexpressing HA-ubiquitin; whilst we had previously failed to see any clear 
changes in our RPE1 KO cells (Marcassa et al., 2018; Riccio et al., 2019; 
Sargent et al., 2016). By mass spectrometry analysis, I found that PMP70 (or 
ABCD3) is ubiquitylated at K260 upon inhibition or deletion of USP30 in SH-
SY5Y cells but failed to pick up any changes in PEX5 ubiquitylation.  
Kim’s group have further demonstrated that following amino acid starvation, 
the peroxisome E3 ligase PEX2 ubiquitylates PEX5 and PMP70 to recruit the 
adaptor protein NBR1 for the engulfment of peroxisomes into autophagosomal 
membranes (Riccio et al., 2019; Sargent et al., 2016). Contrasting with our 
observation in SH-SY5Y cells, Kim and colleagues measured a global 
reduction in PEX14 expression and a decrease of ABCD3 positive 
peroxisomes when knocking down USP30 in HeLa cells (Riccio et al., 2019). 
In our proteomic analysis, PEX14 and ABCD3 protein levels remained stable 
upon USP30 inhibition or depletion. Overall, we did not measure any global 
shift in peroxisomal proteins number. It is important to note that I did not use 
the SKL-Keima construct to directly assess whether USP30 deletion increases 
pexophagy in SH-SY5Y cells.  
 
5.5.6.2 Common substrates with Parkin 
When performing ubiquitylomic analysis on mitochondria enriched fractions of 
depolarised USP30 KO SH-SY5Y cells, I found that USP30 deubiquitylated 
many residues on OMM proteins. Most of these proteins were also substrates 
of Parkin such as GDAP1 or members of the TOM and VDAC complexes 
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(Rusilowicz-Jones et al., 2020). This was in agreement with proteomic studies 
performed in cells overexpressing Parkin which were either co-expressing 
USP30 or depleting it (Bingol et al., 2014; Cunningham et al., 2015).  
However, when specifically assessing the residues modified by USP30 and 
Parkin respectively, I noticed that these enzyme’s ubiquitylating and 
deubiquitylating activities do not fully overlap.  About 1/3 of USP30 target lysine 
residues in top hit proteins (VDACs, TOMMs, GDAP1, SYNJ2BP, PTRH2 and 
ABCD3) have not been reported to be ubiquitylated by Parkin (Sarraf et al., 
2013; Rose et al., 2016; Ordureau et al., 2018, 2020). Congruently, many 
Parkin ubiquitylation sites were unaffected by USP30 deletion or inhibition: I 
measured thirteen TOMM70 ubiquitylated residues, which are Parkin 
substrates, that did not change with the loss of USP30. 
While we were writing the manuscript for our paper, the Harper lab published 
a series of mass spectrometry experiments including a ubiquitylome analysis 
performed in mitochondrial fractions of USP30 KO iNeurons. They concluded 
that USP30 deubiquitylates a pool of Parkin substrates but that the majority of 
Parkin ubiquitylation sites are unaffected in USP30-\- iNeurons. Their new 
conclusion is in agreement with our own hypothesis wherein we propose that 
USP30 sets the threshold for Parkin activation by suppressing the initial 
ubiquitin-phosphorylation burst by PINK1 rather than directly opposing Parkin 
ubiquitylation (Ordureau et al., 2020). 
 
5.5.6.3 Ribosome-associated Quality Control 
In the total ubiquitylome dataset but not in the mito-ubiquitylome, the ribosomal 
protein RPS20 was a strong hit: its K4 and K8 residues were five times more 
ubiquitylated with USP30 deletion and inhibition. Interestingly, those sites have 
been reported to be ubiquitylated by ZNF598 in the context of Ribosome-
associated Quality Control (RQC) (Sundaramoorthy et al., 2017), (see short 
review: (Ikeuchi et al., 2019)). The E3 ubiquitin ligase ZNF598 and the 40S 
ribosomal protein RACK1 mediated ubiquitylation of 40S ribosome proteins, 
such as RPS20, to alleviate ribosome stalling through the dissociation and 
recycling of the ribosomal subunits. USP30 could therefore oppose ZNF598 
and fine tunes RQC. The K4- and K8-ubiquitylation of RPS20 was unchanged 
in the mito-ubiquitylome. This could either suggest that USP30 loss of function 
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induces stalling of primarily cytosolic or ER associated ribosomes or that 
prolonged mitochondria depolarisation indirectly promotes ribosomal stalling 
revealing the involvement of USP30 in this process.  
Other DUBs have recently been linked to RQC. Eric Bennett’s team performed 
a DUB screen using an RQC-fluorescence probe (GFP-poly(A)-CherryFP) to 
search for DUBs limiting RQC activation. They found that OTUD3 and USP21 
efficiently opposed ZNF598 ubiquitylation of RPS10 and RPS20 (Garshott et 
al., 2020). Using a specific USP9X inhibitor, my colleague Anne Clancy found 
that USP9X instead positively regulates RQC by stabilising the E3 ligase 
ZNF598 (Clancy et al., 2020). 
Another link between USP30 and RQC was found in the ubiquitylome analysis 
performed in mitochondria enriched samples following 4h depolarisation. The 
mitochondrial peptidyl-tRNA hydrolase PTRH2 was highly ubiquitylated in the 
absence of USP30. This was confirmed in two replicate experiments 
performed by Emma where PTRH2’s K48 residues was ubiquitylated four 
times more with USP30 deletion (Rusilowicz-Jones et al., 2020). In vitro 
studies report that PTRH2 has a hydrolase activity suggesting it functions in 
tRNA recycling and translation regulation (Pereda et al., 2004). Cytosolic 
PTRH1 was shown to release nascent chains from stalled ribosomes during 
RQC. In vitro, mitochondrial PTRH2 has also the ability to release those 
nascent chains from 60S ribosome-nascent chain complex and 80S stalled 
ribosomes (Kuroha et al., 2018). 
As USP30 is a mitochondrial anchored protein it potentially could regulate 
mRNA translation and protein synthesis at mitochondria, and more specifically, 
at the TOM complex (Nakamura and Hirose, 2008; Marcassa et al., 2018). 
Indeed, western blotting data points towards TOMM20 as one of the key 
substrates of USP30. On top of this, our lab has previously shown that USP30 
associates with both TOMM20 and TOMM22 independently of its catalytic 
activity (Liang et al., 2015). The mass spectrometry analysis now has added 
additional TOM components to the list of USP30 substrates, which I have not 
probed for before (TOMM5, TOMM40 and TOMM70). Both TOMM20 and 
TOMM22 serve as cytosolic receptors in the presequence import pathway; 
they bind to the precursor proteins via hydrophobic interactions and promote 
their translocation into the TOMM40 barrel (Araiso et al., 2019; Tucker and 
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Park, 2019). Mitochondrial protein synthesis is most likely occurring in the 
vicinity of the TOM complex and USP30. Consolidating this hypothesis, a cryo-
EM study revealed that the TOM complex directly interacts with ribosomes 
(Gold et al., 2017).   
 
 
To further delve into USP30 function and its application in in vivo models I will 
characterise two novel Drosophila models in Chapter VI: the mt-Keima and the 




Chapter 6: The mt-keima Drosophila: an 
innovative tool to study mitophagy in vivo 
 
6.1 Introduction 
There is considerable interest in understanding the process of mitophagy in 
vivo. Thanks to mitophagy probes, such as the mt-QC or mito-Keima reporters, 
it is now possible to study mitophagy not only in live cells but also in whole 
organisms. Both the Finkel and Ganley labs have engineered mouse models 
of mitophagy, the mt-Keima and the mito-QC mice respectively (Sun et al., 
2015; McWilliams et al., 2016). Here I present the mt-Keima fly, a novel model 
for the study of mitophagy. In this Chapter I will detail how this fly model has 
been generated initially by Aitor Martinez, then follow with its characterisation 
and finally, I will reveal a new model we have produced: the Usp30 knockout 
fly, which when crossed with the mt-Keima fly can provide indications on the 
function of Usp30 within the brain. 
 
6.2 Generation of mt-Keima Drosophila models 
 
 The mt-Keima fluorophore 
As explained in Chapter III, Keima is a pH-dependent dual-excitation 
fluorophore: its excitation peak shifts from 440nm to 586nm with increasing 
acidity (Figure 6.1), (Katayama et al., 2011). It was engineered by the 
Miyawaki lab, first as a homotrimeric complex (tKeima) then mutated into 
dimeric (dKeima) or monomeric (mKeima) forms (Kogure et al., 2006). These 
3 variants have the same excitation peaks and but have slightly different 
emission spectra: tKeima and dKeima peak at 616 whereas mKeima peaks at 
620nm (Kogure et al., 2006). dKeima has the particularity of being 2-fold 
brighter than mKeima and tKeima; mKeima has the advantage of responding 
more strongly to pH than dKeima: at pH4 mKeima’s 586/440 ratio is 2-fold 
higher than dKeima’s (Katayama et al., 2011; Kogure et al., 2006). Thus, 
Miyawaki’s group made use of mKeima to produce a mitophagy probe: they 
fused mKeima with a tandem COXVIII-mitochondrial targeting sequence 
(MTS), which targets it to the mitochondrial matrix (Katayama et al., 2011).   
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Figure 6.1: Schematic 
representation of the mt-Keima 
mitophagy reporter. 
A) Keima is a pH-ratiometric 
fluorophore and is tagged onto the 
mitochondrial matrix targeting 
sequence of COX VIII. When 
expressed in cells, the mt-Keima 
probe is targeted to the mitochondrial 
matrix and has a dual excitation that 
is pH dependent. At pH4, mt-Keima is 
preferentially excited at 561 nm 
whereas at neutral pH it is more 
excitable at 445 nm. This enables an 
easy discrimination between healthy 
mitochondria and mitolysosomes. B) 
Graph representing mt-Keima’s 
excitation and emission spectra at 
pH8 (mitochondrial pH, in green) and 
pH4 (lysosomal pH, in red). Dashed 
line represents emission wavelength. 
At pH8 mt-Keima excitation’s peaks 
at 440nm; at pH4 it peaks at 586nm. 
Mt-Keima’s emission spectra is 
constant and peaks at 620nm. 
Imaging setup: Mt-Keima is 
sequentially imaged using a 3i 
spinning disk confocal microscope 
(Ex445/Em620 then Ex561/Em620). 
The excitation settings are annotated 
on the graph. This graph is adapted 
from Sun et al., 2017 (Figure 1). 
Interestingly, mt-mKeima (hereafter referred to as mt-Keima) is acid stable 
which makes it resistant to lysosomal degradation. The probe therefore 
permits to follow the targeting of mitochondria to lysosomal compartments. 
Similarly, Aitor Martinez-Zarate, a former post-doctoral researcher in my host 
lab, generated a Keima reporter targeted to peroxisomes in order to monitor 
pexophagy. He flanked mKeima with SKL, a peroxisomal targeting sequence. 
Together with Aitor, I employed U2OS cells stably expressing Keima-SKL to 
optimise imaging settings and assess the response of Keima to cellular pH 
(Figure 6.2). One advantage of using the SKL-Keima over the mt-Keima probe 
for this assay is that peroxisomes maintain the same dimensions whether they 
undergo stress or not, unlike mitochondria which can switch from 
















































Figure 6.2: pH titration of the Keima fluorophore in U2OS-SKL-Keima cells. 
A) U2OS-SKL-Keima cells were grown in DMEM and sequentially imaged on a 3i 
spinning disk confocal microscope equipped with an EMCCD camera and a 40X 
objective lens (Em445/Ex610 then Em561/Em610). The media were then exchanged 
for solutions (143mM KCL, 1.17mM MgCl2, 1.3mM CaCl2, 5mM Glucose) first at pH8, 
7, 6, 5 then 4 and mixed with 10μM nigericin, a K+/H+ ionophore that equalises the 
extra- and intra-cellular pH. Finally, the cells were incubated with 50mM NH4Cl. Citric 
acid (20mM) was used for pH solutions ranging from pH 4-6 and HEPES (10mM) for 
pH 7-8 The cells were equilibrated for 5min and imaged in between each buffer 
exchange. Scale bar: 10μm. B) Plot representing the pixel intensity value in Ex561 
images over Ex445 images. The plots were generated on FIJI using the 

























































































































We made use of nigericin, a K+/H+ ionophore to equilibrate the intracellular pH 
with the extracellular pH and exchanged the medium with buffers ranging from 
pH4-8. With each buffer, we sequentially imaged the cells using a spinning 
disk confocal microscope equipped with 445nm and 561nm lasers 
(Ex445/Em600 then Ex561/Em600) (Figure 6.2A). We false coloured the 
images: Ex445 in green and Ex561 in red. In the absence of nigericin and when 
the cells were still in DMEM, we only observed a few red-puncta which 
reflected basal pexophagy (Figure 6.2A-B). Most peroxisomes were 
preferentially exited at 445nm (green in our false coloured scheme), thus 
experienced the neutral pH of the cytosolic environment. Upon pH titration 
(pH8 to pH4), we observed a clear shift in Keima’s excitation peak, from 445 
to 561nm, correlating with media acidification.  
As the the Miyawaki lab had previously described with mKeima purified 
recombinant proteins (Ex440 and 586), we found that the 445/561 ratio 
approached 1 at pH6 in U2OS cells overexpressing Keima-SKL (Katayama et 
al., 2011). When treating the U2OS-SKL with 50mM NH4Cl, which neutralises 
lysosomes, we lost all “red puncta” (peroxisomes in acidic lysosomes). We 
thus confirmed that our imaging set up (Ex445/Em600 then Ex561/Em600) is 
suitable for ratiometric Keima imaging. 
 
  Characterisation of UAS-mt-Keima strains 
Aitor Martinez-Zarate created a mt-Keima Drosophila fly model. He made use 
of the UAS-GAL4 system to actively direct mt-Keima’s expression in chosen 
tissues. To do so, he inserted the mt-Keima sequence from the mammalian 
plasmid mt-mKeima (h)-pIND(SP1), kindly donated by Atsushi Miyawaki, into 
a Drosophila pUAST plasmid (Katayama et al., 2011). Sequencing of the thus 
created mt-Keima-pUAST plasmid revealed it was missing one MTS. A 
tandem MTS was reported to increase the import efficiency of fusion proteins 
to mitochondria (Galanis et al., 1991). However, using the online prediction 
tool MITOPROT and through preliminary transfection experiments, Aitor 
Martinez-Zarate assessed that a single COX VIII presequence was sufficient 
to target Keima to mitochondria.  
The mt-Keima-pUAST plasmid was then injected in wildtype (w1118) 
Drosophila embryo by Bestgene Inc (California, USA). This pUAST plasmid 
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integrated randomly into the fly genome via its P-element, which encodes for 
P-transposase (Brand and Perrimon, 1993). Multiple strains were screened, 
and the insertions sites were analysed by Aitor Martinez-Zarate and his 
colleague Juanma Ramirez (UPV-EHU, Spain). They selected four UAS-mt-
Keima strains: two of which carried the mt-Keima reporter on the 2nd (M3 and 
M7) and two on the 3rd (M2 and M4) chromosome. 
I then assessed by western blot analysis the level of Keima expression of those 
four UAS-mt-Keima strains when crossed with either ubiquitous (tub-GAL4) or 
a neuronal (elav-GAL4) GAL4 driver strains (Figure 6.3A-B). UAS-mt-Keima 
M3 and M7 crossed with elav-GAL4 expressed over 2-fold more Keima than 
UAS-mt-Keima M2 and M4. With tub-GAL4, all UAS-mt-Keima crosses 
expressed mt-Keima in a similar fashion.  
Keima was reported to be resistant to lysosomal degradation (Katayama et al., 
2011). We thus wondered if mt-Keima would accumulate over time in our 
Drosophila model. We measured the level of mt-Keima expression in old (20-
25 days post hatching) versus young (0-5 days post hatching) flies and 
compared those flies to mito-GFP expressing ones (Figure 6.3C). Similar to 
mito-GFP, mt-Keima did not accumulate overtime; indicating that mt-Keima 
ultimately gets processed. 
I then observed mt-Keima expression in embryonic neuronal cultures by 
confocal microscopy (Figure 6.4A-C). With a 445nm excitation, mt-Keima 
formed a tubular network which colocalised with the mitochondrial dye 
Mitotracker deep red (Ex640/Em665) (Figure 6.4B). Complementary to our 
work, our collaborators in Alex Whitworth’s group reported that mt-Keima co-
localised with the mitochondrial protein ATP5A in larval epidermis cells  (Lee 
et al., 2018). With a 561nm excitation, mt-Keima fluoresced brightly at punctate 
structures that colocalised with the lysosomal dye Lysotraker blue 
(Ex405/Em422). This confirmed that despite only having one MTS, mt-Keima 
was targeted to Drosophila mitochondria and underwent a shift in its excitation 
peak from 445 to 561nm once in lysosomal compartments. 
Using the mt-Keima mouse, which was also engineered with the mt-mKeima 
(h)-pIND(SP1) plasmid, the Finkel lab demonstrated that mt-Keima-
mitolysosome formation is dependent on core components of the autophagy 
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machinery: ATG5 and ATG7,  confirming that mt-Keima reports on mitophagy 
processes in vivo (Sun et al., 2015).  
 
 
Figure 6.3: Western blot characterisation of UAS-mt-Keima fly strains. 
Four strains of UAS-mt-Keima Drosophila (M7, M3, M2 and M4) were crossed with 
two GAL4 driver strains having (A) a pan-neuronal driver (elav) or (B) a ubiquitous 
driver (tub): UAS-mt-Keima M7/+; elav-GAL4/+ (elav> M7), UAS-mt-Keima M3/+; 
elav-GAL4/+ (elav> M3), UAS-mt-Keima M2/elav-GAL4 (elav> M2), UAS-mt-Keima 
M4/elav-GAL4 (elav> M4), UAS-mt-Keima M7/+; tub-GAL4/+ (tub> M7), UAS-mt-
Keima M3/+; tub-GAL4/+ (tub> M3), UAS-mt-Keima M2/tub-GAL4 (elav> M2), UAS-
mt-Keima M4/tub-GAL4 (tub> M4).  
The heads (A) or whole bodies (B) of the F1 progeny were snap-frozen in liquid 
nitrogen 0 to 4 days post-hatching, then lysed in Laemmli buffer. The corresponding 
lysates were probed with anti-Keima antibody. The parental GAL4 strains were used 
as controls: elav and tub. In (B), the lysates were compared to mt-Keima/tub 
recombinant flies (R1 and R2) lysates: tub-GAL4, UAS-mt-Keima M2/+. C) The 
expression levels of mt-Keima (K: M7; tub-GAL4, UAS-mt-Keima M2/+) and mt-GFP 
(G: tub-GAL4, UAS-mt-GFP/+) were assessed in young (0-5 days post hatching) and 
old (25-30 days post hatching) flies and compared to a control stain (C: tub-GAL4/+). 






























































































































Figure 6.4: mt-Keima co-localises with mitochondria and lysosomal dyes in 
embryonic neuronal cultures. 
Neurons dissected from stage 11 embryo (E11) of UAS-mt-Keima M7; elav-
GAL4,UAS-mtKeima M2 Drosophila were extracted and grown on concanavalin A 
coated slides. They were either (A) untreated or incubated for 30 min with (B) 100nM 
Mitotracker Deep Red or with (C) 5μM Lysotracker Blue. Images were acquired 
sequentially using a 3i spinning disk confocal microscope with a 63x objective and an 
EMCCD camera. Scale bar: 10μm (higher zoom in top panels). Representative 
images from two experiments. 
 
 
In parallel, Aitor assessed whether common mitophagy triggers could induce 
mitophagy in embryonic neuronal cultures expressing mt-Keima (Appendix 
5). He treated neurons with AO (10µM each), DFP (1mM) and paraquat 
(100µM) for 24h. Paraquat is a mitochondrial toxin that promotes motor 
impairments, reduced lifespan and mitophagy induction in Drosophila (Bingol 
et al., 2014; Moskal et al., 2020). As observed in mammalian cell models, the 
AO treatment resulted in a complete fragmentation of the neuronal 
mitochondrial network. Importantly, each compound promoted mitophagy in 
the mt-Keima fly neurons, thus validating that the mt-Keima fly is a relevant 
model to study mitophagy in vivo.  
mt-Keima 445 mt-Keima 561 MERGE
mt-Keima 445 Mitotracker MERGE





6.3  Characterisation of basal mitophagy in live larvae and adult tissue. 
 
Next, I analysed basal mitophagy in the mt-Keima fly. Drosophila larvae have 
the benefit of being transparent and thus enable the direct observation of tissue 
and organs without the need for dissection (Figure 6.5). I found that mitophagy 
was heterogenous across tissues and within organs. I observed that 
Drosophila larval body wall muscles showed low levels of mitophagy (low 
561/445 ratio) whilst larval epidermal cells and anal pad cells had high 
numbers of mitolysosomes (Figure 6.5B-C). 
The anal pads are two symmetrical monolayers of large cuboidal cells covered 
by a cuticle and surrounding the anus (Jarial, 1987). Together with the 
Malpighian tubules, the anal pads regulate water and ion homeostasis 
between the hemolymph and the surrounding medium (Andersen et al., 2017; 
Jarial, 1987). EM analysis of the anal pads have revealed that these cells are 
rich in mitochondria and lysosome-like dense bodies which would support our 
observations (Jarial, 1987). I found the anal pads showed a clear pattern of 
mitophagy: some cells were hotspot of mitophagy whilst others seemed devoid 
of mitolysosomes.  
The gut was another organ showing a high 561/445 ratio particularly in the mid 
gut (Figure 6.5B-vii,viii) and at the anterior midgut, in structures reminiscent 
of the gastric caeca (small tubules, here seen behind the brain, Figure 6.5B-
iv). Unfortunately, the gut is located at a depth in the larval tissue that makes 
it difficult to obtain clear images of individual intestinal cells at a high 
magnification (Figure 6.5C).  
I then analysed the larval brain (Figure 6.5B-iv,v,vi). The larval brain is divided 
into three major structures comprising two brain lobes and the ventral nerve 
cord (VNC) (Figure 6.5A). In these images, only the VNC is clearly 
distinguishable. The neuropils, tube-like structures rich in neurites located at 
the centre of the VNC, appeared to undergo very low levels of mitophagy (low 
561/445 ratio), (Figure 5.5B-iv). The 561/445 ratio seemed higher when 
focussing on higher planes, above the neuropiles and into the cortex, where 
are found the neuronal cell bodies and glial cells (Figure 6.5B-v).  
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Figure 6.5: Mitophagy distribution across a mt-Keima Drosophila larvae. 
 A) Illustration depicting the structural organisation of a stage III Drosophila 
melanogaster larvae with specific organs highlighted: brain (green), guts (orange), 
body wall muscles (blue), anal pads (yellow). B) Stage III larvae expressing 
ubiquitously the mt-Keima probe, UAS-mt-Keima M7; tub-GAL4, UAS-mt-Keima 
M2/+, were anesthetised using chloroform and imaged sequentially on a 3i spinning 
disk confocal microscope. Four z-stacks were taken for each larva using a 10X 
objective lens and an sCMOS camera. Representative images of the four z-stacks 
are presented on panel B. Scale bar: 100μm. GC: Gastric caeca; VNC: Ventral nerve 
cord; np: Neuropils. C) The larvae were then imaged using the 63X objective lens. 
Representative image of the epithelium, muscle, anal pad and gut cells are laid out in 
panel C. Scale bar: 30μm. The asterisk points towards a cell showing no apparent 
mitophagy. Data from three experiments.  
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I compared mt-Keima with mito-GFP larva to assess whether the mt-Keima 
probe expression pattern reflects mitochondria organisation (Figure 6.6). Just 
like mt-Keima, mito-GFP is targeted to mitochondria by the presequence of 
COX VIII (Pilling et al., 2006). Mt-Keima’s organellar and cellular organisation 
mirrored that of mito-GFP. Some organs such as the anal pads had a very high 
expression level of mito-GFP which reflects the high mitochondria density 
present this organ (Jarial, 1987). However, the heterogeneity in mitophagy we 
had observed in the anal pads of the mt-Keima larvae was not reflected in the 
images we obtained for this organ in the mito-GFP fly. Other tissues such as 
body wall muscles showed strong mito-GFP fluorescence but very little 
mitolysosomes, thus indicating that mitophagy was not simply a function of 
mitochondrial abundance in the tissue. 
I then went on to characterise mitophagy in 0-5 days old adult mt-Keima flies. 
The adult Drosophila has a highly pigmented exoskeleton which prevents the 
direct imaging of the interior of the organism. The animals were hence 
anesthetised with cold, their tissues dissected and imaged live within 30 min 
of dissection (Figure 6.7). As Drosophila wings are transparent, they were 
simply plucked off the organism and then imaged by confocal microscopy 
(Figure 6.7B). Mitolysosomes accumulated at the wing veins and wing hinges. 
Interestingly, wings have 200-300 chemosensory and mecanosensory 
neurons situated at the costal, L1 and L3 veins. These neurons meet up with 
glial cells in the hemolymph and form nerve bundles that can easily be 
monitored by microscopy (Fang et al., 2013). Hence the wing is an interesting 
model to study neuronal or glial mitophagy. A preliminary study had employed 
the mito-GFP Drosophila model to indirectly assess mitophagy in the wing 
through measurements of mitochondria size and number (Cao et al., 2017). 
This study reported an age-dependent increase in axonal mitochondria 
fragmentation and suggested that mitophagy occurred rarely in axonal 
mitochondria. Indeed, they found that neither knocking down or mutating 
autophagy genes (Atg12, Atg17) or Pink1 and Parkin affects axonal 
mitochondria (no difference in number or length) and axonal integrity. Instead, 
they proposed that in the wing axonal mitochondrial quality control would rather 
rely on fusion and fission. The UAS-mt-Keima fly could be used to confirm or 
refute this theory if crossed with specific neuronal GAL4 drivers.   
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Figure 6.6: Mitochondria distribution throughout a stage III (L3) mito-GFP 
larvae.  
A) Illustration depicting the structural organisation of a stage III Drosophila 
melanogaster larvae with specific organs highlighted: brain (green), guts (orange), 
body wall muscles (blue), anal pads (yellow). B) Stage III larvae expressing 
ubiquitously mito-GFP: tub-GAL4, UAS-mito-GFP/+, were anesthetised using 
chloroform and were imaged sequentially on a 3i spinning disk confocal microscope 
with an sCMOS camera. Four z-stacks were taken for each larva using a 10X 
objective lens. Representative images of the four z-stacks are presented on panel B. 
Scale bar: 100μm. C) The larvae were then imaged using the 63X objective lens. 
Representative image of the epithelium, muscle, anal pad and gut cells are laid out in 
panel C. Scale bar: 30μm. Data from two experiments.  













The testis was another organ with a high mitophagy signal in Drosophila 
(Figure 6.7C). The high 561/445 ratio was particularly concentrated at the 
base of the testis where late spermatid and mature sperm are localised. 
Indeed, spermatogenesis is compartmentalised within the Drosophila testis. At 
the apical end (white asterisk) are found the germline stem cells that undergo 
asymmetric division producing goniablast and daughter stem cells. The 
goniablast undergo four rounds of mitosis, then towards the middle of the 
testis, the resulting spermatocytes undergo meiosis to form spermatids (the 
“onion stage” spermatids are indicated with a white arrow), which then 
elongate to form late spermatid and ultimately sperm cells, towards the base 
of the testis (orange asterisk) (Demarco et al., 2014). Whilst the complete 
elimination of sperm mitochondria also known as  paternal mitochondria 
destruction (PMD)  is mediated by endocytic and autophagic pathways, it 
occurs only after fertilisation in the zyogtic cytoplasm (Politi et al., 2014).   
The high 561/445 ratio I observed at the base of the testis could however be 
linked to spermatid individualisation. During this process, the individualisation 
complex (composed of 64 investment cones rich in actin) divides the 
spermatids and strips off unnecessary cytoplasmic constituents: such as 
organelles (including excess mitochondria), membranes or mitochondrial DNA 
(DeLuca and O’Farrell, 2012; Fabrizio et al., 1998; Tokuyasu et al., 1972). 
These constituents accumulate in the spermatid syncytium (cyst) and form an 
enlarged structure called the cyst bulge. At the end of the individualisation 
process, the cyst bulges detach from the spermatids and are then called waste 
bags (Fabrizio et al., 1998; Tokuyasu et al., 1972), [review: (Fabian and Brill, 
2012)]. It has been hypothesised that the waste bag degradation occurs 
through phagocytosis(Tokuyasu et al., 1972). This phenomenon could thus be 
detected by the mt-Keima probe. 
As I had observed a strong 561/445 ratio in larval gut, I assessed whether the 
adult Drosophila gut was similarly a hotspot for mitophagy (Figure 6.7D). 
Unlike its larval counterpart, the adult Drosophila gut had only a moderate 
number of mitolysosomes. 
Finally, I observed the adult brain (Figure 6.7E). Mitophagy appeared 
homogenous and low across the central brain except for the boundaries 
between the main brain structures. The external lobes (medulla) and the 
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associated intermediate segment (lobula and lobula plate) seemed to have a 
higher number of mitolysosomes. However, only the use of a specific GAL4 
driver could give clear indications as to what compartment or subcellular cell 




Figure 6.7: Basal mitophagy in adult mt-Keima Drosophila. 
A) Diagram showing the anatomy of a male adult Drosophila melanogaster. B-E) 
Confocal images of dissected tissues from 0-5 days old mt-Keima Drosophila (UAS-
mt-Keima M7; tub-GAL4, UAS-mt-Keima M2/+): B) base and mid-section of a wing 
with its costal, L1, L2, L3, L4 and L5 veins, C) testis, D) gut and E) brain. m.: medulla, 
l.: lobula, l.p.: lobula plate. In C) are annotated the testis apical tip (white asterisk), the 
“onion stage” spermatids (white arrow) and the base of the testis (orange asterisk). In 
E), are shown 3 sections of the brain: dorsal, mid and ventral (top to bottom panel). 
The images were acquired sequentially using a spinning disk confocal, an sCMOS 
camera and a 10X objective lens. Scale bar 100μm. Data from three experiments. 
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I next focussed on the larval epidermal cells to assess the involvement of Pink1 
and Parkin in basal mitophagy. I crossed UAS siRNA strains targeting Pink1 
and Parkin or a wildtype fly (w1118) with the tubulin driven mt-Keima fly. The 
F1 progeny was then analysed by confocal microscopy: UAS-mt-Keima M7/+; 
tub-GAL4, UAS-mt-Keima M2/+ (CTRL), UAS-mt-Keima M7/UAS-Parkin 
RNAi; tub-GAL4, UAS-mt-Keima M2/+ (Parkin RNAi) and UAS-mt-Keima 
M7/UAS- Pink1 RNAi; tub-GAL4, UAS-mt-Keima M2/+ (Pink1 RNAi) (Figure 
6.8). Crossing the mt-Keima fly with the UAS-RNAi lines reduced the number 
of mt-Keima alleles in the progeny, thus diming the signal emitted by the 
fluorophore whilst enhancing background signal and therefore impeding the 
analysis. Mitophagy was quantified following the method described by the 
Finkel lab: the signal intensity measured with the 561nm excitation was plotted 
against the emission detected using the 445nm excitation. Then the plots were 
divided into 4 quadrants to separate the pixels originating from mitolysosomes 
(b) from the rest of the pixels (a, c and d). The mitophagy index represents the 
“mitolysosome pixel” (b) over the sum of all pixels (Figure 6.8B) (Sun et al., 
2015). From this experiment it appeared that neither Pink1 nor Parkin 
knockdown lines diminished basal mitophagy and, if anything, rather increased 
the mitophagy index (Figure 6.8C). However, when looking at mitophagy per 
individual, it appeared that mitophagy rates also varied widely between 
individuals of the same genotype. This interindividual variation was also 
observed in a preliminary experiment in which we submitted mt-Keima larvae 





Figure 6.8: Knocking down Pink1 and Parkin in mt-Keima flies. 
Mt-Keima expressing flies and wildtype, UAS-Pink1 or UAS-Parkin RNAi models were 
crossed and their F1 progeny analysed by confocal microscopy (3i spinning disk 
confocal microscope and sCMOS camera): UAS-mt-Keima M7/+; tub-GAL4, UAS-mt-
Keima M2/+ (CTRL), UAS-mt-Keima M7/UAS-Parkin RNAi; tub-GAL4, UAS-mt-
Keima M2/+ (Parkin RNAi), UAS-mt-Keima M7/UAS- Pink1 RNAi; tub-GAL4, UAS-
mt-Keima M2/+ (Pink1 RNAi). A) Representative images of the epithelium of L3 
larvae. 63X objective lens. Scale bar: 30μm. B) Plot representing the pixel intensity 
value in Ex561 images against Ex445 images. The plots were generated on FIJI using 
the “pixelAnalysis” plugin coded by Dave Mason. BG = area with no mitochondrial 
staining (background intensity). The plots are divided in 4 quadrants (green lines, limit 
set at 13,000- and 22,000- pixel intensity for Ex561 and Ex445 respectively), to 
separate: pixels originating from the mitochondria in acidic compartments “b” from the 
rest of the network “a”, “c” and “d”. The mitophagy index (M.I.) was calculated as 
follows: pixels b/ (pixels (a - BG) + b + c + d). C) Graph representing the mitophagy 
index per image and per individual. Data from obtained from one experiment, 6 


































































































Figure 6.9: Mitophagy in mt-Keima flies in response to hypoxia. 
Mt-Keima expressing stage III larvae (UAS-mt-Keima M7; GAL4-tub, UAS-mt-Keima 
M2/+) were incubated in a hypoxia (4% O2) or normoxia (21% O2) chamber for 6h 
then imaged sequentially on a spinning disk confocal microscope with an sCMOS 
camera and using a 63X objective lens. For each condition, four individuals were 
analysed and six images of the epidermal cells were taken per individual. Scale bar: 
30μm. The mitophagy index was quantified for each image using the FIJI plugin 
“pixelAnalysis” coded by Dave Mason. One representative image per individual with 



























































































































6.4  Engineering and preliminary characterisation of a USP30 knockout 
Drosophila. 
 
To further understand the role of USP30 in vivo, I decided to engineer a Usp30 
knockout fly (Figure 6.10). The mutagenesis was performed by WellGenetics 
Inc. in wildtype flies (w1118) using CRISPR-Cas9 and homology-dependent 
repair, following the method described by Kondo and Ueda (Figure 
6.10A),(Kondo and Ueda, 2013). They made use of a pairs of gRNAs and a 
donor template to delete most of Usp30’s (also known as CG3016) coding 
region sequence (CDS) and knock-in a selection marker (hsp70::w) in its 
place. This selection marker encodes for the orange coloured eye phenotype 
which facilitates genotype screening.  
Except for the orange coloured eyes, the Usp30 knockout flies did not present 
any particular morphological features (Figure 6.10B). They were the same 
size as their wildtype counterpart, they had normal wing posture and no visible 
indentations on their core and limbs. We verified that they were genuine 
USP30 knockout flies by RT-qPCR (Figure 6.10C). As most of the CDS was 
expected to be deleted, no mRNA encoding for Usp30 should have been 
expressed. I extracted total mRNA from Usp30 knockout flies following the 
protocol described by Bogart and Andrews and amplified exons of the CDS 
(Bogart and Andrews, 2006). No mRNA was detected in the Usp30 knockout 
fly, thus validating this model. 
Unlike USP30 mutations, deleting other mitophagy regulators such as Pink1 
or Parkin leads to strong phenotypical impairments: Pink1 and Parkin null 
mutants have deep indentations in the thorax and downturned wings which are 
both caused by the degeneration of flight associated muscles (Greene et al., 
2003; Clark et al., 2006; Park et al., 2006). Those features are accompanied 
with reduced motor functions: the null mutants are slower at climbing and 
unable to fly. Moreover, Pink1 and Parkin null flies have a reduced lifespan 
and males are infertile due to spermatogenesis impairments. Although Usp30 
KO flies do not present any visible impairments we decided to assess their 




Figure 6.10: Engineering a Usp30 knockout Drosophila 
A) Usp30 depletion was performed by WellGenetics Inc. in wildtype Drosophila 
(w1118) through CRISPR-mediated mutagenesis using two pairs of sgRNAs. Most of 
the coding region was deleted and replaced by an eye-marker cassette (hsp70::w, 
orange eyes), as shown on the schematic. Schematic provided by WellGenetics.  
B) Representative pictures of both male and female wildtype (w1118) and Usp30 
knockout flies. C) Usp30 mRNA expression was assessed by RT-qPCR in both 
wildtype and knockout flies using two sets of primers. Relative expression = 2-ΔΔct 
normalised to αtub84b. D) Graph representing the percentage of survival (ie: 
percentage of living flies per age category) per genotype and sex. Three experiments, 
50 flies per sex and genotype each (total 150 flies). Error bars represent SD.  
E) Climbing assay: the graph represents the average height, in centimetres, climbed 
within 20s by 12-day-old flies classified per genotype and sex. n=4, error bars 
represent SD. A total of 200 flies were analysed per condition. Test: One-way anova, 









































































Usp30 KO males were particularly sensitive to the loss of Usp30 as decreased 
viability was observed from 5 days post eclosion onwards (Figure 6.10D). 
Following 21 days post eclosion, only 32% of Usp30 KO male had survived 
against ~85% of Usp30 KO females and WT flies. The life expectancy of most 
Usp30 KO male did not exceed 35 days (4% survival) whilst at this age the 
pool of female KO and WT individuals had only dropped by ~40%.  
Both male and female Usp30 KO flies however presented motor defects 
(Figure 6.10E). To quantify this, I performed climbing assays (also known as 
negative geotaxis assays): 12 days old flies were placed in a graduated tube, 
the tube was briefly taped to stimulate climbing and the flies were filmed. At 
20s post stimulation, the length climbed by each fly was measured (Gargano 
et al., 2005). I found that, on average, wildtype males and females could climb 
4cm and 6cm respectively within 20s. However, this difference was not 
significant. Usp30 KO flies were significantly slower than their wildtype 
counterpart: within 20s, males and females only climb approximatively 0.7 and 
1.2cm respectively.  
 
As USP30 inhibits mitophagy I wondered if the reduced motor functions would 
correlate with abnormal mitophagy rates (Figure 6.11). I have previously seen 
that the optic lobes of the adult Drosophila undergo high levels of mitophagy. 
Moreover, my colleagues Natalia Sanchez-Soriano’s and Pilar Okenve-Ramos 
had optimised a protocol for Drosophila brain dissection and imaging of mt-
Keima in a specific region of the optic lobes called the medulla (Illustrated in 
Figure 6.11C). I thus crossed mt-Keima and Usp30 KO flies to obtain the 
following F1 progeny: Usp30 KO; UAS-mt-Keima M7/+; tub-GAL4, UAS-mt-
Keima M2/+.  
We compared mitophagy rates in young (7-9 days old) and old male (29-33 
days old) of both WT and Usp30 KO genotypes (Figure 6.11B and D). This 
preliminary experiment suggested that the mitophagy index of young Usp30 
KO flies was ~2-fold greater than young WT flies. Interestingly, in WT flies, 
mitophagy appeared to increase with age in the medulla. We recorded a 1.3-
fold increase of the mitophagy index between these two categories. However, 
old Usp30 KO flies had the lowest mitophagy rate of all categories: on average 
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the mitophagy index was of 6.2x104 (old KO) against 22.5 x104 (old WT), 16.8 





Figure 6.11: Usp30 depletion raises mitophagy at the medulla in young flies. 
A) Usp30 knockout and Usp30 wildtype Drosophila were crossed with mt-Keima 
reporter flies to obtain the following F1 males: +; UAS-mt-Keima M7/+; GAL4-tub, 
UAS-M2/+ (WT) and Usp30 KO; UAS-mt-Keima M7/+; GAL4-tub, UAS-M2/+ (KO). 
The brains of young (7-9 days old) and old (29-33 days old) WT and Usp30 KO flies 
were dissected and imaged live on a spinning disk confocal using a 63X objective 
lens. One z-stack of images was taken per medulla. Three to five individuals were 
analysed per condition and both medullas were imaged when possible. A maximum 
projection was applied onto the z-stacks. Scale bar: 30μm. B) The mitophagy index 
was measured and plotted for each medulla using the FIJI plugin “pixelAnalysis” 
coded by Dave Mason. Plots shown correspond to the images in A. C) Schematic of 
the adult Drosophila brain. The medullas are highlighted in dark orange. The 
rectangles indicate the area imaged by confocal microscopy. D) Graph representing 
the mitophagy index per condition. Each dot represents one medulla. Data from one 
experiment. 
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 Basal mitophagy is heterogenous across organs and tissues 
Using mt-Keima, I found that mitophagy was widespread in larvae and adult 
Drosophila but was also heterogenous across tissues and organs. In mt-Keima 
larvae for example, mitophagy was particularly low in body wall muscles and 
high in epidermal and anal pad cells. Using their mito-QC flies, Alex 
Whitworth’s group confirmed that mitolysosomes were abundant in the larval 
epidermis (Lee et al., 2018). Following our publication, two other groups 
presented mt-Keima flies both derived from the mammalian mt-mKeima (h)-
pIND(SP1) plasmid (Cornelissen et al., 2018b; Kim et al., 2019). Kim et al., 
confirmed  that in mt-Keima flies, mitophagy levels are low  in larval body wall 
muscles (Kim et al., 2019). Consistent with the observations made in larvae, 
the Whitworth lab further describe that mitophagy is low in pupal and adult 
flight muscle (Lee et al., 2018). 
 
When I assessed mitophagy in the VNC of the larval brain it appeared that the 
neuropils (region enriched in neurites) had low mitophagy whilst mitophagy 
was more elevated in the cortex (region enriched in neuronal cell bodies and 
glial cells). Our colleagues in the Whitworth lab also closely assessed 
mitophagy in larval CNS by dissecting the VNC (here referred to as the ventral 
ganglion) of both mito-QC and mtKeima larvae (Lee et al., 2018). In those 
images, mitolysosomes were clearly distinguishable in larval CNS cell bodies. 
 
In mice, mitophagy has likewise been described as heterogenous across 
organs. Unlike Drosophila, muscles (skeletal, tongue) of mito-QC mice have 
elevated mitophagy (McWilliams et al., 2016). Other organs with high energy 
demands such as kidneys, the heart, the brain, or the retina have been 
reported to have high levels of basal mitophagy in mt-Keima and mito-QC mice 
(Sun et al., 2015; McWilliams et al., 2016, 2018, 2019). However, this should 
not be taken as a rule of thumb, as other highly metabolically active organs 
such as the thymus or the spleen were reported to have on average lower rates 




 Basal mitophagy is compartmentalised within tissues and organs 
I discovered that mitophagy was also compartmentalised within organs and 
tissues. The anal pads were a striking example. These structures were 
composed of patches of cells with numerous mitolysosomes and cells with no 
detectable mitolysosomes. In the adult brain mitophagy was particularly 
elevated in the medulla. 
These observations are in agreement with the data published by the Ganley 
group using the mito-QC mouse: in the adult mice, kidney mitophagy is 
restricted to the proximal convoluted tubules (PCT) and retinal mitophagy is 
enriched at the outer nuclear layer (ONL)  (McWilliams et al., 2016, 2018, 
2019).  
 
 Basal mitophagy is regulated developmentally 
When I compared mitophagy in larvae and adult mt-Keima Drosophila, it 
appeared that mitophagy was regulated developmentally: the gut for example, 
was a hotspot of mitophagy in the larvae but had a low mitophagy index in the 
adult fly.  
Kim and colleague’s data in mt-Keima fly corroborated this hypothesis. They 
measured an increase in mitophagy during embryonic development. 
Mitophagy was especially elevated between stages E13 and E17 (Kim et al., 
2019). 
Similar observations have been made in mice. When focussing on the 
developing eye, the Ganley lab found that mitophagy hot spots varied between 
embryonic and adult retina. At the embryonic stage E16.5 mitophagy was 
restricted to the inner neuroblast layer whilst mitophagy was enriched in the 
retinal outer nuclear layer in adult mito-QC mouse (McWilliams et al., 2019). 
Likewise mitophagy varies in location and degree during mouse kidney and 
heart development (McWilliams et al., 2016).  
 
 Pink1 and Parkin mildly affect basal mitophagy in Drosophila 
I crossed Pink1 and Parkin RNAi lines with the mt-Keima fly and mitophagy 
appeared to be mildly affected by Pink1 or Parkin depletion in larvae epidermal 
cells. I was however unable to draw any real conclusions from this dataset as 
 295 
there was too high interindividual differences in mt-Keima expression amongst 
larvae of the same genotype.  
To overcome the difficulties arising from interindividual differences, Emma 
Rusilowicz and I started generating a new mt-Keima fly: the stripy fly (Figure 
6.12). Wildtype flies will be transfected with a tubulin-mt-Keima vector, 
containing two COX VIII MTS, to constitutively express mt-Keima. Those flies 
will then be crossed with UAS-tagBFP, hh-GAL4 flies. The hh-GAL4 
(hedgehog) driver will promotes the expression of UAS in stripes across the 
Drosophila larva. The resulting stripy fly (tub, mt-Keima; UAS-TagBFP, hh-
GAL4) can then be crossed with any UAS strain, for example expressing 
RNAis, to obtain F1 progeny larvae baring both wildtype and knockdown cells 
within the same tissues with the latter identifiable by the BFP fluorescence. 
 
Using the mito-QC model, which is considerably brighter than mt-Keima, our 
colleagues found that Pink1 and Parkin deletion mutants and wild-type flies 
have comparable numbers of mitolysosomes in the larval epidermis cells (Lee 
et al., 2018). They further observed mitophagy in larval, adult brain and adult 
DA neurons and found that only the larval brain was sensitive to Pink1 
mutation: in the larval brain, the number of mitolysosomes is decreased by 
~10% in Pink1 B9 mutants. This thus suggests that Pink1 and Parkin minimally 
affect basal mitophagy in Drosophila (Lee et al., 2018).  
 
 Usp30 appears to oppose basal mitophagy in the medulla of young 
Drosophila. 
In a preliminary experiment, I observed that Usp30 depletion can raise 
mitophagy levels in the medulla of young Drosophila. I found that mitophagy 
in young (7-9 days of age) Usp30 KO flies was increased by 1.9-fold compared 
to wildtype flies. However, in old Usp30 KO (29-33 days of age) flies mitophagy 
was decreased on average by 4-fold compared to their wildtype counterparts. 
From our survival curves, we know that only ~5% of Usp30 KO males survived 
to 29-33 days of age against 75% for WT males. 
In the “old” category we were thus only looking at the “fittest” Usp30 KO flies. 
This could imply that low mitophagy correlated with higher probability of 
survival in the absence of Usp30. Two hypotheses could explain this 
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observation, either a natural selection was made towards USP30 KO flies with 






Figure 6.12: Drosophila model to express UAS-RNAi in stripes within tissues. 
Schematic representation of a “stripy” fly. Wildtype flies will be transfected with a 
tubulin-mt-Keima vector to constitutively express mt-Keima. They will then be crossed 
with UAS-tagBFP, hh-GAL4 flies. Hh-GAL4: Hedgehog driver which promotes the 
expression of the UAS as stripes across the organism during larval stage. Final stripy 
flies genotype: tub, mt-Keima; UAS-TagBFP, hh-GAL4. When crossed to a UAS-RNAi 
strain, these flies will express the RNAi only in the hh-stripes and those will fluoresce 
in blue thanks to the UAS-TagBFP. This will enable us to directly compare mitophagy 
rates in WT vs knockdown cells within the same tissue and in L3 larvae. 
 
  
UAS-RNAi Expressing cells 
All cells constitutively express mt-Keima
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 Ageing and mitophagy 
In the same experiment as mentioned above I noticed that mitophagy in the 
medulla was enhanced by 1.3-fold between young (7-9 day old) and old (29-
33 days old) wildtype flies. Interestingly, the Vandenberghe lab reports that 
mitophagy increases with age in adult fly muscle: at 3 weeks and 4 weeks post 
eclosion, mitophagy is multiplied 4-fold and 8-fold respectively compared to 1-
week-old mt-Keima flies. This increase in mitophagy was abolished by the 
overexpression of a kinase dead Atg1 mutant, thus confirming the dependency 
on autophagosome (Cornelissen et al., 2018b). The degree of this increase of 
basal mitophagy with age seems to be tissue and cell specific. Indeed, our 
colleagues from the Whitworth lab have looked at mitophagy in DA neurons 
from the PPL1 cluster and found that it wasn’t markedly increased between 2- 
and 30-day-old individuals: on average they detected 5 versus 6 
mitolysosomes per DA cells in young and aged flies respectively (Lee et al., 
2018).  
Data collected in mice point in the other direction, mitophagy recorded in the 
dentate gyrus of the mt-Keima mice decreases by 70% with age (21/23- versus 
2/3-month-old mice) (Sun et al., 2015). 
 
Using the Pink1B9 mutant and Parkin RNAi flies, the Vandenberghe group 
confirmed that the absence of Pink1 or Parkin does not reduce basal 
mitophagy in the flight muscles of 1-week-old fly. However, they demonstrated 
that Pink1 loss of function mutation and Parkin knockdown supresses the age-
dependent increase in mitophagy observed in the indirect flight muscles of 3-
weeks and 4-weeks old flies (Cornelissen et al., 2018b).  
The Vandenberghe lab also assessed the involvement of DUBs in age-
associated mitophagy in vivo using their mt-Keima fly and focussed on Usp15 
and Usp30 (Cornelissen et al., 2018b). They previously had shown using 
mitochondrial enrichment assays that a small pool of USP15 localised to 
mitochondria in HEK293 cells and had reported that USP15 opposed Parkin-
mediated mitophagy HeLa cells overexpressing Parkin (Cornelissen et al., 
2014). In mt-Keima flies, Usp30 (CG3016) and CG8334 RNAi rescued 
mitophagy deficiency caused by Parkin RNAi in 4-week-old Drosophila flight 
muscle. They report that CG8334 is a homolog of human USP15 although 
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CG8334 has more homology with human USP32 (FlyBase, (Clague et al., 
2013, 2019)). They further demonstrated that CG8334 but not Usp30 RNAi 
rescued mitophagy in Pink1B9 aged flies. However, neither CG8334 nor Usp30 
RNAi further enhanced age-induced mitophagy in wildtype flies (Cornelissen 
et al., 2018b).  
 
 Usp30 KO fly fitness 
Using Usp30 KO flies, I found that the complete deletion of Usp30 reduced 
motor function (in 12-days old adult flies of both genders), decreased male life 
expectancy and increased male death at all stages of adulthood. A systematic 
DUB knockdown screen reported similar findings: Usp30 RNAi flies died soon 
after eclosion and performed poorly at geotaxis assays (geotaxis assay 
measured over 40 days) (Tsou et al., 2012).  
Counterintuitively, Baris Bingol reported that Usp30 RNAi was able to rescue 
the motor functions (climbing assay) of Pink1B9 mutant and paraquat treated 
flies (Bingol et al., 2014). Furthermore, Usp30 RNAi also extended the life 
expectancy of paraquat treated flies to 168h compared to 120h in control flies. 
These observations correlated with recovered dopamine production in Pink1B9 
flies. Usp30 RNAi was also able to restore mitochondrial morphology in the 
indirect flight muscles of Park25 flies, which were otherwise swollen with 
disorganised cristae. Interestingly expressing Usp30 RNAi in solely in 
dopaminergic neurons (Ddc or TH GAL4 drivers) was sufficient to protect flies 
against paraquat. 
These discrepancies could relate to the extent of the knockdown compared 
Usp30 knockout. However, Baris Bingol reported that the RNAi line used in his 
study led to a 90% reduction in Usp30 mRNA (Usp30 RNAi NIG 3016R-2) 
against a 36% decrease seen with the RNAi line used by Sokol Todi group, 
with the latter being sufficient to cause climbing impairments and reduced life 
expectancy (Usp30 RNAi VDRC 110616)(Bingol et al., 2014; Tsou et al., 
2012). 
 
Thus, it appears that depleting Usp30 is overall detrimental towards Drosophila 
fitness but can alleviate PD-like symptoms in young (1-3 days old) Pink1 and 
Parkin mutant Drosophila. Usp30 deletion might unleash excessive mitophagy 
 299 
in Drosophila. It would be interesting to knockdown Usp30 in specific tissues 
to assess what causes the loss in fitness. Using inducible RNAi lines, one 





Chapter 7: Final conclusions 
 
New cues on the mechanisms underlying Parkinson’s disease have arisen in 
the past two decades with the identification of risk factor genes involved in 
hereditary and sporadic forms of PD. PARK2/PRKN (Parkin) and 
PARK6/PINK1 mutations are causative of early onset and recessive forms of 
PD whilst being core regulators of mitophagy. Defects in mitochondrial quality 
control are thought to underly PD pathogenesis in those patients. Mitophagy 
and mitochondrial impairments might not be solely restricted to individuals with 
PINK1 or PRKN mutations. Congruent with this hypothesis, Post-mortem 
analysis of the brains of patients with sporadic PD and analysis of patient 
derived cells report on the presence of mitochondrial impairments. These 
include deficiencies in the respiratory chain components, Complex I in 
particular, and somatic mtDNA deletions (Chen et al., 2019). 
The work presented in this thesis aimed at gaining a deeper understanding of 
the PINK1-Parkin pathway of mitophagy and specifically focussed on USP30, 
the DUB known to oppose Parkin at mitochondria (Bingol et al., 2014; 
Cunningham et al., 2015; Liang et al., 2015). 
 
7.1 Mitophagy is widespread, compartmentalised and developmentally 
regulated in Drosophila melanogaster. 
I have characterised the mt-Keima fly which enables the study of mitophagy in 
vivo. The mt-Keima and the mito-QC fly (the latter produced in parallel by the 
Whitworth lab) were the first Drosophila models generated for in vivo imaging 
of mitophagy (Lee et al., 2018). Using embryonic neuronal cultures, I confirmed 
that mt-Keima is targeted to mitochondria and mitolysosomes, and further 
established that mitophagy could be induced in this model employing common 
mitophagy triggers.  
By live microscopy, we and others have found that mitophagy is widespread 
but also heterogenous across Drosophila organs and tissues (Cornelissen et 
al., 2018a; Kim et al., 2019; Lee et al., 2018). I found that mitophagy is 
particularly high in tissues such as the larval anal pads, or larval gut cells whilst 
it is low in larval body wall muscles. I then observed that mitophagy is regulated 
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developmentally and that it increases with age in the brain of wildtype adult 
Drosophila. Both observations were confirmed by the Yun and Vandenberghe 
labs respectively (Cornelissen et al., 2018a; Kim et al., 2019). I obtained 
preliminary data suggesting that Usp30 deletion enhances mitophagy rates in 
the brains of young adult Drosophila. These studies are currently being 
followed up by my colleagues Emma Rusilowicz-Jones and Francesco Barone 
(manuscript in preparation). Knocking-out USP30 was also found to increase 
mitophagy in mouse embryonic hippocampal neurons overexpressing mt-
Keima (Phu et al., 2020).  
 
7.2 USP30 regulates basal and depolarisation induced mitophagy 
Using the mito-QC reporter in USP30 KO and USP30 inhibitor treated 
mammalian cells, I demonstrated that USP30 regulates basal and 
depolarisation-induced mitophagy (Marcassa et al., 2018).  
In agreement with other mass spectrometry studies, I reported that USP30 
deubiquitylates OMM proteins including a subset of Parkin substrates, upon 
depolarisation (Rusilowicz-Jones et al., 2020; Bingol et al., 2014; Cunningham 
et al., 2015; Ordureau et al., 2020). I further showed that USP30 limits the 
accumulation of phosphorylated ubiquitin moieties at the OMM, revealing that 
USP30 may function upstream of PINK1. Increased levels of pS65-ubiquitin 
were also measured in USP30 KO iNeurons by the Harper lab when using low 
concentrations of depolarisation agents (Ordureau et al., 2020). 
Interestingly, the phosphorylation of OMM ubiquitin moieties by PINK1 might 
be more dynamic than expected and thus not an absolute barrier to USP30’s 
deubiquitylase activity. Recently, two pSer65-Ub phosphatases have been 
identified, PTEN-L and PPEF2, and were reported to participate in mitophagy 
repression: they suppress PINK1-mediated phosphorylation of OMM ubiquitin, 
decrease Parkin recruitment to mitochondria and reduce the proteasomal 
degradation of OMM proteins induced by mitochondria depolarisation (Wall et 
al., 2019; Wang et al., 2018). These phosphatases could enable USP30 to act 
both upstream and downstream of PINK1. 
 
Western blotting experiments which I performed in USP30 KO SH-SY5Y cells 
led me to speculate that MARCH5 and HUWE1 are priming E3 ligases which 
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oppose USP30 and ubiquitylate the TOM complex to initiate the PINK1/Parkin 
feedforward loop. Congruently, Matsuda’s group has demonstrated that Parkin 
ubiquitylates OMM proteins more efficiently in the presence of MARCH5 in 
HeLa cells overexpressing Parkin (Koyano et al., 2019a). 
I suggest that MARCH5, HUWE1 and USP30 set the threshold for mitophagy 
induction (See model: Figure 7.1). However, further analysis and replicate 




Figure 7.1: Model detailing USP30’s function in mitophagy in SH-SY5Y cells. 
The mitochondrial DUB USP30 localises at the TOM complex and opposes priming 
E3 ligases, such as cytosolic HUWE1 and mitochondrial MARCH5, from ubiquitylating 
proteins in the vicinity of the TOM complex. Upon depolarisation of the mitochondrial 
membrane, PINK1 accumulates at the TOM complex and phosphorylates both the 
surrounding ubiquitin and the E3 ligase Parkin at Ser65. This enables the recruitment 
of Parkin to mitochondria which then amplifies the ubiquitin signal. Autophagy 
adaptors (NDP52, OPTN, TAX1BP1, p62) bring the autophagosomes to the 
ubiquitylated mitochondria. By opposing TOM complex ubiquitylation, USP30 set the 








































7.3 USP30 regulates basal pexophagy 
I found that a pool of endogenous USP30 localises at peroxisomes. Elena 
further demonstrated, using the SKL-Keima probe, that USP30 regulates basal 
pexophagy (Marcassa et al., 2018). By mass spectrometry I then discovered 
that the deletion of USP30 enhances PMP70 ubiquitylation at K260, 
suggesting that the peroxisomal protein is a substrate of USP30. The Kim lab 
found that USP30 opposes starvation-induced mitophagy by deubiquitylating 
PMP70 and PEX5, substrates of the E3 ligase PEX2 (See model: Figure 7.2), 




Figure 7.2: Model for USP30-regulated pexophagy. 
A pool of USP30 localises at the peroxisomal membrane where it opposes PEX2-
mediated ubiquitylation of Pex5 and PMP70. Pexophagy adaptor proteins (NBR1 and 
p62) bind ubiquitin moieties on proteins of the peroxisomal membrane and enable the 
engulfment of peroxisomes in autophagosomes. 
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7.4 A role for USP30 in fine-tuning RQC and protein import at 
mitochondria? 
 Ribosome Quality Control and USP30 
The mass spectrometry analysis suggests that USP30 deubiquitylates the 
ribosomal protein RPS20 (40S subunit), and more precisely deubiquitylates its  
K4 and K8 ubiquitin moieties. These sites are known to be ubiquitylated by 
ZNF598 in order to alleviate ribosomal stalling through the dissociation and 
recycling of the ribosomal subunits (Sundaramoorthy et al., 2017), (see short 
review: (Ikeuchi et al., 2019). Furthermore, I found that the peptidyl RNA 
PTRH2, likely involved in releasing nascent chains from stalled ribosome, is 
highly ubiquitylated in the absence of USP30 (Kuroha et al., 2018). I thus 
proposed that USP30 might fine tunes ribosomal quality control (See model: 
Figure 6.3). 
EM studies performed in yeast have described that a pool of cytosolic 
ribosomes are in close contact with mitochondria (Kellems et al., 1975; 
Crowley and Payne, 1998). More recently it was demonstrated that RPL17A, 
a 60S ribosomal protein, co-precipitates with TOMM22 and TOMM40 (Gold et 
al., 2017). EM analysis revealed that these ribosomes are orientated such as 
to permit co-translational import (Gold et al., 2017).  
USP30 may thus be involved in ribosome quality control during mitochondrial 
protein translation. Further validation of the mass spectrometry analysis would 
be needed draw definitive conclusions on that matter. 
 
 Protein import and USP30 
Amos had shown that USP30 associates with both TOMM20 and TOMM22 
(Liang et al., 2015). I have now seen, by proteomic analysis, that USP30 
ubiquitylates nearly all TOM complex subunits (Rusilowicz-Jones et al., 2020). 
We deduced that USP30 primarily functions at the TOM complex. I found that 
a few matrix and IMS targeted proteins (GRSF1, HSPD1, HSPE1, MDH2, 
MTCH2, NDUFB5, PRDX3) are deubiquitylated by USP30. Both Harper’s and 
Bingol’s group published complementary mass spectrometry studies revealing 
that many more IMS and matrix proteins are substrates of USP30 (Phu et al., 
2020; Ordureau et al., 2020). Bingol’s group revealed that USP30 and 
MARCH5 fine tune protein import: MARCH5 ubiquitylates import intermediates 
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to target them for proteasomal degradation whilst USP30 permits the import of 





Figure 7.3: Model for USP30’s role in mitochondrial protein translation and 
import. 
The cytosolic ubiquitin E3 ligase ZNF598 ubiquitylates RPS20, a 40S ribosomal 
subunit, at K4 and K8 to alleviate ribosome stalling and promotes the dissociation of 
the ribosomal subunits. In this model, USP30 would remove K4- and K8-ubiquitin from 
RPS20 to prevent aberrant dissociation. The 60S ribosomal subunit binds to the TOM 
complex enabling co-translational import to mitochondria. MARCH5 ubiquitylates 
importing proteins to send them for proteasomal degradation. USP30 allows protein 
import by deubiquitylating them. 
 
 
7.5 USP30 is an actionable target in PD 
Pharmacological inhibition of USP30 is of interest in the context of PD as 
USP30 is the main DUB opposing PINK1 and Parkin. 
Together with my colleagues, I found that deleting USP30 did not affect the 
viability or growth of SH-SY5Y, HCT116, RPE1 and U20S cells. CRISPR KO 
essentiality screens also report that overall USP30 deletion is well tolerated 
across cell lines, which makes USP30 an attractive drug target (Lenoir et al., 
2018; Meyers et al., 2017).  
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I have presented a novel, highly specific and potent USP30 inhibitor (FT385) 
which recapitulates the effects of USP30 KD and KO in mammalian cells. I 
have shown that FT385 enhances the ubiquitylation of OMM proteins, 
including Parkin substrates, that it stimulates the PINK1-dependent 
phosphorylation of mitochondria and that it augments basal mitophagy in SH-
SY5Y cells. 
The effects of USP30 inhibition in vivo remains to be tested. It would be 
interesting generate mt-Keima flies expressing human USP30 and to measure 
mitophagy in those flies following a treatment with FT385. One could also 
assess the effect of FT385 on PINK1 and Parkin mutant flies. Promising results 
came from the Bingol lab, which reported that knocking down USP30 could 
rescue motor function, structural defects of mitochondria, and 
neurodegeneration in PINK1 and Parkin null mutant flies (Bingol et al., 2014). 
We however found that the complete deletion of USP30 is deleterious for 
Drosophila as it reduces their motor abilities and decreases male viability.  
 
Overall, this thesis discloses new exciting roles of USP30 in the context of 
pexophagy, basal or induced-mitophagy, and possibly in mitochondrial co-
translational import; putting a renewed emphasis on the relevance of USP30 
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